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Cardiac power output is a central haemodynamic measur  which describes pumping 
capability and performance of the heart. This is a unique measure as it accounts for 
both, flow- and pressure-generating capacities of the heart. Cardiac power output 
(CPO) is calculated from mean arterial pressure and car iac output. Popular non-
invasive methods for cardiac output measurement today include rebreathing methods. 
From the practical and clinical perspective it is important to know which of the 
commonly measured cardio-respiratory variables, obtained from a cardiopulmonary 
exercise test, are good predictors of peak CPO in healt y but also in heart failure 
populations. Until now there has been no measurement of cardiac power output in 
patients implanted with a left ventricular assist device (LVAD) and those explanted 
(recovered) patients. In a comparison study design it has been shown that peak cardiac 
power output differentiates well during cardiac restoration using LVADs and 
emphasizes the benefits of this therapy. It seems that CPO has the potential to be a 
key physiological marker of heart failure severity and can guide the management of 
LVAD patients. Furthermore as a consequence of acute reduction of LVAD support, 
there is a decrease in cardiac pumping capability and exercise performance. A 
decrease at rest and at peak exercise, expressed in p rcentages, was higher in central 
haemodynamics, particularly in CPO, than in the conventionally measured peak 
oxygen consumption. This suggests that CPO is more sensitive to acute reduction of 
LVAD support than oxygen consumption. In patients with severe heart failure and 
those implanted with an LVAD, the relationship betwen peak CPO and peak oxygen 
consumption is only modest. In healthy adults and LVAD explanted patients this 
relationship was high. No strong relationship was found between peak CPO and 
anaerobic threshold, circulatory power, oxygen pulse or ventilatory efficiency in 
LVAD implanted and patients with severe heart failure. Finally, regarding different 
modalities of exercise training, in contrast with resistance training, aerobic exercise 
training may increase both maximal flow-generating capacity of the heart and peak 
oxygen consumption and also delays anaerobic metabolism in patients with stable 
chronic heart failure. Improved peak oxygen consumption, following aerobic exercise 
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GLOSSARY OF TERMS 
Apoptosis: A form of programmed cell death in multicellular organisms.  
Anaerobic threshold: Exercise oxygen consumption that marks the transitio  
between no change or little change in arterial lactate concentration and the sustained 
increase in concentration of lactate (also known as the lactate threshold). Postulated 
by some authors to be the oxygen consumption above which anaerobic energy 
production substantially supplements aerobic energy p oduction. 
Bio-reactance method: A novel, non-invasive, easy to perform method for 
continuous measurement of cardiac output based on the discovery that changes in 
aortic blood volume induce small changes in the frequency of electrical signals 
propagating across the thorax.  
Body surface area: The total surface area of the human body. It is the product of the 
weight in kg times the height in cm divided by 3600. 
Borg scale: A scale which is used for individual to rate their perceived level of 
exertion during exercise.   
Bruce protocol: Treadmill exercise test which is conducted in three minute stages. 
Each 3 minutes the workload is increased by a combination of increasing the speed 
and the grade of the treadmill.  
Cardiac index: A cardiodynamic measure (l.min-1.m2) which is obtained dividing 
cardiac output by the body surface area.    
Cardiac output: The volume of blood (l.min-1) pumped from the heart each minute 
and expressed in units of litters per minute. It is he product of the average stroke 
volume per beat and the heart rate.  
Cardiac pumping capability: The maximum performance of the heart that can be 
achieved during stimulation. 
Cardiac pumping reserve: The difference in cardiac power output between resting 
and maximally stimulated states.  
Cardiac power output: Is a descriptor of overall cardiac function, calculated from 




Circulatory power:  Is the product of systolic arterial pressure and oxygen uptake, 
expresses in mmHg.l .O2
.min-1. 
Cardiac resynchronisation therapy: Cardiac resynchronization therapy (CRT) is a 
proven treatment for selected patients with heart failure-induced conduction 
disturbances and ventricular dyssynchrony. When used in combination with stable, 
optimal medical therapy, CRT is designed to reduce symptoms and improve cardiac 
function by restoring the mechanical sequence of ventricular activation and 
contraction. CRT uses a specialized pacemaker to re-c ordinate the action of the right 
and left ventricles in patients with heart failure. CRT re-coordinates the beating of the 
two ventricles by pacing both ventricles simultaneously. 
Desensitization: Is a method to reduce or eliminate an organism's negative reaction to 
a substance or stimulus. 
Dobutamine: Dobutamine is a direct-acting inotropic agent whose primary activity 
results from stimulation of the β-receptors of the heart while producing less marked 
chronotropic, hypertensive, arrhythmogenic or vasodilatory effects. 
Ejection fraction: Stroke volume divided by end-diastolic volume.  
End-diastolic volume: Is the volume of blood in a ventricle at the end of filling 
(diastole). 
Fat-free mass: The mass (weight) of the body that is not fat, including muscles, bone, 
skin and organs. 
Fibrosis: Is the formation or development of excess fibrous connective tissue in an 
organ or tissue as a reparative or reactive process, as opposed to a formation of 
fibrous tissue as a normal constituent of an organ or tissue. 
Functional residual capacity: Volume of gas in lungs after maximal expiration.  
Heart failure: Is a condition that can result from any structural and functional cardiac 
disorder that impairs the ability of the heart to fill with blood or pump a sufficient 
amount of blood through body.  
Heteroscedasticity: When the amount of error increases as the measurement value 




greatest amount of measurement error). 
Homoscedasticity: When there is no relation between the error and the siz  of the 
measured value.  
Hydraulic power output:  Is a description of the heart’s capability to act s pump          
and maintain circulation.  
Inflammation:  Complex biological response of vascular tissues to harmful stimuli, 
such as pathogens, damaged cells, or irritants. It is a protective attempt by the 
organism to remove the injurious stimuli as well as initiate the healing process for the 
tissue.  
Lean body mass: The sum of the body’s fat-free mass and essential fat. 
Likert scale: A rating scale measuring the strength of agreement towards a set of 
clear statements. 
Oedema: Is observable swelling from fluid accumulation in body tissues. Oedema 
most commonly occurs in the feet and legs, where it is referred to as peripheral 
oedema. 
Oxygen consumption: The amount of oxygen utilized by the body’s metabolic 
processes in a given time, expressed in millilitres or litres per minute, STDP.  
Oxygen pulse: Oxygen uptake (ml.min-1) divided by heart rate (b.min-1) i.e. the 
volume of oxygen consumed per given stroke volume.  
Oxygen uptake: The amount of oxygen extracted from the inspired air in a given 
period of time, expressed in millilitres or litres per minute. This can be differed from 
oxygen consumption under conditions in which oxygen is flowing into or being 
utilized from the body’s stores. In the steady-state, oxygen uptake equals oxygen 
consumption.   
Mass spectrometry: Measurement of fractional concentrations of the comp nents of 
a gaseous mixture on the basis of their mass : charge r tio alone.  
Mean arterial pressure: Is a pressure estimated by the auscultation of the systolic 
and diastolic blood pressure over the brachial artery. It is equal DBP+0.412(SBP-




Minute ventilation:  The volume of the air taken into or exhaled from the body in one 
minute. This is conventionally expressed in litres p r minute. 
Mitral regurgitation:  A valvular heart disease also known as mitral insufficiency, is 
the abnormal leaking of blood through the mitral valve, from the left ventricle into the 
left atrium of the heart. 
Modified Bruce Protocol: Treadmill exercise test which contains two preliminary 
three minute stages of 2.7 kph at 0% incline and 2.7 kph at 5% incline. It is then 
followed by the standard Bruce protocol.   
Myocytolysis: Degenerative change (often reversible) that occurs to myocytes upon 
myocardial strain. This phenomenon tends to occur when neighboring cardiac muscle 
loses its ability to contract (i.e. in ischemia or infarction). The remaining viable 
muscles, as the result, strain to compensate for the loss of other muscles in order to 
deliver the necessary cardiac output. During the process, myocardial cells are 
stretched and stressed to produce new contractile elements. 
Necrosis: A form of traumatic cell death that results from acute cellular injury, 
apoptosis, in general, confers advantages during an organism's life cycle.  
Parameter:  A statistical quantity, such as a mean or standard eviation of a total 
population, that is calculated from data and describes a characteristic of the 
population as opposed to a sample from the population. It is a measurement or value 
on which something else depends. 
Peak cardiac power output: The highest cardiac power output achieved during a 
maximum work rate test.  
Peak oxygen consumption: The highest oxygen consumption achieved during a 
maximum work rate test.  
Postcardiotomy (postpericardiotomy) syndrome: Medical condition which indicate 
a complication that occur after open-heart surgery. The condition is possibly caused 
by and autoimmune process triggered by a virus.  
Power or work rate:  This reflects the rate at which work is performed, . g., work per 
unit of time. It is measured in watts (kg m2/sec3 or joule/sec) or in kilopond meters per 




Pulmonary blood flow: Is the blood flow that perfuses the ventilated part of the 
alveoli. 
Residual volume: Volume of gas in the lungs after maximal inspiration.  
Respiratory exchange ratio: The ratio of carbon dioxide output to oxygen uptake per 
unit of time.  
Stroke volume: The volume of blood ejected from a ventricular in a single beat. 
Stroke work index: A measure of the work by the heart with each contraction, 
adjusted for body surface area; equal to the stroke v lume of the heart multiplied by 
the arterial pressure and divided by body surface area.   
Tidal volume: The amount of air inspired or expired during a normal breathing cycle. 
Ultrasonography (sonography): Is an ultrasound-based diagnostic imaging 
technique used to visualize muscles and internal organs, their size, structures and 
possible pathologies or lesions. 
Ultrasound: Is a sound with a frequency greater the upper limit of human hearing, 
this limit being approximately 20 kilohertz (20,000 hertz).  
V slope method: A technique that allows detection of the onset of lactic acidosis 
during an incremental exercise test when one notes an accelerated rate of carbon 
dioxide output compared to oxygen uptake.  
Variable:  A variable is a quantity whose value may vary over the course of an 
experiment (including simulations), across samples, or during the operation of a 
system. Variables are generally distinct from parameters, although what is a variable 
in one context may be a parameter in another. 
Ventricular compliance: As the ventricle fills with blood, the pressure and volume 
that result from the filling are determined by the compliance of the ventricle. 
Compliance curve is plotted as the change in volume over the change in pressure. The 
slope of the relationship is the reciprocal of the compliance, which is sometimes 
referred as ventricular “stiffness”.    
Ventricular filling pressure: The pressure in the ventricle as it fills with blood.  




injury to the left ventricle.  
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CHAPTER 1: INTRODUCTION 
1.1 Context 
This thesis focuses on metabolic, ventilatory and haemodynamic measurements, 
obtained from a cardiopulmonary exercise test, in healt y adults and patients with 
moderate to severe heart failure. A number of measur ments obtained from a 
cardiopulmonary exercise test have been used to assess functional capacity in a 
healthy population, but also to evaluate responses to medical treatment and exercise 
therapy, to assess progression of disease process, and to determine prognosis in heart 
failure patients (Ingle et al., 2008). Most commonly reported and routinely measured 
cardio-respiratory variables include peak oxygen cosumption, peak carbon dioxide 
production, oxygen consumption at anaerobic threshold, minute ventilation, 
ventilatory efficiency, oxygen pulse, heart rate, and rterial blood pressure. Compared 
with these variables, central haemodynamic measurements such as cardiac output and 
cardiac power output have been less frequently report d within the literature. 
Nonetheless, the importance of the measurement of power- and flow-generating 
capacities of the heart (e.g. cardiac power output and cardiac output) is essential to 
evaluate overall cardiac function and cardiac performance, particularly in heart failure 
patients.  
Currently, it seems that of all the heamodynamic variables in use, cardiac power 
output has the potential to represent the best overall cardiac function and performance 
of the cardiac pump. According to Dr Tan, the main fu ction of the heart is to provide 
hydraulic energy to maintain circulation (Tan, 1986, 1987, 1991). Hydraulic power 
output or cardiac power output is a measure of the heart’s capability to act as a 
mechanical pump (Cotter et al., 2003). The rate of hydraulic energy output is 
calculated from the multiplication of flow- and pressure-generating capacities of the 
heart (e.g. cardiac output and mean arterial blood pressure). Therefore, the maximum 
performance of the cardiac pump, its pumping capability, can be represented by its 
power output during maximal stimulation (Tan, 1986). When the mechanical function 
of the heart deteriorates (e.g. heart failure), the pumping capability of the heart is also 
reduced. A number of studies have shown that cardiac power output is a powerful and 




1990; Roul et al., 1995; Williams et al., 2001; Fincke et al., 2004; Mendoza et al., 
2007; Lim et al., 2008), and therefore may play an important role in risk stratification 
in heart failure.   
A recent review by Mezzani et al. (2008) suggests that central heamodynamic 
measurements (e.g. cardiac output) under exercise in heart failure patients as an 
invasive procedure, has possible risks for the patients. Nonetheless, measurement of 
central haemodynamics is not unimportant, as in the genesis of the heart failure “an 
initial cardiac abnormality is essential” (Clark et al., 1996). With the availability of 
several non-invasive methods today (e.g. CO2 or inert gas or rebreathing, bio-
reactance method, etc.), measurement of cardiac output and cardiac power output 
responses to exercise could become a standard clinical tool for evaluation and 
management of heart failure patients.   
The definition of advanced heart failure, (also called severe, end-stage, refractory 
heart failure) includes symptoms which limit daily activities (New York Heart 
Association III and IV) despite the inclusion of strong pharmacological therapy with 
angiotensin-converting enzyme inhibitors, β-blockers, digoxin and diueretics (Adams 
and Zannad, 1998). Despite advances in the medical management of heart failure the 
only really effective form of therapy for patients with advanced heart failure is cardiac 
transplantation (Yacoub, 2001). Transplantation offers an effective alternative for 
many patients with advanced heart failure, yet the lack of donors still currently limits 
the number of transplantations performed annually natio wide. The success and 
limitations of transplantation have stimulated alternative therapies for patients with 
advanced heart failure.  
Mechanical circulatory support in the form of a left ventricular assist device (LVAD) 
is a viable therapy for severe end-stage heart failure (Frazier, 2002). To date a number 
of clinical trials have shown clear benefits of LVAD in terms of survival and 
improved quality of life. The LVAD is not therefore considered as bridge to cardiac 
transplantation only, but also as destination therapy (Lietz et al., 2007; Rose et al., 
2001) and bridge to recovery (Birks et al., 2006). 




LVAD (Jaski et. 1997). Cardio-pulmonary exercise testing and evaluation of exercise 
capacity is a standardized procedure for heart failure evaluation in most world heart 
transplantation centres. To date, several studies investigated functional capacity using 
a cardiopulmonary exercise test in patients implanted with an LVAD (Murali et al., 
1991; Jaski et al., 1993; Levin et al., 1994; Foray et al., 1996; Mancini et al., 1998; 
Jaski et al., 1999; De Jonge et al., 2001; Maybaum et al., 2007). Surprisingly, cardiac 
power output has not yet been reported in patients implanted with an LVAD and those 
who have had the device explanted following sufficient myocardial recovery.  
Prior to the late 1980s, bed rest and restricted physical activity were recommended for 
all stages and forms of heart failure (Working Group Report, 2001). Research, 
however, over the past 20 years has expanded the understanding and knowledge of the 
role of exercise training in patients with left ventricular dysfunction and heart failure. 
Over time it has become clear that patients with CHF may benefit from exercise 
training so much that it has been recommended by a number of international scientific 
organizations such as the American Heart Association and the European Society of 
Cardiology (Pina et al., 2003; Working  Group Report, 2001). It has been shown that 
exercise training is firstly safe in CHF patients (Smart and Marwick, 2004) and can 
improve peak oxygen consumption (Duscha, 2008; Pinaet al, 2003; Working Group 
Report, 2001), muscle strength and mass (Braith and Beck, 2008), New York Heart 
Association Class (Hambrecht et al., 2000), quality of life (Belardinelli et al., 1999), 
and also reduces hospital admission and mortality rate (Piepoli et al., 2004). Clinical 
evidence suggests that both aerobic and resistance exercise training may improve 
exercise tolerance in patients with chronic heart filure (CHF). Whether the two 
modalities of exercise training (aerobic and resistance) have a similar effect on 
cardiac power output and other cardio-respiratory variables remains unclear.  
1.2 Aims and Objectives for the Thesis 
Over the years, peak oxygen consumption has been used as a “gold” standard among 
other cardiopulmonary exercise measures in heart failure evaluation and prognosis. It 
has, however, several key limitations in the assessm nt of cardiac function. In chronic 
heart failure, peak oxygen consumption can be influe ced by comorbidities and non-




anaemia, abnormal reflex response, and obesity (Fleg and Lakata, 1988; Wilson et al., 
1995). Therefore, peak oxygen consumption should be considered as an indirect 
indicator of cardiac function/dysfunction, particularly in patients with severe heart 
failure and heart transplant candidates.  
By introducing a novel, central heamodynamic measure ch as cardiac power output 
in cardiopulmonary exercise testing procedure at the Harefield Heart Science Centre, 
the present thesis firstly aimed to enable better selection for cardiac transplantation 
and LVAD implantation, potential risk stratification and improvement in clinical 
practice. Currently, there is a lack of evidence to sh w that cardiac power output has 
been evaluated in patients implanted with a LVAD. Secondly, the current work aimed 
to answer the question whether aerobic or resistance exercise intervention have 
similar effect on overall cardiac function represented by cardiac power output in 
patients with stable chronic heart failure. 
The objectives of this thesis were:  
1. To assess the agreement between gas exchange variables measured by the two 
metabolic systems;  
2. To compare CO2 and inert gas rebreathing methods for cardiac output measurement 
at rest and at peak exercise;  
3. To review the existing literature regarding cardi c power output and determine 
future research directions;  
4. To assess the relationship between peak cardiac power output and a number of 
cardio-respiratory variables obtained from cardiopulmonary exercise testing in 
healthy adults;  
5. To evaluate cardiac power output in LVAD-implanted and explanted (recovered) 
patients and severe heart failure patients;  




acute reduction of LVAD support;  
7. To determine the relationship between peak cardiac power output and selected 
cardio-respiratory variables in LVAD implanted and explanted (recovered) patients 
and those with severe heart failure patients;  
8. To investigate reproducibility of cardiac power output and selected cardio-
respiratory variables in patients with stable chronic heart failure;  
9. To assess the effect of aerobic and resistance exercise training on cardiac power 
output and selected cardio-respiratory variables in patients with stable chronic heart 
failure. 
1.3 Structure of the Thesis 
This thesis conforms to the modern style where each chapter represents a self-
contained study which contributes in a coherent manner to the overall aim of the 
thesis (Figure 1.1). Each chapter will take the style of a conventional paper. The final 
chapter is a brief summary written according to thestyle of the British Medical 
Journal. This includes two sections: 1) what is already known of the topic; and 2) 


































Figure 1-1 Outline of PhD  
Chapter 1: Introduction 
Chapter 2: Lack of agreement between gas exchange variables measured by two       
metabolic systems  
Chapter 3: Comparison of cardiac output determined by different rebreathing 
methods at rest and at peak exercise  
Chapter 4: Cardiac power output in healthy and diseased populations: a literature 
review 
Chapter 6: Comparison of cardiac power output and exercise performance in 
patients with left ventricular assist devices, explanted (recovered) patients and 
those with severe heart failure  
Chapter 5: Relationship between peak cardiac power utput and selected cardio-
respiratory variables in healthy adults 
Chapter 10: The effect of aerobic versus resistance exercise training on cardiac 
power output and selected cardio-respiratory variables in patients with stable 
chronic heart failure  
Chapter 9: Reproducibility of cardiac power output and selected cardio-respiratory 
exercise test variables in patients with stable chronic heart failure  
Chapter 8: Relationship between peak cardiac pumping capacity and exercise-
derived prognostic indicators in patients with severe h art failure and those 
implanted and explanted with a left ventricular assist device 
Chapter 7: Resting and exercise haemodynamic and metabolic responses to acute 
reduction of LVAD support: assessment of myocardial recovery 




Chapters two and three were undertaken before starting the main research on the 
topic of cardiac power output. These chapters describe new technological advances in 
regards to gas exchange and heamodynamic measurements duri g a cardiopulmonary 
exercise test. Specifically, Chapter two reports the findings on the agreement 
between gas exchange variables measured by two metabolic systems, one of which 
has recently appeared on the market and does not have published data on its 
performance. Chapter three demonstrates results on non-invasive cardiac output 
measurements by different rebreathing methods at rest but also at peak exercise. Well- 
established carbon-dioxide rebreathing methods were compared with a newly- 
developed inert gas rebreathing method. Chapter four is a review of available 
literature which is related to cardiac power output measured in both healthy and 
diseased populations. The final sections of Chapter four outlines recommendations 
for future work, most of which will be undertaken in the following chapters. Chapter 
five shows the relationship between peak cardiac power output and a number of gas 
exchange variables, routinely measured during cardiopulmonary exercise tests, in a 
cohort of healthy adults. Chapter six compares cardiac power output and exercise 
performance in patients implanted and explanted with an LVAD, and those with 
severe heart failure. For the first time cardiac power output has been evaluated in this 
unique category of patients. Chapter seven demonstrates haemodynamic and 
metabolic responses to acute reduction of LVAD support in patients implanted with 
an LVAD. 
Chapter eight reports the findings of the relationship between peak cardiac power 
output and selected exercise-derived prognostic indicators in heart failure patients in 
patients with severe heart failure and those implanted and explanted with an LVAD. 
Chapter nine illustrates reproducibility of cardiac power output and selected cardio-
respiratory variables in patients with stable chronic heart failure, whereas Chapter 
ten investigates whether different modalities of a 12-week exercise programme (e.g. 
aerobic and resistance) have similar effect on cardiac power output and selected 
cardiorespiratory variables. Finally, Chapter eleven provides a brief, integrated 
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CHAPTER 2: LACK OF AGREEMENT BETWEEN GAS 
EXCHANGE VARIABLES MEASURED BY TWO METABOLIC 
SYSTEMS 
Abstract 
Introduction: Technological advances have contributed to the development of 
portable metabolic systems. A recently-introduced online metabolic measuring system 
(Innocor, Innovision, Denmark) has only limited data vailable on the reliability and 
validity of metabolic measurements. The purpose of this study was to assess the 
consistency and agreement between gas exchange variables measured by the Innocor 
and an alternative online metabolic system (CardiO2, Medical Graphics Corp., St 
Paul, MN, USA) during an incremental exercise test. Methods: After obtaining local 
ethical approval and informed consent, 15 healthy subjects (34±11 years) performed 
an incremental exercise test to volitional fatigue sing the Bruce protocol. The 
Innocor and CardiO2 systems were placed in series, with the Innocor mouthpiece 
attached into the pneumotach of the CardiO2. Metabolic data were analysed during the 
last 30 seconds of each stage and at peak exercise. Results: There were non-
significant differences (p>0.05) between the two systems in estimation of oxygen 
consumption ( 2OV& ) and in minute ventilation (EV& ). Mean Cronbach’s alpha for 
2OV&  and EV&  was 0.94 and 0.92. The Bland-Altman analysis reveal d that limits of 
agreement were -7.17 to 7.18 ml.kg-1.min-1 and -0.52 to 0.55 l.min-1 for 2OV& , and -
8.74 to 10.66 l.min-1 for EV& . Carbon dioxide production ( 2C
O
V& ) and consequently 
respiratory exchange ratio (RER) measured by the Innocor were significantly lower 
(p<0.05) through all stages. At peak exercise the 2C
O
V&  difference of 7.5% was not 
statistically different (p>0.05), while the RER value remained significantly different 
(p<0.05). The CardiO2 measured fraction of expired carbon dioxide (FeCO2) 
significantly higher (p<0.05) through all exercise stages. Conclusion: The differences 
in estimated 2C
O
V&  are due to a systematic overestimation in FeCO2. Although there 
were non significant differences in estimated 2OV&  and measured EV&  between the 
Innocor and the CardiO2, the limits of agreement appear to be wide and unacceptable 




be used interchangeably, as to do so could affect the diagnosis of an individual 
patient.        
2.1 Introduction 
2.1.1 Historical Perspective 
Exercise testing provides a global assessment of the integrative exercise responses 
involving the pulmonary, cardiovascular, neuropsychological, and skeletal muscle 
systems, none of which are adequately reflected by measuring individual system 
functions (Weisman et al., 2003). For over two centuries physiologists have been 
interested in monitoring the respiratory gas exchange of oxygen and carbon dioxide 
during different types of exercise (Macfarlane, 2001). Historically, the first technique 
with considerable advances was made in 1911 in the Oxford School of Respiratory 
Physiology by Douglas. The Douglas bag method today is still considered as a 
criterion method and serves as the “gold standard” for gas exchange measurements 
(Basset et al., 2001). The Douglas bag method is based on open circuit spirometry and 
involves the collection of exhaled air in large, impermeable canvas bags (Consolazio 
et al., 1963). The subsequent measurement of gas fractions of oxygen (FeO2) and 
carbon dioxide (FeCO2) is then performed using chemical methods described y 
Scholander (1947) or Haldane and Priestly (1935). Apart from its accuracy, 
reproducibility and simplicity, the Douglas bag method has several disadvantages and 
its own sources of error (Carter and Jeukendrup, 2002). Firstly, the measurement on a 
breath-by-breath basis is not possible and therefore rapid changes in ventilation (EV& ) 
or oxygen consumption ( 2OV& ) cannot be studied. Secondly, the method is time 
consuming due to requirements for gas collection and its analysis. Also, the bags are 
usually made of a PVC material, which might be slight y permeable to the external air 
(Carter & Jeukendrup, 2002). These factors have little consequence on the gas 
measurement and do not invalidate the Douglas bag method (Hodges, 2005). 
During the 1960s and 1970s, a number of new electroni  devices were introduced 
such as rapidly responding gas analysers and a variety of flow-sensing devices. These 




produced a dedicated metabolic analysis method with online data recording 
(Macfarlane, 2001). Beaver et al. (1973) were the first to develop an online computer 
system for breath-by-breath measurement of alveolar gas exchange. Since that time a 
considerable number of automated systems have been developed, with over a dozen 
manufacturers. 
2.1.2 Recent Metabolic Systems 
Today, the use of automated metabolic gas analysis systems, also called metabolic 
measurement carts, has become common in cardiopulmonary exercise testing 
throughout the world. They have become essential tools for diagnosing 
cardiorespiratory performance, not only in healthy and sporting populations, but also 
in those with different cardiovascular and ventilatory pathophysiological 
abnormalities. Metabolic gas analyser systems have permitted the automated breath-
by-breath measurement of both oxygen consumption (2OV& ) and carbon dioxide 
production ( 2C
O
V& ) measurements (Macfarlane, 2001). Also, some of these systems 
provide noninvasive measurement of the anaerobic threshold (Beaver et al., 1985), 
cardiac output (Vanhess et al., 2000) and respiratory gas exchange kinetics (Whipp 
and Ward, 1990).  
As a new online metabolic analysis system becomes available, information on its 
performance, particularly of its validity and reliab lity is essential. Based on these data 
scientists and clinicians should make decisions about the suitability of the system 
against their own requirements (Hodges, 2004). Automated systems for measuring 
metabolic function during exercise should increase th accuracy, reliability and 
objectivity of such tests (Yeh et al., 1987). However, limited knowledge is available 
about the validity and reliability of the measurements produced by a number of these 
commercially available systems (Carter and Jeukendrup, 2002).     
A few studies have focused on making direct comparisons of new automated systems 
over the past decade (Babineau et al., 1999; Brent and Papadopoulos, 2005; Jackson 
et al., 1983; Jacobs et al., 1999; Maiolo et al., 2003; Melanson et al., 1996; Miles et al. 




eliminate diurnal and day-to-day variations reported by Armstrong and Costill (1985). 
On the other hand, several studies made comparisons between the new automated 
systems and the Douglas bag procedure as a criterion method (Basset et al., 2001; 
Carter and Jukendrup, 2002; Engebretson, 1998; Hodges, 2004; La Mere et al., 1993; 
McLaughlin et al., 2001; Miodownik et al., 2000; Porszasz et al., 1994; Prieur et al., 
1997; Unnithan et al., 1994).  
A recently-introduced online metabolic measuring system (Innocor, Innovision, 
Denmark) has no current published data available on the reliability and validity of 
metabolic measurements during both submaximal and maximal exercise. Reliability is 
an integral part of validity which pertains to the consistency of a measure (Thomas 
and Nelson, 2001). According to Safrit et al. (1989) reliability is defined as the 
consistency of measurements, or of an individual’s performance on a test or the 
absence of measurement error. It has also been suggested that other terms such as 
‘agreement’, ‘concordance’, ‘consistency’, ‘reproducibility’, ‘repeatability’  and 
‘stability’ have been used in the literature interchangeably with ‘reliability’ (Atkinson 
and Nevill, 1998). The purpose of this study was to assess the reliability (consistency 
and agreement) between gas exchange variables measured by the Innocor and an 
alternative online metabolic system (CardiO2, Medical Graphics Corp., St Paul, MN, 
USA) during a standard incremental exercise test. This study examined whether the 
Innocor metabolic system can be used interchangeably with the CardiO2 system 
without affecting the diagnosis of an individual patient. 
2.2 Validity and Reliability of Metabolic Measureme nt 
Systems 
According to Macfarlane (2001) a great number of researchers feel that many fully 
automated systems have become a “black box” which can generate high densities of 
data without the user having sufficient understanding of how the breath-by-breath 
data were generated. This suggests that considerable c re is needed when comparing 
metabolic data obtained from different or even identical automated metabolic 
systems. It is well known that errors in calculation of 2OV&  can be caused by errors in 
measurements of ventilation, the fractions of oxygen and carbon dioxide, as well as 




al., 1995). Gore et al. (1997) stated that the validity and reliability of metabolic 
systems using an integrated or biological approach involving humans is problematic 
as humans are not reliable standards and may not be able to generate sufficiently high 
flow rates (up to 220 l.min-1).  
The reliability of an automated gas analysis system will be influenced by the 
variability of each physiological measure. The total obtained variability is the 
summary of the biological and technical differences (Macfarlane, 2001).  Biological 
variability accounts for about 90% of the total variability, with only 10% or less of the 
variability coming from technical problems. Armstorng and Costil (1985) reported 
day-to-day variability of 2OV&  and EV&  measurements may alter by 4% and 3.6%, 
respectively. 
An electronic literature search was used to identify the validity and reliability studies 
which compared two or more laboratory-based automated metabolic systems. It is 
important to record that the results of the search showed that several papers exist 
(Jacobs et al., 1999; Koh et al., 2005; Maiolo et al., 2003; McLaughlin et al., 2001; 
Melanson et al., 1996; Twaddle et al., 2005; Wideman et al., 1996; Wong and 
Duncan, 2005) which aimed to determine the validity and/or reliability of portable 
telemetric systems. However, the literature review of these systems was beyond the 
scope of this review.        
2.2.1 Validity Studies – Automated Metabolic Analyser System vs. 
“Gold Standard” 
2.2.1.1 Medical Graphics CPX/D system validity studies   
Hodges (2004) assessed the validity and reliability of the CardiO2 (Medical Graphics 
Corp., St Paul, MN, USA) metabolic analyser system compared with a criterion 
method (Douglas bag) using 20 subjects aged 33±11 years. They performed an 
incremental exercise test to volitional fatigue described by Bruce et al. (1973). 
Respiratory gas exchange data were analysed during the last 30 seconds of each stage 




between the CardiO2 and Douglas bag method. Peak 2OV&  and 2C
O
V&  values 
measured by the two systems differed by 6%. These diff rences were significant 
(p<0.05). Peak EV& , FeO2 and FeCO2 values recorded by the two systems were not 
significantly different (p<0.05). Stage by stage analysis revealed a range of 
differences in each of measured variables during the exercise test. The highest 
differences were for 2OV&  (14%) occurring at stage two, 2C
O
V&  (14%) at stage one, 
EV&  (10%) at stages one and four, and FeCO2 (6%) during peak exercise. FeO2 was 
constant through all stages of the exercise test with a maximum difference of 1%. The 
author concluded that the CardiO2 system is valid and reliable in assessment of FeO2 
and FeCO2 across a range of exercise intensities. However, significant error exists in 
the system’s measurement of expiratory flow. The measurement error in the CardiO2 
system may result from software application of the system. Although during peak 
exercise the data for 2OV& , 2C
O
V&  and EV&  were both valid and reliable.  
A study by Engebretson (1998), using 30 subjects aged between 17 to 53 years, 
compared Medical Graphics CPX/D system over a wide range of work rates, 
including maximum values, whilst in series with a conventional Douglas bag system. 
The steady-state values at the end of three minutes ex rcise showed no significant 
differences between the systems in EV&  and 2OV& , but there were significant 
differences (<3.6%) in 2C
O
V&  variation, respiratory exchange ratio (RER), FeO2, and 
FeCO2, which the author noted were within the 4% standard r nge of most metabolic 
systems. Porszasz et al. (1994) focused not only on validating the Pitot tube 
flowmeter from the Medical Graphics system, but also evaluated the system’s validity 
and reproducibility. They performed 23 tests on four participants at rest and during 
exercise. The Medical Graphics CPX/D system produce values for 2OV&  that were 
within 5.9%, whereas 2C
O
V&  was within 3% of the Douglas bag values at rest. 
During exercise, computer 2OV&  averaged of 101.8% and 2C
O
V&  averaged of 100.6 
of the bag values.  However, EV&  produced absolute differences ranging  from +1.1 
l .min-1 at low flow rates to -2.6 l.min-1 at higher flow rates, and were generally within 
the ±2% target range. The authors concluded that the symmetrically disposed Pitot 




valid and reliable.   
Prieur et al. (1998) compared Douglas bag measurements of 2OV&  to those obtained 
with a Medical Graphic CPX/D system (n = 7) during exercise under both normoxic 
and hyperoxic conditions. Using two-way ANOVA and Student’s t-test, these authors 
reported non-significant differences (p>0.05) between two systems either in 2OV& , 
2C
O
V&  or EV& . The authors concluded that the CPX/D system is stable and valid for 
assessing 2OV&  at a moderate hypoxia. However, the tests were from submaximal 
exercise only and did not include maximal efforts. 
Walschlager and colleagues (1996) determined the validity of assessing 2OV& , 
2C
O
V& , and EV&  using two Medical Graphics systems (CPX/D and CPX Express) 
against the Douglas bag method. Fifteen well-trained male runners and cyclists with 
moderate to high exercise capacities, aged from 23 to 40 years, were recruited. 
Subjects performed an incremental exercise test either running or cycling. Differences 
in 2OV& , 2C
O
V& , and EV&  between the traditional and the CPX/D and the CPX 
Express were determined using paired t-tests. Differences between the Douglas bag 
and CPX/D and the CPX Express were for EV& 5.2% and 5.9%, for 2OV&  3.9% and 
2.2%, and for 2C
O
V&  2.6% and 4.9%, respectively. These authors concluded that the 
Medical Graphics systems were valid when compared to the Douglas bag method.   
From the above it can be concluded that the Medical Gr phics automated metabolic 
system provides a valid equipment for measurement of gas exchange and ventilation 
measures.  
2.2.1.2 Validity and repeatability of other metabolic systems  
Carter and Jeukendrup (2002) compared the validity and reliability of three online 
metabolic systems (Oxycon Alpha, Jaeger, Wuerzburg, Germany;  Oxycon Pro, 
Jaeger, Wuerzburg, Germany; and Pulmolab EX670, Morgan Medical, Kent, UK) 




systems produced higher mean values for EV&  compared to the Douglas bag. The 
Pulmolab produced significantly lower mean values for 2OV&  when compared to the 
Douglas bag. No differences for 2OV&  were reported between other systems. Also, no 
differences were reported between any of the systems for total mean 2C
O
V&  and RER 
at lower intensity of exercise (100 W), whilst at higher intensity (150 W) the 
Pulmolab produced significantly higher mean values for 2C
O
V&  and RER. Carter and 
Jeukendrup (2002) concluded that the Oxycon Alpha and Oxycon Pro are valid 
systems for generating accurate respiratory data for 2OV& , 2C
O
V&  and RER  during 
steady state exercise up to 150 W. These findings are supported by Rietjens et al. 
(2001), who found no differences for respiratory variables throughout an incremental 
cycle test between the Oxycon Pro and Douglas bag system. Further, Basset et al. 
(2001) assessed the accuracy of a computerized metabolic system using inspiratoy 
and expiratory methods of measuring ventilation (TrueMax 2400, ParvoMedics, Salt 
Lake City, UT) in eight male subjects aged 27.5±5.6 years. The criterion Douglas bag 
method assessed EV&  and fractions of O2 and CO2 in expired gas (FeO2 and FeCO2) 
for subsequent calculation of 2OV& , 2C
O
V&  and RER. The results of this study 
showed that the close agreement exists between ParvoMedics system and Douglas 
bag method for all of the gas exchange variables. Al o, Unnithan et al. (1994) 
assessed the validity of the Sensormedics S2900Z autom ted metabolic system 
against values recorded from a Douglas bag method in ten active, healthy children 
aged 11.6±2.3 years. The validity was assessed using two different exercise intensities 
either walking or running on a treadmill during physiological steady state. Significant 
differences were found in measurements of 2C
O
V&  (3.6%) and FeCO2  (6.5%) at high 
ventilatory flow. The authors noticed that possible reasons of differences in 2C
O
V&  
are water vapour and mixing capacity of the mixing chamber. The inability of the 
infrared sensors to cope with the water vapour could have contributed to the greater 
variability in 2C
O
V& . Unnithan et al. (1994) concluded that the Sensormedics system 
is valid instrument for gas exchange measurement. However, it is important to add 
that the authors did not state how many measurements f ll within 95% limits of 
agreement. Also, the results showed that positive bas lay marginally outside of the 




The study by Miles et al. (1994) evaluated the reproducibility of four metabolic 
systems (Q-PLEX I/Corival ergometer, Quinton Instrument Co., Seattle, WA; 
SensorMedics 2900/Ergometrics ergometer, SensorMedics Corp., Yorba Linda, CA; 
MGC 2001 Mijnhardt ergometer, Medical Graphics Corp., St. Paul, MN; and MGC 
CPX/Medifit ergometer, Medical Graphics Corp.). Results of this study showed that 
all four system demonstrated excellent reproducibility (<5%) for values obtained 
during either submaximal or maximal exercise. While EV&  and 2OV&  were similar for 
all the systems during light intensity of exercise, the CPX system measured a higher 
2C
O
V&  compared with other systems. Surprisingly, this study reported that the 
average 2OV& peak varied by 22% among the systems. The authors concluded that this 
might be due to differences in the hardware and software used to acquire and process 
the information. Miles et al. (1994) argued that substantial differences in data were 
due to gas analyser transport delay, different indiv dual analyser times (dynamic 
response) and inherent noise in the respiratory signals. It was suggested that each 
manufacturer should describe clearly the way in which the basis measurements of 
oxygen and carbon dioxide concentration as well as ventilation are calculated to 
produce 2OV& , 2C
O
V&  and EV& . Also, La Mere at al. (1993) examined the 
reproducibility of a single maximal test on three mtabolic systems (Quinton QPLEX 
I, Quinton Instrument Co., Seattle, WA, USA; Sensor Medics 2900, Sensor Medics, 
Yorba Linda, CA, USA; and the Medical Graphics 2001, Medical Graphics Co., St. 
Paul, MN, USA). Each of three metabolic analyser system was independently 
compared with the Douglas Bag method. This study report d small but significant 
mean differences in peak 2OV&  between systems, with the QPLEX and the Medical 
Graphics systems tending to overestimate  2OV&  peak compared to the Douglas bag 
method. The Sensor Medics system tended to underestimate EV&  by 2.8 l
.min-1 while 
the Medical Graphics system overestimated EV&  by 3.1 l
.min-1. There was significant 
difference between the Sensor Medics and Medical Grphics systems and a non-
significant difference between the QPLEX and the Medical Graphics systems. Despite 
the statistical significance of the differing measurements the authors considered their 
practical significance small enough to be acceptable. Further, Jackson and colleagues 




exercise system. This system was compared to an estblished component refereed 
system (Applied Electrochemistry O2 analyser, Beckman LB-2 CO2 analyser, and 
Parkinson-Cowab CD-4 gasometer) during simultaneous measurements of oxygen 
consumption. Two systems were placed in series. The results showed that the 
reliability estimated from both systems were extremely high, exceeding 0.981. The 
authors concluded that 2OV&  measured by the Gould system was highly reliable and 
reproduced the measurements obtained by the refereed system. Additionally, 
Miodownik et al. (2000) developed a semi-automated gas exchange measurement 
system based on a Douglas bag design. This system was validated using a modified 
version of the quantitative funnel burner lung model and standard water volume 
displacement. The validated system was further compared to the SensorMedics 
Deltatrac (mixing chamber Yorba Linda, California, USA) and Medical Graphics 
CPX (breath-by-breath) systems (Medical Graphics Corp., St. Paul, MN, USA). The 
Sensor Medics Deltatrac average 2OV&  and 2C
O
V&  error was 11.4% and 2.1%. The 
Med Graphics CPX average 2OV&  and 2C
O
V&  error was 2.6% and 1.7%, respectively. 
The Deltatrac and CPX systems both tended to increase 2OV&  errors as FIO2 was 
increased. There was no significant difference in 2C
O
V&  measurements for all 
devices. Miodownik et al. (2000) further suggested that the increasing inaccuracy of 
the automated systems was traced to the limitations of their flow measuring devices.  
A study by Babineau et al. (1999) reported differences from 5 to 10 ml.kg.min-1 (10-
17%) between three metabolic systems in the absolute and relative values of 
2OV& max and in the volume of expired gas for submaximal and maximal work, 
respectively. Furthermore, Hodges (2004) cited the study by Hiilloskorpi et al. (2000) 
which reported a significant difference between 6% and 22% in 2OV& max between 
three metabolic analyser systems. 
From previous cited studies it is clear that the results from different brands of 
automated metabolic systems can vary by surprisingly significant amounts. These 
variations have commonly been explained in the literature with following reasons 
(Miles et al., 1994): 1) differences in hardware and software used to acquire and 
process the information; 2) presence of the water vapour in the analyser which can 




important influence on the accurate calculation of 2OV&  (Beaver et al., 1973; and 
Cole, 1954); 3) substantial differences in data reduction which will occur due to 
correction for the varying alveolar oxygen concentration retained in the lung between 
breaths of different length and gas analyser transport delay; 4) temporal alignment of 
gas flow; 5) accuracy and reproducibility of flow and gas fraction measurements 
(Noguchi et al., 1982) 6) different individual analyser rise times (dynamic response), 
inherent noise in the respiratory signals, interpolating data between known points, and 
smoothing the record , such as with a five point moving average (Beaver et al., 1973).    
Hodges (2004) suggested that probably the greatest problem in metabolic gas analysis 
systems today is the exact temporal alignment of gas flow with gas analysis. 
According to Proctor et al. (1996) the delay time between gas flow and gas analysis 
can cause an error in 2OV&  measurements of up to 30% at high breathing frequencies. 
Furthermore, Hodges (2004) suggested standardisation of the procedure when 
comparing two or more systems in the following aspects: 1) type of exercise protocol 
(e.g. step vs. ramp); 2) type of exercise (e.g. treadmill vs. cycle); 3) manner in which 
systems are compared (e.g. in series, in parallel or repeated measures); 4) timing of 
measurements (e.g. mid-stage, last minute of each st ge, etc.); 5) acceptable limits for 
gas exchange measurements; and 6) the way in which data are treated for statistical 
analysis.    
2.2.2 Acceptable Level of Accuracy 
It has been suggested that respiratory volumes should be accurate within ±2% or 
within ±50 ml (Macfarlane et al., 2001). For the overall measurement of 2OV& , an 
early suggestion was that repeated Douglas bag measures hould be within ±4% 
(Wagner et al., 1973). Davies et al. (1974) considere  a much higher level of 
agreement of ±10% to be acceptable. Thoden (1991) suggested a precision of less 
than ±1 ml.kg-1.min-1 over repeated tests, but acknowledged that ±2 ml.kg-1.min-1 was 
a more realistic day-to-day variation, and that over a period of a week the same 
individual should be within ±3 ml.kg-1.min-1. Skinner et al. (1999) recommended that 
the CV using an automated system should be within 4-9%. Further, Babineau et al. 




2OV&  determination or 2-3 ml
.kg-1.min-1. Differences varying from 3% to 10% can be 
found in the literature (Hodges, 2005). 
Thus for the purposes of this study, a value of 4% will be considered to lie within the 
acceptable range. The limits of agreement of ±1.2 l.min-1 for minute ventilation and 
±0.15 l.min-1 for oxygen consumption will be acceptable, as suggested by Basset et al. 
(2001).                 
2.2.3 Rationale and Purposes of the Study 
The Innocor (Innovision, Denmark) is a new commercial automated metabolic system 
which has been primarily developed to measure non-ivasively cardiac output at rest 
and during exercise. However, the manufacturer has also produced a breath-by-breath 
module which allows measurements of 2OV& , 2C
O
V& , and EV&  interactively with 
haemodynamic data. Before purchasing the Innocor automated metabolic system, it 
was considered prudent to evaluate its agreement with existing metabolic system.  
Currently, there is no published information concering both the validity and 
reliability of the Innocor metabolic measurements. There are, however, such data on 
the CardiO2 (Medical Graphics Corp., St Paul, MN, USA). Thus, the purpose of this 
study was to assess consistency and agreement between gas exchange variables 
measured by the Innocor and the CardiO2 during an incremental exercise test. 
The Innocor system should be used in later studies for testing people with heart 
failure. It was reasonable to establish its consistency and agreement by comparing 
with the CardiO2 system before proceeding to the following stage. This study 
examined whether the Innocor metabolic system can be used interchangeably with the 
CardiO2 system without affecting the diagnosis of an individual patient. 
2.2.4 Research Hypotheses 
H1 – There will be a non-significant difference between gas exchange variables 
measured by the two metabolic systems. 




the two metabolic systems. 
H3 – There will be acceptable levels of agreement betwe n gas exchange variables 
measured by the two metabolic systems.    
2.3 Methods 
2.3.1 Subjects 
Fifteen healthy adults (ten males and five females), staff and students of a South East 
UK University gave their signed informed consent to participate in this investigation. 
Subjects were recruited by personal contact. None of the subjects were taking any 
medications that might interfere with physiological responses and none had any 
limitations to strenuous exercise as determined by a standard physical activity 
readiness questionare (PAR-Q) adapted from Thomas and Nelson (2001). Subjects 
reported that they were active (e.g. walking, running, swimming, cycling, and weight 
lifting approximately 2-3 times per week). However, none were engaged in regular 
structured training programme. All subjects were familiar with graded exercise 
testing. Subjects were asked to refrain from eating for a minimum of 2 h prior to the 
test and from vigorous exercise on the day of and the day before the test. All 
procedures were in accord with the local research guidelines as approved by the 
Faculty ethics committee and the declaration of Helsinki. 
2.3.2 Equipment 
2.3.2.1 Innocor system design 
The Innocor (Innovision, Odense, Denmark) is a compact device intended to be used 
for non-invasive measurement of cardiac output using a  inert gas (N2O) rebreathing 
methodology. It incorporates a breath-by-breath module to measure gas exchange 
variables (e.g. fractions of expired O2 and CO2 (FeO2 and FeCO2), minute ventilation 
( EV& )) and to calculate a number of derived variables (.g oxygen consumption 
( 2OV& ), carbon dioxide production ( 2C
O




functionality with the breath-by-breath option, the Innocor is still a compact device. 
The total weight of the instrument is less than 10 kg (Figure 2.1). 
   
                                                                                                                    
Figure 2-1 Inncoor metabolic gas analyser.  
Subjects are connected to the Innocor by a disposable ru ber mouthpiece, attached 
directly to the respiratory valve unit (RVU). The RVU is connected to the Innocor via 
a 6 tube connector for controlling the pneumatic valves, bag filling and evacuation, 
and a tube for measuring the mouth piece pressure.  Th  gas sample line and airflow 
umbilical are also connected to the RVU. Gas data analysis is performed and results 
presented by the Innocor software (version 5.05). Monitoring and presentation of the 
data is via the Innocor integrated computer with a Pentium MMX and Windows NT / 
XP embedded operating system. Measurement of airflow is performed by a pressure 
difference pneumotach. CO2 gas analysis is performed by the photo acoustic gas 
analyser which uses the principle of Photo Acoustic Spectroscopy (PAS). Oxygen is 
analysed using an oxygen sensor (Oxigraf Inc., USA) based on the principle of laser 
diode absorption spectroscopy. Only the oxygen sensor eeds 1-point calibration on a 
regular basis by the user while both oxygen sensor and photoacoustic gas analyser 
require multi-point calibration performed by manufacturer periodically (6-12 months).  
The manufacturer reported accuracy for measurements of ventilation ±1%, while for 
O2 and CO2 concentrations ±0.01%.  




provided in detail in Appendix II.1.  
2.3.2.2 Medical Graphics CardiO2 system design 
The CardiO2 (Medical Graphics Corp., St Paul, MN, USA) is an automated breath-by-
breath respiratory gas analysis system with integrad 12-lead stress ECG diagnostic 
exercise testing system (Cardio Perfect ST 2001, Cardio Control, Delft, Netherlands). 
Together with other computerised metabolic systems, the CardiO2 measures volume, 
flow and gas fractions. It provides the advantage of a single, light weight, sample line 
and pressure transducer umbilical. Subjects performed the exercise test using a motor 
driven treadmill. Subjects are connected to the metabolic cart by means of a 
disposable rubber mouthpiece, attached directly to the flowmeter, to which the gas 
sample line and airflow umbilical were connected. Gas analysis is performed and 
results presented by the BreezeSuite (version 5.0) gas exchange testing software 
(Medical Graphics Corporation, St. Paul, Minnesota, USA). The software presents 
respiratory data as 30-second means. Monitoring and presentation of the data is via a 
personal computer (Dell Precision 340 Pentium 4, Dell Computer Corporation, Texas, 
USA). Gas analysis is performed by means of Zirconia electrochemical (O2) and 
infrared (CO2) analysers. Airflow is measured by means of a pitot tube flowmeter. 
This operates by incorporating prevent bi-directional differential pressure. The 
manufacturer of the CardiO2 reported accuracy for measurement of ventilation ±3% 
or 50 ml, while for O2 and CO2 concentrations ±0.03%. 
Characteristics of CardiO2 measurement of airflow, gas sampling, carbon dioxie and 
oxygen detection is provided in detail in Appendix II.2.   
2.3.3 Procedure 
2.3.3.1 Calibration 
Both systems were calibrated before each exercise te t according to manufacturer 
recommendations. The gas mixtures used for the CardiO2 calibration were 5% CO2 , 
12% O2 in balanced N2 (calibration gas) and 21% O2 in balanced N2 (references gas). 




performed by user) and O2 adjustment to the ambient air prior to the test. In order to 
obtain simultaneous measurements the two systems were placed in series and 
subsequently calibrated according to the manufacturers’ ecommendations before the 
exercise test. The volume calibration was performed using a certified volume syringe 
(MedGraphics, St Paul, Minn) of 3 litres following the two systems were placed in 
series. The Innocor respiratory valve unit, with bacterial filter, was attached into the 
pneumotach of the CardiO2 system using a five cm flexible tube. Both systems were 
attached to the subject’s face mask, where the pneumotach of the CardiO2 system was 
closer to the subject’s mouth and the Innocor respiatory valve unit was 10 cm from 
the subject’s mouth (see Figure 2.2). Such configuration increased dead space and the 
distance between the subject’s mouth and the Innocor gas sensors.  
 
Figure 2-2  Pictorial description of the installation of the two systems 
a) face mask, b) CardiO2 pneumotach with flow sensor and gas sample line, c) 
flexible tube, d) Innocor respiratory valve unit with bacterial filter, flow sensor and 












2.3.3.2 Pre-test procedure 
Following calibration the Innocor respiratory valve unit together with the CardiO2 
pneumotachometer were attached to the Innocor support arm above the front side of 
the treadmill. Age, height and weight were obtained b fore exercise testing. Weight 
was measured using a Secca scale and height was measured on a wall-mounted 
stadiometer. All subjects were instructed on the use of Borg 6-20 Rating of Perceived 
Exertion (RPE) scale to ascertain their perception of effort during each test.  
2.3.3.3 Testing procedure 
All tests were performed by an incremental exercise test to volitional fatigue on a 
motor driven treadmill (Cardio Control, Delft, Nethrlands) using the protocol 
described by Bruce and colleagues (1973). The Bruce protocol begins with 3-minute 
stages of walking at 1.7 mph and 10% gradient. Thereafter, the grade is incremented 
2% every 3 minutes, and the speed is incremented 0.8 mph every 3 minutes until the 
treadmill reaches 18% grade and 5 mph. After this, e speed is increased by 0.5 mph 
every 3 minutes. During the test, expiratory gas waanalysed repeatedly using both 
the Innocor and CardiO2 systems, sampled on a breath by breath basis. Metabolic data 
were analysed during the last 30 seconds of each stge and at peak exercise.   
2.3.4 Statistical Analysis 
All statistical analysis was performed using SPSS version 13.0 (SPSS Inc., Chicago, 
IL, USA). Prior to the statistical analyses all data were screened for univariate and 
multivariate outliers using Z-scores and Mahanolobis d stance test. In order to 
determine differences between the Innocor and CardiO2 system, a t-test for paired 
samples or Wilcoxon signed rank test were used. Statistic l significance was indicated 
if p<0.05. Bland-Altman plots (Bland and Altman, 1986) were constructed to assess 
agreement between gas exchange variables measured by the Innocor and CardiO2 
system. Cronbach’s alpha (Cronbach, 1951) was calculated to demonstrate 
consistency in individual measure between the two systems. Values are expressed as 





Subjects were aged 34±11 years; height, 173±11.2 cm; weight, 70.7±12.7 kg. All 15 
subjects completed the first three stages of the Bruce protocol. Twelve subjects 
completed stage four and finished the test during sta e five, while only three subjects 
completed the stage five and entered stage six before terminating the test. The three 
sets of results from the end of the stage five were not included for comparison due to 
the small sample size. Table 2.1 illustrates the peak values measured by the Innocor 
and the CardiO2 metabolic systems.  
 
Table 2.1 Differences in Measured Gas Exchange Variables at Pe k Exercise of Bruce 
Protocol between Innocor and CardiO2 (N=15) – Paired samples t-test (t) and 
Wilcoxon signed rank test (z)  






   t     z   p 
  Cronbach’s  
     Alpha 
FeO2 (%) 17.29±0.54 17.31±0.52 -0.16    - 0.87      0.78 
FeCO2 (%)  3.69±0.59 3.97±0.39 -1.71    - 0.11      0.35 
2OV&  (ml.kg-1.min-1) 39.63±10.34 39.69±8.33 -0.04    - 0.97      0.89 
2OV&  (l.min-1) 2.88±1.02 2.83±0.80 0.49    - 0.63      0.95 
EV&  (l.min-1) 79.62±28.72 81.31±32.76 -0.61    - 0.56      0.97 
2C
O
V&  (l.min-1) 2.95±1.14 3.19±1.21 -1.40    - 0.19      0.91 
RER 1.02±0.13 1.11±0.14* - 2.07 0.04      0.53 
FeO2 - fraction of expired oxygen; FeCO2 - fraction of expired carbon dioxide; 2OV& - 
oxygen uptake; EV&  - minute ventilation; 2C
O
V&  - carbon dioxide production; RER - 
respiratory exchange ratio; * = Indicates the Innocor result is significantly different 
from the CardiO2 system (p<0.05).    
At peak exercise the Innocor measured FeO2 quivalent to the CardiO2 system, with 
non significant difference. Mean peak 2OV&  in both relative (ml
.kg-1.min-1) and 




2%, respectively. EV&  at peak exercise measured by the Innocor was slightly 
underestimated (by 2%) compared with the CardiO2 system. FeCO2 measured by the 
Innocor at peak exercise was lower by 7% compared with the CardiO2 system, while 
2C
O
V&  and RER were lower by 7.5% and 8%. RER difference was the only 
significant (p<0.05) measure. Cronbach’s alpha showed that at peak exercise all 
variables except FeCO2 and RER have acceptable or high consistency.     
Stage by stage analysis revealed a range of differenc s in measured variables 
(Appendix I). Figures 2.3 to 2.9 show the results for respiratory variables measured by 
the Innocor and CardiO2 systems through all exercise stages.  
For FeO2 and 2OV&  the differences between the two systems ranged from 2% - 7%, 
dependant on the stage. The difference of 5% in measur d FeO2 was significant at 
stage one (p<0.05) (Figure 2.3). Estimated 2OV&  in relative and absolute units was not 
significantly different (Figures 2.5 and 2.6). Cronbach’s alpha ranged from 0.80 to 
0.99, with an average of 0.88 for relative 2OV& , and from 0.93 to 0.95 with an average 
of 0.94 while for absolute 2OV&  (Appendix I). 
FeCO2, 2C
O
V& and RER measured by the Innocor were significantly lower compared 
with CardiO2 (Figures 2.4, 2.7 and 2.9). The differences for FeCO2 ranged from 12% 
- 20%, while for 2C
O
V& and RER from 9% - 22% and 8% - 15%. Cronbach’s alpha 
ranged from 0.20 to 0.77 for FeCO2 , 0.84 to 0.94 for 2C
O
V&  and 0.22 to 0.61 for 
RER. 
EV&  measurements recorded by the Innocor were higher compared with CardiO2 
throughout all exercise stages, but these differences were not significant (Figure 2.8) 
and ranged from 2% - 7%. Cronbach’s alpha for measur d EV&  ranged from 0.84 to 
0.98, with an average of 0.92.     










 Figure 2-3                                                                   Figure 2-4       
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  Figure 2-9 
  
Bland-Altman analysis which included data from the end of each exercise stage and 
from peak exercise showed that the Innocor reported higher VE values by a mean 
value of 0.96 l.min-1 compared with the CardiO2 and the limits of agreement of -8.74 






























Figure 2-10 Bland-Altman plot to demonstrate limits of agreement shown by the two 
metabolic systems in measuring EV& . The solid line is at the bias (mean of the 
difference) and the dashed lines represent lower and upper limits of agreement (±2SD 
of the mean difference). 
  
Mean difference between the two systems in estimated 2OV&  in relative and absolute 
units were 0.02 ml.kg-1.min-1 and 0.04 l.min-1 and the limits of agreement were -7.15 
to 7.18 ml.kg-1.min-1 and – 0.52 to 0.55 l.min-1 (Figures 2.11 and 2.12).     
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Figures 2.3 – 2.9 Differences in 
means of gas exchange variables 
between the Innocor and CardiO2 
systems through four exercise 
stages of Bruce protocol. 
*indicates significant difference 




































Figure 2-11 Bland-Altman plot to demonstrate limits of agreement shown by the two 
metabolic systems in measuring relative 2OV& . The solid line is at the bias and the 




























Figure 2-12 Bland-Altman plot to demonstrate limits of agreement shown by the two 
metabolic systems in measuring absolute 2OV& . The solid line is at the bias and the 
dashed lines represent lower and upper limits of agreement. 
 
Figure 2.13 shows that systematic bias exists between the two systems in estimation 
of 2C
O
V&  through different stages of exercise. 2C
O
V&  was underestimated by a mean 




































Figure 2-13 Bland-Altman plot to demonstrate limits of agreement shown by the two 
metabolic systems in measuring 2C
O
V& . The solid line is at the bias and the dashed 
lines represent lower and upper limits of agreement.   
 
Bland-Altman analysis also revealed that a mean difference in measured FeO2 
between the two systems was -0.19 % and the limits of agreement were -1.77 to 1.38 
%. For FeCO2 mean difference between the two systems was -0.59 % with upper and 
lower limits of agreement of -1.87 and 0.70 %.  
2.5 Discussion 
The purpose of this study was to assess the reliability (consistency and agreement) 
between gas exchange variables measured by the Innocor and the CardiO2 during an 
incremental exercise test.  
The results of this study demonstrated that the Innocor metabolic system yielded 
mean 2OV& , in both absolute and relative values, that were close to those obtained by 
the CardiO2 system, with non significant differences. Apart from stage one, measured 
FeO2 was also non significant between the two systems.  
As suggested, the Cronbach’s alpha coefficient should be used to indicate a degree of 




recommended that the Cronbach’s alpha should be a minimum of 0.90, and 0.95 to be 
desirable for clinical application. Based on this as umption it may be suggested that 
the Innocor and the CardiO2 showed high consistency in measured EV&  and 
derived 2OV& .  
The present 2OV&  values compare favourable with finding by Engebretson (1998) 
who reported difference less than 3.6% in measured 2OV&  between the Medical 
Graphics CPX/D system and the Douglas bag. Furthermore Porszasz et al. (1994) 
found that Medical Graphics CPX/D produced values of 2OV&  that were within 5.9% 
compared to the Douglas bag, while Walschlager et al. (1996) demonstrated 
differences of 3.9% and 2.2% in measured 2OV&  between the CPX/D and the CPX 
Express compared with the gold standard.  In contrast Hodges (2004) reported that 
2OV&  in both absolute and relative values was significantly (p<0.05) underestimated 
(up to 14%) by the CardiO2 compared with the Douglas bag during all exercise stages 
as well as at peak exercise. However, following recommendation of the manufacturer 
and installation of the drying cartridge, Hodges (2004) suggested that difference 
would decrease by 5%. The author concluded that the CardiO2 is a valid system for 
measuring respiratory variables.  
Bland-Altman plots also revealed that there was no systematic bias in reported 2OV&  
in both absolute and relative units between the Innocor and CardiO2. This can be 
recognised by the mean of the difference being centred closely to zero. However, the 
limits of agreement for 2OV&  were large and seem to be unacceptable in exercise 
testing. Furthermore this study demonstrates that even a high Cronbach’s alpha 
coefficient must be taken with caution when examining consistency between two 
measurements. Hence when reporting statistical results, it is important to consider 
practical and clinical implications of the results before making conclusions and 
further recommendations.  
It may be noticed that the Innocor measured EV&  slightly, but not significantly higher 




alpha indicated high conistency in measured EV&  between the two systems, whilst the 
Bland-Altman analysis revealed no systematic bias. However, the limits of agreement 
were wide (-8.74 to 10.66 l.min-1) and this is also unacceptable in exercise testing.  
A study by Miles et al. (1994) demonstrated that the Medical Graphics CPX 
automated system produced the lowest EV& measurement among four different 
metabolic systems. Furthermore, Hodges (2004) report d that EV&  measured by 
CardiO2 system was significantly (p<0.05) underestimated through all exercise stages 
compared with the Douglas bag (up to 10%). Also, Walschlager et al. (1996) found 
that the Medical Graphics CPX Express and CPX/D underestimated EV&  by 5.9 and 
5.2 % compared with the Douglas bag, while Engebretson (1998) showed no 
significant differences between the Medical Graphics CPX/D and the gold standard in 
EV&  measurements. Only one study by La Mere at al. (1993) illustrated that the 
Medical Graphics 2001 system overestimated EV&  by 3.1 l
.min-1 compared with the 
gold standard.      
Although both the Innocor and CardiO2 systems use the principle of differential 
pressure for measurement of airflow, one of the potential sources of error is the 
method and equation used to estimate the BTPS factor (H dges, 2004). When a 
subject exhales during a cardiopulmonary exercise te t, he air leaves the lungs and 
enters the spirometer at 33-35°C (Cole, 1954) and is saturated with water vapour 
(Beaver et al., 1973). Most volume type spirometers assume instantaneous cooling of 
the air as it enters the spirometer, although errors can occur due to incorrect 
assumptions of instantaneous cooling of the air (Hodges, 2004). Depending on the 
environmental temperature, the BTPS correction factor ould be as large as 10% 
(Crapo, 1994). Further, the distance between the flow sensor and the mouth may be 
another potential source of error (Hodges, 2004). As stated earlier, the two systems 
were placed in series where the CardiO2 pneumotach was inserted into the face mask. 
Than the Innocor respiratory valve unit with a bacterial filter was attached into the 
CardiO2 pneumotach using a flexible tube. This made the distance between the 
Innocor respiratory valve unit and subject’s mouth of 10 cm. However, it is important 




possible due to equipment design. Additionally, slight overestimation of EV&  may be 
due to the presence of water vapour in the analysers, temporal alignment of a gas flow 
or analyser rise time (dynamic response) as suggested by Beaver et al. (1973).             
2C
O
V&  values reported by the Innocor were significantly lower than those by the 
CardiO2.  These differences were due to a systematic underestimation of FeCO2. 
Although the Innocor measured EV&  slightly higher during all exercise stages, this was 




Miodownik et al. (2000), when comparing a newly developed semi-automated 
metabolic system based on a Douglas bag design and the Med Graphics CPX, 
reported a non significant difference of 1.5% in 2C
O
V& . Unnithan et al. (1994) 
assessed the validity of the Sensormedics automated metabolic system against the 
Douglas bag method and found out that measured 2C
O
V&  was significantly different 
by 3.6% at high ventilatory flow. 2C
O
V&  measured by the Truemax 2400 metaboic 
system was in close agreement with values obtained by the Douglas bag method 
(Basset et al., 2001). When compared with the Douglas bag method, the Med 
Graphics CPX Express and CPX/D systems underestimated 2C
O
V&  by 4.9% and 
2.9% (Walschlager et al., 1996). In agreement with this finding Hodges, (2004) 
reported that the CardiO2 system produced a lower 2C
O
V&  in range of 6% to 14%, 
while Engebretson (1998) also noted significant differences in 2C
O
V&  and RER 
measured by the Medical Graphics system. By contrast, few studies reported no 
significant differences in measured 2C
O
V&  between the Medical Graphics systems 
and the Douglas bag method (Porszasz et al., 1994; Prieur et al., 1998). Miles et al. 
(1994) reported that the Medical Graphics CPX system measured a higher 2C
O
V&  
compared with three other metabolic systems.   
Apart from increased dead space and the distance between the Innocor sensors and the 
subject’s mouth, differences in measured FeCO2 may be explained by the 




developed portable multigas analyser which uses the principle of photoacoustic 
spectroscopy with an infrared spectrum. In contrast, the CardiO2 uses a standard 
infrared carbon dioxide analyser. Furthermore reported differences may be due to 
differences in the software used to acquire and process the information.  These 
technological differences may contribute to the poor consistency in measured FeCO2 
and derived 2C
O
V&  and RER between the two systems. An additional problem is that 
of correcting water vapour pressure in the expired air, as this pressure may be quite 
different to that in the calibration gas (Davies et al., 1974). Although mass 
spectrometers can be adjusted automatically to ignore the contribution of water 
vapour (effectively measuring dry air), most CO2 analysers are sensitive to the 
presence of water vapour (Macfarlane, 2001). Ignoring the effects of water vapour 
pressure can lead to errors of up to 25% (Beaver et al., 1973). The inability of the 
infrared sensors to cope with the water vapour could have contributed to the greater 
differences in FeCO2. Furthermore, as the dead space was increased, this could 
potentially enhance higher water condensation, and possibly affect CO2 analyser and 
measurement of FeCO2.  
In summary, although the Innocor yielded similar mean values of 2OV&  and EV&  to 
those obtained by the CardiO2 system, it has been shown that they were not within 
acceptable levels of agreement. Furthermore 2C
O
V&  and RER were systematically 
underestimated over a wide range of exercise intensiti s due to lower FeCO2 
measurements. From this study it is difficult to say which metabolic systems measures 
more precisely. However, it may to suggested that tese two systems cannot be used 
interchangeably on the same patient without affecting he diagnosis of an individual 
patient.  
2.5.1 Study limitations 
The same order of equipment was followed during all performed tests, where the 
Innocor’s sample points were 10 cm far from subject’s mouth. Increased the distance 
and possibly increased water condensation could effect CO2 sensors and lead to the 
systematic error. However reversing the order of systems was not possible due to the 




Furthermore the Innocor respiratory valve unit, with a bacterial f lter, was attached 
into the flow meter of the CardiO2 system using a five centimetres long flexible tube. 
This bacterial filter could increase the resistance to airflow during exercise and 
consequently increase the subject’s discomfort with an effect of terminating the 
exercise test earlier.  
2.6 Conclusion 
The proper interpretation of exercise test data depends on accurate data collection and 
correct calculations. The use of automated metabolic gas analysis systems has become 
common in cardiorespiratory exercise testing today. As a new online metabolic 
analysis system becomes available, information on its performance is essential. 
Therefore scientists and clinicians can make decision about suitability of the systems 
for their own requirements. 
The design of this study allowed direct comparison between a recently introduced 
automated metabolic gas analysis system (Innocor, Innovision, Denmark) and the 
CardiO2 (Medical Graphics Corp., St Paul, MN, USA) during exercise . The results of 
this study revealed that the Innocor produces very similar mean values of 2OV&  and 
EV&  to those obtained from the CardiO2 system. However, the Bland-Altman analysis 
revealed that limits of agreement for 2OV&  and EV&  were wide, and therefore not 
acceptable in cardio-pulmonary exercise testing. 
The data from the present study suggest that significa t difference exists in the 
systems’ estimation of 2C
O
V&  and RER. This discrepancy is due to FeCO2 which was 
measured systematically higher by the CardiO2.    
It may be concluded that that the Innocor and the CardiO2 metabolic systems cannot 
be used interchangeably, as to do so could affect the diagnosis of an individual 
patient. Results from the present study support previous suggestion that considerable 
care is needed when comparing metabolic data obtained from different automated 






Armstrong, L. E., Costill, D. L. (1985) Variability of respiration and metabolism: 
responses to sub maximal cycling and running, Research Quarterly for 
Exercise and Sport, 56, 93-96. 
Atkinson, G., Nevill, A. M. (1998) Statistical methods for assessing measurement 
error (reliability) in variables relevant to sports medicine, Sports Medicine, 26, 
217-238. 
Babineau, C., Leger, L., Long, A., Laurent, B. (1999) Variability of maximum oxygen 
consumption measurement in various metabolic systems, Journal of Strength 
and Conditioning Research, 13, 318-324. 
Basset, D., Howley, E., Thompson, D., King, G., Strath, S., McLaughlin, J., Parr, B. 
(2001) Validity of inspiratory and expiratory methods of measuring gas 
exchange with a computerized system, Journal of Applied Physiology, 91, 
218-224. 
Beaver, W. L., Wasserman, K., Whipp, B. J. (1973) On-line computer analysis and 
breath-by-breath graphical display of exercise functio  tests, Journal of 
Applied Physiology, 34, 128-132. 
Beaver, W. L., Wasserman, K., Whipp, B. J. (1985) Improved detection of lactate 
treshold during exercise using a log-log transformation, Journal of Applied 
Physiology, 59, 1936-1940. 
Bland, M. J., Altman, D. G. (1986) Statistical methods for assessing agreement 
between two methods of clinical measurements, Lancet, 1, 307-310. 
Bland, M. J., Altman, D. G. (1997) Statistics notes: Cronbach's alpha, British Medical 
Journal, 314, 572. 
Brent, T. J., Papadopoulos, C. (2005) Assessment of the Kb1-c portable metabolic 
measurement system during submaximal cycle and treadmill exercise, 
Medicine and Science in Sports and Exercise, 37, S25-S26. 
Bruce, R. A., Kusumi, F., Hosmer, D. (1973) Maximal oxygen intake and 
nomographic assessment of functional aerobic impairment in cardiovascular 
desease, American Heart Journal, 85, 546-542. 
Carter, J., Jeukendrup, A. E. (2002) Validity and reliability of three commercially 
available breath-by-breath respiratory systems, European Journal of Applied 




Cole, P. (1954) Recording of respiratory air temperature, Journal of Laryngology, 68, 
295-307. 
Consolazio, C. F., Johnson, R. E., Pecora, L. J. (1963) Physiological measurements of 
metabolic function in man, McGraw-Hill, New-York. 
Crapo, R. O. (1994) Standardisaton of spirometry. Medical section of the lung 
Association, American Journal of Respiratory Care, 152, 1107-1136. 
Cronbach, L. J. (1951) Coefficient alpha and the internal structure of tests, 
Psychometrika, 16, 297-334. 
Davies, E. E., Hahn, H. L., Spiro, S. G., et al. (1974) New technique for recording 
respiratory transients at the start of exercise, R spiration Physiology, 20, 69-
79. 
Engebretson, J. E. (1998) Validity of a breath by breath gas exchange analysis system, 
Medicine Science in Sports and Exercise, 30, S330. 
Gore, C. J., Catcheside, P. G., Grenc, S. N., Bennett, J. M., Laforgia, J. (1997) 
Automated VO2max calibrator for open-circuit indirect calorimetry systems, 
Medicine and Science in Sports and Exercise, 29, 1095-1103. 
Haldane, J. S., Priestly, J. G. (1935) Respiration, Oxford University Press, New York. 
Hiilloskorpi, H., Manttari, A., Pasanen, M. (2000) The comparison between three 
different respiratory analysers, Medicine and Science in Sports and Exercise, 
31, S354. 
Hodges, L. G. (2004) Ph.D. Thesis: Cardiac power output in healthy adults and 
patients with peripheral vascular disease. In Research Centre for Health 
Studies, Buckinghamshire Chilterns University College, Buckinghamshire, 
UK. 
Hodges, L. G., Brodie, D. A., Bromley, P. D. (2005) Validity and reliability of 
selected commercially available metabolic analyzer system, Scandinavian 
Journal of Medicine and Science in Sport, 15  271-279. 
Howley, E. T., Bassett, D. R., Welch, H. G. (1995) Criteria for maximal oxygen 
uptake: review and commentary, Medicine and Science in Sports and 
Exercise, 29, 1292-1301. 
Innovision (2005) Innocor - Service manual, Odense, Denmark. 
Jackson, A. S., Hartung, G. H., Bradley, P. W. (1983) An evaluation of an automated 




Medicine and Science in Sports and Exercise, 15, 144. 
Jacobs, P. L., Nash, M. S., Mintz, D. C. (1999) Asses ment of fractional expired gases 
and air flow by an ambulatory metabolic analyzer, In online Journal of 
Exercise Physiology, Vol. 2, No. 4, American Society of Exercise 
Physiologists. 
Jones, N. L., Kane, J. W. (1979) Quality control of exercise test measurements, 
Medicine Science and Sports, 11, 368-372. 
Koh, Y., Chacko, A., Biggerstaff, K. D. (2005) Accuracy of the Cosmed K4b2 
telemetry system during different intensities of exercise, Medicine and Science 
in Sports and Exercise, 37, Supplement S22-S23. 
La Mere, V. J., Brown, K., Wigglesworth, J. K., Edwards, J. E. (1993) 
Reproducibility between three metabolic systems and validation by Douglas 
bag method, Medicine and Science in Sports and Exercise, 25, S9. 
Macfarlane, D. J. (2001) Automated metabolic gas analysis systems, Sports Medicine, 
31, 841-861. 
Maiolo, C., Melchiorri, G., Lacopino, L., Masala, S., Lorenzo, A. (2003) Physical 
activity energy expenditure measured using a portable telemetric device in 
comparison with a mass spectrometer, British Journal of Sports Medicine, 37, 
445-447.  
McLaughlin, J. E., King., G. A., Howley, E. T., Bassett, D. R., Ainsworth, B. E. 
(2001) Validation of the Cosmed K4 portable metabolic system, International 
Journal of Sports Medicine, 22, 280-284. 
Melanson, E., Freedson, P., Hendelman, D., Debolb, E. (1966) Reliability and validity 
of a portable metabolic measurement system, Canadian Journal of Applied 
Physiology, 21, 109-119. 
Miles, D. S., Cox, M. H., Verde, T. J. (1994) Four commonly utilized metabolic 
systems fail to produce similar results during submaxi al and maximal 
exercise1994, Sports Medicine, Training and Rehabilitation, 5, 189-198. 
Miodownik, S., Carlon, V. A., Ferri, E., Burda, B., Melendez, J. A. (2000) System of 
automated gas-exchange analysis for the investigation of metabolic processes, 
Journal of Applied Physiology, 89, 373-378. 
Noguchi, H., Ogushi, Y., Yoshiya, I., Itakura, N., Yamabayashi, H. (1982) Breath-by-




response, Journal of Applied Physiology, 52, 79-84. 
Porszasz, J., Barstow, J., Wasserman, K. (1994) Evaluation of a symmetrically 
disposed Pitot tube flowmeter for measuring gas flow during exercise, Journal 
of Applied Physiology, 77, 2659-2665. 
Prieur, F., Busso, T., Castells, J., Bonnefoy, R., Benoit, H., Geyssant, A., Denis, C. 
(1998) Validity of oxygen uptake measurements during exercise under 
moderate hyperoxia, Medicine and Science in Sports and Exercise, 36, 958-
962. 
Proctor, D. N., Beck, K. C. (1996) Delay time adjustment to minimise errors in breath 
by breath measurement of VO2 during exercise, Journal of Applied 
Physiology, 81, 2495-2499. 
Rietjens, G. J., Kuipers, H., Kaster, A. D., Keizer, H. A. (2001) Validation of a 
computerized metabolic measurement system (Oxy-Pro) during low and high 
intensity exercise, International Journal of Sports Medicine, 22, 291-294. 
Roca, J., Whipp, B. J., Agusti, A. G., Anderson, S. D., Casaburi, R., Cotes, J. E., 
Donner, C. F., Estenne, M., Folgering, H.,  Higenbottam, T. W., Killian, K. J., 
Palange, P., Patessio, A., Prefaut, C., Sergysels, R., Wagner, P., D., Weisman, 
I. (1997) Clinical exercise testing with reference to lung disease: indications, 
standardization and interpretation strategies, European Respiratory Journal, 
10, 2662-2689. 
Safrit, M. J., Cohen, A. S., Costa, M. G. (1989) Item response theory and the 
measurement of motor behaviour, Research Quarterly for Exercise and Sport, 
51, 325-335. 
Scholander, P. F. (1947) Analyser for accurate estimation of respiratory gases in one 
half cubic centimetre dimples, Journal of Biological Chemistry, 167, 235. 
Skinner, J. S., Wilmore, K. M., Jaskolska, A., Jaskol i, A., Daw, W. E., Rice, T., 
Gagnon, J., Leon, A. S., Wilmore, J. H., Rao, D. C., Bouchard, C. (1999) 
Reproducibility of maximal exercise test data in the eritage family study, 
Medicine and Science in Sports and Exercise, 31, 1623-1628. 
Thoden, J. S. (1991) Testing aerobic power, In Physiological testing of the high 
performance athlete (Ed, MacDougall, J. D., Wenger, H. A., Green, H.) 
Human Kinetics, Champain, IL, pp. 107-173. 




Kinetics, Champaign, IL. 
Unnithan, V., Wilson, J., Buchanan, D., Timmons, J., Paton, J. (1994) Validation of 
the Sensormedics (S2900Z) metabolic cart for paediatric exercise testing, 
Canadian Journal of Applied Physiology, 19, 472-479. 
Vanhees, L., Defoor, J., Schepers, D., Brusselle, S., Reybrouck, T., Fagard, R. (2000) 
Comparison of cardiac output measured by two automated methods of CO2 
rebreathing, Medicine and Science in Sports and Exercise, 32, 1028-1034. 
Wagner, J. A., Steven, M. H., Dahms, T. E. (1973) Validation of open circuit method 
for the determination of oxygen consumption, Journal of Applied Physiology, 
34, 859-863. 
Walschlaer, S., Edwards, D., Berry, M. (1996) Assesment of the Medical Graphics 
CPX EXPRESS and CPX/D Automated Respiratory Gas Analysis Systems, 
MedGraphics: Cardiorespiratory Diagnosis Systems, 1-4. 
Wasserman, K., Hansen, J. E., Sue, D. Y., Casaburi, R., Whipp, B. J. (1999) 
Principles of Exercise Testing and Interpretation, Lippincot Williams and 
Wilkins, Baltimore, Maryland. 
Weisman, M. I., Casaburi, R., Marciniuk, D., Beck, K. Zeballos, J., Swanson, G. 
(2003) American Thoracis Society/American College of Chest Physicians: 
Statement on Cardiopulmonary Exercise Testing, American Journal of 
Respiratory and Critical Care Medicine, 167, 211-277. 
Whipp, B. J., Ward, S. (1990) Physiological determinants of pulmonary gas exchange 
kinetics during exercise, Medicine and Science in Sports and Exercise, 22, 62-
71. 
Wideman, L., Stoudemire, N., Pass, K., McGinnes C., Gaesser, G., Weltman, A. 
(1996) Assessment of the aerosport TEEM 100 portable metabolic 
measurement system, Medicine and Science in Sports and Exercise, 28, 509-
515. 
Wong, P., Macfarlane, D. J. (2005) Validity of two automated metabolic gas analysis 
systems at rest and during exercise, Medicine and Science in Sports and 
Exercise, 37, Supplement S24. 
Yeh, M. P., Adams, T. D., Gardner, R. M. (1987) Turbine flowmeters vs. Fleisch 
pneumotachometer: a comparative study for exercise te ting, Journal of 




CHAPTER 3: COMPARISON OF CARDIAC OUTPUT 
DETERMINED BY DIFFERENT REBREATHING METHODS AT 
REST AND AT PEAK EXERCISE  
Abstract 
Introduction: The non-invasive determination of cardiac output (TQ& ) is of value in 
human physiology, especially clinical cardiology. Popular rebreathing methods today 
are the carbon dioxide (CO2) rebreathing method (or indirect Fick) and the inert gas 
(nitrous oxide and sulphur hexafluoride) rebreathing method. The indirect 
measurement of mixed venous partial pressure of carbon dioxide using the CO2 
rebreathing technique can be estimated by the exponntial method described by 
Defares (1958) or by the equilibrium method described by Collier (1956). The 
purposes of this study were: 1) to examine any differences between the equilibrium, 
exponential and inert gas rebreathing methods for measuring TQ&  at rest, 2) to 
evaluate reproducibility of these three methods at res , and 3) to assess agreement 
between the exponential and inert gas rebreathing methods at peak exercise. 
Methods: Following local ethics committee approval and informed consent, 17 
healthy adults (10 males and 7 females) visited the exercise laboratory on separate 
days. Resting TQ&  was measured in a sitting position. The two measurements were 
separated by a five minutes rest. Twelve subjects performed a series of three 
incremental exercise tests to volitional fatigue using the Bruce protocol. The first test 
was used to determine the subjects’ peak oxygen consumption. The other two exercise 
tests were used to measure TQ&  at peak exercise using the exponential and inert gas 
rebreathing methods. Results: The exponential method produced significantly higher 
(p<0.01) estimates at rest (averaging 10.9 l.min-1) compared with the equilibrium 
method (averaging 6.6 l.min-1) and the inert gas rebreathing method (averaging 5.1 
l .min-1). There were non-significant differences (p>0.05) in repeated measures for 
either method at rest. The exponential method had a larger variability (5.3%) than 
inert gas rebreathing method (4.8%), with the equilibrium method having the least 
variability (4.1%). At peak exercise there were non-significant differences between 
the exponential and inert gas rebreathing methods (p=0.14). The mean difference 




l .min-1 and the limits of agreement were -0.49 to 0.79 l.min-1. Conclusion: Based on a 
previous study that the resting TQ&  for healthy adults is 5 l
.min-1, it is reasonable to 
suggest from this study that the inert gas rebreathing method seems to be more valid 
than the exponential and equilibrium methods for measuring TQ&  at rest. At peak 
exercise the exponential and inert gas rebreathing methods produced similar results 
and showed acceptable limits of agreement. Therefore the two methods may be used 
interchangeable at peak exercise. 
3.1 Introduction 
Knowledge of cardiac output is essential in many clinical situations and also of great 
value in human physiology, especially clinical cardiology. The measurement of 
cardiac output is useful in examining a patient’s initial cardiovascular status and the 
cardiovascular response to various therapeutic interventions. Wasserman et al. (1999) 
suggested that cardiac output measurement is useful when trying to assess whether the 
patient’s reduced O2 uptake is due to reduced O2 transport or failure of the muscles to 
extract O2. 
Cardiac output is defined as the quantity of blood pumped into the aorta each minute 
by the heart (Guyton and Hall, 1996) and is usually expressed as litres per minute. 
This is also the volume of blood that circulates throughout the body and is responsible 
for transporting substances to and out from the tissue . Cardiac output is the product 
of the volume of blood ejected in each heart beat (stroke volume) and the frequency 
of heart beating per minute (heart rate) as below  
TQ&  = SV x Cf ……………………………………………………………………….(1) 
 where TQ&  is cardiac output, SV is stroke volume and Cf  is heart rate. 
For young, healthy men, the resting cardiac output averages about 5.6 l.min-1, while 
for adults it is often stated to be 5 l.min-1 (Guyton and Hall, 1996). 




invasive and non-invasive techniques for measuring cardiac output.  
In 1870 Fick developed the original method and set ou the equation for the 
measurement of cardiac output in steady state (Laszlo, 2004). This method is based on 
the principle of conversion of mass and is known as the Fick principle. Using oxygen 
as the test gas, it is the reference method or “gold standard” for cardiac output 
measurements to which all other methods are referred (Sun et al., 2000). According to 
the Fick principle “the output of fluid from a pump in a closed circuit system, can be 
determined from any change in concentration of a substance between the output and 
the input of the pump, and from the quantity of substance taken up by the fluid during 
a given time period” (McArdle, 2000).  Fick states that the amount of a substance 
removed from or taken up by an organ per unit of time is equal to the arterial 
concentration minus the venous concentration of that substance multiplied by the 
blood flow through the organ (Wilmore and Costill, 2004). If the organ is represented 
by the total human body, the relationship between oxygen consumption ( 2OV& ), the  
a-v O2 difference (arterial and venous concentration of oxygen), and cardiac output 
( TQ& , blood flow through the body) is expressed as the Fick equation: 
2OV&  = TQ&  x a - v O2 diff …………………………………………………………..(2)                            
TQ&  = 2OV&  / CaO2 – Cv O2 …………………………………………………………(3) 
According to the direct Fick technique the measurement of these variables involves 
venous cannulation and heart catheterization. This procedure is however, not without 
risks for the patient and therefore is not justifiable in many situations, especially 
during exercise (Ohlsson and Wranne, 1986). In the group of invasive techniques are 
also thermodilution and dye dilution methods (furthe  description of these techniques 
is out of the scope of this chapter). However, apart from their complicated procedures, 
it has been suggested that invasive techniques are the most accurate for measuring 
cardiac output (Nugent et al., 1994). 
During the 20th century, many non-invasive techniques for measuring cardiac output 




1966), doppler ultrasound (Rawles and Haites, 1984), radionuclide angiography 
(Jeremy et al., 1985) and different gas rebreathing methods.  
Rebreathing methods are based on the principle that the rate of uptake or excretion of 
physiological or non-physiological gases is determined from analysis of alveolar gas 
exchange. Based on this assumption it is possible to calculate pulmonary capillary 
blood flow which constitutes cardiac power output (Sackner, 1987).   
This chapter describes differences between carbon di xide and inert gas (nitrous 
oxide, sulphur hexafluoride) rebreathing methods.  
3.1.1 Carbon Dioxide Rebreathing Method (Indirect Fick) 
One of the several non-invasive techniques, the CO2 rebreathing technique or indirect 
Fick method, estimates cardiac output from expired air measurements, using the 
following equation: 
TQ&  = 2C
O
V&  / C(v  - a)CO2 ………………………………………………………...(4)  
Where TQ&  is cardiac output, 2C
O
V&  is the volume of carbon dioxide produced, and 
C(v  - a)CO2 is the difference in carbon dioxide concentration in arterial and mixed 
venous blood.   
Carbon dioxide is virtually absent from inspired air, has high solubility, is relatively 
unaffected by non-uniformity of alveolar 2C
O
 in the lung, and has a virtually linear 
slope to its dissociation curve over the physiologic range (Butler, 1965). Many gases 
are highly diffusible through the pulmonary membrane. Gas pressure in pulmonary 
capillary blood comes into equilibrium with that ofthe alveoli during the brief 
interval in which blood takes up oxygen from the lungs. If one knows the gas 
concentration in the alveoli, the gas concentration in the systemic arterial blood can be 
estimated (McHardy et al., 1967). To determine the blood flow through the capillaries 
the subject is required to breathe a foreign gas. The average concentration of the gas 




same period of time is used to calculate cardiac output (Hodges, 2004). 
Carbon dioxide production is measured using breath-by-breath analysis by an online 
metabolic analyser. Pressure/concentration of venous carbon dioxide (P/Cv 2C
O
) 
and pressure/concentration of arterial carbon dioxie (P/Ca 2C
O
) are predicted by 
using rapid 2C
O
 analysers. Mixed venous 2C
O
 can be estimated by the exponential 
method described by Defares (1958) or by equilibrium method described by Collier 
(1956). Partial pressure of mixed venous CO2 (Pv CO2) is derived from the 
rebreathing method.  
The exponential method involves analysing the exponential rise in end tidal carbon 
dioxide (PETCO2) as the subject rebreathes from a bag containing 4% CO2, 35% O2, 
and the balance N2. The method requires that the subject rebreathes an initial gas 
mixture of 4% CO2. The bag is filled with approximately 1.5 to 2 times the subject’s 
tidal volume. As the subject rebreathes, the PETCO2 gradually increases and 
approaches 2c
o
Pv . End tidal CO2 is measured using a capnograph. During 
rebreathing the CO2 tension in the bag gradually increases with the number of 
respiration towards a limiting value. This limit is the CO2 tension of the mixed venous 
blood (Defares, 1958). Using the technique described y Heigenhauser and Jones 
(1979) and later refined by Da Silva et al. (1985), a best fit line is plotted through the 
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Figure 3-1 Exponential rebreathing capnograph tracing adapted from Medical 
Graphics Corporation (1993). 
The blood leaving the lungs contains a high concentration of CO2. The blood is 
circulated through the body and more CO2 is added. Recirculation occurs at 
approximately 15 seconds at rest and 10 seconds during exercise (Da Silva et al., 
1985), when the exponential rise in CO2 from rebreathing reaches the venous CO2 
level. A line of best fit is plotted through the end tidal CO2 points.  
The method is dependant on the initial CO2 value and a uniform breathing pattern. A 
respiratory rate of 40 breathes per minute has been r commended during rest and 
exercise (Da Silva et al., 1985). 
The equilibrium method requires the subject to rebreathe a high concentration of CO2 
until equilibrium is reached. This causes the lung to contain much more CO2 than the 
venous blood, reversing the natural concentration gradient. The CO2 will be moving 
from the lung in the arterial blood, and more CO2 is added to the body, causing the 
rise on venous CO2. The CO2 gradient that has been reversed comes into equilibri m 
on passing through the lungs. Therefore, the CO2 concentration at the lungs is in 
equilibrium with CO2 in mixed venous blood. The arterial CO2 concentration is 
estimated from end tidal CO2 levels using a capnograph (Figure 3.2). According to Da 
Silva (1985) recirculation takes approximately 10 to 15 seconds, which means that the 
























rebreathing manoeuvre should be completed within 10 to 15 seconds. A respiratory 
rate of greater than 40 breathes per minute speeds up the equilibrium (Da Silva, 
1985). The equilibrium method for determining 2c
o
Pv  and 2c
o




 equilibrium is reached across alveolar membranes (Klausen, 
1965). A plateau is considered satisfactory when an inspired-expired CO2 difference 
is less than 0.1% in two successive breathes and plateau occurred within 15 sec 











Figure 3-2 Equilibrium rebreathing capnograph tracing. 
3.1.1.1 Validity and reliability of carbon dioxide rebreathing methods 
A number of studies have been investigated to evaluate the validity and reliability of 
carbon dioxide rebreathing methods for measuring cardiac output at rest and during 
exercise. It has been compared with the direct Fick and other invasive and non-
invasive methods, as shown below.  
Muiesan et al. (1968) compared the equilibrium CO2 rebreathing technique and the 
direct Fick method at rest in 17 healthy adults. They found a correlation coefficient of 
0.94 (p<0.001). Cardiac output values measured by the direct Fick were slightly 
higher (7.52%) than those obtained using the CO2 rebreathing method. All values lay 
within 13% of the line of identity (the distance of each measured value squared from 
the line of best fit).  In a separate experiment, Muiesan et al. (1968) found a high 
correlation (r=0.97) between 2c
o
Pv  as measured by the exponential and the 
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equilibrium method. Furthermore, Reybrouck et al. (1978) compared the exponential 
CO2 rebreathing technique with the direct Fick method f r measuring cardiac output 
at rest and during exercise in 16 healthy subjects. They found a moderate correlation 
at rest (r=0.646, p<0.001), and a high correlation was reported during exercise 
(r=0.958, p<0.001) between the two methods. During exercise it was found that 12% 
of the direct Fick and 10% of the exponential CO2 rebreathing measurements were 
found to fall outside of the line of identity compared with 48% of the rebreathing 
measurements at rest. A study by Ferguson et al. (1968) reported a very low 
coefficient of correlation (r=0.22, p<0.05) between the dye dilution method and the 
exponential CO2 rebreathing method at rest. During exercise, a high correlation of 
0.87 (p<0.05) was reported. These results suggest that the exponential CO2 
rebreathing method is a poor indicator of cardiac output at rest. Ohlsson and Wranne 
(1986) compared the exponential CO2 rebreathing method with the direct Fick during 
recumbent exercise in 13 patients. Results demonstrated that high relationship 
between the two methods exists (r=0.91, p<0.001). However, they noticed that cardiac 
output measured by the exponential CO2 rebreathing method was significantly higher 
(p<0.001) than values obtained with the direct Fick method. These differences 
decreased gradually as intensity of exercise increased. Ohlsson and Wranne (1986) 
also reported no significant difference in cardiac output measured by CO2 rebreathing 
method on separate days. Furthermore, Franciosa (1976) evaluated the equilibrium 
CO2 rebreathing method in seriously ill patients. He found that the equilibrium 
method underestimates cardiac output compared to dye dilution and direct Fick 
method.          
Nugent et al. (1994) compared cardiac output as measur d by the equilibrium CO2 
rebreathing method with direct Fick and thermodilution method at rest in 11 patients 
undergoing routine cardiac catheterization. The equilibri m method gave significantly 
lower results compared with the direct Fick (4.80 vs. 5.53 l.min-1). This also applied 
when comparing the equilibrium method with the thermodilution (4.96 vs. 5.69 l.min-
1). Also, Nugent and colleagues (1994) assessed reproducibility of the equilibrium 
CO2 rebreathing technique in 10 healthy subjects at res and during exercise. 
Measurements were made in triplicate on 3 separate d ys. The equilibrium method 




became more reproducible on exercise (5.6% and 5.4%).  
Correlation coefficient used for method comparison in this context must be viewed 
with caution (Bland and Altman, 1986). That is highly dependent on the range of 
values within the given sample and it cannot assess y tematic bias (Bland, 2002). 
The Pearson correlation coefficient does not indicate the extent to which the new 
measurements agree with an existing measurement, threfore this cannot be used to 
enable the direct method to be replaced with the indirect method. This can only be 
distinguished through the use of a method of assessing the limits of agreement 
between the methods, such as suggested by Bland and Altman (1986). The Bland-
Altman method involves plotting the sum of the differences between the two methods 
against the average difference between the two methods. It is unlikely that the two 
measurements will agree exactly but it is an advantage to know how much the new 
measurement agrees with the old. The two methods of measurement agree if the 
difference is small enough to use the methods interchangeable. The differences are 
quantified by estimating the bias, which is the mean difference between the two 
methods and the limits of agreement. The limits of agreement are calculated from the 
mean and standard deviation of the difference. If the mean is close to zero there is a 
lack of systematic bias, the two measurements (methods) agree and the direct method 
could be substituted for the indirect method.    
According to Nugent et al. (1994) the equilibrium method was found to underestimate 
cardiac output by mean value of 0.73 l.min-1 compared with the direct Fick. Nugent et 
al. indicated acceptable validity and limits of agreement (-0.09 to -1.37 l.min-1) for the 
equilibrium method. A study by Cowley et al. (1986) compared the thermodilution 
technique with the equilibrium method. Using the Bland-Altman analysis they 
reported that limits of agreement were ranged from -0.37 to 0.47 l.min-1. Russel et al. 
(1990) reported wider limits of agreement (-1.80 to 1.24 l.min-1) when comparing the 
equilibrium method with the dye dilution technique.  
It has been suggested that the coefficient of variation (CV) is a statistical measure 
which should be used in reproducibility studies (Bland, 2002). The CV assumes that 
the largest test retest variation occurs in the indiv duals scoring the highest values on 




Nevill, 1998). Holmgren (1960) and Clausen et al. (1970) reported that the direct Fick 
method had a CV of 5.5-7.5%, whereas the CO2 rebreathing method is more variable 
with CV of 8.2% (Clausen et al. 1970).  Godfrey and Wolf (1972) supported the 
notion that the CV for cardiac output derived from the equilibrium method is smaller, 
being as accurate and reproducible as any of other dir ct methods. Zeidifard et al. 
(1972) investigated the reproducibility of the equilibr um method at rest and during 
exercise. They reported that the CV was high at rest but fell during exercise (up to 
5.7%). Nugent et al. (1994) also found the equilibrium technique had a higher CV at 
rest (9.1%), and became more reproducible during exercise (5.6% and 5.4%). Rogers 
et al. (1997) determined the reproducibility of the exponential method measuring 
2c
o
Pv  during exercise in four healthy subjects. The CV for 2c
o
Pv , determined by 
the CO2 rebreathing technique, was 3.3% which compares favour ble with 3.2% 
found by Clausen et al. (1970) for the direct measurement of pulmonary 2c
o
Pa . 
Smith et al. (1988) compared cardiac output measurements taken by electrical 
bioimpedance with the equilibrium carbon dioxide rebreathing techniques, both at rest 
and during exercise. No significant difference was found between the two methods at 
rest, while during exercise the equilibrium method verestimated cardiac output 
compared with  electrical bioimpedance technique (p<0.005). However, Smith and 
colleagues (1988) thought that the impedance signals m y become distorted during 
exercise, and this may cause inaccurate measurements.  
Vanhees et al. (2000) investigated the reproducibility of the exponential CO2 
rebreathing method. They subsequently compared both the equilibrium and 
exponential method at rest and during exercise in order to determine which method is 
superior in terms of reproducibility and clinical practicability. Twelve healthy men 
performed five graded exercise tests with a one-week interval. The equilibrium 
method was performed rebreathing from a bag containi g high concentration of CO2 
(8.5%), O2 (21%) with the balance nitrogen; the exponential method was performed 
using lower concentrations of CO2 (4%). Estimated cardiac output was not 
significantly different between duplicate measurements at rest nor at any level of 
exercise with either method. At rest the mean difference (l.min-1) between duplicates 
and the coefficient of repeatability were 0.58 and 5.12, respectively for the 




rest, the exponential method showed a tendency toward larger variability than the 
equilibrium method. The exponential method produced significantly higher (p<0.001) 
estimates at rest (9.8 l.min-1) compared with the equilibrium method (6.5 l.min-1). A 
second measurement at rest seemed to be more valid th n the first. Reproducibility 
improved for both methods with increasing workloads. During exercise, both methods 
produced comparable values for cardiac output. Because of higher CO2 concentration, 
the equilibrium method produced unpleasant side effcts (e.g. dizziness, headache and 
dyspnoea) compared to the exponential method and led more subjects to premature 
interruption of the exercise test (Vanhees et al., 2000). 
From previous cited studies it may be concluded that t e exponential method is more 
appropriate and valid for use during high intensity exercise. The equilibrium method, 
however, has been suggested to be more valid for measuring cardiac output at rest.       
3.1.2 Inert Gas Rebreathing Method 
The inert gas rebreathing method, also known as the foreign gas rebreathing method, 
is an old technique first proposed by Bornstein (1910) and developed by Krogh and 
Linhard (1912). The Bornstein modification of the Fick principle states that if a 
physiologically inert gas is inhaled, its partial pressure in the pulmonary capillary 
blood equals that in the lungs. The change in the amount of the gas in the lungs, in an 
interval before recirculation occurs, equals its alveo ar concentration times its 
solubility in blood and the amount of blood to which the gas is exposed during the 
interval (Rigatto et al., 1961).  
Butler (1965) noted that the ideal gas for the measurement of pulmonary blood flow, 
which constitutes cardiac output in the absence of intrapulmonary  shunt flow 
(Sackner, 1987), should be soluble in blood, relatively insoluble in lung tissue, easily 
analysed, and completely removed in the body. These asp cts should eliminate the 
problem of recirculation. It should be an inert gas, its solubility in blood should not be 
influenced by the concentration of haemoglobin and it should not itself influence the 
pulmonary blood flow (Butler, 1965).  Foreign gases usually used in the inert gas 
rebreathing method are physiologically inert, blood soluble gases such as acetylene, 




The principle of the inert gas rebreathing method is to let the subject breath a gas 
mixture containing a non-physiological soluble gas in a closed rebreathing assembly, 
which concentration in blood before rebreathing can be assumed to be zero (Hoeper et 
al., 1999). When the gas is inhaled it is rapidly taken up in the pulmonary capillary 
blood stream at a rate proportional to the effectiv pulmonary capillary blood flow. 
When the gas comes into contact with the blood in the lung capillaries, it is dissolved 
and is thus washed out by the blood perfusing the lungs (Liang et al., 2005). The 
pulmonary blood flow is therefore proportional to the rate of washout of blood soluble 
compound, which is measured continuously by a gas an lyser (Liang et al., 2005). 
The rate of soluble gas disappearance allows the calculation of the pulmonary blood 
flow (Hoeper et al., 1999). Additionally, some systems today use gas mixture, which 
apart from an inert soluble gas (nitrous oxide, N2O) also contains small amount of 
insoluble gas (sulphur hexafluoride, SF6). This blood insoluble compound is used to 
determine the lung volume, which is required in the equation used to calculate cardiac 
output for the measured washout curve of the blood soluble compound (Liang et al., 
2005). During the rebreathing period the concentration of insoluble gas (SF6) 
decreases from the initial value in the bag to final equilibration value obtained after a 
few breaths. Since the volume of the rebreathing bag is known, the total systematic 
volume can be determined simply from dilution of the insoluble gas.  
Calculations of the cardiopulmonary parameters are based on single-alveolar lung 
model and assumptions included in the model are (Innovision, 2005): 1) complete and 
instantaneous mixing in the volume consisting of alveo ar and dead space air and bag 
volume, 2) instantaneous equilibration of the soluble gas between the alveoli and 
blood, and between alveoli and tissue, 3) constant pulmonary blood flow and constant 
volume of lung tissue, 4) negligible mixed venous concentration of soluble gas 
throughout the rebreathing period.     
In the past, measurements of pulmonary blood flow and cardiac output by an inert gas 
rebreathing method have been performed using mass spectrometers (Liu et al., 1997; 
Hoeper et al., 1999; Darren et al., 1998; and Rosenthal and Bush, 1997). However, 
mass spectrometers are bulky, difficult to operate and require frequent calibration and 
maintenance (Gabrielsen et al., 2002). These factors have significantly limited the 





More recently, an accurate infrared photoacoustic gas analyser has been introduced 
for the continuous analysis of ventilatory gas concentrations (Clemensen et al., 1994). 
Compared with conventional mass spectrometers, this analyser weighs less, is stable, 
less expensive, less complicated for use and therefor  acilitates clinical use 
markedly.  
3.1.2.1 Validity and reliability of inert gas rebreathing method 
Liang et al. (2005) examined a new device (Innocor, Innovision, Denmark) for non-
invasive measurement of cardiac output at rest using a  inert gas (N2O, SF6) 
rebreathing method. It was compared with conventional techniques such as 
thermodilution, echocardiography and left ventricular radiography in 34 patients with 
heart failure. Using linear regression and Bland Altman analysis, they reported that 
strong positive correlations (r=0.94) exists between cardiac output measured by the 
inert gas rebreathing method and thermodilution. However, the Bland-Altman plot 
showed that the inert gas rebreathing method produced systematically lower values 
for cardiac output (by mean of 0.66 l.min-1, p<0.001) than those obtained by the 
thermodilution. The inert gas rebreathing method did not correlate with the other two 
non-invasive methods used in this study. The authors c ncluded that the inert gas 
(N2O, SF6) rebreathing method is an easy, safe and well established method for non-
invasive measurement of cardiac output with good pros ects for clinical application in 
heart disease patients. Further, Gabrielsen and colleagues (2002) compared an inert 
gas rebreathing method, which uses an infrared photoac ustic gas analyser system, 
with the direct Fick and thermodilution method at rest in 11 patients with heart failure 
or pulmonary hypertension. Using the Bland-Altman analysis, they reported the 
means difference (bias) and limits of agreement (±2 SD) to be 0.6±1.2 l.min-1 when 
comparing the direct Fick and inert gas rebreathing method. The same values were     
-0.8±1.3 l.min-1 when comparing the direct Fick and thermodilution methods. In 
conclusion they argued that the inert gas rebreathing method, with a new 
photoacoustic gas analyser, provides at least as reli ble a measure of cardiac output as 
did thermodilution. Agostoni et al. (2005) examined the validity and repeatability of 




method. They compared cardiac output measurements by he inert gas (N2O, SF6) 
rebreathing method with cardiac output obtained by the direct Fick and 
thermodilution method. Twenty chronic heart failure patients in stable condition 
participated in the study. Results (mean ± SD) showed that cardiac output measured at 
rest by inert gas rebreathing method was 5.1±1.3 l.min-1, direct Fick 5.0±1.3, and 
thermodilution method 4.5±1.2 l.min-1. At peak exercise, the inert gas rebreathing 
method and direct Fick also produced similar cardiac outputs (11.3±3.2  l.min-1 vs. 
11.2±3.2 l.min-1), while the thermodilution method overestimated peak cardiac output 
compared to the other two methods (11.7±3.7). Agostoni et al. (2005) also reported 
that the coefficient of variation was 10.8% for thein rt gas rebreathing method. They 
concluded that cardiac output in heart failure patients measured at rest and during 
exercise by the inert gas rebreathing method is repeatable and agrees closely with 
those obtained by direct Fick and thermodilution method. Christensen et al. (2000) 
investigated measurements of cardiac output by the inert gas rebreathing method and 
the thermodilution technique in 14 critically ill patients. Results demonstrated that 
mean difference between paired estimates was 0.01 l.min-1, and the standard deviation 
for differences was 1.19 l.min-1. Also, 95% limits of agreement were calculated and
the interval for this bias was 0.47 to -0.45, respectiv ly. Coefficients of variation for 
cardiac output measures were 8% for rebreathing method and 12% for thermodilution 
method.  
Additionally, a number of articles have examined validity and reliability of inert gas 
rebreathing method using acetylene as a testing gas (Barker et al., 1999; Darren et al., 
1998; Hoeper et al., 1999; Johnson et al., 2000; Liu et al., 1997). Findings of these 
studies suggest that this method for measuring cardiac output is in good agreement 
and correlates highly with invasive techniques. Further review of this topic is out of 
the scope of this chapter. 
3.1.3 Rationale and Purposes of the Study 
Currently, there are limited number of studies which compared two or more different 
rebreathing methods for measuring cardiac output at rest and at peak exercise. Before 
discussing cardiac output further, it was considere s nsible to evaluate which of the 




cardiac output at rest. Based on previous suggestion (Vanhees et al., 2000) that the 
exponential, rather than the equilibrium method should be used at high intensity 
exercise, this study evaluated the exponential and inert gas rebreathing methods at 
peak exercise.    
The purposes of this study were: 1) to examine any differences between the 
equilibrium, exponential and inert gas rebreathing methods for measuring TQ&  at rest, 
2) to assess reproducibility of these three methods at rest, and 3) to evaluate 
agreement between the exponential and inert gas rebreathing methods at peak 
exercise.   
3.1.4 Research Hypotheses 
H1 – There will be a significant difference between the exponential, equilibrium and 
inert gas rebreathing methods for measuring cardiac output at rest.  
H2 – There will be a non-significant difference between duplicated measures of 
cardiac output measured with these three methods. 
H3 – There will be acceptable levels of agreement betwe n the exponential and inert 
gas rebreathing methods at peak exercise.   
3.2 Methods   
3.2.1 Subjects     
After obtaining ethical approval and informed consent, 17 healthy adults (ten males 
and seven females) from a South East UK University volunteered to participate in the 
study. Subjects were recruited by personal contact. They visited the exercise 
laboratory on three occasions on separate days. Subjects reported that they were 
physically active, but none were engaged in regular structured programme. They were 
asked to refrain from eating for a minimum of 2 h prior to the test and from vigorous 
exercise on the day of and the day before the test. All procedures were in accord with 




Declaration of Helsinki.  
3.2.2 Equipment  
3.2.2.1 Innocor – Inert gas rebreathing method 
The Innocor (Innovision, Odense, Denmark) recently introduced a compact device, 
primarily developed to measure cardiac output non-invasively at rest and during 
exercise. The Innocor is the first device on the market which uses an inert gas 
rebreathing method. For the inert gas rebreathing method, the Innocor uses nitrous 
oxide (N2O) and sulphur hexafluoride (SF6). The gas distribution system controls the 
pneumatics for the respiratory valve unit and the filling/evacuating of the rebreathing 
bag (Innovision, 2005). The gas bolus is stored in a pressurized gas bottle which is 
connected to a respiratory valve unit under pneumatic control. The pressure of 0.4 bar 
is sufficient to activate the balloons in the respiratory valve unit. Before the 
rebreathing test, the port to the bag is closed by inflating the balloon. When the 
rebreathing starts, the port to the rebreathing rubber bag is opened by releasing the 
pressure of the balloon, simultaneously closing theport to ambient air. The 
rebreathing bag is filled prior to a test with an oxygen enriched mixture containing 
typically 0.5% N2O and 0.1% SF6. The filling of the bag is achieved in two steps. 
Firstly, a bolus part is filled from the gas contaiing 94% O2, 5% N2O and 1% SF6. 
Secondly, the rest comes from ambient air via an air pump. Under normal resting 
conditions it is recommended to use 10% bolus and 90% air, which gives a mixture of 
28.3% O2, 0.5% N2O and 0.1% SF6 (Innovision, 2005). During exercise it can be 
necessary to increase the bolus due to high oxygen uptake to avoid a low oxygen 
concentration at the end of the test.        
 The Innocor uses the principle of photoacoustic spectroscopy as described in Chapter 
2. This principle operates by pulsatile exposure of the measured gases to filtered light, 
the absorption of which creates pressure oscillations. The amplitude of the oscillation, 




3.2.2.2 CardiO2 - Carbon dioxide rebreating methods 
The equilibrium or exponential carbon dioxide rebreathing methods were performed 
using the CardiO2 (Medical Graphics Corp., St. Paul, Minnesota, USA) system. The 
CardiO2 system is equipped with an integrated module for the measurement of cardiac 
output. This is a mobile free-standing unit. It consists of mouthpiece assembly 
connected to a rotary valve which has two movements to allow a three-way operation.  
The first movement exposes inspire and expire ports wi h one way valves for the 
measurement of 2OV& . The second movement connects the subject to a rebreathing 
anaesthetic 6 l black rubber bag. The bag is filled manually with a mixture of higher 
(equilibrium method) or lower (exponential method) CO2 concentration from gas 
cylinders located at the base of the unit. The module is connected to gas analysers to 
measure O2 and CO2. Subjects are connected to the metabolic cart by means of a 
disposable rubber mouthpiece, attached directly to the flowmeter, to which the gas 
sample line and airflow umbilical are connected.  
3.2.3 Procedure 
3.2.3.1 Pre test procedure  
Both systems were calibrated before each test according to manufacturers’ 
recommendations. On arrival at the laboratory, subjects were asked for their 
completed physical activity readiness questionnaire fo ms and questioned about their 
medical health. Subjects were then required to complete the informed consent form in 
front of the researcher who countersigned it as a witness. Subjects had their mass 
recorded using floor scale (Seca model 761, Vogel ad H lke, Germany) and height 
recorded using a freestanding stadiometer (Leicester Height Measure, Invicta Plastics, 
Oadby, Leicester, UK) prior to test.  Subjects received instructions about breathing 
pattern and fitting the mouthpiece and nose clip.  
3.2.3.2 Testing procedure 
Subjects were randomly allocated to three groups. In a third of the subjects, the 




rebreathing method on the second and third visits. With the other two groups, the 
order was changed. After a resting period of 5 min in the sitting position on a chair, 
the rebreathing manoeuvre was performed in duplicate wi h an interval of 5 min 
between the measurements to allow eliminate of CO2 or N2O. The second 
measurement at rest was required to ensure the reproducibility of the technique.  
Twelve subjects performed a series of three incremental exercise tests to volitional 
fatigue using the Bruce protocol on separate days. The first test was used to determine 
subjects’ peak oxygen consumption. The other two exercise tests were used to 
measure TQ&  at peak exercise using the exponential and inert gas rebreathing methods.  
The exponential method was performed using a gas mixture of 4% CO2, 34% O2 and 
balance N2, while in the equilibrium method subjects rebreathd a gas mixture of 10% 
CO2, 35% O2 and balance N2. A 6 l anaesthetic rubber bag was filled with 
approximately 1.5 to 2 times the subject’s tidal volume. For either CO2 rebreathing 
method, a breathing frequency higher than 40 breaths per minute was used.  This was 
ensured by the researcher saying “in” and “out” whilst looking at the stopwatch. The 
other researcher pushed the plunger at the end of expiration to switch the subject to 
rebreathe the gas mixture from the bag. This was rebreathed for a maximum of 15 
seconds and then the plunger was pulled out and the subj ct rebreathed room air. A 
capnograph trace was produced on the screen whilst t e subject rebreathed the gas 
mixture.    
In the inert gas rebreathing method the bag volume was calculated automatically 
(40% of the predicted vital capacity at rest) and the bag was evacuated and filled 
automatically. Before each measurement, the subject put on a nose clip. A constant 
ventilation rate was ensured by having the subject breath in synchrony with a 
graphical tachymeter on the computer screen set at 20 breaths per minute. A constant 
ventilation volume was ensured by having the subject completely empty the 
rebreathing bag with each breath. The rebreathing system software calculated cardiac 
output from the rate of uptake of N2O into the blood. This was based on the slope of 
the regression line through logarithmically transformed expiratory (i.e. alveolar) N2O 




the SF6 concentration. The first two or three breaths were excluded from the analysis 
due to initial incomplete gas mixing.  
3.2.4 Data Analysis  
All statistical analysis was performed using SPSS version 13 (SPSS Inc., Chicago, IL, 
USA). Prior the statistical analysis all data were screened for univariate (Z-scores) 
and multivariate (Mahanolobis distance test) outliers. Descriptive statistics was 
performed in order to check data for parametric assumptions (normal distribution and 
homogeneity of variance). To test difference between three different methods for 
measuring cardiac output at rest, one-way analysis of variance (ANOVA) was used. 
To identify the groups that differed significantly from one another, a post hoc Tukey’s 
test was performed. T-tests for paired samples were used to assess differences in 
repeated measures at rest, as well as to examine differences in TQ&  at peak exercise 
measured by the exponential and inert gas rebreathing methods. Statistical 
significance was indicated if p<0.05. Bland-Altman plots were constructed to evaluate 
agreement between different methods (Bland and Altman, 1986). Coefficient of 
variation (CV) was used to assess reproducibility of each method at rest.  
3.3 Results  
Subjects were aged 37±11 years, weight 74±17 kg, hei ht of 172±8 cm with the mean 
maximal oxygen uptake of 46.6±7.2 ml.kg-1.min-1, respectively. Analysis of variance 
revealed that there was a significant difference betwe n the three methods (F=43.03). 
The Tukey post hoc test demonstrated that mean cardiac output measured by the 
exponential method was significantly higher (p<0.01), respectively, than those 
measured by the equilibrium or inert gas rebrathing method (Figure 3.3). The 
difference in measured cardiac output of 1.4 l.min-1 between the equilibrium and inert 
gas rebreathing method was not significant (p=0.08). Individual and mean values of 
cardiac output (l.min-1) determined by exponential, equilibrium and inert gas 
rebreathing method are presented in table III.1 (Appendix III). Mean cardiac output 
measured by the exponential method was higher by 4.5 l.min-1 and 5.8 l.min-1 












Figure 3-3 Mean values of cardiac output measured at rest by the exponential (EXP), 
equilibrium (EQU) and inert gas (IGR) rebreathing methods  
*  = indicates that cardiac output measured by the EXP was significantly higher than 
those measured by EQU and IGR methods (p<0.01). 
Bland-Altman analysis revealed that the mean difference between duplicate measures 
and limits of agreement were -0.13 (-2.71 to 2.45) l .min-1 for the exponential method, 
0.19 (-0.57 to 0.96) l.min-1 for the equilibrium method and -0.15 (-1.18 to 0.87) l.min-1 
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There was no statistically significant difference in duplicate cardiac output values 
measured by any of the three rebreathing methods at rest (Table 3.1). The CV 
demonstrated that the exponential method showed a tndency toward larger variation 
than the equilibrium and inert gas rebreathing methods. 
 
Table 3.1 Differences in Cardiac Output Values at Rest Measured by the Three 






p - Value CV (%) 
EXP  10.9±2.7 11±2.9 0.68 5.3 
EQU 6.7±1.5 6.5±1.5 0.06 4.1 
IGR 5±0.8 5.1±0.9 0.24 4.8 
Figures 3.4-3.6 Bland-Altman plots to 
demonstrate limits of agreement between 
duplicate measures of cardiac output 
determined by the exponential (EXP) 
equilibrium (EQU) and inert gas 
rebreathing methods (IGR). The solid 
line is at the bias (mean of the difference) 
EXP – exponential CO2 rebreathing method; EQU – equilibrium CO2 rebreathing 
method; IGR – inert gas rebreathing method. 
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Figure 3-7 Bland-Altman plot to demonstrate limits of agreement between the 
exponential and inert gas rebrathing methods at peak exercise. The solid line is at the 
bias and the dashed lines represent lower and upper limits of agreement (±2SD of the 
mean difference). 
There was a non-significant difference between the exponential and inert gas 
rebreathing methods at peak exercise (p=0.14). The mean TQ&  values were 19.7±4.0 
l .min-1 and 19.9±4.1 l.min-1 measured by the exponential and the inert gas rebreathing 
methods, respectively. Bland-Altman analysis showed that the mean difference and 
the limits of agreement were 0.15 (-0.49 to 0.79) l.min-1 as shown in the Figure 3.7. 
Individual and mean peak TQ&  values measured by the exponential and inert gas 







3.4 Discussion      
3.4.1 Validity of the Three Rebreathing Methods at Rest  
The purposes of this study were: 1) to examine any differences between the 
equilibrium, exponential and inert gas rebreathing methods for measuring TQ&  at rest, 
2) to assess reproducibility of these three methods at rest, and 3) to evaluate 
agreement between the exponential and inert gas rebreathing methods at peak 
exercise.   
Validity of the cardiac output has previously been established by comparing invasive 
methods with the equilibrium (Cowley et al., 1986; Franciosa, 1976; Muiesan et al., 
1968; Nugent et al., 1994; Smith et al., 1988) and the exponential method (Ferguson 
et al., 1968; Ohlsson and Wranne, 1986; Reybrouck et al., 1978). Ferguson et al. 
(1968) reported a very low coefficient of correlation between the exponential and dye 
dilutions methods at rest. Reybrouck et al. (1978) found moderate correlation between 
the exponential and direct Fick methods at rest.  
In the present study the estimates of resting cardiac output obtained with the 
exponential method were higher than one would expect in healthy subjects and were 
significantly higher than those obtained by the equilibrium and inert gas rebreathing 
methods. Resting cardiac output values obtained in this study compare favourably to 
those reported by Vanhees et al. (2000). They report d that cardiac output measured 
by the equilibrium and exponential method were 6.3 l .min-1 and 9.1 l.min-1 
respectively compared with 6.6 l.min-1 and 10.9 l.min-1 found in this study. Previous 
studies have also reported that exponential method en s to overestimate cardiac 
output at rest when compared with direct Fick, dye ilution and equilibrium CO2 
rebreathing method (Ferguson et al., 1968; Ohlsson and Wranne, 1986; Reybrouck et 
al., 1978). On the other hand, it has been reported that the equilibrium method rather 
underestimates cardiac output at rest compared with the direct Fick or dye dilution 
method (Franciosa, 1976; Muiesan et al., 1968; Nugent et al., 1994). Cowley et al. 
(1986) using the Bland-Altman analysis demonstrated good narrow limits of 
agreement (ranged from -0.37 to 0.47 l.min-1) between the equilibrium method and 




to 1.24 l.min-1) when comparing the equilibrium with dye dilution. However, it has 
been frequently suggested that the equilibrium method is more valid than the 
exponential method for measuring cardiac output at rest, while during high intensity 
exercise the exponential method is preferred (Muiesan et al., 1968; Vanhees et al., 
2000).  
Butler (1965) has questioned the validity of both CO2 rebreathing methods used to 
obtain 2c
o
Pv  for cardiac output measurement. Hamilton (1962) also pointed out 
several objections to the rebreathing method and argued that using the lungs as a 
tonometer for determining 2c
o
Pv  can be inaccurate. Firstly, he suggested that there                                                   
is an appreciable quantity of residual arterialized blood (or other fluids) in the lungs 
which can absorb CO2 from the inspired mixture. Secondly, this CO2 can combine 
with fluids other than intravascular. Thirdly, there is a constant increase in values 
obtained for 2c
o
Pv  as rebreathing time is prolonged what may cause slow mixing, 
diffusion, and the equilibrium of arterialized pulmonary blood. However, the last 
objection is not applicable in this study because the rebreathing time was controlled 
automatically and never exceeded 20 sec and 15 sec for the exponential and 
equilibrium method. McHardy (1967) pointed out that since neither the haemoglobin 
concentration nor the pH of arterial and mixed venous blood is usually available when 
cardiac output is estimated by a CO2 rebreathing method, a standard CO2 dissociation 
curve is often used to derive blood CO2 content from 2P
c
o
. Nevertheless the position 
and slope of the CO2 dissociation curve may vary from subject to subject and both are 
affected by changes in oxygen saturation, haemoglobin and pH of the blood 
(McHardy, 1967).      
The inert gas rebreathing method, performed using the Innocor system, has been 
validated against other invasive and non-invasive mthods. Liang et al. (2005) 
compared inert gas rebreathing method with thermodilution, echocardiography and 
left ventricular radiography. This study reported high correlation between the 
thermodilution and inert gas rebreathing method, but also suggested that the inert gas 
rebreathing method systematically underestimated car iac output compared with 
thermodilution, by a mean of 0.66 l.min-1. Further Gabrielsen at al. (2002) found the 




compared with the direct Fick and inert gas rebreathing method.  A study by Agostoni 
et al. (2005) assessed chronic heart failure patients who were in a stable condition. 
They reported cardiac output at rest measured by inert gas rebreathing method of 5.1 
l .min-1, compared with the direct Fick and thermodilution of 5.1 l.min-1 and 4.5 l.min-1. 
Finally, Christensen et al. (2000) demonstrated very good narrow limits of agreement 
of -0.45 to 0.47 between the inert gas rebreathing method and thermodilution at rest.  
The finding of the present study suggests that the mean cardiac output measured at 
rest by the equilibrium method was higher by 1.4 l.min-1 compared with the inert gas 
rebreathing method. Analysis of variance revealed that no statistically significant 
difference exists between the two methods. However, th  magnitude of the difference 
in measured cardiac output between these two methods may have practical and 
clinical implications. There are several reasons why this difference may occur. It has 
been suggested that rebreathing manoeuvre performed at rest may require a certain 
effort by the subject, and therefore increase cardiac output (Ohlsson and Wranne, 
1986). The breathing pattern required a frequency of 40 breaths per minute during the 
equilibrium method compared with 20 breaths per minute required by the inert gas 
rebreathing method. A high breathing frequency may influence higher O2 demands of 
particularly respiratory muscles and consequently icrease cardiac output. Secondly, 
during the inert gas rebreathing method, the rebreathing volume was controlled by 
asking the subject to empty the bag at each inspiration. Consequently subjects used 
the same tidal volume during each rebreathing manoeuvre. Also, the rebreathing bag 
was evacuated and then refilled with appropriate air volume automatically before the 
inert gas rebreathing manoeuvre. On the other hand, for the equilibrium as well as for 
the exponential method, the rebreathing bag was filled with approximately 1.5 to 2 
times the subject’s tidal volume. During the rebreathing manoeuvre it was not 
possible to control the subject’s tidal volume as with inert gas rebreathing method. 
Damgaard and Norsk (2005) showed that reducing and changing the rebreathing 
volume during the test may influence the cardiac output result. Furthermore, higher 
estimates of cardiac output produced by the equilibrium method may occur due to 
high measurement of end-tidal carbon dioxide levels (Nugent et al., 1994). This may 
be caused by inaccurate estimates of arterial CO2 levels which can be due to non-




As suggested earlier, resting cardiac output for young healthy men averages about 5.6 
l .min-1, while for adults it is often stated to be 5 l.min-1 (Guyton and Hall, 1996). The 
age of subjects participated in this study ranged from 26 to 58 years with an average 
of 37 years. It is reasonable to suggest from the results of this study that the inert gas 
rebreathing method seems to be more valid than the exponential and equilibrium 
method for measuring TQ&  at rest. 
3.4.2 Reproducibility of the Three Rebreathing Methods at Rest 
“If cardiac output is measured under standardized conditions on one day, these values 
are assumed to be valid on the next day, as long as the circulatory situation is stable” 
(Ohlsson et al., 1983; page 9).  
This study reported good reproducibility and low coefficient of variation of all three 
rebreathing methods for measuring cardiac output at res . Also, there was no 
significant difference between repeated measures with either method. The Bland-
Altman analysis revealed that the limits of agreement between repeated measures 
were a little broader for the inert gas rebreathing method compared with the 
equilibrium method. However, they are not as wide as the limits of agreement 
obtained by the exponential method. Furthermore, th coefficient of variation (CV) 
was also higher for the exponential method (5.3%) compared with the equilibrium 
(4.1) and inert gas rebreathing method (4.8%).  
Holmgren (1960) and Calusen et al. (1970) reported that direct Fick method had a CV 
of 5.5 and 7.5%, respectively. The results of the present study on reproducibility of 
either CO2 rebreathing method for measuring cardiac output at rest are also in close 
agreement with those obtained by Vanhees et al. (2000). They reported the mean 
difference between duplicates and the coefficient of repeatability (twice the SD of 
difference) of 0.58 and 5.12 for the exponential method and -0.25 and 3.25 for the 
equilibrium method.  Nugent et al. (1994) found that the equilibrium method gave 
reproducible results between replicates at rest with a CV of 9.1% and became more 
reproducible on exercise (5.6% and 5.4%). Also, Zeidifard et al. (1972) reported that 
CV was higher at rest and fell during exercise (5.7%) for the equilibrium method. On 




exponential method during exercise which compares favourable with 3.2% found by 
Clausen et al. (1970). A study by Christensen et al. (2000) was the only one which has 
been investigated to assess the reproducibility of the inert gas rebreathing method 
using the Innocor system. They reported a CV of 8%. 
Due to poor reproducibility of the CO2 rebreathing method at rest, Ferguson et al. 
(1968) have recommended performing repeated measurements to achieve a reliable 
estimate of cardiac output at rest. The positive learning effect of the rebreathing 
manoeuvre has been reported by Vanhees et al. (2000).  Vanhees et al. also 
recommended repeated measurements at rest where the firs  measurement is used for 
familiarization and should not be used in interpretation. In the present study all 
subjects were very familiar with rebreathing manoeuvr  having taken part in an earlier 
study to assess cardiac output using the CO2 rebreathing technique. This is likely to 
have contributed substantially to the high level of reproducibility in all three 
rebreathing methods.   
3.4.3 Agreement between the Exponential and Inert Gas Rebreathing 
Methods at Peak Exercise 
It has been suggested that the exponential, rather than the equilibrium method should 
be used during high intensity exercise (Muiesan et al., 1968; Vanhees et al., 2000). A 
high coefficient of correlations was reported when compared the exponential with the 
direct Fick and dye dilution methods during exercise (Ferguson et al., 1968; Ohlsson 
and Wranne, 1986; Reybrouck et al.,1978). On the otr hand, Agostoni et al. (2005) 
evaluated inert gas rebreathing method against the direct Fick and thermodilution 
methods during exercise in heart failure. They concluded that cardiac output measured 
during exercise by the inert gas rebreathing is repeatable and agrees closely with those 
obtained by the direct Fick and thermodilution methods. 
In the present study, the exponential and inert gas rebreathing methods produced non-
significantly different TQ&  values at peak exercise. Bland-Altman analysis revealed 
good narrow limits of agreement between the two methods, with the mean difference 




favourably with those reported earlier (Agostoni et al., 2005; Christensen et al., 2000; 
Cowley et al., 1986; Gabrielsen et al., 2002; Nugent et al., 1994). It is important, 
however, to outline an advantage of the inert gas rebreathing method.  
In order to determine TQ&  both methods use blood soluble gases, CO2 or N2O. 
However, the inert gas rebreathing method in addition uses the insoluble gas (SF6) 
which concentration curve provides direct information n regards of complete mixing 
of gases within alveoli (Gabrielsen et al., 2002). Thus compared to the exponential, 
the inert gas rebreathing method contains an inheret valuation of the degree of gas 
mixing.  This is very important assumption of rebreathing methods. Therefore, it is 
reasonable to suggest that the inert gas rebreathing method may measure TQ&  more 
precisely compared with the exponential CO2 rebreathing method.           
3.5 Conclusion 
Availability of a valid, reliable, easily applied, non-invasive method for measuring 
cardiac output is of great value in clinical and scientific environment. The present 
study evaluated different rebreathing methods for measuring cardiac output at rest and 
at peak exercise. Resting QT values produced by the inert gas rebreathing method 
agreed well with previously suggested values in healt y adults, more so than those 
obtained by either the equilibrium or the exponential method. The equilibrium and 
particularly the exponential CO2 rebreathing method tended to overestimated cardiac 
output at rest compared with the inert gas rebreathing method. The difference in 
measured cardiac output by the inert gas rebreathing method and the equilibrium 
method is likely to be due to differences in uniformity of breathing pattern. The inert 
gas rebreathing method has a lower required breathing frequency. It also has the 
capability to control lung volumes during rebreathing, and to estimate degree of gas 
mixing. On this basis it is believed that the inert gas rebreathing method has the 
potential to measure QT more precisely than both CO2 rebreathing methods used in 
this study. All three methods produced very similar v lues of resting cardiac output 
between duplicated measures, demonstrating good reliability. At peak exercise the 
exponential and inert gas rebreathing methods produced non-significantly different 




agreement between the two methods. Therefore the expon ntial and inert gas 
rebreathing methods may be used interchangeable for measuring TQ&  at peak exercise.      
The inert gas rebreathing method used in this study is totally non-invasive, easily 
performed, valid and reliable method for measuring cardiac output. It is a useful tool 
for monitoring cardiac output not only in healthy population, but also in patients with 
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CHAPTER 4: CARDIAC POWER OUTPUT IN HEALTHY 
AND DISEASED POPULATIONS – A LITERATURE REVIEW  
Abstract 
The aim of this chapter was to review existing litera ure which has evaluated different 
aspects of cardiac power output. It has been shown that cardiac power output is a 
direct indicator of overall cardiac function. Cardiac power output represents the 
heart’s ability to act as a mechanical pump and produce hydraulic energy which is 
used to maintain circulation. It takes account of both pressure and flow and is equal to 
the product of cardiac output and mean arterial pressure, expressed in watts. It has 
been demonstrated that cardiac power output plays a major role in risk stratification 
and prognosis in heart failure patients. Also it has been suggested that peak cardiac 
power output is a more powerful indicator of heart f ilure prognosis than commonly 
used peak oxygen consumption. Firstly, this review describes the concept of cardiac 
power output and its definition. Secondly it concentrates on the analysis of cardiac 
power output in healthy adults. Furthermore the chapter evaluates cardiac power 
output and its role in heart failure patients and in peripheral vascular disease. Also this 
review analyses the effect of exercise programmes on cardiac power output in both 
health and disease. Finally the chapter provides recommendations for future 











4.1 Introduction – The Concept of Cardiac Power Out put and 
Its Definition 
The heart is a muscular mechanical pump with an ability to generate both flow and 
pressure (Cotter et al., 2003). The main function of the heart is to provide hydraulic 
energy to maintain the circulation through which the body supplies nutrients (oxygen) 
and removes waste products to and from metabolising tissues (Tan, 1987; Tan 1991). 
Bergel et al. (1969) were the first to consider theheart as a power generator and 
measured cardiac power output. It is only since the 1980s that the measurement has 
received more attention (Firth et al. 1981) and has gained wider acceptance in clinical 
practice. In the middle 1980s, Lip-Bun Tan described the mechanical pumping 
capability of the heart and its practical implications in acute and chronic heart failure 
(Tan, 1986). Of all haemodynamic variables in use, Tan (1986) advocated that 
hydraulic power output best represents the performance of the cardiac pump. 
Furthermore hydraulic power output is a measure of the heart’s capability to act as a 
pump and maintain circulation (Cotter et al. 2003). The corollary statement of this 
concept is that the function of the heart is to provide hydraulic energy to maintain the 
circulation (Tan, 1991).   
Cardiac performance consists of two important terms (Tan, 1987): 1) cardiac 
pumping capability which presents the maximum performance that can be achieved 
by the heart during stimulation, and 2) cardiac pumping reserve which is the 
difference in performance between the basal resting state and the maximally 
stimulated state (Figure 4.1). Cardiac reserve has been found to be a major 
determinant of exercise capacity in heart failure, and pumping capability a major 
determinant of prognosis in patients with severe heart failure (Tan, 1991). The 
concept of cardiac reserve provides further insight into pathological and clinical 
mechanisms that contribute to heart failure (Wright and Tan, 1999). Nevertheless each 
heart has its own ceiling peak pumping performance that is physically impossible to 
exceed (Cotter et al., 2003). This peak value would alter only if the intrinsic condition 
of the heart is altered, e.g. after an acute myocardial infarction or after successful 
relevant cardiac surgery (Williams et al., 2005a). Cardiac pumping capability is a 
direct and objective indicator of how relatively good or impaired the heart is as a fluid 
























                                                                                                                                                            
Figure 4-1 Schematic diagram demonstrating cardiac functional reserve of individual 
hearts on a normal functional state, in various degre s of heart failure (HF) and 
cardiogenic shock. Adapted from Williams et al. (2005a). 
The delivery of oxygen to metabolising tissues depends on the rate of blood flow – 
cardiac output. An increase in blood flow can be achieved by vasodilatation or by 
increasing the arterial perfusion pressure (Tan, 1987). Since all vessels have an upper 
limit of vasodilatation, and since the vasculature of other organs cannot vasoconstrict 
to an infinite extent, the only way to increase blood flow is by increasing the arterial 
perfusion pressure through greater pressure generation by the heart (Tan, 1991). This 
increase in pressure assumes an even greater importance in the perfusion of exercising 
skeletal muscle because of the higher tissue pressure developed during muscle 
contraction, in particular during isometric exercise (Williams et al., 2005a). The 
product of cardiac output and aortic (arterial) pressure gives the term cardiac 
hydraulic power output or cardiac power output (Tan, 1986).  
A continuous supply of hydraulic energy from the pumping action of the heart is 
required to maintain the circulation. Thus, the heart is a generator of hydraulic energy 
(Tan, 1987). Without this energy, circulation would come to a standstill due to the 
opposing frictional and separational forces (Tan, 1991; Cotter et al., 2003). The rate at 
which the heart imparts energy into the circulation s cardiac power output, which 
presents an ideal measure of heart’s pumping performance. Therefore Tan (1987) 
suggested that cardiac pumping capability may be red fined as the maximum power 
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output achieved by the heart during maximal stimulation. Cardiac pumping reserve is 
defined as the increase in power output as its performance is increased from the basal 
resting state to the maximally stimulated state. It has been suggested that cardiac 
power output is the most logical variable to represent cardiac performance (Tan et al. 
1989). Also Bain et al. (1990) reported that cardiac power output is an expression of 
the hydraulic power output of the heart and as such derived from both central and 
peripheral haemodynamic measurements, cardiac output and mean arterial pressure. 
From the aspect of physics, ‘power’ is ‘energy per unit of time’.  
The following equation is used to calculate cardiac power output: 
CPO = TQ&  x MAP x K………………………………………………………………(1)  
Where CPO is cardiac power output in watts (W), TQ& is cardiac output in l
.min-1, 
MAP is the estimated mean arterial pressure in mmHg, and K the conversion factor 
(=2.22  x 10-3). The formula for calculation of the mean arterial pressure (below) has 
been suggested by Meaney et al. (2000):    
MAP = DBP + 0.412 (SBP – DBP)………………………………………………….(2) 
Where DBP is diastolic blood pressure in mmHg, SBP systolic blood pressure in 
mmHg. Hodges (2004) reported that from a regression analysis, cardiac output has the 
greater influence (r = 0.89, SEE = 0.53 l.min-1) on cardiac power output than mean 
arterial pressure (r = 0.48, SEE = 1.02 mmHg).   
The normal resting value of cardiac power output for an average sized man with a 
cardiac output of 5 l.min-1 and blood pressure of 120/80 mmHg is about 1 watt, bu  at 
peak exercise it may rise to 4-8 watts (Tan, 1991).  
While cardiac output is commonly used to assess cardiac function, it clearly 
overestimates the changes in the overall function of the normal heart (Goldspink, 
2005). This is because pressure generation increases with healthy ageing and is not 
allowed for when measuring only flow-generating capacity of the heart. In contrast, in 




cardiac function (Chantler et al., 2006). This is because both the flow and pressure 
generating capacities of the heart decline in these patients. Taken together, these 
examples clearly illustrate the need to measure both the flow and pressure generating 
capacities of the heart to determine overall cardiac function meaningfully (Goldspink, 
2005).    
Cooke et al. (1998) were the first who assessed physiological cardiac reserve using a 
non-invasive CO2 rebreathing method. They tested 70 subjects with a wide range of 
cardiac function, from heart failure patients to athletes. In previous studies involving 
evaluation of cardiac power output and cardiac reserv  (Tan, 1986; Tan, 1987; Tan et 
al., 1991; Timmins et al., 1992), the haemodynamic variables were measured 
invasively using Swan-Ganz catheters. In these studies cardiac stimulation was also 
achieved pharmacologically, using incremental dobutamine infusion. However, it is 
not necessarily indicative or representative of physiological cardiac reserve which is 
obtained during exercise (Cooke et al., 1998). Wright and Tan (1999) concluded that 
exercise testing plays an essential and integral role in the evaluation and treatment of 
chronic heart failure. In addition, Cooke et al. (1998) pointed out two important 
clinical implications. Firstly, it is no longer reasonable to assume that haemodynamic 
measurement of cardiac function is unimportant in the management of patients with 
heart failure, and secondly that cardiac reserve is probably the best available objective 
indicator of overall cardiac function.     
Cardiac power output has been studied in both healthy nd diseased populations. This 
chapter concentrates on review of the existing literature on cardiac power output. It is 
divided in the following sections: 1) cardiac power output in healthy adults; 2) cardiac 
power output and its role in heart failure patients; 3) cardiac power output in patients 
with peripheral vascular disease; 4) cardiac power output and its relationship to other 
cardiorespiratory variables in health and disease; nd 5) exercise and cardiac power 





4.2 Cardiac Power Output in Healthy Adults 
Many studies over the last two decades have evaluated cardiac power output in a 
clinical population, while only a few recent studies have analysed cardiac power 
output in healthy adults. This may be explained by the fact that cardiac power output 
appears to be of great value in evaluation and prognosis in clinical, especially heart 
failure, populations. Cardiac power output is a measure which clearly not only 
differentiates the function of healthy from impaired hearts, but also contributes to the 
further management of those with variable impaired h art function (Cooke et al., 
1998). It seems logical that more data should be available about cardiac power output 
in healthy populations. Data obtained from healthy people may be used as a ‘standard’ 
against which cardiac capacity can be evaluated for the purposes of research and for 
clinical studies in a population with cardiac disea (Bromley et al., 2006).  
It has been suggested that heart rate may respond to strenuous exercise by increasing 
from about 70 beats per minute to about 180 beats per minute and stroke volume from 
about 70 ml to 110 ml or more (Tan, 1991). In these circumstances cardiac output 
increases from 5 l.min-1 to 20 l.min-1 or even more. As stated above, the normal resting 
cardiac power output for an average sized man is about 1 W, but at peak exercise it 
may rise to 4-8 W (Tan, 1991). Nicholls and Riley (2001) reported that the normal 
range for cardiac power output has not yet been establi hed. Thus Bromley et al. 
(2006) were the first to define the normal physiological range for peak cardiac power 
output in healthy adults. In addition they evaluated age and sex related variations of 
cardiac output.  
In Bromley at al.’s study, 102 healthy adults (50 males and 52 females, age range 
from 19 to 64 years) performed an incremental exercis  test protocol described by 
Bruce et al. (1973). Oxygen consumption, carbon dioxi e production, minute 
ventilation, tidal volume and respiratory exchange ratio were obtained using an online 
breath-by-breath metabolic gas analysis system. Also, at peak exercise blood pressure 
was recorded manually by auscultation over the right brachial artery. Following the 
peak exercise test and a rest period of 40 minutes, subjects performed the second bout 




within 5% of the 2OV&  peak obtained during the incremental test. Cardiac output was 
measured using the CO2 rebreathing method described by Defares (1958). Once near 
peak values had been reached, the metabolic system was switched to the cardiac 
output measurement screen and the cardiac output val e was obtained within 15 
seconds. Bromley et al. (2006) used one-way analysis of variance and t-tests to 
establish difference in peak cardiac power output between the subgroups. Results of 
this study showed that peak cardiac power output ranged from 3.11 to 7.94 W (mean 
5.26±1.03W) in men and from 2.53 to 5.57 W (mean 3.69±0.64 W) in women. The 
difference in peak cardiac power output between men and women and between 
younger (<45 years) and older (45-65 years) subjects was significant. When men <45 
years were compared with men 45-65 years the difference in peak cardiac power 
output was also significant. However, there was a non-significant difference between 
women <45 years and women 45-65 years. Additionally the findings of this study 
suggest that sex accounts for a greater proportion of the variance in peak cardiac 
power output than age. Bromley et al. (2006) concluded that age-related loss of 
functional myocardial mass in the male heart (see blow) is accompanied by a 
significant reduction in peak cardiac power output. Al hough Bromley et al. (2006) 
did not measure resting cardiac power output, they reported that cardiac pumping 
reserve was 3.36±1.16 W in their study. This conclusion was drawn from previous 
suggestions that resting cardiac power output in healt y adults to be between 1 and 
1.2 W (Tan, 1986, 1991; Cooke et al., 1998). However, Bromley et al. (2006) were 
not able to assess any possible differences in resting cardiac power output between 
men and women, and possible effect of aging on resting cardiac power output. If 
resting cardiac power output is affected by gender and ageing then people with the 
same peak cardiac power output will have different peak cardiac reserves due to 
different starting points (resting cardiac power output). Additionally, Chantler et al. 
(2005) illustrated the impact and importance of normalizing data for differences in 
body size before interpreting measurements of overall cardiac function between 
different populations of subjects. This study yielded novel findings that highlight the 
fact that cardiac power output is significantly affected by body size and composition. 
Thus valuable results reported by Bromley et al. (2006) on ‘normal’ physiological 
range of cardiac power output, should be considered with caution because differences 




Ollivetti et al. (1995) reported that ageing was asociated with ventricular myocardial 
mass, aggregate number of mononucleated and binucleated myocytes, and average 
cell diameter and volume in the female heart. Further, it has been observed that the 
male heart looses nearly 1 g per year of myocardium, affecting both the left and right 
sides of the heart and accounting for the loss of approximately 64 million cells. 
Olliveti et al. (1991) showed that about one third of the cardiomyocytes are lost from 
the human male heart between the ages of 17-90 years. Although some of the 
remaining viable cardiomyocytes undergo adaptive hypertrophy, this does not 
compensate for the progressive decline in myocyte numbers. Interestingly, the rate of 
cardiomyocyte attrition in the female heart is considerable less (Olivetti et al., 1995). 
There is no doubt that the loss of these contractile ells compromises the pumping 
capability of the heart (Goldspink, 2005). It is, however, important to emphasize that 
these age-related effects based on measuring cardia power output are not pronounce 
as when cardiac output alone is used as the index of cardiac function (Goldspink, 
2005).  
Chantler et al. (2004) tested the hypothesis that he lt y ageing is associated with a 
decrease in peak cardiac power output and cardiac reserve and also that endurance 
training improves cardiac power output. Results revealed that in sedentary men peak 
cardiac power output and cardiac reserve declined significantly by 16 and 18% 
between the ages 20 and 60 years. In contrast with to ese effects of ageing, the 
veteran athletes demonstrated significantly higher p ak cardiac power output and 
cardiac reserve values than their age-matched sedentary counterparts at both 50 and 
60 years. Moreover, these trained individuals demonstrated similar or better cardiac 
function than the sedentary 20 year-old subjects (Chantler et al., 2004). In subsequent 
study Chantler et al. (2006) determined whether the functional impacts of cardiac 
impairment through ageing and heart failure are similar or different. Study population 
consisted of three groups of subjects: 1) twelve sedentary untrained healthy men aged 
21 years, 2) fourteen sedentary untrained men aged 60 years, 3) eleven patients with 
heart failure (NYHA III) aged 58 years. In consistency with previous, this study 
revealed that ageing from early (20 years) to later (60 years) resulted in a reduction of 
peak aerobic capacity by about 30%. Additionally, heart failure produced a further 




group. The most prominent difference between the impact of ageing and of heart 
failure on cardiac function was their opposite effects on cardiac pressure generating 
capacity of the aging hearts was preserved and even slightly enhanced, whereas heart 
failure significantly compromised cardiac pressure g nerating capacity. When 
compared with the same age group of healthy controls, heart failure diminished the 
pressure generating capacity of patients by 23%. Further, the flow generating 
capacity, on the other hand, was reduced 22% secondary to ageing, with further 
reduction of about 27% due to heart failure. Finally, the power generating capacity of 
the heart was reduced to a smaller extent of 15% thoug  ageing, but by a much greater 
further reduction of 57% by heart failure. The reseve capacity of the heart to impart 
hydraulic energy to maintain the circulation during peak exercise stress test was 
reduced by 16.5% through ageing and a much greater further reduction of 72% by 
heart failure.        
From a practical and clinical perspective it has been suggested that it would be useful 
to estimate peak cardiac power output from measurements taken at lower exercise 
intensities (Hodges, 2004). Thus Hodges (2004) examined whether peak cardiac 
power output could be predicted accurately from submaximal values. A study 
evaluated the relationship between oxygen consumption, blood lactate concentration, 
carbon dioxide production and cardiac power output at submaximal levels of exercise. 
Also, the study by Hodges (2004) determined the effct that the accumulation of lactic 
acid has during progressive exercise on the measurement of cardiac power output. In 
Hodges’ study, 19 healthy adults completed three fiv  minutes stages of exercise on a 
treadmill at 25%, 50% and 75% of each subject’s predet rmined maximal oxygen 
consumption. Cardiac output was measured every four minutes into each exercise 
stage using the exponential rebreathing technique. Capillary blood sampling was 
accomplished three minutes into each stage and lactate analysed immediately. 
Metabolic data were obtained online using the breath-by-breath CardioO2 system, 
while blood pressure was measured manually every two minutes. Results of this study 
demonstrated that a high correlation exists between blood lactate and cardiac output (r 
= 0.8, p<0.05) and cardiac power output, (r = 0.9, p<0.05). Prediction of peak cardiac 
power output from submaximal values was calculated following regression analysis 




variables included in the equation were blood lactate at 25% and 75% of peak oxygen 
consumption and cardiac power output measure at 25%and 75% of peak oxygen 
consumption. This model represented 82% of the variance and a standard error of 
estimate of 0.38 W. It has been argued that this model combines practicality and 
economy, as it would involve only two stages of submaximal exercise (Hodges, 
2004). Furthermore results illustrated that it was not possible to exclude the highest 
measurement, cardiac power output at 75% of peak oxygen uptake from the 
regression equation, as this was the most important v riable used in the equation and 
accounted for approximately 50% of the variance alone. If this regression equation 
were to be used in the future investigations, the patient would have adequate time to 
recover between predictor measures and would not need to exercise to volitional 
fatigue (Hodges, 2004). However, in order to calculate someone’s submaximal 
functional capacity (e.g. 75% of 2OV& ), the investigator must know what is the 
maximal   functional capacity (e.g. 100% of 2OV& ). Hodges (2004) did not clearly 
suggest which method should be used to predict peak 2OV&  in the case when no 
maximal exercise test is performed. There is evidence which shows that 2OV& peak 
may be predicted based on age, gender, height and weight in both healthy and 
diseased populations (Wasserman et al., 1999). However, the formulae for calculating 
predicted 2OV& peak should be treated with caution, especially when working in a 
clinical environment and with seriously ill patients. Furthermore, the practical 
implication of assessing peak cardiac power output from submaximal values comes 
into a question when there is a need for measuring peak cardiac power output, but the 
patient is not able to achieve 75% of predicted 2OV& peak (e.g. severe heart failure). 
Also, taking blood samples twice to measure blood lactate combined with metabolic 
measurements at a high breathing frequency, places this model on the periphery of 
clinical use. Nonetheless, Hodges’ study produces better understanding of the concept 
of cardiac power output and expands its theoretical framework. 
There are limited number of studies which evaluated car iac power output in healthy 
subjects (Bain et al., 1990; Bromley et al., 2006; Cooke et al., 1998; Hodges, 2004; 
Marshall et al., 2001). Some of these studies examined the relationship between peak 




the effect of exercise programme in cardiac power output in healthy adults. These 
aspects of cardiac power output in healthy and alsodi eased populations will be 
discussed in some of the following subheadings of this chapter.    
4.3 Cardiac Power Output and Its Role in Heart Fail ure 
Patients  
Tan (1991) reported that one major shortcoming in the management of cardiac 
dysfunction is the lack of a satisfactory definition of heart failure. It has been 
suggested that without a clear definition, there is no common ground for research and 
treatment (Tan, 1991). Before defining heart failure, Tan (1991) turned firstly on the 
heart function, which is de facto to provide hydraulic energy in order to maintain 
circulation. Following this idea, Tan (1991) pointed out that the definition of heart 
failure can then be simply stated as ‘the failure of the heart to function as it should’. 
Also, Williams et al. (2005) pointed out that heart f ilure is impairment of function, 
instead of structure which may or may not have contributed to the dysfunction.  Thus 
morbidity experienced by patients with chronic heart f ilure is due to a reduction in 
functional capacity (Wright and Tan, 1999). Alteration in central haemodynamic, 
ventilation, peripheral circulation, neurohormonal activity and skeletal muscle all 
contribute to impaired clinical status (Wright and Tan, 1999). According to Tan 
(1991) two essential questions are whether the patient’s heart is in terminal failure, 
and what is the most suitable treatment.  
In 1986 Tan pointed out that in the management of severe heart failure, clinicians 
would value an objective means of determining the point at which a patient’s heart 
has failed critically (Tan, 1986). Tan (1986) further suggested that the three major 
determinants of prognosis in heart failure are (1) mechanical pumping capability of 
the heart, (2) its electrical state, and (3) the rat  of progression of the underlying 
disease. It has been clearly stated that cardiac power output has a more than 
theoretical value in defining maximum cardiovascular capacity, particularly in 
patients who are limited in their exercise capacity by both cardiac and other physical 
conditions (Bain et al., 1990).  




reduction in the maximum performance of the pump (Tan, 1986). With a major 
impairment, the heart occasionally cannot maintain its normal resting pumping level 
(the proposed level of 1 W). When the mechanical function of a cardiac pump has 
deteriorated to the extent that, however hard to may be stimulated, its maximum 
performance no longer exceeds its ‘normal’ resting level, then the condition of the 
failing heart is incompatible with sustained survival (Tan, 1986). In other words, if the 
maximum cardiac power output of the failing heart is below 1 W, then the likelihood 
of long-term survival of the patient is very small. Conversely, if the maximum 
performance greatly exceeds the normal resting level, th n factors other than the 
mechanical state of the heart become more dominant i  determining the prognosis 
(Tan, 1986) e.g. malignant arrhythmia, further myocardial infarction (Tan, 1987). It 
has also been suggested that haemodynamic measurements during stress (e.g. exercise 
or pharmacological intervention) gives a clearer indication of failing cardiac function 
than haemodynamic evaluation at rest (Tan et al., 1989).   
Tan (1986) studied 63 patients of which 26 had acute chronic heart failure due to 
myocardial infarction, and remainder were in chronic or acute heart failure, symptom 
class III-IV according to New York Heart Association (NYHA) classification. Cardiac 
output and arterial pressure were measured invasively using thermodilution catheters 
and cannula. Baseline control data were recorded at leas  10 min after insertion of the 
cathether and cannula. Maximum stimulation was achieved by using the incremental 
infusion of dobutamine. Maximum stimulation was determined by the absence of a 
further rise in cardiac power output, the onset of angina, or serious arrhythmia. Each 
patient was followed up for one year. Student’s t test and Wilcoxon rank sum were 
used to determine significant differences. The results of this study showed that of the 
23 patients with a peak cardiac power output of less than 1 W, all but three died of 
progressive heart failure within one year of the study; 1 of the 3 survivors had cardiac 
transplantation; 36 of the 40 patients with a peak c rdiac power output of more than 1 
W survived more than one year. Based on these results it seems possible to identify 
patients whose hearts are in terminal mechanical failure. These results are consistent 
with the findings of Tan and Littler (1990), who evaluated the prognostic value of 
cardiac power output and cardiac pumping reserve in cardiogenic shock patients. This 




outcome was uniformly death. Above this level, some patients had sufficient cardiac 
reserve to be able to respond to the dobutamine stimulation to produce peak cardiac 
power output of >1 W. These patients survived more than a year.  
Tan (1986) suggested that cardiac response on dobutamine infusion gives valuable 
information on prognosis in heart failure. Also it has been suggested that maximal 
exercise testing provides the best form of classification for cardiac failure patients 
(Wright and Tan, 1999). Tan (1986) further reported that the use of a pharmacological 
agent was based on expediency, since clearly physiological stimulation (e.g. an 
exercise stress test) was neither feasible nor desiable in many of the patients (Tan, 
1986). However, it was logical to assess the possible relationship between the 
pharmacological and the physiological stimulation of peak cardiac power output. Thus 
in the following investigation, Tan et al. (1989) compared cardiac pumping capability 
measured during an incremental dobutamine infusion with that measured during 
symptom limited exercise. They studied 31 patients with moderate to severe heart 
failure. Baseline and peak haemodynamic data were measured invasively using 
thermodilution and arterial cannulas. Patients firstly performed maximal cycle 
ergometry in a semierect position starting at 10 to 25 W and increasing in steps of 10-
25 W every three minutes. The workloads were selectd so that the patients reached 
peak exercise in less than 10 minutes. After patients had rested for four hours, they 
were given increasing doses of dobutamine starting at 2.5 µg.kg-1.min-1 and increasing 
by 2.5 to 5.0 µg.kg-1.min-1 every 5-10 minutes to a maximum of 15-30 µg.kg-1.min-1. 
The maximum dose was reached when there was no further increase in cardiac output 
and cardiac power output, or when a symptom became intolerable or important 
arrhythmia developed (Tan et al., 1989). This study showed that both dobutamine and 
exercise increased heart rate, cardiac index, cardiac power output and left ventricular 
stroke work index. Results demonstrated that peak crdiac pumping capability 
measured during dobutamine stimulation correlates wll ith that measured during 
symptom limited exercise testing. However, the correlation coefficient was not 
reported. The peak values of all variables (except ardiac index) produced by both 
forms of stimulation were not statistically different. However it was noticed that 
maximal cardiac output values were higher in the dobutamine group. This may be 




the heart converted more of its pressure generating capacity into a flow generating 
capacity (Williams et al., 2005a). Bland-Altman analysis showed good agreement 
between the cardiac pumping capability as evaluated by measuring peak cardiac 
power output during maximal dobutamine challenge and maximal exercise. Also, it 
was pointed out that dobutamine challenge may be the best method of assessing 
cardiac pumping capability particularly when the patient is unable or unwilling to 
undergo maximal exercise testing (Tan et al., 1989). This study concluded that 
pharmacological stress using dobutamine is as good as physiological stress for cardiac 
stimulation. There is no doubt, however, that cardiopulmonary exercise testing 
provides more data than the pharmacological stimulation (e.g. oxygen uptake, 
anaerobic threshold etc). Taken together with cardiac power output and cardiac 
reserve these data are likely to provide deeper insight into the clinical status of a 
patient. Therefore it is reasonable to suggest that physiological rather than 
pharmacological stimulation of the heart should be us d wherever possible.    
At present no single exercise test is able to provide complete evaluation of a patient 
with cardiac dysfunction (Wright and Tan, 1999). However, the main objectives of 
exercise testing in patients with chronic heart failure are to improve understanding of 
pathophysiological mechanisms, to confirm the quantity of symptoms and their 
severity, to predict prognosis and to assess treatment (Wright and Tan, 1999). In 
addition to exercise testing, it is important to notice that the type of exercise chosen to 
stress the heart is also important in determining the extent of impairment of cardiac 
reserve (Tan, 1987). Tan (1987) using the data from Saltin et al. (1973) pointed out 
that in young healthy subjects there is a pronounced difference between the cardiac 
power output obtained at maximal workload tolerated for just 3-4 minutes (mean 
cardiac power output 7.7 W) and obtained during a maxi al effort sustained for 6-9 
minutes (6.6 W). Similarly, in heart failure patients, a faster rise in exercise workload 
appears to stress the heart more than a slower protocol by virtue of the greater 
maximal cardiac power output attained with the faster protocol (Lipkin et al., 1986).    
The information based on peak cardiac performance is most helpful in determining 
the prognosis and in formulating management plans (Tan, 1991). There is a view that 
patients with poor prognosis should be resuscitated only if definitive treatment is to be 




1991). Further it has been suggested that similar princi les can be applied to patients 
with less severe heart failure with the only difference being that the mechanical 
dysfunction of the heart is not as immediately respon ible for the prognosis as in 
cardiogenic shock (Tan, 1991). Other factors may also be influential in determining 
the prognosis of heart failure such as arrhythmia. This is more likely to occur in those 
with heart failure than without, and may effect progression of the underlying disease 
(e.g. further myocardial infarction) (Tan, 1991). The survival rate becomes less 
dependant on pure mechanical factors and more depenant on these other factors 
when the pump failure is less severe (Tan, 1991).  
An earlier suggestion was that the only way to improve cardiac pumping capability is 
by altering the design of the pump by surgery or with compensatory hypertrophy and 
dilatation (Tan, 1991). Therefore, the principal consideration in treating any heart 
failure patient should be identification and correction of structural defects (e.g. 
pericardial aspiration in tamponade or valvular replacement in valve lesion) (Tan, 
1991). However, more recently it has been shown that cardiac pumping reserve and 
consequently peak cardiac power output may be improved with exercise training in 
both healthy and heart failure populations (Marshall et al., 2001; Patwale et al., 2006; 
Wright et al., 2002). The effect of exercise on cardi c power output will be discussed 
later in this chapter.     
Accurate classification of heart failure patients according to severity of illness is 
essential in order to formulate a management strategy (Wright and Tan, 1999). This 
study pointed out that no system presently exists which adequately classifies patients. 
The New York Heart Association provided a valuable classification system which has 
been used almost universally for about half of century (Wasserman et al., 1999). It has 
four functional classifications based on the perceived activity level (peak 2OV& ) of the 
patient. Specifically, it has been suggested that a peak 2OV&  level of ≤14 ml
.kg-1.min-1 
be used as a ‘cut off’ point and as a key criterion f r the acceptance of ambulatory 
patients for transplantation (Chomsky et al., 1996). Furthermore, patients with a peak 
2OV&  >20 ml
.kg-1.min-1 have a good prognosis and those with peak 2OV&  <10 ml
.kg-
1.min-1 have a limited prognosis (Roul et al., 1995). Conversely, it has been well 




muscle deconditioning, obesity, motivation, gender, and age (Chomsky et al., 1996; 
Fleg and Lakata, 1988; Wilson et al., 1995).   However, the NYHA system continues 
to be widely used despite its poor sensitivity in determination of functional capacity 
(Cohen-Solal and Gourgon, 1991; Franciosa, 1984) and prediction of prognosis (Van 
Den Broek et al., 1992; Wright and Tan, 1999). It has been further suggested, because 
of good correlation with peak 2OV& , that maximal cardiac output and the derived peak 
cardiac power output and cardiac reserve are used a alternative measures (Tan, 
1991). On the other hand Wilson et al. (1995) reported dissociation between peak 
2OV&  and haemodynamic dysfunction in transplant candidates. They concluded that 
more than 50% of the potential heart transplant candidates with a reduced peak 2OV&  
level exhibit only mild or moderate haemodynamic dysfunction during exercise. 
Wilson et al. (1995) recommended that haemodynamic responses to exercise should 
be directly measured in the potential transplant candidates to confirm severity of 
circulatory dysfunction. It has been therefore suggested that the role of peak 2OV&  in 
risk stratification of heart failure should be reconsidered. Thus Wright and Tan (1999) 
reported that a more integrated approach incorporating measurement of exercise 
haemodynamic should be in use, focusing on cardiac power output. It has also been 
reported that some other variables such as anaerobic threshold (Gitt et al., 2002) and 
ventilatory efficiency (Kleber et al., 2000) have higher prognostic importance than 
2OV& .  
Roul et al. (1995) were the first group to evaluate the prognostic value of peak cardiac 
power output during maximal exercise testing. They examined 50 patients with 
chronic heart failure in functional class II and III of the NYHA, with an average age 
and ejection fraction of 54 years and 20%, respectiv ly. The haemodynamic data were 
obtained by thermodilution at rest and during exercis  which was performed on a 
recumbent cycle ergometer (25 W every three minutes). 2OV&  of all patients was 
determined during a new exercise test on a cycle ergometer. Patients were followed 
up for an average of 21.2 months. Cox analysis showed that exercise cardiac power 
output, exercise left ventricular work indices and exercise peak 2OV&  were the most 
useful factors for assessing the prognosis of patients with NYHA II and III chronic 




patients with a short-term poor prognosis, and peak 2OV&  was also accurate to predict 
prognosis. Roul et al. (1995) concluded that invasive haemodynamic parameters are 
best for determining the prognosis of patients with chronic heart failure, while peak 
2OV&  can, however, be as useful. It may be noted that cardiac power output and 
cardiac reserve play an important role in prognosis f heart failure not only in severe 
heart failure, but also in earlier stages of heart failure (e.g. NYHA II and III).   
Furthermore, a study by Williams et al. (2001) asses ed the prognostic value of peak 
cardiac power output, measured non-invasively using CO2 rebreathing method at rest 
and during maximal cardiopulmonary exercise testing. The study group included 219 
unselected consecutive patients, mean age 56 years, with stable congestive heart 
failure. They were followed up for a mean period of 4.64 years. Peak cardiac power 
output (< and >1.96 W) and peak 2OV&  (< and >14 ml
.kg-1.min-1) were entered as 
categorical variables. Results demonstrated that of the patients with a peak cardiac 
power output of <1.96 W, the mortality rate (32%) was considerably higher than those 
with a peak cardiac power output >1.96 W (8%). Univariate analysis revealed that rest 
and peak cardiac power output (either continuous or dichotomized at 1.96 W), resting 
and peak cardiac output and peak 2OV&  predicted survival. However, when peak 2OV&  
was dichotomized at 14 ml.kg-1.min-1, this did not predict survival using a univariate 
model. Multivariate analysis identified peak cardiac power output as the only 
independent predictor of mortality. In conclusion, this study reported that peak cardiac 
power output at a level of 1.96 W is the best predictor of outcome in this group of 
patients with congestive heart failure. According to Williams et al. (2001) the non 
predictive value of peak 2OV&  may be linked to the fact that it is only an indirect 
indicator of peak cardiac performance. This study clearly described a critical cut-off 
value of peak cardiac power output which differentiates heart failure patients with a 
good and bad prognosis. It is remarkable that despite marked differences in methods 
and patient population, the results of studies by Roul et al. (1995) and Williams et al. 
(2001) are highly consistent.   
Further, Marmor and Schneeweiss (1997) estimated peak cardiac power output and 




10 healthy volunteers. They were followed up for three years after haemodynamic 
assessment at rest and after incremental dobutamine st mulation. Cardiac power 
output was estimated non-invasively using Doppler utrasonography. They found that 
patients with good cardiac reserve (>1.5 W) survived w ll. However, eight of the nine 
patients with a cardiac reserve of less than 1.5 W died. In this study, using multiple 
logistic regression analysis, cardiac reserve was found to be the only significant 
predictor of survival. Moreover Fincke et al. (2004) evaluated clinical, angiographic, 
and significance in prognosis of haemodynamic variables of 541 patients with 
suspected cardiogenic shock secondary to left ventricula  dysfunction after acute 
myocardial infarction. Haemodynamic variables were obtained by right heart 
catheterization. Fincke et al. (2004) attempted to etermine a cut-off value for cardiac 
power output that is most accurately related to outc me of cardiogenic shock. A 
resting cardiac power output of 0.53 W was found to be most accurate predictor of in 
hospital mortality. The probability of in hospital mortality with cardiac power output 
≤0.53 W was 58%, whereas the probability of survival given a >0.53 W was 71%. 
Fincke et al. (2004) concluded that in acute heart f ilure the patient becomes 
haemodynamically unstable, and most of the cardiac pumping potential is recruited in 
order to sustain life. Hence, cardiac power output measurements in patients with acute 
heart failure at rest represent most of recruitable reserve available during the acute 
event, and their measurement reflects the severity of the patient’s condition (Fincke et 
al., 2004). Recently, Mendoza et al. (2007) also evaluated the prognostic value of 
cardiac power output in a broad spectrum of patients with acute cardiac disease 
undergoing pulmonary artery catheterization. Results indicated that the inhospital 
mortality rate was significantly higher among patien s with cardiac power output 
≤0.53 W compared with those with cardiac power output >0.53 W. Mendoza et al. 
(2007) concluded that cardiac power output is a strong, independent predictor of 
inhospital mortality in a broad spectrum of patients with primary cardiac disease 
undergoing pulmonary artery catheterization.  
Most recently, Lim et al. (2008) using non-invasive in rt gas rebreathing methodology 
compared the prognostic value of peak cardiac output, left ventricular stroke work 
index and cardiac power output to peak oxygen consumption in heart failure patients 




performed in 171 heart failure patients with mean ejection fraction of 24%. Follow-up 
period averaged 337 days. Endpoints consisted of death, urgent transplant or left 
ventricular assist device implantation. Peak oxygen co sumption was 12.9 ml.kg-
1.min-1 and peak cardiac power output 1.7 W. The variables analysed included peak 
oxygen consumption, peak cardiac output, left ventricular stroke work index, 
ventilatory response to exercise, anaerobic threshold and peak cardiac power output. 
On multivariable Cox regression analysis, only ventilatory response to exercise, peak 
cardiac output and peak cardiac power output were predictive, with cardiac power 
output being the most powerful predictor. Lim et al. concluded that peak cardiac 
power output, measured non-invasively, is an independent predictor of outcome that 
can enhance the prognostic power of peak oxygen consumption in the evaluation of 
heart failure patients.     
In summary, this section described the role of cardiac power output and cardiac 
reserve in patients with heart failure. As earlier suggested, the pumping capability 
(peak cardiac power output) is the most powerful predictor of prognosis in heart 
failure, while cardiac pumping reserve is a major determined of exercise capacity in 
heart failure (Cotter et al., 2003; Tan, 1991).  
4.4 Cardiac Power Output in Patients with Periphera l 
Vascular Disease  
As pointed out above, the aim of this chapter was to review all existing literature on 
cardiac power output, including healthy and diseased populations. Only one study has 
been published which evaluated cardiac power output in patients with peripheral 
vascular disease (Hodges et al., 2006). Surprisingly, this study reported similar peak 
cardiac power output values as those reported in severe heart failure. 
‘Peripheral vascular disease is a condition characte ized by atherosclerotic occlusive 
disease of the lower extremities’ (Association, 2003; page 3334). Commonly 
measured clinical parameters (e.g. 2OV& , TQ&  and other metabolic data) are not 
routinely measured in patients with peripheral disease. Claudication free walking time 
or distance and maximal claudication-limited walking time or distance are the most 




et al., 2006). This study uniquely examined cardiovascular variables in patients with 
peripheral vascular disease.   
Fifty consecutive patients completed an incremental treadmill exercise test with two 
minutes stages. Speed and inclination were increased ev ry two minutes by 3.2 km.h-1 
and 2%. Results showed that mean peak cardiac power utput was 2.86 watts. 
Nineteen percent of patients had a peak cardiac power utput of <1.96 watts. Further, 
results demonstrated that mean cardiac output was 9.8 l.min-1, mean arterial pressure 
126.8 mmHg and 2OV&  13.85 ml
.kg-1.min-1. Hodges et al. (2006) indicated that 
surprisingly there is a relative lack of research concerning systematic measurements 
with this group of patients. Based on previous research, the authors reported that 
patients with peripheral vascular disease have the same relative risk of mortality and 
morbidity from cardiovascular events as patients with a history of established 
coronary disease.     
Based on this study it is suggested that assessment of cardiac power output is not only 
a useful measure in heart failure patients, but also in those with peripheral vascular 
disease. This consideration should have more implication in clinical practice helping 
doctors and consultants to make the right decisions f r their patients.   
4.5 Cardiac Power Output and Its Relationship to Ot her 
Cardiorespiratory Variables in Health and Disease 
In normal subjects the maximum oxygen uptake is limited by the ability of the 
cardiovascular system to deliver oxygen to the muscle rather than by the tissue’s 
ability to utilise oxygen (Clausen, 1977). This limitation is, according to Tan (1987), 
more acute in heart failure. In heart failure the reduction in maximal oxygen transport 
to the muscle results from three major factors: 1) reduced cardiac pumping reserve, 2) 
reduced constrictor reserve of vessels supplying the non exercising tissues, and 3) 
reduced vasodilatory capacity of the vessels perfusing the exercise muscles (Tan, 
1987).  
Only a few studies exist which analysed the relationship between cardiac power 




several studies exist which assessed this relationship in diseased populations.    
Hodges (2004) examined the relationship between peak cardiac power output and 
peak oxygen uptake in 102 healthy adults (50 males and 52 females). This 
relationship was assessed by the Pearson product moment correlation coefficient. 
Analysis revealed that a high (r=0.8, p<0.05) correlation between the two variables. 
Subgroup analysis by gender showed a moderate correlation between cardiac power 
output and peak oxygen uptake (males, r=0.58, femals, r=0.61, p<0.05). This 
difference was explained by the difference in heart size and fat free mass between 
males and females. Furthermore Hodges (2004) reported the correlation between peak 
cardiac power output and circulatory power was high (r=0.86). Circulatory power has 
been used as ‘surrogate’ marker of cardiac power output (Cohen-Solal et al., 2002). 
Also, Hodges (2004) reported that the correlation between peak cardiac power output 
and peak cardiac index was high (r=0.81). In addition, Hodges (2004) also found that 
there was a non-linear relationship between cardiac power output and blood lactate 
concentration. There was an exponential relationship between the two variables, but it 
could be explained as two distinct linear relationship  with a break point at 3.2 W. 
However, Hodges (2004) suggested that there were insufficient data points to make a 
judgment about whether the break point indicates th lactate threshold. Overall the 
relationship between blood lactate and cardiac power utput was high (r=0.95).      
Cooke et al. (1998) tested the hypothesis that cardiac power output and cardiac 
reserve correlated with peak oxygen consumption. In this study 70 subjects with a 
wide range of cardiac function, from trained athletes to transplant candidates, 
performed treadmill cardiopulmonary exercise tests with non-invasive estimation of 
haemodynamic parameters (CO2 rebreathing method). Bruce or modified Bruce 
protocols were used. It was found that at peak exercise, cardiac power output was 
significantly related to maximal aerobic capacity (r=0.87, p<0.001). The relationship 
between cardiac output and maximal oxygen consumption was also high (r=0.92, 
p<0.001). Furthermore, peak cardiac power output correlated well with exercise 
duration (r=0.62, p<0.001), suggesting that cardiac reserve is a major determinant of 
exercise capacity. In this study cardiac reserve ranged from 0.27 to 5.65 W, indicating 





Bain et al. (1990) investigated whether resting cardiac power output can be used to 
predict maximum cardiovascular function and reserve as determined by exercise. 
They also investigated whether the relationship betwe n exercise time and cardiac 
power output is stronger than the relationship betwe n the more traditional 
haemodynamic variables and exercise time. Forty-one pati nts with moderately severe 
to severe chronic heart failure were exercised on a cycle ergometer. The mean 
ejection fraction was 25.9%. Haemodynamic data at res and during exercise were 
obtained by the thermodilution method using a Swan-G z catheter. Patients 
exercised commencing at 25 W and increasing by 15 W increments every three 
minutes until stopped by dyspnoea or exhaustion. Results of this study revealed that 
resting cardiac power output moderately correlated with exercise duration (r=0.53), 
while peak cardiac power output had a high correlation with exercise duration 
(r=0.79). Cardiac reserve was also highly correlated with exercise duration (r=0.8). 
Furthermore, resting cardiac index was moderately correlated (r=0.51) with exercise 
duration, while maximum cardiac index correlated well with exercise duration 
(r=0.73). This study pointed out that diuretic therapy increased activation of various 
neuroendocrine mechanisms and may have caused increased catecholamine levels, 
increased plasma rennin activity (which may subsequently fall as diueresis 
progresses) and increased arginine-vasopressin levels causing an increased heart rate 
and systematic vascular resistance. This leads to a rise in mean arterial blood pressure, 
whilst stroke volume decreases. Bain et al. (1990) concluded that resting cardiac 
power output is a poor predictor of cardiovascular functional potential. On the other 
hand, the authors indicated that maximum cardiac power output and the ability to 
increase cardiac power output through exercise are closely correlated with exercise 
time and are therefore good descriptors of functional cardiac reserve. Further it has 
been suggested that cardiac power output has a more than theoretical value in defining 
maximum cardiovascular capacity, particularly in patients who are limited in their 
exercise capacity by both cardiac and other physical conditions (Bain et al., 1990). 
Roul et al. (1995) reported that none of the exercis  variables obtained during 
catheterization were strongly correlated to data at res . As previous studies have 
shown, peak cardiac power output in this study was ell correlated to peak cardiac 




Finally, Williams et al. (2005b) using non-invasive methods, evaluated the 
relationship between direct and indirect indices of cardiac pumping capacity in 219 
patients with chronic heart failure. Results demonstrated that circulatory power 
correlated well with cardiac power output (r=0.84) at peak exercise. However, there 
was a weak but statistically significant relationship between circulatory power at rest 
and cardiac power output at rest (r=0.48). In addition his study revealed a simple 
linear regression equation to allow the calculation of cardiac power output from 
circulatory power: CPO=0.905 x CP – 0.409, with a good fit (adjusted R2=70.5%). 
Circulatory power as an index of cardiac function is the product of systolic blood 
pressure and oxygen uptake. Therefore it should be considered with caution although 
oxygen uptake may be influenced by non-cardiac factors.  
Many studies have shown that resting haemodynamic parameters poorly correlated 
with exercise capacity. On the other hand it has been frequently shown that peak 
cardiac power output has a high correlation with peak oxygen uptake, cardiac index, 
circulatory power and exercise time.  
4.6 Exercise Training and Cardiac Power Output in H ealth 
and Disease 
Controlled clinical studies have recently demonstrated that both in-hospital and home-
based exercise training programmes of various intensiti s induce favourable clinical 
effects by significantly increasing aerobic capacity, delaying the onset of anaerobic 
metabolism, reducing the sympathetic drive, and increasing the vagal tone 
(Belardinelli et al., 1999). According to Tan (1991), whether a therapeutic 
intervention can increase the exercise capacity of a heart failure patient depends on its 
ability to: 1) augment the effective cardiac pumping reserve; 2) improve the way the 
vasculature distributes the pump output; and 3) improve the way the active skeletal 
muscles utilise the substrates delivered to them (e.g. oxygen extraction). It has been 
suggested that in normal healthy subjects exercise training improves cardiac reserve 
and also exercise capacity (Saltin et al., 1968). Apart from exercise training it has also 
been suggested that pharmacological conditioning using vasodilatators (e.g. 
dobutamine) has a positive effect on exercise capacity (Tan, 1987). However further 




this review.  
A few studies have investigated the effect of exercis  training on cardiac power output 
in healthy and diseased populations.  
Marshall et al. (2001) examined the effect of an unsupervised low-budget home based 
exercise training programme of moderate intensity on peak cardiac power output, 
cardiac reserve and aerobic capacity. Nine healthy middle-aged subjects participated 
in a randomized cross-over study. Each subject was tested following eight weeks of 
training (training phase) and eight weeks of ‘non-exercising’ using a 1-min 
incremental treadmill test. During the exercise training protocol, participants trained 
for eight weeks at home using a static upright cycle. They were instructed to exercise 
at 50 rev.min-1 for a 20 min period on five days per week. The resistance on the 
flywheel was set to produce a heart rate that was con istent with a 2OV&  of 75-80% of 
the 2OV&  max achieved during the control incremental test. Participants also 
completed a daily exercise diary. During the non-exercise control phase, all 
participants were instructed to carry out their pre-baseline activities and to avoid any 
additional exercise. Also, during each visit a self-assessment questionnaire, based on a 
Likert scale was completed. An ANOVA and Student’s t test were used to analyse 
data between each period of the study. Results of this s udy revealed that peak cardiac 
power output increased significantly by 16% and cardiac reserve by 21%. A major 
contribution to these improvements was observed in the significant 11.2% rise in peak 
stroke volume and peak cardiac output which increased by 12%. There were non-
significant changes in resting cardiac power output as well as in mean arterial pressure 
between both experimental conditions. Following the training period, when compared 
with the non-exercise control period, all subjects had a significantly lower heart rate at 
rest. Also at submaximal exercise the mean heart rate w s lower after training than 
after the non-exercise control phase. 2OV& max increased significantly by 9% as well 
as exercise time after the training phase. Mean body weight did not alter significantly 
following exercise phase. Peak heart rate and anaerobic threshold did not alter from 
exercise training. Although the intensity of the exercise programme was the same for 
all participants (75-80% of peak 2OV& ) and individual differences in anaerobic 




change following exercise. The improvement in aerobic capacity and cardiac power 
output do not result in an increase in anaerobic threshold. However the relationship 
between these variables, particularly cardiac power output and anaerobic threshold, 
has not yet been established.  It has been also shown that in regard to the responses to 
the self-assessment questionnaire, subjects were significantly more positive in their 
perception of their health, fitness and levels of activity. Marshall et al. (2001) 
concluded that home-based, unsupervised exercise training on a cycle ergometer can 
improve cardiac function, aerobic capacity, exercis duration and quality of life. 
However, it was noted that the exercise programme was the same throughout the eight 
weeks. Based on evidence that changes in intensity and volume of exercise training 
can lead to further improvement of functional abilities (Bompa, 1994), it is prudent to 
suggest that the reported results could have been even better.  
A study by Wright et al. (2002) investigated whether exercise rehabilitation improves 
cardiac performance as well as functional capacity following coronary artery bypass 
grafting. Six weeks postoperatively, 22 patients were randomised either to attend the 
hospital based exercise rehabilitation programme or supervise their own recovery. The 
patients performed a maximal cardiopulmonary exercis  test one week before and one 
week after rehabilitation. Those in the rehabilitation group attended once a week for 
six weeks. On each occasion they completed 12 aerobic exercise stations specifically 
designed to incorporate the use of different skeletal muscle groups. Each week the 
level of exercise was increased to incorporate more rep titions or a greater workload. 
The two study groups were similar in size and demographic characteristics. At 
baseline, both groups demonstrated similar resting a d exercise cardiopulmonary 
responses. Following the six week study period, neither group showed any significant 
changes in resting parameters. However, there was significant increase in peak cardiac 
output (11.3±2.2 to 12.2±1.7 l.min-1), peak cardiac power output (2.97±0.84 to 
3.31±0.7 W) and overall cardiac reserve (1.92±0.72 to .19±0.53 W) in those who 
underwent formal rehabilitation, while no significant changes were shown in control 
group. Furthermore exercise time and peak 2OV&  increased significantly in the 
rehabilitation group (11.2±3.6 to 13.2±3.1 min, and 20.5±4.6 to 22.3±3.4 ml.kg-1.min-
1) and also in the control group (10.8±4.9 to 12.3±47 min, and 20.4±6.4 to 22.7±6.9 




ventilation/rate of oxygen uptake (EV& / 2OV& ) at 1 l
.min-1 of 2OV& , and the rate of 
ventilation/rate of carbon dioxide (EV& / 2C
O
V& ) at 1 l.min-1 of 2C
O
V& , decreased 
significantly in the rehabilitation group (28±5 to 26±4 l.min-1 and 33±5 to 31±4 l.min-
1) respectively. In conclusion Wright et al. (2002) suggested that the provision of 
cardiac rehabilitation post coronary artery bypass graft in many UK centres may be 
insufficient and needs to include more frequent exercis  training sessions over a 
sustained period. The study pointed output that the benefits of exercise training on 
functional capacity and cardiopulmonary function in patients with ischeamic heart 
disease are absolutely clear. In contrast with Marshall et al.’s (2001) study, Wright et 
al. (2002) increased the level of exercise each week. Further comparison of these two 
studies show that benefits gained by an exercise programme were very similar. 
However patients performed exercise less frequently and the exercise training was 
two weeks shorter compared with the healthy population. This suggests that, due to 
exercise training, patients with ischeamic heart disease tend to increase cardiac power 
output and aerobic capacity the same as healthy adults.  
Patwala et al. (2006) performed a randomised controlled trial to assess whether 
exercise rehabilitation increases the benefits of cardiac resynchronisation therapy 
(CRT). Twenty-eight patients were recruited and tested pre, three months post and six 
months post CRT. At each visit triplicate resting cardiac output measurements were 
made using the equilibrium method. A modified Bruce protocol was performed to 
assess peak 2OV&  and peak cardiac output was measured after 30 min rest using the 
exponential method. After the three months test the patients were randomised into 
either on exercise group or a control group. The exrcise group underwent a 
programme consisting of three visits per week. Each visit was made up of 20 min of 
treadmill walking and 10 min cycling. After three months of the exercise programme, 
the patients were tested at the six months stage along with the control group. Results 
demonstrated that there were no significant differences between the groups at 
baseline. By three months there was a significant improvement in NYHA class, 
exercise duration, peak 2OV& , peak cardiac power output and cardiac reserve in both
the control and the exercise group (p<0.05). After a period of randomization to 




the exercise haemodymanic measures (p<0.05), while the control group showed no 
significant changes over this period in any of measured variables. Patawala et al. 
(2006) concluded that exercise rehabilitation leads to an improvement in exercise 
haemodynamic measures. It has been suggested that exercis  rehabilitation should be 
considered for all patients following CRT. 
Hodges (2004) evaluated the influence of a 12-week exercise therapy programme on 
cardiovascular and respiratory dynamics in patients wi h peripheral vascular disease. 
Forty-one patients with mean age of 63 years completed an initial graded exercise test 
to maximum claudication. Then patients were randomly assigned to one of three 
groups: 1) home-based exercise, 2) supervised exercise, and 3) and control group for 
12 weeks. Patients were retested at six weeks, 12 weeks and 12 weeks post 
intervention. Patients in the home-based intervention were asked to go walking three 
times per week for a period of 30 min. In the supervis d group, patients visited the 
hospital twice weekly. Each supervised exercise session lasted for approximately 45 
minutes. During this session patients were encouraged to walk on a treadmill (2 mph 
and 75% of initial grade achieved during the exercise test) until they reached stage 
three or four on the peripheral vascular pain scale and had accrued up to thirty 
minutes of exercise. Repeated measures ANOVA was used to identify any differences 
between the groups. In contrast with previously cited studies, the results demonstrated 
that there were no significant changes in oxygen consumption and peak cardiac power 
output between or within groups. However, significant change was reported in 
maximum walking distance in the supervised group. Hodges (2004) suggested that a 
greater intensity, duration and frequency of exercis  sessions appear to be required 
before improvements in oxygen consumption and peak cardiac power output are 
demonstrated.  A more intense intervention may result in the patients being able to 
sustain longer periods of exercise training, which could result in cardiovascular 







4.7 Recommendation for Future Research  
1. The anaerobic threshold has been proposed as a submaximal index of exercise 
capacity, independent of the subject’s motivation, and has been classically defined as 
the point where lactate increases in plasma during exercise, as a consequence of the 
transition from total aerobic to aerobic plus anaerobic metabolism (Corra et al., 2004). 
Also it has been shown that anaerobic threshold identifi d patients at high risk of 
early death from chronic heart failure better than peak 2OV&  (Gitt et al., 2002). 
Surprisingly there is no study which has examined the relationship between anaerobic 
threshold and peak cardiac power output in either healt y or heart failure population. 
Hence more investigation is required to evaluate possible relationship between the 
two variables. 
2. In patients with severe (advanced) heart failure, prolonged unloading of the 
myocardium with the use of a left ventricular assist device (LVAD) has been reported 
to lead to myocardial recovery in small numbers of patients for varying periods of 
time (Birks et al., 2006). LVADs are increasingly used as a bridge to cardiac 
transplantation and may represent a permanent altern tive therapy for the 
management of end stage heart failure (Mancini et al., 1998). Only a few studies have 
evaluated exercise performance, while no study has reported cardiac power output and 
cardiac reserve in this group of patients. Therefore it will be useful to evaluate cardiac 
power output and cardiac reserve and their relationship to other commonly measured 
variables in those with LVADs.  
3. Research over the past 15 years expanded the understanding and knowledge about 
the role of exercise training in patients with chronic heart failure (Gianuzzi et al., 
2001). A commonly used type of exercise training in patients with chronic heart 
failure is aerobic training. However, a study by Maior na et al. (2000) demonstrated 
that use of combined aerobic and resistance training improves functional capacity as 
well as strength in chronic heart failure. Further r search is needed to determine the 
effect of different types of exercise on cardiac power output and cardiac reserve in 
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CHAPTER 5: RELATIONSHIP BETWEEN PEAK CARDIAC 
POWER OUTPUT AND SELECTED CARDIO-RESPIRATORY 
VARIABLES IN HEALTHY ADULTS 
Abstract 
Introduction: Several studies have demonstrated relationships between overall 
cardiac function represented by cardiac power output and other most commonly 
reported cardio-respiratory variables in both healthy and diseased populations. There 
is, however no evidence to show how peak cardiac power output (CPO) correlates 
with anaerobic threshold (AT), carbon dioxide production ( 2C
O
V& ), minute 
ventilation ( EV& ) and oxygen pulse (OP). The purpose of this study was to assess the 
relationship between peak CPO and AT, 2C
O
V& , EV&  and OP.  This study additionally, 
evaluated the relationship between CPO and the following variables at peak exercise: 
oxygen consumption ( 2OV& ), circulatory power (CP), cardiac index (CI), cardi c 
output ( TQ& ), stroke volume (SV), heart rate (HR) and mean arteri l pressure (MAP). 
Methods: Following local ethics committee approval and informed consent, 37 
healthy adults (23 males and 14 females, means and SD, age 38±12 years, weight 
74±15 kg, height 173±10 cm) performed an incremental exercise test to volitional 
fatigue on a motorised treadmill using the Bruce protocol. Cardio-respiratory 
measurements were recorded on a breath-by-breath basis constantly throughout the 
test using an on-line metabolic analyzer (CardioO2, Medical Graphics, St Paul, 
Minnesota, USA). Blood pressure was measured at the end of each stage as well as at 
peak exercise. Anaerobic threshold was calculated aft r the exercise test using the V 
slope method. Followed a 40 min recovery, the subjects performed a constant 
maximum workload exercise test for at least 4 min to a 2OV&  of at least 95% of the 
maximum level obtained during the incremental test. Cardiac output was measured 
using the exponential CO2 rebreathing method. Results: Mean and SD values for the 
variables investigated were: CPO=4.72±1.13 W; TQ& =19.7±4.6 l
.min-1; MAP=108±7.8 
mmHg; HR=179.5±14.4 beats.min-1; SV=109.4±22.7 ml.beat-1; CI=10.4±2.1 l.min-
1.m2; CP=500±169 mmHg.l .min-1; 2OV& =2.78±0.84 l
.min-1; AT=1.60±0.45 l.min-1; 
OP=15.5±4.1 ml.beat-1; 2C
O
V& =3.46±1.13 l.min-1 and EV& =97.9±32.4 l




linear regression model, the following variables were independent predictors of peak 
CPO: AT (r2=0.22, p<0.01); EV&  (r
2=0.28, p<0.01); OP (r2=0.32, p<0.01); 2C
O
V&  
(r2=0.41, p<0.01); 2OV&  (r
2=0.59, p<0.01); CP (r2=0.45, p<0.01); CI (r2=0.58, 
p<0.01); TQ&  (r
2=0.90, p<0.01); SV (r2=0.88, p<0.01); HR (r2=0.12, p<0.05). Non 
significant association between CPO and MAP at peak exercise was found (r2=0.05, 
p=0.16). Conclusion: In healthy adults AT, 2C
O
V& , EV&  and OP explain 22% to 41% 
of the variance, while 2OV&  and CI explain 59% and 58% of the variance in peak 
CPO. TQ&  and SV explain 90% and 88% of the variance respectively. Only central 
haemodynamic measures such as peak cardiac output and stroke volume are good 
predictors of maximal cardiac pumping capability, while those others routinely 
measured cardio-respiratory variables, including oxygen consumption, should be 
considered with caution in interpretation of overall c rdiac function.  
5.1 Introduction 
The measurement of hydraulic power (cardiac power output) generated by the heart 
provides a supreme opportunity for quantifying cardiac pumping capability (Tan, 
1987). Cardiac power output offers a major advantage over simply measuring cardiac 
output or blood pressure within individual compartments of the cardiovascular system 
(Bain et al., 1990). Cardiac power output is a uniqe measure which takes into 
account both blood pressure and flow. It represents the heart’s ability to act as a 
mechanical pump and produce hydraulic energy which is used to maintain circulation 
(Tan, 1991). It is therefore not surprising that cardi c power output has been proposed 
to be a direct and probably the best indicator of overall cardiac function (Tan, 1986). 
Peak cardiac power output is a major determinant of exercise capacity (Tan, 1986; 
Cooke et al., 1998) and a powerful predictor of prognosis in heart failure (Tan, 1986; 
Roul et al., 1995; Williams et al., 2001).   
Until now, the majority of the studies that have investigated measurement of cardiac 
power output have been conducted in clinical populations, particularly in heart failure 
(Tan, 1986; Tan et al., 1989, Bain et al., 1990; Cooke et al., 1998; Roul et al., 1995; 




included measurements from a healthy population. Cooke et al. (1998) measured gas-
exchange and haemodynamic responses in 70 subjects with widely ranging cardiac 
function but only eight of the subjects were healthy normal volunteers with no known 
cardiac or pulmonary disease. Marshall et al. (2001) measured resting and peak 
cardiac power output together with other cardio-respiratory variables in nine healthy 
subjects before and after an eight-week exercise training programme. More recently, 
Bromley et al. (2006) determined physiological range of peak cardiac power output in 
healthy adults (n=102). Only Hodges (2004) investigated the relationship between 
cardiac power output and other exercise variables in large cohort of healthy adults, but 
this study did not include measures of anaerobic threshold.  
Anaerobic threshold is a good predictor of performance in a variety of endurance 
activities (e.g. running, cycling, race walking) in both trained and untrained 
populations (Weltman, 1995). Anaerobic threshold is al o an effective index of 
cardiopulmonary exercise capacity in patients with different cardiopulmonary 
disorders (Wasserman, 1999) and an excellent predictor of prognosis in heart failure 
(Gitt et al., 2002). 
At present there are no data which assess the possible relationship between cardiac 
power output and anaerobic threshold in either healt y or diseased subjects. Peak 
cardiac power output has not been previously correlated with measure of: carbon 
dioxide production, minute ventilation and oxygen pulse taken at peak exercise.         
5.1.1 Definitions and Physiological Bases of Measured Variables 
5.1.1.1 Cardiac power output (CPO) 
Cardiac power output has been defined as a direct indicator of overall cardiac function 
which is calculated from the product of cardiac output and mean arterial pressure 
expressed in Watts (Tan, 1986). The concept of cardiac power output has been 




5.1.1.2 Anaerobic (ventilatory) threshold (AT) 
Anaerobic threshold is the point at which the metabolic demands of exercise can no 
longer be met by available aerobic sources and at which an increase in anaerobic 
metabolism occurs, reflected by an increase in blood lactate concentration (Wilmore 
and Costill, 2004). It is the point at which lactate begins to accumulate in the blood, 
when the rate of lactate appearance in the blood exceeds the rate of its removal, 
causing an increase in ventilation (Myers and Ashley, 1997). Anaerobic threshold is 
also known as the lactate threshold, lactic acid thres old, gas exchange threshold or 
ventilatory threshold, regardless of which methodolgy is used in determination. Non 
significant difference and high relationship was reported between lactate and 
ventilatory thresholds (Beaver et al., 1986; Wyatt, 1999; and Gaskill et al., 2001).  
The basis behind the link between the lactate and ve tilatory threshold is an increased 
chemoreceptor drive (Swanson, 1979; and Whipp, 1994). As lactate accumulates, 
there is a reduction in pH. This increases chemoreceptor drive to the respiratory 
centres (Astrand and Rodahl, 1986). Because of buffering of lactic acid, there is an 
increase in 2C
O
 and H+ (Ganong, 1983). When there is a rise in arterial 2P
c
o
 due to 
increased tissue metabolism and insufficient alveolar ventilation, ventilatory 
stimulation takes place (Wasserman et al., 1999). Also Wasserman (1976) found that 
the delivery of 2C
O
 to the lungs drives ventilation.  
5.1.1.3 Peak (maximal) oxygen consumption ( 2OV& ) 
Maximum oxygen consumption ( 2OV& max) is defined as the highest rate of oxygen 
that can be taken up and utilized by the body during severe exercise (Bassett and 
Howley, 2000). It is one of the main variables in the field of exercise physiology, and 
is frequently used to indicate the cardio-respiratory fitness of an individual. 2OV&  can 
be computed from blood flow and 2O  extraction by the tissues, as expressed in the 
Fick equation. Factors that can influence 2O  availability are: oxygen carrying 
capacity of the blood (available hemoglobin, arterial 2O  saturation, and dissociation 
curve shifts with temperature, 2C
O




volume), redistribution of peripheral blood flow, and extraction by the tissues 
(capillary density, mitochondrial density and function, adequacy of perfusion, and 
tissue diffusion).  
As 2OV&  increases with increasing external work, one or moe determinants of 2OV&  
approach limitations (e.g. stroke volume, heart rate, or tissue extraction) and 2OV&  
versus work rate may begin to plateau. Achieving a clear plateau in 2OV&  has 
traditionally been used as the best evidence of 2OV& max which is the best index of 
aerobic capacity and the gold standard for cardio-respi atory fitness (Johnson et al., 
2003). However, in clinical testing situations, a clear plateau may not be achieved 
before symptom limitation of exercise (Myers et al., 1989). Consequently, 2OV& peak is 
often used as an estimate for 2OV& max indicating that for practical purposes 2OV& max 
and 2OV& peak may be used interchangeably (Johnson et al., 2003). 
5.1.1.4 Carbon dioxide production ( 2C
O
V& ) 
Carbon dioxide production has been defined as the amount of 2C
O
 produced by the 
body’s metabolic processes and in some circumstances rel ased by buffering reactions 
within the body (Wasserman et al., 1999). During exercise 2C
O
V&  is determined by 
factors similar to those that govern 2O  uptake such as cardiac output, 2C
O
 carrying 
capacity of the blood and tissue exchange (Johnson et al., 2003). During short-
duration exercise, glycogen is used primarily by the muscles for energy, and the 
relationship between 2O  consumption and 2C
O
 production is almost equimolar. As 
such, during progressive exercise 2C
O
V&  increases nearly as much as does 2OV&  over 
the lower work rate range, with an average 2C
O
V& - 2OV&  relationship slightly less 
than 1.0 (Wasserman, 1999). There is typically a rel tiv ly sharp change in 2C
O
V& -
2OV&  slope toward the midrange of the 2OV&  response. This results in a steeper, but 
typically quite linear, profile over the upper work rate range (Wasserman et al., 1999). 
The steeper slope reflects the 2C
O
 generated in excess of that produced by aerobic 




these high work rates. With anaerobic metabolism, 2C
O
V&  increases as results of a 
chemical reaction between hydrogen ions from lactate and dissolved 2C
O
.    
5.1.1.5 Minute ventilation ( EV& ) 
Minute ventilation is defined as the volume of air t ken into or exhaled from the body 
in one minute and is the product of tidal volume and breathing frequency (Wasserman 
et al., 1999). Increased ventilation during exercis is one of the primary means by 
which arterial blood regulates gases and acid-base status under of the augmented 
metabolic demands of exercising muscles (Johnson et al., 2003). The rise in EV&  with 
exercise is associated with an increase in both tidal volume and frequency of 
breathing. In health, increases in tidal volume are primarily responsible for increases 
in ventilation during low levels of exercise (Gallagher et al., 1987). As exercise 
progresses, both tidal volume and breathing frequency increase until 70-80% of peak 
exercise and thereafter an increase in breathing frequency predominates (Gallagher et 
al., 1987). In both the steady-state and during exercis  transients, EV&  responds in 
close proportion to 2C
O
 (Wasserman et al., 1999).     
5.1.1.6 Oxygen pulse (OP) 
The ratio of 2OV&  to heart rate is conventionally termed as the “oxygen pulse” (OP) 
and reflects the amount of 2O  extracted by the tissues of the body per heart beat
(Wasserman et al., 1999). According to the modified Fick equation, OP is numerically 
equal to the product of stroke volume and arterial-venous 2O  difference. It is not, 
therefore, surprising that OP has been used by some authors as an estimator of stroke 
volume during exercise (Wasserman et al., 1999). At any given work rate, the subject 
with the greatest maximal working capacity normally has the highest OP, and the 
subject with the lowest maximal working capacity normally has the lowest OP 




5.1.1.7 Circulatory power (CP) 
Circulatory power represents the volume of 2O  added to the mixed venous blood by 
the lungs and transferred to the systematic arterial circulation, against a pressure 
gradient, by the heart (Nicholls et al., 2002). It is calculated as the product of oxygen 
uptake and systolic blood pressure (Cohen-Solal et al., 2002). Cohen-Solal et al. 
suggested that circulatory power may be assumed to mirr r the cardiac power output 
at peak exercise. This is only true if arterial-venous 2O  difference does not differ 
much at peak exercise among subjects, and systolic and mean arterial pressure 
increase in parallel during exercise. These assumptions may be acceptable in a healthy 
population, whereas in those with cardiovascular disor ers they must be considered 
with caution. Cohen-Solal et al. (2002) therefore recommended that the circulatory 
power should not be viewed as a perfect surrogate of cardiac power output, but as a 
new global ‘easy to measure’ index that incorporates, besides arterial-venous 2O  
difference, heart rate, stroke rate, and blood pressur  responses.  
5.1.1.8 Cardiac index (CI) 
Cardiac index is defined as cardiac output to body surface area ratio. The original 
reason for using the cardiac index as a means for exp essing cardiac output for 
individuals of different sizes was that the basal metabolic rate in human beings is 
generally expressed in terms of surface area (Guyton, 1996). One would expect the 
cardiac output to be greater in a large person compared with a small person (Guyton, 
1996). In the clinical environment cardiac index is widely used as an indicator of 
cardiac function and blood flow. However this may not be the best method of 
normalizing cardiac output for body size (Hodges, 2004). Cardiac output may be 
better related to body volume, as this takes into account how far the blood has to 
travel in order to meet the demands during exercise (Hodges, 2004).    
5.1.1.9 Cardiac output ( TQ& ) 
Cardiac output is the flow of blood from the heart in a particular period of time. It is 




1999). Cardiac output increases with exercise to support the increasing metabolic 
demands of the tissues. In healthy subjects, TQ&  is a linear function of 2OV&  and does 
not vary as a function of either sex or state of training (Johnson et al., 2003). Also 
Proctor et al. (1998) demonstrated that neither age nor gender has significant impact 
on the TQ& - 2OV&  relationship during submaximal cycle ergometry among chronically 
endurance-trained individuals. Increases in TQ&  are initially accomplished by 
increases in stroke volume and heart rate, and then at moderate to high intensity 
exercise almost exclusively by increases in heart rate. The increase in TQ&  is largely 
driven by vagal withdrawal and by increases in either circulating or neurally produced 
catecholamines.       
5.1.1.10 Stroke volume (SV) 
Stroke volume is the amount of blood ejected from left ventricle during contraction. 
Stroke volume also changes during exercise to allow the heart to work more 
efficiently. However there are conflicting data about stroke volume changes as a 
person goes from very low rates of work to maximal work or exhaustion. Most 
researchers agree that stroke volume increase with increasing rates of work but only 
up to 40-60% of maximal capacity (Wilmore and Costill, 2004). At that point, stroke 
volume is thought to plateau, remaining essentially unchanged up to and including the 
point of exhaustion. Others have reported that SV continues to increase up through 
maximal exercise intensities (Zhou et al., 2001). The mechanism of SV increase 
during exercise has commonly been explained by the Frank-Starling law, which states 
that the primary factor in controlling stroke volume is the extent to which the ventricle 
stretches and consequently contract.   
5.1.1.11 Heart rate (HR) 
Heart rate reflects the amount of work the heart must do to meet the increased 
demands of the body when engaged in activity (Wilmore and Costill, 2004). In 
healthy subjects, HR increases linearly with increasing 2OV& . Increases in HR are 
initially mediated by a decrease in parasympathetic activity (vagal withdrawal) and, 




5.1.1.12 Mean arterial pressure (MAP)    
As exercise intensity increases, reflex control of the distribution of cardiac output 
causes some characteristic changes in blood pressure and vascular resistance (Perloff 
et al., 1993). In working muscles, there are local mediators that cause intense 
vasodilatation that increases blood flow to support metabolic demands. In addition, 
non-working muscles are vasoconstricted from reflex increases in sympathetic nerve 
activity. The net result is a fall in systematic vascular resistance, but systolic blood 
pressure typically rises progressively with an increase in 2OV& . Diastolic blood 
pressure typically remains constant or may decline slightly (Johnson et al., 2003). 
Mean arterial pressure is calculated from the following equation: DBP + 0.412 x (SBP 
– DBP), where SBP is systolic blood pressure and DBP is diastolic blood pressure 
(Meaney et al., 2000). 
5.1.2 Non-invasive Methods for Determination of Anaerobic Threshold  
Increases in lactic acidosis can be determined non-i vasively by observing the 
patterns of change in 2C
O
V&  and EV&  relatively to 2OV&  as exercise intensity 
increases. The following are the two most commonly used methods.  
5.1.2.1 Ventilatory equivalent method 
The ventilatory equivalent method involves the simultaneous analysis of the 
ventilatory equivalent of oxygen (EV& / 2OV& ), the ventilatory equivalent for carbon 
dioxide EV& / 2C
O
V& , end-tidal PO2 (PETO2) and end-tidal PCO2 (PETCO2). According to 
this method anaerobic threshold is defined as the int nsity of activity (e.g. 2OV& ) 
which causes the first rise in EV& / 2OV&  without a simultaneous rise in EV& / 2C
O
V&  
(Reinhard et al., 1979).  
In response to a progressive exercise test, the linear pattern of increase in 2C
O
V&  and 
EV&  seen at low work rates changes to a curvilinear pattern at high work rates 




linearly. EV&  and 2C
O
V&  initially accelerate in a proportional manner above the AT. 
Therefore, EV& / 2OV&  and PETO2 increase, whereas EV& / 2C
O
V&  and PETO2 remain 
constant for a brief period of time (isocapnic buffering) due to the lack of 
hyperventilation with respect to 2C
O
, despite the development of metabolic acidosis 
(Wasserman et al., 1999).  
5.1.2.2 V-Slope method     
Beaver et al. (1986) aimed to derive an objective mathematical method, based on 
buffering of lactic acid, which could reliably locate anaerobic threshold. Importantly it 
should be independent of the sensitivity of ventilatory control mechanisms. The 
method involves the analysis of the behaviour of 2C
O
V&  as a function of 2OV&  during 
progressive exercise tests. The point of exceeding the lactate threshold is 
accompanied by the buffering of lactic acid by [HCO3
-] with a consequent increase in 
2C
O
V& (Beaver et al., 1986). This results in a transition in the relationship between the 
2C
O
V&  and 2OV&  which is the underlying element on all methods of anaerobic 
threshold detection by gas exchange (Wasserman et al., 1999). Since the method to 
detect AT is based on analyzing the slopes of 2O  and 2C
O
 volume curves, Beaver et 
al. (1986) termed this procedure V-slope method. As thi  method uses simultaneous 
measurements of 2C
O
V&  and 2OV& , it is independent of the subject’s ventilatory 
response and insensitive to irregularities of breathing. It is therefore inappropriate to 
use the term ventilatory but rather anaerobic, lactate or lactate acidosis threshold 
(Wasserment et al., 1999).      
Wasserman et al. (1999, p. 74) explained V-slope method as following: “When the net 
increase in lactate accumulation produces an acidosis, 2C
O
V&  accelerates relative to 
2OV& . When these variables are plotted against each other, e relationship is 
composed of two apparently linear components, the lower of which (S1) has a slope 
of slightly less than 1.0, whereas the upper component (S2) has a slope steeper than 
1.0. The intercept of these two slopes is the AT as measured by gas exchange”.  




automated metabolic gas analyzers. For the purpose of the present study the V-slope 
method will be used to identify the point of AT.   
5.1.3 Rationale and Purposes of the Study 
There are few studies which have evaluated the relationship between overall cardiac 
function (represented by cardiac power output) and other commonly reported cardio-
respiratory variables in healthy adults. Anaerobic threshold has been used as a 
criterion of the ability of the circulatory system to deliver and utilize oxygen during 
exercise (Cohen-Solal et al., 1994) and an objectiv parameter of cardiopulmonary 
exercise capacity (Gitt et al., 2002). At present there is no study which has examined 
the relationship between peak cardiac power and a submaximal index of 
cardiopulmonary exercise capacity such as anaerobic threshold (AT) in healthy adults. 
Also peak cardiac power output has not previously been correlated with: carbon 
dioxide production ( 2C
O
V& ), minute ventilation ( EV& ) and oxygen pulse (OP), as 
measured at peak exercise. The first purpose of the present study was, therefore, to 
assess the relationship between peak CPO and AT, 2C
O
V& , EV&  and OP in healthy 
adults. Furthermore the study evaluated the relationship between cardiac power output 
(CPO) and the following cardio-respiratory variables measured at peak exercise: 
oxygen consumption ( 2OV& ), circulatory power (CP), cardiac index (CI), cardi c 
output ( TQ& ), stroke volume (SV), heart rate (HR) and mean arteri l pressure (MAP). 
5.1.4 Research Hypotheses 
H1 – There will be a significant positive relationship between peak CPO and AT, 
2C
O
V& , EV&  and OP. 
H2 – There will be a significant positive relationship between peak CPO and 2OV& , 






Healthy subjects were recruited from a South-East UK University. The advertisement 
of the study used the university website, e-mail addresses and posters. Contact details 
of the research team were clearly displayed. All subjects who volunteered to 
participate in the study received an information sheet, medical history/lifestyle and 
physical activity readiness questionnaire (PARQ). 
Twenty-three healthy men and 14 women ranging from 20 – 63 years of age were 
enrolled. Subjects with any history of cardiovascular, pulmonary, metabolic and 
neuromuscular problems or taking prescribed mediations known to affect 
cardiovascular or respiratory function were excluded. All subjects were asked to 
refrain from eating two-hours prior to testing. Subjects were instructed to abstain from 
caffeine and alcohol 12 hours prior to exercise testing, to abstain from cigarette 
smoking three hours prior testing, and to avoid heavy physical exertion during the 48 
hours preceding the test. This study was approved by the appropriate Faculty Ethics 
Committee. All subjects gave their written informed consent. 
5.2.2 Experimental Design 
This study took the form of a correlation study with various cardiovascular (OP, CP, 
CI, TQ& , SV, HR, MAP) and respiratory (AT, 2OV& , 2C
O
V& , EV& ) measures being 
designated as the independent variables and CPO being d signated as the dependent 
variable.  
5.2.3 Equipment 
Exercise tests were performed using a treadmill adjustable for gradient and speed 
(Cardio Control, Delft, The Netherlands). Breath-by-breath 2OV& , 2C
O
V& , end-tidal 
partial pressure of 2C
O
, tidal ventilation, and respiratory rate were all measured 
using an online metabolic gas analyser (CardiO2, Medical Graphics Corporation, St 




(Cardio Perfect ST 2001) which was used to monitor heart rate and rhythm prior and 
during the exercise test. Blood pressure was measurd manually by auscultation using 
a sphygmomanometer (ERKA, Kallmeyer Medizintechnik, Germany) and Littman 
stethoscope (3M Health care, St Paul, MN, USA). 
5.2.4 Procedure  
5.2.4.1 Pre-test procedure 
On arrival at the laboratory, subjects were asked for their completed PARQ forms and 
questioned about their medical health.  Subjects were then required to complete the 
informed consent form in front of the researcher who countersigned it as a witness. 
Subjects had their mass measured using a floor scale (Seca mode 761, Vogel and 
Halke, Germany) and height recorded using a freestanding stadiometer (Leicester 
Height Measure, Invicta Plastics, Oadby, Leicester, UK) prior to exercise testing.  
Three out of 37 subjects were unfamiliar with using a treadmill and they were asked 
to complete a familiarisation procedure. During this process subjects were instructed 
on treadmill walking, balance and posture. All other subjects were familiar with 
whole testing procedure, including the fitting face mask, as they had participated in a 
previous exercise testing study with similar characteristics. Subject were asked not to 
talk during the test and instead, they were instructed to use hand signals to express 
their feelings: 1) “thumbs up” – meant that the subject was feeling good and able to 
carry on, 2) “thumbs to the side” – meant that the subject was starting to get tired, 3) 
“thumbs down” – meant that the subject wanted to stop the exercise test. In addition 
subjects were familiarised with the use of the Borg Scale (Borg, 1970) and also 
instructed how to use to an emergency stop button which was located at the front of 
the treadmill. 
ECG electrodes (Blue Sensor, Medicotest, Olstykke, D nmark) were attached 
according to the standard lead configuration for exercise testing and the ECG cables 
were connected. In order to minimise both interference with the exercise limbs and 
the signal to noise ration, the cables were secured around the subject’s waist be means 




blood pressure was measured and a resting ECG was also monitored prior to the of 
exercise test.  
5.2.4.2 Testing procedure 
Exercise testing included two stages separated by a 40 min recovery period, as 
described below. 
Stage 1 – Determination of maximal aerobic capacity. In this stage all subjects 
performed an incremental exercise test (Bruce et al., 1973) to determine peak oxygen 
consumption. The Bruce protocol begins with 3 min stages of walking at 1.7 mph and 
10% gradient. Thereafter, the grade is incremented 2% every 3 minutes, and the speed 
is incremented 0.8 mph every 3 minutes until the treadmill reaches 18% grade and 5 
mph. After this, the speed is increased by 0.5 mph every 3 min. The Bruce protocol 
has been widely used for exercise stress testing (ACSM, 2000). Blood pressure was 
measured every two minutes into each stage and during peak exercise. Following 
blood pressure measurements, the subject pointed on the Borg scale which was 
located a front of him to indicate the subjective fe ling of exercise. On approximately 
every minute of the test, subjects were also asked “Are you feeling ok?” They replied 
with thumb signals as described above. The test was terminated when the subject 
desired to stop or when the researcher considered the subject was unable to continue 
exercising. For an early test termination, the researcher used the criteria recommended 
by the ACSM (2000): 1) onset of angina or angina like symptoms, 2) significant drop 
(20 mmHg) in systolic blood pressure or a failure of the systolic blood pressure to rise 
with an increase in exercise intensity, 3) excessive rise in blood pressure: systolic > 
260 mmHg or diastolic pressure >115 mmHg, 4) signs of poor perfusion: light 
headiness, confusion, ataxia, pallor, cyanosis, nausea or cold and clammy skin, 5) 
failure of heart rate to increase with increased exercise intensity, 6) noticeable change 
in heart rhythm, 7) subjects requests to stop, 8) physical and verbal manifestation of 
severe fatigue, and 9) failure of the testing equipment. The criteria adopted by the 
researcher for the achievement of peak 2OV&  were the absence of a rise in 2OV&  with 
an increase in exercise intensity and a respiratory exchange ratio >1.15.    




and heart rate were continuously monitored and the treadmill was stopped when the 
subject’s heart rate returned within 5% of the initial resting values.  
Stage 2 – Cardiac output measurement. Stage 2 was performed following a 40-minute 
rest period. During the rest period the equipment was reconfigured and also 
recalibrated. Recalibration was necessary because ther  was a change in the dead 
space of equipment. The configuration used for monitori g cardiac output has a dead 
space of 80 ml and the normal mouthpiece and pneumotach configuration used during 
the first test has a dead space of 50 ml. The anaesthetic bag was filled with 4% carbon 
dioxide, 35% oxygen and the balance nitrogen. A 6 l anaesthetic rubber bag was filled 
with approximately 1.5 to 2 times the subject’s tidal volume. Peak cardiac output was 
measured at maximal exercise by the exponential 2C
O
 rebreathing method described 
by Defares (1958). The exponential 2C
O
 rebreathing method was described in more 
details in Chapter 3.  
The second stage of the testing procedures was a constant maximal workload exercise 
tests of approximately five minutes in duration. The treadmill speed and incline were 
initially set to the highest completed or nearly completed stage of the incremental 
protocol. The gradient and the speed were than adjusted on an individual basis to 
enable the subject to sustain the exercise for at least five minutes and a 2OV&  of at 
least 90% of the maximum attained during incremental test. Once the subject had 
reached 95% of peak 2OV& , the researcher pushed the plunger to switch the subject to 
rebreathing the gas mixture from the bag for 15 seconds after which the plunger was 
pulled out and the subject breathed room air. An exponential capnograph tracing was 
produced whilst the subject rebreathed the gas mixture. The line of best fit was plotted 
through the end-tidal 2C
O
 pressure points using the technique described by DaSilva 
et al. (1985). The first point in the graph was rejected. Once the line of best fit had 
been completed the computer systems generated the cardia  output estimate by means 
of the indirect Fick method as described in Chapter 3. Peak blood pressure was 




5.2.5 Calculations and Statistical Analysis 
The cardiac power output was calculated from the product of cardiac output and mean 
arterial pressure using the following equation (Cooke et al., 1998): CPO = (TQ&  x 
MAP) x K, where CPO is cardiac power output in Watts (W), TQ&  is cardiac output in 
l .min-1, MAP is mean arterial pressure in mm Hg and K is the conversion factor (2.22 
x 10-3). The mean arterial pressure was calculated as DBP + 0.412 x (SBP – DBP), 
where SBP is systolic blood pressure and DBP is diatolic blood pressure (Meaney et 
al., 2000).  
All statistical analysis was carried out using SPSS version 13.0 (SPSS inc. Chicago, 
Illinois, USA). Prior to statistical analysis, data were checked for univariate and 
multivariate outliers using standard Z-distribution cut-offs and Mahalanobis distance 
tests respectively. Normality of distribution was asessed using a Kolmogorov-
Smirnov test. Correlation between peak cardiac power output and selected cardio-
respiratory variables were assessed by univariate lnear regression analysis. When 
data met parametric assumptions the relationship between cardiac power output and 
other cardio-respiratory variables was assessed using Pearson’s product moment 
coefficient of correlation. The Spearmen rank-difference correlation was used when 
data did not meet parametric assumption. The meaningfulness of coefficient of 
correlation was evaluated by calculating the coefficient of determination (r2). 
Differences in measured variables between men and women were determined using 
independent samples t-tests and percentage differenc s were calculated. Statistical 









Demographic details and physical characteristics of the studied population are 
presented in Table 5.1. 
Table 5.2 shows the peak values of cardiac power output and other measured cardio-
respiratory variables at peak exercise. The range of peak 2OV&  indicates clearly that 
subjects come from a wide variety of aerobic capacities. The range of peak cardiac 
power output illustrates the wide variety of power output generated by the heart in 
healthy adults. The subjects achieved the following results during the incremental 
exercise test: exercise duration 11.9±2.6 minutes, relative peak oxygen consumption 
37.7±9.9 ml.kg-1.min-1, anaerobic threshold 21.8±5.7 ml.kg-1.min-1 and respiratory 
exchange ratio 1.23±0.10. During the second test when TQ&  was measured, subjects 
achieved a mean peak 2OV&  of 102±11% of that attained in the first test.  
Table 5.1 Descriptive Statistics of Subjects’ Demographic and Physical 
Characteristics Details 
Men, N=23 Women, N=14 All subjects, N=37 
Parameter 
Mean+SD Range Mean+SD Range Mean+SD Range 
Age (years) 34±9.7 20-59 44.5±12.3* 24-63 38.2±11.8 20-63 
Weight (kg) 80.2±14.3 55.5-116 64.1±8.9* 52.5-80 74.5±14.6 52.5-116 
Height (cm) 178.9±7.2 165-194.3 163.3±5.6* 153.2-172.5 173.3±10.0 153.2-194.3 
BMI (kg.m2) 24.9±3.6 20.1-29.2 24.2±3.6 19.1-31.3 24.7±3.5 19.2-29.3 
BSA (m2) 2.0±0.2 1.6-2.4 1.7±0.1* 1.5-1.9 1.9±0.2 1.5-2.4 
   
From all cardio-respiratory variables measured at peak exercise only mean arterial 
pressure was not significantly different between men and women (p=0.38) (Table 
5.2). The percentage difference between men and women for CPO and TQ&  were 33 
and 32%, respectively.  
BMI-body mass index, BSA-body surface area;  




In order to decrease the effect of body size on peak CPO, allometric scaling model 
was used as suggested by Chantler et al. (2005). The positive relationship between 
peak CPO and body surface area was found (r=0.64, p<0.01). Therefore peak CPO 
was allometrically scaled to body surface area using the exponent for body surface 
area of 0.81 as suggested (Chantler et al., 2005). Peak CPO was then not significantly 
different between men and women (3.02±0.44 vs. 2.35±0.35 W/m2, p=0.23) with 
mean percentage difference between men and women of 22%.   
 
Table 5.2 Gender Differences in Measured Cardio-respiratory Variables  
Men, N=23 Women, N=14 All Subjects, N=37 Cardio-
respiratory 
Variables Mean+SD Range Mean+SD Range Mean+SD Range 
CPO (W) 5.40±0.78 4.06-7.18 3.60±0.55* 2.72-4.41 4.72±1.13 2.72-7.18 
TQ&  (l.min-1) 22.4±3.5 16.5-28.7 15.2±2.0* 10.7-17.8 19.7±4.6 10.7-28.7 
CI (l . min-1 . m2) 11.4±2.0 8.6-15.6 9.0±1.3* 5.8-11.4 10.5±2.1 5.8-15.6 
HR (beats . min-1) 185±12 156-205 171±14* 154-192 180±14 154-205 
SV (ml . beat-1) 121.5±18.2 80.5-151.9 89.5±13.5* 68.2-115.6 109.4±22.7 68.2-151.9 
MAP (mmHg) 109±7.1 96.3-121.6 106.6±8.9 89.8-123.0 108.1±7.8 89.8-123 
CP  
(mmHg . l . min-1) 
610±110 377-791 320±45* 247-408 500±109 247-791 
OP (ml . beat-1) 18.0±2.9 12.5-24.0 11.3±1.7* 9.0-15.0 15.5±4.1 9.0-24.0 
AT (l . min-1) 1.84±0.37 1.33-2.69 1.20±0.23* 0.89-1.61 1.60±0.45 0.89-2.69 
2OV&  (l . min-1) 3.30±0.58 2.12-4.40 1.92±0.32* 1.49-2.43 2.78±0.84 1.49-4.40 
2C
O
V&  (l . min-1) 4.18±0.76 2.59-5.69 2.28±0.38* 1.61-2.82 3.46±1.13 1.61-5.69 
EV&  (l 
. min-1) 117.6±22.6 62.3-166.4 65.5±14.8* 46.6-89.4 97.9±32.4 46.6-166.4 
     
 
CPO-cardiac power output, TQ& -cardiac output, CI-cardiac index, HR-heart rate, SV-stroke 
volume, MAP-mean arterial pressure, CP-circulatory power, OP-oxygen pulse, AT-anaerobic 









When men and women data were pooled, coefficients of correlation were significant 
between peak absolute values of CPO and other cardio-respiratory variables as shown 
in Figures 5.1 – 5.10. Only peak mean arterial pressure was not significantly 




































    














































































              
Figure 5-5                                                            Figure 5-6 
 
 



































   



































                                        
Figure 5-9                                                   Figure 5-10 
 
Figures 5-7 – 5-10 Relationship between peak cardiac power output (CPO) and peak 
cardiac index (CI), peak cardiac output (TQ& ), peak stroke volume (SV), peak heart 
rate (HR). 
Figures 5-1 – 5-6 Relationship between peak cardiac power output (CPO) and 
anaerobic threshold (AT), peak oxygen consumption (2OV& ), peak carbon dioxide 
production ( 2C
O
V& ), peak minute ventilation (EV& ), peak oxygen pulse (OP) and 





Peak cardiac power output correlated well with exercis  duration (r=0.66, p<0.01).  
Subjects achieved 96 and 92% of maximal predicted heart rate during incremental and 
single stage exercise test. When these values were cor lated with peak CPO there 
was none significant relationship between peak CPO and peak heart rate (r=0.10 and 
0.14, p>0.05).     
Subgroup analysis by gender demonstrated that peak CPO correlated to TQ& , SV, CI 
and 2OV&  in the similar way in men and women as shown in Table 5.3. 
 
Table 5.3 Relationship between Peak CPO and Selected Variables in Men and 
Women 
 Men, N=23 Women, N=14 
  Correlation with peak CPO  Correlation with peak CPO 
 Mean+SD r p Mean+SD r p 
TQ&  (l.min-1)  22.4±3.5 0.90 <0.01 15.2±2.0 0.82 <0.01 
SV  
(ml.beat-1) 
121.5±18.2 0.89 <0.01 89.5±13.5 0.88 <0.01 
CI 
(l.min-1.m2) 
11.4±2.0 0.64 <0.01 9.0±1.3 0.62 <0.05 









CPO-cardiac power output, TQ& -cardiac output, SV-stroke volume, CI-cardiac index, 2OV& -





Numerous cardio-respiratory indices of exercise tolerance are routinely measured 
during exercise test. Many of these are used either to grade severity or provide 
prognosis in many cardiovascular diseases. The present study aimed to assess the 
relationship between peak cardiac power output and a umber of cardio-respiratory 
variables which are commonly measured during cardio-pulmonary exercise testing. 
This is the first study to analyse the relationship between peak cardiac power output 
and anaerobic threshold, carbon dioxide production, mi ute ventilation and oxygen 
pulse. Also for the first time the relationship betw en peak cardiac power output and 
peak stroke volume as a component of cardiac output has been analysed.   
One novel finding from this study is that AT, 2C
O
V& , EV&  and OP explain only 22% 
to 41% of the variance in peak CPO in healthy adults, whereas 2OV&  and CI explain 
59% and 58% of the variance. Cardiac output and stroke volume, however explain 
90% and 88% of the variance in peak cardiac power output. This suggests that most of 
the cardio-respiratory variables routinely measured during cardiopulmonary exercise 
testing are only weakly related to overall cardiac function. Overall cardiac function is 
much more strongly associated with central haemodynamic variables such as cardiac 
output and stroke volume.  
5.4.1 Relationship between Peak Cardiac Power Output and Anaerobic 
Threshold  
The anaerobic threshold is an objective parameter of cardiopulmonary exercise 
capacity (Wasserman et al., 1999) which has been considered to be a good predictor 
of performance in a variety of endurance activities ( .g. running, cycling, race 
walking) and for both trained and untrained populations (Weltman, 1995). Myers and 
Ashley (1997) also suggested that the level of work that can be sustained prior to 
lactate accumulation is an accurate predictor of endurance performance. In a clinical 
population (e.g. heart failure), whose cardiac functio  response to incremental 
exercise is impaired in proportion to the severity of pump dysfunction, determination 




(Matsumura et al., 1983) and to predict outcome (Gitt et al., 2002).  Finally, the 
anaerobic threshold has been used as a criterion of the ability of the circulatory system 
to deliver and utilize 2O  during exercise (Cohen-Solal et al., 1994). 
Taking into account the above facts and considering cardiac power output as direct 
indicator of overall cardiac function, one would exp ct a strong positive relationship 
between the CPO and AT. The present results from healthy adults demonstrate only a 
moderate relationship between these variables suggetin  that a higher anaerobic 
threshold does not necessary indicate better cardiac performance as represented by 
peak cardiac power output. More precisely, calculated coefficient of determination 
indicates that differences in peak cardiac power output may explain only 22% of the 
variance observed in anaerobic threshold. This may in part be attributable to the 
contribution of the peripheral muscles characteristics (e.g. mitochondrial content, 
capillary density) to the anaerobic threshold (Basset and Howley, 2000), whereas 
cardiac power output is reflection of central haemodynamics.   
5.4.2 Relationship between Peak Cardiac Power Output and Peak 
Carbon Dioxide Production and Minute Ventilation 
Carbon dioxide production is linked to both circulation through the Fick equation and 
respiration through the level of ventilation (Hachamowitch et al., 1991). During 
exercise 2C
O
V&  is determined by factors similar to those that govern 2O  uptake such 
as cardiac output, 2C
O
 carrying capacity of the blood and tissue exchange (Johnson 
et al., 2003). On the other hand EV&  is closely linked to 2C
O
V&  at all times. During 
rest or very mild exercise, the relationship between EV&  and 2C
O
V&  can vary widely, 
predominantly because of psychogenic factors and difference in partial arterial CO2 
pressure ( 2c
o
Pa ) and dead space-tidal volume ratio (Sun et al., 2002). During heavy 
exercise above anaerobic threshold, however, the incr ases in EV&  relative to 2C
O
V&  is 
variable and depended on the decrease in pH and 2c
o
Pa  induced by the lactic 
acidosis (Wasserman et al., 1999). An increase in EV&  out of proportion to the increase 
in 2C
O




For respiratory compensation of metabolic acidosis, alveolar ventilation must increase 
and remain increased to eliminate CO2 produced at a reduced mean alveolar CO2 
tension (Wasserman et al., 1967).   
An increase in EV&  is partially affected by an increase in 2C
O
V&  during exercise in 
healthy subjects, while the transport of 2C
O
V&   is depended on blood flow 
(Wasserman et al., 1999). Results from the present tudy support the interaction of 
different physiological mechanisms (e.g. metabolic, circulatory and ventilatory) 
during progressive exercise (Wasserman et al., 1967). This is reflected by positive 
moderate correlation between peak cardiac power output on one side and peak 2C
O
V&  
and EV&  on the other. 
5.4.3 Relationship between Peak Cardiac Power Output and Peak 
Oxygen Pulse  
As previously stated oxygen pulse is the ratio of 2OV&  and HR and reflects the amount 
of oxygen extracted from the blood per heart beat. From the modified Fick equation, 
the 2O  pulse is numerically equal to the product of stroke volume and arterial-mixed 
venous 2O  content difference. Therefore the 2O  pulse has also been used as an 
estimator of stroke volume during exercise (Wasserman et al., 1999). The 2O  pulse 
normally increases with incremental exercise test bcause of increases in both SV and 
2O  extraction. However, a low, unchanging, flat 2O  pulse reflects deconditioning, 
cardiovascular disease (e.g. heart failure, coronary artery disease), and early exercise 
limitation due to ventilatory constraints or symptoms (Johnson et al., 2003). Therefore 
2O  pulse may be used as an index of cardiovascular function or dysfunction (Johnson 
et al., 2003). 
The present study is the first to assess the relationship between peak cardiac power 
output and peak 2O  pulse. Results clearly demonstrate moderate positive relationship 
between the two variables as measured at peak exercise. Based in this finding it 




partially but clearly can not be considered as an index of cardiac function only. 
5.4.4 Relationship between Peak Cardiac Power Output and Peak 
Cardiac Output, Stroke Volume, Heart Rate and Mean Arterial Pressure 
During progressive exercise test there is a linear r lationship between cardiac output 
and work rate (Wilmore and Costill, 2004). This is not surprising as the major purpose 
of the increase in TQ&  is to meet the muscles’ increased demand for 2O . During an 
incremental exercise test both components of cardiac output (stroke volume and heart 
rate) increase linearly up to 40 – 60% of maximal 2OV& , and thereafter an increase in 
TQ&  is mainly due to an increase in HR (Wilmore and Costill, 2004). It has been 
shown that SV increases up to exercise intensities of 40 – 60% of maximal 2OV&  in 
sedentary normal young subjects and normal men (Astrand et al., 1964; Higginbotham 
et al., 1986). In contrast, a plateau in SV does not occur at specific exercise intensity, 
but rather continues to increase with further increase in work rate. This has mostly 
been reported in highly trained endurance athletes (Zhou et al., 2001). Proctor et al. 
(1998) found that SV continued to increase between 40 – 70% of maximal 2OV&  in 
endurance trained men but not in woman. As exercise intensity increases to near 
maximal level (90% of maximal 2OV& ) there is a significant age-related difference in 
the maintenance of SV (Proctor et a., 1998). In younger men SV continued to increase 
slightly but in older men was maintained. At higher work intensities there is also trend 
for a decline in SV within the older groups (men and women combined) (Proctor et 
al., 1998).  
Cardiac power output takes into account both blood fl w, represented by cardiac 
output, and pressure represented by mean arterial pressure. Results from the present 
study clearly demonstrate that peak cardiac power output is highly correlated with 
peak cardiac output but not significantly with its other component, mean arterial 
pressure. This is in agreement with finding reported by Hodges (2004) who also found 
that cardiac output has a greater influence than mean arterial pressure on total cardiac 
power output. Based on these findings one may speculat  that, in order to assess 




measurement of cardiac output only may overestimate overall cardiac function of the 
normal heart (Goldspink, 2005). This is because pressure generation increases with 
healthy ageing and is not allowed for when measuring o ly flow-generating capacity 
of the heart. In contrast, in patients with heart filure, measurements of cardiac output 
alone underestimate overall cardiac function (Chantler et al., 2006). This is because 
both the flow and pressure generating capacities of the heart decline in these patients. 
Taken together, these examples clearly illustrate the need to measure both the flow 
and pressure generating capacities of the heart to determine overall cardiac function 
meaningfully (Goldspink, 2005). Also considering the eart as a hydraulic pump 
which produces hydraulic energy used to maintain circulation (Tan, 1986), it is 
necessary to evaluate not only the aspect of flow but also the pressure generating 
capacity of the heart. This is one of the main reasons why cardiac power output has 
been proposed to be the best indicator of overall cardiac function (Tan, 1986).  
Furthermore none of the previous studies have evaluated the relationship between 
peak cardiac power output and the components of cardiac output such as stroke 
volume and heart rate. The results of the present study clearly demonstrated that in 
healthy adults, peak cardiac power output was strongly correlated with peak stroke 
volume but weakly correlated with peak heart rate. Moreover stroke volume explains 
88% while heart rate only 12% of the variance in cardiac power output. 
5.4.5 Relationship between Peak Cardiac Power Output and Peak 
Circulatory Power      
Cohen-Solal et al. in 2002 established a new measur termed ‘circulatory power’ 
which they believe may be used as a surrogate of cardiac power output in heart failure 
population. Circulatory power (CP) is the product of peak 2OV&  and systolic blood 
pressure and as such has a high prognostic value in h art failure (Cohen-Solal, 2002). 
Circulatory power used 2OV&  as a surrogate for TQ& , and systolic blood pressure for 
mean arterial pressure. According to Nicholls et al. (2002) CP is therefore not as 
appropriate as cardiac power output, but the information for its calculation is available 
from any cardiopulmonary exercise test without the ne d for special equipment. It has 




et al., 2002). 
Hodges (2004) was the first to analyse the relationship between peak cardiac power 
output and peak circulatory power. The study indicated positive high correlation 
between the two variables in 102 healthy adults (r=0.86). Williams et al. (2005) also 
reported high correlation between peak CPO and peakCP (r=0.84), although in 219 
chronic heart failure patients. In the present study, this relationship between the two 
variables was lower (r=0.67). Although Hodges (2004) and Williams et al. (2005) also 
used 2C
O
 rebreathing methodology to determine TQ& , one may expect stronger 
relationship between peak CPO and peak CP in the present study. Presumably the 
number of subjects, which in Hodges’ study was almost tripled and in Williams et al. 
even more, may contribute to the stronger relationship between peak CPO and peak 
CP previously reported. 
5.4.6 Relationship between Peak Cardiac Power Output and Peak 
Oxygen Consumption 
It is well known that maximal oxygen consumption has been highly dependent on 
cardiac output. It is not surprising as direct Fick equation clearly shows that 2OV&  is 
the product of cardiac output and arterial-venous 2O content difference. In the 
exercising human, maximal 2OV&  is limited by the ability of the cardio-respiratory 
system to deliver 2O  to the exercising muscles, not by the ability of skeletal muscles 
to extract 2O  (Basset and Howley, 2000). This statement has been supported by the 
following three points: 1) when 2O  delivery is altered (by e.g. blood doping, hypoxia, 
or beta-blockade), maximal 2OV&  changes accordingly, 2) the increase in maximal 
2OV&  with training results primarily from an increase in cardiac output (not an 
increase in arterial-venous 2O  difference), and 3) when a small muscle mass is 
overperfused during exercise, it has an extremely high capacity for consuming oxygen 
(Basset and Howley, 2000).  




or heart failure populations, almost all studies have reported high coefficients of 
correlation between peak CPO and peak 2OV& . Hodges (2004) reported coefficient of 
correlation of 0.80 between peak CPO and 2OV& . Cooke et al. (1998) reported r=0.92 
between the two variables in 70 subjects with a wide range of cardiac function, from 
trained athletes to transplant candidates, and finally Roul et al. (1995) found an r of 
0.84 between peak CPO and peak 2OV&  in 50 chronic heart failure. 
In the present study the finding regarding the relationship between peak cardiac power 
output and peak oxygen consumption agrees well with those mentioned above, clearly 
indicating that 59% of peak CPO may be predicted by peak 2OV& . It is well known 
that 2OV&  may be influenced also by non-cardiac factors (e.g. muscle conditioning, 
motivation, obesity). Therefore evaluation of cardic function by measurement 2OV&  
only may lead to wrong conclusions.   
5.4.7 Relationship between Peak Cardiac Power Output and Peak 
Cardiac Index 
In a clinical environment, cardiac index is widely used as an indicator of cardiac 
function and blood flow (Guyton and Hall, 1996). The original reason for using the 
cardiac index as a means for expressing cardiac output for individuals of different 
body sizes was that the basal metabolic rate in human beings is generally expressed in 
terms of body surface area (Guyton and Hall, 1996). Berkson and Boothby (1936) 
found a higher correlation between basal metabolic rate and body surface area than 
basal metabolic rate and mass.  
In the present study coefficient of correlation between peak cardiac power output and 
peak cardiac index was high. High coefficient of correlation between the two 
variables has also been previously reported in healt y adults (r=0.81), and in heart 
failure (r=0.94) (Hodges, 2004; Roul et al., 1995). From these and previous results it 
is not difficult to conclude that body dimensions ifluence cardiac power output as 




5.4.8 Gender and Body Size Related Differences in Measured 
Variables and Reported Relationships 
Hutchinson et al. (1991) examined the relationship between cardiac size to maximal 
oxygen consumption in males and females. They found that left ventricular mass 
accounted for 63.8% of the gender for maximal 2OV&  and the combination of left 
ventricular mass and fat free mass accounted for 98.7% of the gender related 
difference. Hutchinson and colleagues provided an explanation that differences in 
body size dimensions contributed to difference in cardio-respiratory variables between 
men and women. From the present study it was also po sible to illustrate a significant 
difference in gender in most of the measured cardio-respiratory variables except peak 
mean arterial pressure (Table 5.2).  
It seems that the mean arterial pressure is independent of body size (Dobein, 1956). In 
contrast, cardiac output is known to be influenced by body size with a larger body 
mass creating a greater 2O  demand (Collis et al., 2001).  
In the present study the absolute values of peak cardiac power output in men were 
33% higher than those in women. Chantler et al. (2005) found that CPO is 
significantly affected by body size and composition, and strongly suggested that 
whenever possible CPO should be allometrically scaled for lean body mass. Chantler 
and colleagues also suggested that in the absence of research tools such as dual-
energy X-ray absorption (DEXA), body surface area or even body mass should be 
used in a clinical or field setting to generate body size independent CPO data. When 
peak CPO data were allometrically scaled to body surface area in the present study, 
the difference between men and women was 11% less when compared with the 
absolute peak CPO values. In agreement with Chantler e  al. (2005) this result 
indicates the importance of normalizing CPO data for differences in body size when 
comparing different groups of subjects. This will avoid wrong interpretations and 
conclusions which may have practical implications ad consequences.  
Furthermore in the present study subgroup analysis revealed that strength of the 




between men and women (Table 5.3). It also appears th t in the present study the 
difference in age between men and women of ~10 years does not affect these 
relationships. This finding is in agreement with one reported by Proctor et al. (1998) 
who found that neither gender nor age has a significa t impact on TQ& - 2OV&  
relationship. 
5.4.9 Study Limitations    
Total number of subject participated in the present study was 37 (23 men and 14 
female). In those previously cited studies which also evaluated the relationship 
between cardiac power output and other cardio-respiratory variables the number of 
participant was higher than in the present study. This possibly may explain some 
lower coefficient of correlation obtained in the present study compared with previous 
similar studies. Nevertheless it appears that even th  lower number of participants 
recruited in the present study was enough to identify relationships which have not 
been previously reported between CPO and e.g. AT, 2C
O
V& , EV& , OP and SV. 
The 2C
O
 rebreathing method used in the present study does nt allow continuous 
measurement of TQ& , and it has been recognised as major limitations of this technique 
in the present but also in the previous studies which used the same methodology. 
However continuous monitoring would reveal if cardic power output reaches a 
similar plateau during exercise to that of oxygen co sumption. 
In the present study no resting measurement of TQ& , and consequently CPO were 
taken. This was due to the issues surrounding the technicality of the two very different 
measurements. In the Chapter 3 it was clearly indicated that resting TQ&  is measured 
more accurately and precisely using the equilibrium 2C
O
 method. To use both, the 
exponential method for  TQ&  measurement at peak exercise and the equilibrium 
method for resting TQ& , would mean that two gas mixtures would be required. Also a 
different configuration of the equipment would be necessary. It was therefore decided 
that due to this technical reasons and also due to time constraints, resting 




pumping reserve and other variables in a cohort of healthy adults were not examined.            
5.5 Conclusion      
The present study is the first to analyse the relationship between overall cardiac 
function represented by cardiac power output and a variety of routinely measured 
physiological variables. Novel findings of the present study clearly indicate that peak 
cardiac power output moderately correlated not only with a submaximal index of 
cardiopulmonary exercise capacity such as anaerobic threshold, but also with carbon 
dioxide production, minute ventilation and oxygen pulse, all measured at peak 
exercise.  
In healthy adults, anaerobic threshold, peak carbon dioxide production, minute 
ventilation and oxygen pulse explain 23% to 41% of the variance, while peak oxygen 
consumption and cardiac index explain 59% and 58% of the variance in peak cardiac 
power output. Cardiac output and stroke volume explain 90% and 88% of the 
variance. This clearly suggests that only central haemodynamic measures such as 
peak cardiac output and stroke volume are good predictors of maximal cardiac 
pumping capability, while those other routinely measured cardio-respiratory variables, 
including oxygen consumption, should be considered with caution in interpretation of 
cardiac function.  
The results from the present study demonstrate that gender does not affect the strength 
of the relationship between peak cardiac power output and cardiac output, stroke 
volume, cardiac index and peak oxygen consumption.  
Finally the present findings support existing evidence that special attention is needed 
when comparing cardiac power output data between different groups of subjects when 
differences in body size are emphasized (e.g. men and women). When data were 
allometrically scaled to body surface area, the difference in cardiac power output 
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CHAPTER 6: COMPARISON OF CARDIAC POWER 
OUTPUT AND EXERCISE PERFORMANCE IN PATIENTS 
WITH LEFT VENTRICULAR ASSIST DEVICES, EXPLANTED 
(RECOVERED) PATIENTS AND THOSE WITH MODERATE TO 
SEVERE HEART FAILURE 
Abstract  
Introduction: Originally a left ventricular assist device (LVAD) was considered as a 
bridge to transplantation. However recent reports demonstrated that the use of an 
LVAD can in many patients prevent the need for subsequent transplantation, being 
considered as a bridge to recovery. A limited number of studies have evaluated 
exercise performance in patients implanted with LVADs and those explanted due to 
recovery, but none of these investigations evaluated cardiac power output (CPO). 
Therefore the aim of the present study was to assess CPO and exercise performance in 
patients implanted with LVADs, those explanted due to myocardial recovery and in 
those with moderate to severe heart failure. M thods: In this cross-sectional study 
design, measurements at rest and at peak exercise of th  Bruce or modified Bruce 
protocol (two preliminary stages with inclination of 0% and 5%) were undertaken 
using non-invasive, inert gas, rebreathing haemodynamic and respiratory gas 
procedures. They were performed on 54 male patients – 20 moderate to severe heart 
failure (HF) patients (age 45±10 yrs), 18 implanted LVAD (IMP) patients (age 39±14 
yrs) and 16 explanted LVAD (EXP) patients (age 41±14 yrs). Results: At rest there 
was a non significant difference in cardiac power output between the HF, IMP and 
EXP patients (p>0.05), whereas cardiac output in the IMP group was higher compared 
with the HF group (5.5±2.1 vs. 4.1±1.3 l.min-1, p<0.05). Peak CPO was significantly 
higher in the EXP than the HF and the IMP patients (HF, 1.90±0.45; IMP 2.37±0.55; 
EXP 3.39±0.61 W; p<0.01) as was peak cardiac output (HF, 9.1±2.1; IMP, 12.4±2.2; 
EXP, 14.6±2.9 l.min-1; p<0.01). Peak CPO was higher in IMP than in HF patients 
(p<0.05). Mean arterial pressure at rest was not significantly different between the 
HF, IMP and EXP patients (p>0.05), whereas at peak exercise mean arterial pressure 
in IMP patients was significantly lower than in EXP patients (p<0.01). Peak oxygen 
consumption was higher in the EXP than the HF and the IMP patients (HF, 15.8±4.1; 
IMP, 19.8±5.8; EXP, 28.2±5.0 ml.kg-1.min-1; p<0.05) as was anaerobic threshold (HF, 




results from the present study suggest that peak cardia  power output differentiates 
well during cardiac restoration using LVADs and emphasizes the benefits of this 
therapy. The use of LVAD improves overall cardiac function and also exercise 
performance. A peak CPO of 1.96 W is considered to be a “cut-off” value for good 
and poor prognosis in heart failure, therefore studied IMP and particularly EXP 
patients appear to have better prognosis than HF patients. Cardiac power output has 
the potential to be a key physiological marker of heart failure severity and can guide 
management of LVAD patients.  
6.1 Introduction 
According to the ACC/AHA Guideline (2005), heart failure (HF) is a complex clinical 
syndrome that can result from any structural or functio al cardiac disorder that 
impairs the ability of the ventricle to fill with or eject blood (inability of the heart to 
function as a pump to support physiological circulation). Typical symptoms and signs 
of heart failure are fatigue and dyspnoea, either at rest or during exercise, and fluid 
retention, which may lead to pulmonary congestion and peripheral oedema (ESC Task 
Force, 2005). Coronary artery disease, hypertension, valvular heart disease, and 
dilated cardiomyopathy are some of the causes of heart failure in the Western world 
(ACC/AHA Guideline, 2005). 
The definition of advanced heart failure, (also called severe, end-stage, refractory 
heart failure) includes symptoms which limit daily activities (NYHA III and IV) 
despite the inclusion of strong pharmacological therapy with angiotensin-converting 
enzyme inhibitors, β-blockers, digoxin and diueretics (Adams and Zannad, 1998). 
Despite advances in the medical management of heartfailure the only really effective 
form of therapy for patients with advanced heart failure is cardiac transplantation 
(Yacoub, 2001). Transplantation offers an effective alt rnative for many patients with 
advanced heart failure, yet the lack of donors still currently limits the number of 
transplantations performed annually nationwide. The success and limitations of 






6.1.1 Left Ventricular Assist Devices – from Idea to the REMATCH 
Mechanical circulatory support (MCS) is a viable thrapy for severe end-stage heart 
failure (Frazier, 2002). To date a number of clinical trials have shown clear benefits of 
MCS in terms of survival and improved quality of life. The MCS is not therefore 
considered as bridge to cardiac transplantation only, but also as destination therapy 
(Lietz et al., 2007; Rose et al., 2001) and bridge to recovery (Birks et al., 2006). 
The first application of a ventricular assist system was in 1963 by DeBakey for 
support of postoperative cardiogenic shock, with successful device removal after one 
week of support with improvement of cardiac function (DeBakey, 1971). In 1968 
Cooley and colleagues first used a circulatory assist device as temporary support until 
cardiac transplantation (Cooley et al., 1969). Since that time, ventricular assist devices 
have been applied as an assist to recovery for postcardiotomy support, the experience 
of which has been documented in multiple studies (Pae et al., 1992; Pennington et al., 
1985). In these experiments, approximately 45% of supported patients were weaned 
from device support, with approximately half of that group surviving to hospital 
discharge, subsequently achieving long-term survival (P e et al., 1992; Pennington et 
al., 1985). 
With the advances in cardiac transplantation during 1980s, ventricular assist systems 
were used as left ventricular devices (LVADs) or as biventricular assist devices for 
support of patients with severe heart failure accompanied by shock and multiple organ 
dysfunction (Kumpati et al., 2001). 
Various circulatory-support devices have been developed for short-term use in 
patients with end-stage heart failure since the beginning of the artificial heart 
programme at the American National Institute of Health in 1964 (Hogness and 
VanAntwerp, 1991). In 1994 the US Food and Drug Administration approved 
pneumatically driven LVADs to be used as a bridge to transplantation, and self-
contained, vented electrical devices were approved for this purpose in 1998 





The successful use of LVADs as a bridge to transplatation for extended periods of 
time led to their consideration for destination therapy, as originally proposed for the 
artificial heart development programme (Frazier et al., 1992; Oz et al., 1997). The use 
of LVADs as destination therapy was proposed in a pros ective study called 
Randomized Evaluation of Mechanical Assistance for the Treatment of Congestive 
Heart Failure (REMATCH) (Rose et al., 1999). 
The REMATCH trial was the first scientific approach validating the original goal of 
destination (permanent) therapy for patients with end-stage heart failure for whom 
donor hearts were not available. This trial had a long period of development from 
proposal in 1993 to initial enrolment of patients in 1998. This prospective randomized 
trial was performed by Rose and colleagues (2001). Inclusion criteria included left 
ventricular ejection fraction ≤25% with severe heart failure symptoms (NYHA class 
IV) for >90 days despite attempted therapy with ACE inhibitors, diuretics, and 
digoxin. Severe limitation had to be documented by peak oxygen consumption of ≤12 
ml.kg-1.min-1 with evidence of anaerobic metabolism. Rose and colleagues randomized 
129 patients who were ineligible for cardiac transplantation to LVAD group (N = 68) 
or “optimal medical therapy” group (N = 61). Kaplan-Meier survival analysis showed 
a 48% reduction in risk of death in LVAD-supported patients. Survival in LVAD-
supported patients was twice that in medically treated controls after 1 year (52% vs. 
25%) and triple after 2 years (23% vs. 8%). Quality of life was also significantly 
improved in those supported with the LVAD. Rose andcolleagues (2001) concluded 
that the use of LVADs in patients with advanced heart f ilure resulted in an 
improvement in survival and quality of life.             
6.1.2 Different Models of Mechanical Circulatory Support  
Mechanical circulatory support can be used as short- or long-term support. The 
incidence of mechanical circulatory support after open-heart surgery is reported to be 
between 0.5% and 3% (Smedira and Blackstone, 2001). The overall survival rate of 
patients treated with mechanical circulatory support f r long-term use as a bridge to 
heart transplantation was reported to be between 70% and 80% (McCarthy et al., 




Pump systems can be divided into five groups, depends o  the operating principles: 1) 
intra-aortic balloon pump, 2) centrifugal pumps, 3) displacement pumps, 4) axial 
blood flow pumps, and 5) total artificial hearts.   
6.1.2.1 Intra-aortic balloon pump (IABP) as circulatory support for 
postcardiotomy heart failure 
The IABP was first introduced in clinical practice in 1967 (Kantrowitz et al., 1968). 
The IABP affects cardiac function positively in several ways. It decreases myocardial 
oxygen demand (systolic unloading) and increases th supply of oxygen to the 
myocardium (diastolic augmentation) (Frazier, 1995). This should favourably 
influence the myocardial oxygen supply demand relationship which can improve the 
myocardial performance.  
6.1.2.2 Centrifugal pumps     
In the Bio-pumpTM the blood is accelerated in a pump house by centrifugal force and a 
nonpulsatile flow is generated. There is need for venous and arterial cannulae and an 
extracorporeal circuit. The tubings may be heparin coated and thereby systemic 
anticoagulation can be reduced. It can include an oxygenator and give full 
cardiopulmonary support. The system is flexibile and can be used as an left 
ventricular assist device (LVAD), right ventricular assist device (RVAD), or 
biventricular assist device (BVAD) (Hosenpud and Greenberg, 2006). 
6.1.2.3 Displacement pumps 
The principle is that blood enters the artificial pump from the heart and is ejected into 
the aorta by the movement of a diaphragm creating pressure variations in the pump. 
Pulsatile flow is created. These pumps can be extracorporeal as the ThoratecTM and 





6.1.2.4 Axial blood flow pumps 
The principles of the axial flow pumps are based on the HemopumpTM (Wampler et 
al., 1988) which is described in more detail below. A rotating impeller ejects blood 
from the left ventricular to the systemic circulation with continuous flow. An 
electromagnetic motor runs the impeller. The pumps are small, valveless, and without 
a compliance chamber. Compared with other pumps, they require less surgery for 
implantation. A variety of pumps for long-term use have been developed, like the 
MicroMed DebakeyTM, the HeartMate IITM, and the Jarvik 2000 HeartTM. 
6.1.2.5 Artificial hearts 
The CardioWestTM is a pulsatile biventricular cardiac replacement system. It is a 
displacement rigid polyurethane pump and contains a smooth, flexibile polyurethane 
diaphragm that separates the blood and two air chambers. Mechanical valves provide 
unidirectional flow. Compressed air from an external drive console moves the 
diaphragm causing ejection of the blood (Copeland et al., 1996).  
6.1.3 Continuous versus Pulsatile Left Ventricular Assist Devices 
In the United States, according to Miller et al. (2007), most of the patients undergoing 
implantation of LVAD as a bridge to heart transplantation have received support from 
pulsatile, volume-displacement devices such as the HeartMate XVE (Thoratec Inc, 
Pleasanton, Calif) or Novacor (WorldHeart, Oakland, Calif) (Figures 6.1 and 6.2). 
These devices fill with and eject blood in a cyclic fashion that is equivalent to the 









                                              
Figure 6-1 HeartMate XVE LVAD                              Figure 6-2 Novacor LVAD 
 
Most of the LVAD explanted patients in the present study have been previously 
implanted with the HeartMate XVE LVAD. Therefore basic technical characteristics 
of the HeartMate XVE LVAD are described below.  
The HeartMate XVE (extended lead vented electric) LVAD consists of an implanted 
blood pump, external XVE system controller, and external power supply components. 
The blood pump is a pusher-plate type device that is capable of producing a stroke 
volume of 83 ml, generating approximately 10 litres of blood per minute, and a beat 
rate of up to 120 beats per minute (Thoratec Corporation, 2004). The pump consists of 
a rigid titanium housing divided in half by a flexible diaphragm. One half functions as 
the blood chamber, while the opposite half serves as a chamber for the electric motor. 
This motor chamber is connected to the external control and power components via a 
percutaneous tube. Displacement of the diaphragm by rotation of the electric motor 
results in pumping of the blood. The inflow and outflow conduits of the device each 
contain a 25-mm porcine valve within a titanium cage to ensure unidirectional blood 
flow. The HeartMate XVE is typically operated in a full-to-empty cycle. Beat rate is 
regulated by an external computer controller from information provided by sensors on 
filling volume within the pump. Beat rate automaticlly increases or decreases to 




The HeartMate XVE LVAD is intended for use as bridge to transplantation in cardiac 
transplant candidates at risk of imminent death from non-reversible left ventricular 
failure. The HeartMate XVE is also indicated for use in patients with NYHA class IV 
end-stage left ventricular failure who have received optimal medical therapy for at 
least 60 of the last 90 days, who have life expectancy of less than two years, and who 
are not candidates for cardiac transplantation. Thedevice is intended for use both 
inside and outside hospital. The HeartMate XVE is contraindicated for patients whose 
body surface area is less than 1.5 m2 (Thoratec Corporation, 2004). 
Pulsatile left ventricular assist devices provide excellent haemodynamic support and 
improve survival to transplantation but have substantial constraints, including the 
need for extensive surgical dissection, the requirement that the patient has a large 
body size, the presence of a large-diameter percutaneous lead, audible pump 
operation, and limitation in long-term mechanical durability that frequently require 
subsequent operations for device exchange (Frazier nd Kirklin, 2006). 
More recently, several left ventricular assist devic s have been designed incorporating 
continuous-flow rotary pump technology with axial configuration. One advantage of 
these newer pumps is a smaller device size, with the potential for extending therapy to 
other populations, including some women and adolescent  (Griffith et al., 2001). 
Another advantage is the potential for greater long-term mechanical reliability owing 
to a simplified design that requires only a single moving part, an internal rotor (Miller 
et al., 2007). Other benefits include less noise from the device and greater comfort for 
patients than with a typical pulsatile pump. Continuous-flow pumps are the HeartMate 
II left ventricular assist system (Thoratec), the MicroMed DeBakey ventricular assist 
device (MicroMed), the Jarvik 2000 Heart (Jarvik Heart), and the VentrAssist left 
ventricular assist system (Ventracor). 
Most of the LVAD implanted patients in the present study have been implanted with 
the HeartMate II LVAD, and therefore technical characteristics of this device will be 
described.  
The HeartMate II LVAD has been successfully tested in more than 40 calves since 




HeartMate II LVAD (Figure 6.2) is a continues-flow device consisting of an internal 
axial-flow blood pump with a percutaneus lead that connects the pump to an external 
system driver and power source. The pump contains an internal rotor with helical 
blades that curve around a central shaft. When the rotor spins on its axis, kinetic 
energy is imparted to the blood, which is drawn continuously from the left ventricular 
apex through the pump and into the ascending aorta. The pump has an implant volume 
of 63 ml and operating revolutions per minute range of 6000 to 15000, and can 
generate up to 10 litres per minute of flow at a mean pressure of 100 mm Hg 
(Thoratec Corporation, 2006). The hydrodynamic performance of continues flow 
pumps is determined primarily by speed of the rotor and by the pressure difference 
that exists across the pump (Grifith et al., 2001).   
The HeartMate II has a manual speed control that can be accessed only by a technical 
operator and that is for use intraopratively and perio ratively. During this period of 
fluid shift and physiologic adjustment, Griffith etal. (2001) suggested that slow rates 
corresponding to lower flow more reliably maintain left heart preload and prevent 
sudden and dramatic negative left atrial and ventricular pressures. Griffith et al. 
(2001) recommended operating in the safe margins of the pressure-flow relationship 
and have been most successful at rates of 8000 to 900 revolutions per minute with 












 Figure 6-3 Components of the continuous-flow left ventricular ssist device-
HeartMate II. The inflow cannula is inserted into the apex of the left ventricular assist 
device, which pumps throughout cardiac diastole and systole into the ascending aorta, 
with the rotor being the only moving part. The LVAD is placed within the abdominal 
wall or peritoneal cavity. A percutaneus lead carries the electrical cable to an 
electronic controller and battery packs, which are worn on a belt and shoulder holster.  
 
It has been suggested that as the speed of pump goes up, the flow and blood pressure 
follow the same trend. At a certain point, with further increase in pump speed, there is 
no increase in blood pressure, and if the speed is further increased the blood pressure 
goes down (in Kormos, 2001). Dr Magovern (Pittsburgh, PA) argued that pump flows 
around 3.5 to 4 litres in most of the patients, andthey are “hoping to get another litre 
or two out from the patients native heart” (in Kroms, 2001). This discussion 
indicates that it is not clear how much of the total cardiac output is delivered by the 
pump and how much from the native heart. Westaby et al. (2006), who used the Jarvik 
2000 LVAD, suggested that at a pump-rotor speed of 10000 revolutions per minute 
produced the resting cardiac output of 5.5 litres pr minute with a mean blood 





According to Myers et al. (2006) blood flow through continuous-flow LVADs 
depends primarily on the differential pressure across the pump when the impeller 
speed is constant. This differential pressure is the difference between left ventricular 
pressure and aortic pressure, which is always changing throughout the cardiac cycle. 
At the start of diastole, left ventricular pressure is at its lowest; this is also when the 
differential pressure is the greatest (Myers et al., 2006). At the end of systole, left 
ventricular pressure and aortic pressure are nearly qual; this is when the differential 
pressure is lowest. As the left ventricular pressure rises during systole, pump flow 
increases because the differential pressure decreass Myers et al. (2006). During 
diastole when the left ventricular pressure decreases (thus increasing the differential 
pressure), the blood flow through the pump also decreases. However, when the pump 
is turned off, blood flow may flow through the pump in both directions.             
In a prospective, multicenter study Miller and associates (2007) recruited 133 patients 
with end-stage heart failure who were on a waiting l st for heart transplantation to 
assess the efficacy of HeartMate II LVAD in providing mechanical circulatory 
support as a bridge to heart transplantation. The survival rate and quality of life were 
also evaluated. Results of this study demonstrated that survival rate was 75% at 6 
months and 68% at 12 months. Furthermore, at 3 months there was significant 
improvement in functional status (according to NYHA class and results of a 6-minute 
walk test). At 24 hours after implantation of the dvice, the cardiac index increased 
from a mean of 2.0 l/m2 preoperatively to 2.8 l/m2. The average pump flow index was 
2.6 l/m2 on the first day at a mean pump speed of 9236 revolutions per minute, and 
increased to 2.8 l/m2 at one month at a mean pump speed of 9502 revolutions per 
minute, with systolic and diastolic arterial blood pressure averaging 96 and 73 mm 
Hg. There was also significant improvement in quality of life. Significant adverse 
events included postoperative bleeding, stroke, right heart failure, and percutaneus-
lead infection. Miller and colleagues concluded that effective haemodynamic support 
for periods of at least 6 months can be achieved with continuous-flow LVAD, with 
improved functional status and quality of life. Miller et al (2007) outlined some of 
possible issues in a use of continuous flow devices. These include the risk of pump 
thrombosis and thromoembolism, with requirement for higher levels of antithrombotic 




Infection remains a potential concern, as with all circulatory devices that have a 
percutaneous component. Also mechanical failure may not be totally avoided by 
continuous flow pump technology, although it appears to be less frequent than with 
some pulsatile pumps. Other issues include the needto determine the optimal pump-
speed settings to provide sufficient blood flow without ventricular arrhythmias and 
difficulty in detecting vital signs in a systematic circulation with reduced pulsatility 
(Miller et al., 2007). In clinical findings some pulsatility is present even in very weak 
hearts during the early post-operative phase, but this pulsatility increases in most 
patients during myocardial recovery (Thalmann et al., 2005). 
Haft et al. (2007) investigated the effects of LVAD support with either a pulsatile, 
volume displacement pump (HeartMate XVE) or continuous-flow rotary pump with 
axial design (HeartMate II) on haemodynamic and exercis  performance in 34 
patients, 16 implanted with HeartMate XVE and 18 implanted with HeartMate II. 
Patients were evaluated with right heart catheterization and echocardiography 
preoperatively and at three months postoperatively and cardiopulmonary exercise 
testing three months postoperatively. Support with e er the XVE or II resulted in 
significant increases in cardiac output and reduction in mean pulmonary artery and 
pulmonary wedge pressures. Exercise capacity at three months was similar between 
groups (% predicted peak 2OV&  - XVE: ~47% versus II: ~49%). Echocardiography at 
three months demonstrated a significantly greater reduction in left ventricular end-
diastolic volume, left ventricular end-systolic volume, and percent mitral valve 
regurgitant volume for the XVE compared with II. Haft et al. (2007) concluded that 
the HeartMate XVE and II provided equivalent degrees of haemodynamic support and 
exercise capacity. The XVE was associated with greate  left ventricular volume 
unloading. Similarly Garcia et al. (2008) found that continuous flow LVADs 
(HeartMate II) are as effective as pulsatile flow LVADs (HeartMate XVE) with 
regard to degree of left ventricular unloading and cardiac haemodynamic.   
Finally, according to manufacturer (Thoratec Corportation, 2006) some of the 
complications associated with the HeartMate LVADs that may occur in greater than 
1% of patients include hepatic dysfunction, renal dysfunction, need for reoperation, 




thrombo-embolism, pulmonary dysfunction, cardiac arrhythmia and myocardial 
infarction.    
6.1.4 Left Ventricular Assist Device as Bridge to Recovery in Clinical 
Trials – Aspects of Cardiac Recovery during Support with LVAD 
Different aspects of cardiac recovery have been report d following LVAD insertion. 
This section describes some mechanisms of cardiac remodelling as suggested by 
Bristow (1998), Francis (1998), Goldstein et al. (1998) and Mann (1999). 
Heart failure is a wide spectrum of anatomic, physiologic and clinical abnormalities in 
the heart. Heart failure is a syndrome whereby some injurious event causes 
myocardial injury which results in abnormal mechanic l properties that, in 
conjunction with the injurious process, produces cardiac remodelling. These processes 
can be sudden or insidious in their development. Injurious events can include a 
chronic myocardial ischemia, exposure to toxins, infectious agents, inflammatory 
responses to systematic illnesses, cardiac volume and pressure overload, genetic 
abnormalities, or unknown (idiopathic) causes. Alterations in myocyte biology 
associated with heart failure include attenuation of n rmal excitation contraction 
coupling mechanisms with a reversion to myiosin heavy chain foetal gene expression 
and beta-adrenergic receptor desensitization. These and additional changes in 
cytoskeletal protein production lead to myocyte hypertrophy, myocytolysis, and 
interstitial fibrosis, setting the stage for cardiac chamber enlargement and myocardial 
hypertrophy. Systolic dysfunction ensues with interstitial fibrosis, causing a stiffening 
of the heart and diastolic dysfunction. Programmed c ll death, or premature apoptosis, 
leads to an accelerated loss of functional myocytes. Altered contractility of the heart 
with chamber geometry remodelling toward more spherical state causes mitral 
regurgitation and diminished stroke volume, which leads to perfusion abnormalities in 
systemic organs. This then causes perpetuation of the heart failure milieu by eliciting 
expression in a variety of neurohumors and mediators of inflammation. Indeed, the 
growth of myocytes seems primarily related to many growth factors subsequently 
liberated, including catecholamines, endothelin, growth hormone, tumor necrosis 
factor, angiotensin-II, and insulin-dependent growth factor. Mechanical stretch is also 




release of intracellular angiotensin-II. This is a very important observation because 
ventricular assist device insertion might effect cardi c recovery primarily by 
attenuating these stretch-induced responses with ventricular unloading. 
As previously mentioned, mechanical circulatory support holds promise not only as a 
bridge to transplantation and as destination therapy, but also as bridge to recovery. 
Today there is evidence that prolonged, near complete unloading of the ventricle with 
the use of an LVAD is associated with structural reve se remodelling (Zafeiridis et al., 
1998) that can be accompanied by functional improvement (Terracciano et al., 2003). 
However, recovery that is sufficient to permit explantation of the device has been 
observed in only 5 to 24% of patients in various serie  (Dandel et al., 2005; Farrar et 
al., 2002; Frazier and Myers, 1999; Frazier et al., 2004; Liden et al., 2007; Mancini et 
al., 1998a; Maybaum et al., 2007; Miller et al., 2007; Simon et al., 2005) with a 
relatively high incidence of early recurrence (Simon et al., 2005). 
According to Frazier (2002) as early as 1992, mechani al, histological, and metabolic 
improvements in LVAD supported patients were being reported including histological 
improvements characterized by normalization of myocyte diameter, decreased 
fibrosis, and decreased myocytolysis. Also normalisation in calcium transport 
mechanisms with sarcoplasmic reticulum, enhanced myocyte contraction, improved 
glucose use, decreased tissue necrosis factor levels, decreased apoptosis of the native 
heart, and improved beta-receptor density were observed (Frazier, 2002).  
Frazier et al. (1996) studied 31 patients after 30 days of implantation. Results of 
echocardiography indicated significant decrease in left-ventricular end-diastolic 
dimension (6.81 to 5.35 cm) and significant improvement in ejection fraction (11% to 
22%) when the device was switched off. In eight patients with advanced idiopathic 
dilated cardiomyopathy Altemose and colleagues (1997) found a decrease in left 
ventricular mass from 505 to 297 g, whereas myocyte diameter also decreased 
significantly after 42 days of support with an LVAD. Also Nakatani and colleagues 
(1996) reported a decrease in left atrial and left v ntricular diastolic and systolic 
diameters after an LVAD insertion from 4.6 to 3.5, 6.3 to 4.1, and 5.9 to 3.6 cm, 
respectively. Left ventricular wall thickness increas d from 1.0 to 1.4 cm for the 




myocyte damage as estimated by the decreased appearnc  of wavy band fibres and 
contraction band necrosis. There was, however, a slight increase in fibrosis but no 
significant change in myocyte diameter (Nakatani et al., 1996). Furthermore Levin 
and associates (1995) demonstrated that chronic unloadi g of the failing ventricle 
with the use of an LVAD resulted in deremodeling, or reversal of the chamber 
enlargement associated with heart failure. Scheinin a d associates (1992) found that 
following an LVAD insertion myocardial tissue demonstrated significant decrease or 
disappearance of stretched fibres with a slight increase in interstitial replacement 
fibrosis, as well as an increase in the diameter of the myocardial fibres. This finding 
was supported also by McCarthy and colleagues (1995). These observations support 
the concept the morphologic parameters are normalized with mechanical circulatory 
support. Dipla et al. (1998) reported that the magnitude of myocyte contraction was 
greater, the time to peak contraction was significantly abbreviated, and the time to 
50% relaxation reduced in patients supported by the ventricular assist device. 
Myocytes removed from the ventricular assist device patients had greater contraction 
than control myocytes at all frequencies of stimulation (Dipla et al., 1998). Findings 
by Zafeiridis and colleagues (1998) also indicated that long-term ventricular assist 
device support was associated with significant reduction in myocyte volume, cell 
length, cell width, and length-to-thickness ratio. These changes were associated with 
reductions in left ventricular dilation and left ventricular mass measured by 
echocardiography and further support the concept of that reverse remodelling occurs 
in response to chronic ventricular assist device sustenance. These findings were 
stressed by Soloff (1998) who argued that morphologic changes were more consistent 
with atrophy of the myocardium than normalization of a severely remodelled heart.   
From the view of molecular remodelling, it was found that patients with advanced 
heart failure undergoing ventricular assist device insertion have extensive cardiac 
myocyte apoptosis, and that prolonged mechanical unloading with an LVAD affect 
apoptosis-inhibiting genes and cardiac myocyte apoptosis by decreasing the extent of 
myoocyte apoptosis overall in the ventricle (Belland et al., 1999). Changes in 
neurohormones were also noted in patients with LVADs as follows: plasma renin 
activity decreased from 57 to 3 nm, angiotensin-II decreased from 237 to 14 U/L, 




518 pg/mL, and arginine vasopression decreased from 6 to 0.8 pg/mL (James et al., 
1995). Accompanying these changes were dramatric improvements in cardiac index 
and central haemodynamics. These observations indicate that circulatory support 
normalizes the peripheral milieu of the heart failure to such an extent that the 
sympathetic and parasympathetic nervous system and neurohumoral expression 
markers characteristic of heart failure are attenuated.    
Takeishi et al. (2000) explored the relationship of mechanical assist device support to 
improved calcium (Ca) cycling. The investigators specifically examined whether 
protein kinase-C activation and decreased Ca-cycling protein levels could be reversed 
by support with a LVAD. Changes were found in protein levels of g-alpha-q, 
phospholipase-C-beta-1, regulators of g-protein signalling, sarcoplasmic reticulum 
calcium ATPase, phospholamban, and translocation of protein kinase-C isoforms. The 
paired pre- and post-LVAD samples revealed that a selective inhibitor of g-alpha-q 
was significantly decreased, while the status of g-alpha-q phospholipase-C-beta-1 and 
regulators of g-protein signalling were unchanged after LVAD implantation. 
Translocation of protein kinase-C isoforms also remained unchanged. The LVAD 
support increased sarcoplasmic reticulum Ca ATPase protein level with 
phospholamban concentration unaffected. Takeishi and colleagues (2000) concluded 
that altered protein expression and stoichiometry of the major cardiomyocyte Ca 
cycling proteins, rather than reduced phospholipase-C-beta-1 activation occurred 
during support with a LVAD, improving mechanical function. Furthermore 
Terracciano et al. (2003) examined changes in Ca handling at the cellular level in 
failing left ventricular tissue taken at LVAD implantation and LVAD removal. The 
results showed that in myocytes from patients after LVAD support there is more Ca 
entry to trigger Ca release and more sarcoplasmic ret ulum Ca content, leading to 
improved contractile function. Also improvement in myocardial mitochondrial 
function after LVAD support was found (Lee et al., 1998). The respiratory control 
index was higher in LVAD patients than in the heart failure patients. Lee et al. 
concluded that cardiomyocyte dysfunction in heart filure may actually be reversed 
with LVAD support.  




Holman et al. (1991) were the first to report a patient receiving an LVAD as bridge to 
transplantation with the device being removed because of satisfactory native heart 
function after longer term support. Cardiac function mprovement was noted in a 19-
year-old man after four weeks of circulatory assistance and at the 70-day mark the 
device was removed with a patient developing normal rest and exercise cardiac 
systolic function. The patients did not have coronay rtery disease (Holman et al., 
1991). Furthermore, Nakatani and associates (1995) reported that out of 31 LVAD 
supported patients, six patients supported more than ree weeks were able to be 
weaned from the ventricular assist device, with four patients doing well, but four 
deteriorating to the point where cardiac transplantation was necessary. Of these six 
patients weaned from the device, two have ischemic heart disease, one valvular heart 
disease, and three idiopathic cardiomyopathy. Loebe and colleagues (1997) reported a 
case of a 36-year-old man with dilated cardiomyopathy who was supported with 
LVAD for more than two years. During the support inerval, gradual functional 
recovery occurred, but a suitable donor organ finally came available. In the 
preparation for the transplant operation, the LVAD was switched off and native 
ventricular function assumed the total cardiac load. Because cardiac performance was 
judged acceptable, the LVAD was explanted and transpl tation not performed with 
the patient continuing to improve. Long-term effects of ventricular unloading on 
cardiac function, humoral anti-beta-1 adrenoreceptor autoantibodies, and myocardial 
fibrosis were studied by Muller et al. (1997). Sevente n patients with nonischemic 
dilated cardiomyopathy were implanted with LVADs for a mean duration of 230 days. 
Results indicated that six patients died, four transplanted, and two supported at the 
time of publication. Five patients (29%) were noted o have significant recovery and 
were weaned after 160 to 794 days of support with follow-up post-device removal of 
51 to 592 days. Antiadrenoreceptor antibodies disappe red during mechanical 
circulatory support and did not increase during after weaning. Cardiac function 
(represented by left ventricular ejection fraction only) and volume density of fibrosis 
remained normal in the successfully weaned patients. It should be noted, however, 
that nine patients did not have any improvement in ve tricular function. Frazier and 
Myers (1999) demonstrated data on five patients having devices removed after 46 to 
447 days. In three patients, the system was removed electively after patients showed 




pump malfunction. One patient died of cardiac-related causes 10 days after ventricular 
assist system removal, with the remaining patients noted to be alive and well at 35, 
33, 14, and three months after system removal. None of the patients had ischemic 
heart disease as the underlying pathologic difficulty. Hetzer and Muller (1999) 
provided evidence that out of 19 LVAD patients supported for up to 26 months, seven 
patients had persistently restored cardiac function for more than eight months and five 
patients for less than five months. Hetzer and Muller suggested that markers of 
successful device removal included decreased ventricula  volumes and improved 
ejection fraction as the pump contribution to circulation was decreased. In 2005 
Dandel et al. reported successful weaning in 32 (24%) out of 131 patients, with a 5-
year survival rate of 78% after explantation.  
In contrast with previous suggestions, recent reports by Liden et al. (2007) and 
Maybaum et al. (2007) reported that a degree of cardiac recovery was insufficient for 
the device to be explanted in most of the patients with chronic heart failure. Liden et 
al. (2007) studied 18 LVAD patients. Cardiac recovery was defined as off-pump left 
ventricular ejection fraction (LVEF) ≥40% together with significant improvement in 
invasive haemodynamic measurements (cardiac index ≥2.5 and pulmonary capillary 
wedge pressure ≤20-23 mm Hg). Patients who met this criterion were considered for 
weaning. Results demonstrated that only three out of 18 patients fulfilled the 
predefined criteria for cardiac recovery and were subjected to device explantation. In 
one patient, a young female with acute myocarditis, the following course was 
uneventful. In the second patient, a male with dilated cardiomyopathy, heart failure 
reoccurred only a few days later. The third patient had a relapse of giant cell 
myocarditis and was transplanted. In conclusion, Liden et al. (2007) argued that 
patients with severe advanced heart failure are unlikely to show significant cardiac 
recovery following treatment with LVAD. Furthermore Maybaum et al. (2007) in the 
LVAD Working Group Recovery Study enrolled 67 patien s on LVADs and found 
that after 30 days of device implantation there wassignificant improvement in LVEF 
(17% vs 34%) and a reduction in left ventricular end-diastolic diameter (7.1 vs 5.1 
cm) and left ventricular mass (320 vs 194 g). Furthermore 34% of patients had LVEF 
>40% with partial device support. The LVEF decreased over the time to pre-LVAD 




size, collagen content, and cardiac tumor necrosis factor-α. Only six subjects (9%) 
underwent LVAD explantation for recovery. Maybaum et al. (2007) concluded that 
cardiac function improves significantly after device implantation, but the degree of 
clinical recovery is insufficient for device explant tion in most of the patients with 
chronic heart failure.   
At present there is only one study, Birks and associates (2006) from Harefield 
Hospital, UK, to demonstrate cardiac recovery with the use of LVADs at significantly 
higher rate than any other in the literature. Data presented in this and the following 
chapter were also collected in Harefield Hospital in collaboration with Dr Birks and 
associates, and therefore description and review of the paper by Birks et al. (2006) is 
emphasized below.  
6.1.5 Harefield Heart Science Centre Study from 2006 
Birks and colleagues (2006) recruited 15 patients with severe heart failure due to 
nonischaemic cardiomyopathy and with no histologic evidence of active myocarditis. 
All patients had markedly reduced cardiac output and were receiving inotropes before 
implantation with LVAD. Compared with all previous reports, Birks et al. (2006) 
clearly emphasized so called “combination therapy” which does not only includes left 
ventricular unloading with the use of LVAD but also “specific pharmacological 
therapy” which together result in cardiac “reverse emodelling”. The preliminary 
overview of combination therapy used in Harefield has been described by Prof 
Yacoub in 2001 (Yacoub, 2001).   
In the study by Birks et al. (2006) pharmacologic regimen consisted of two stages. In 
the first stage, intended to enhance reverse remodelling, treatment with four drugs 
commenced immediately after the patient had been weaned from inotropic therapy 
with adequate end-organ recovery. The four drugs and the maximum titrated doses 
were as follows: lisonopril, 40 mg daily; carvedilol, 50 mg twice daily; 
spironolactone, 25 mg daily; and losartan, 100 mg daily. The second stage of 
pharmacologic therapy was induced after maximal regression in the left ventricular 
end-diastolic diameter had been achieved while the left ventricular assist device was 




weeks according to echocardiography assessment, clebuterol was administrated at an 
initial dose of 40 µg twice daily, when at a dose of 40 µg three times daily, and finally 
at a dose of 700 µg three times daily. The dose was adjusted to maintain the resting 
heart rate at a level below 100 beats per minute. Before clenbuterol was started, 
carvedilol was replaced by the selective β1–blocker bisoprolol. 
Results of the study (Birks et al., 2006) demonstrated that 11(73%) out of 15 patients 
had sufficient recovery to meet the explantation criteria. The mean duration of support 
with a left ventricular assist device was 320 days (range, 63 to 603). In one patient, 
explantation was required because of device failure. In three patients, severe infection 
was present at the time of explantation. The mean LVEF with the pump off for 15 
minutes was 64% before explantation as compared with 12% before implantation; the 
mean left ventricular end-diastolic diameter was ~56 mm as compared with ~75 mm, 
and the mean end-systolic diameter was ~40 mm as compared with 67 mm. Before 
explantation, the mean walking distance in 6 minutes (with the pump off) was 632 m, 
and the mean 2OV& max (with the pump off) was 20.7 ml
.kg-1.min-1, with a mean 
EV& / 2C
O
V&  slope of 32.5. Cardiac catheterization before explantation (with pump off) 
showed a mean right atrial pressure of 5.6 mm Hg, a pulmonary-capillary wedge 
pressure of 9.0 mm Hg (as compared with 23.8 mm Hg during inotropic therapy 
before implantation), a cardiac output of 5.4 litres per minute, a cardiac index of 2.8, 
and a pulmonary artery oxygen saturation of 66.9%.  
Four patients underwent heart transplantation after completing the full course of 
combination therapy. Transplantation was performed b cause of lack of myocardial 
recovery in three patients and the development of appreciable mitral, tricuspid, and 
aortic regurgitation in one. No patient died during the combination therapy. The 
survival rate one and four years after explantation was 90.8% and 81.8%. The 
minimum period of follow-up after explantation was pproximately 4 years (range, 
1519 to 2058 days, mean, 1799 days). All surviving patients continued to be in 
NYHA class I except one, in whom severe heart failure recurred. Finally quality of 
life also improved in those patients, and this was also reported in separate study by 
George et al. (2008). Birks et al. (2006) concluded that sustained reversal of severe 




selected patients with the use of an LVAD and specific pharmacologic regimen. 
According to Birks et al. (2006) the objective of the initial phase of mechanical and 
pharmacological therapy is to reverse ventricular remodelling. Mechanical support 
with an LVAD has been shown to lead to a reduction in euroendocrine activation 
(James et al., 1995) and myocyte hypertrophy (Zafeiridis et al., 1998). Also there is 
evidence to demonstrate that beta-blockers, angiotensin converting-enzyme inhibitors, 
angiotensin II-receptor blockers, and aldosterone atagonists can all reduce left 
ventricular remodelling (Greenberg et al., 1995; Groenning et al., 2000; Tsutamoto et 
al., 2001; Wong et al., 2002). Beta-blockers have multiple beneficial effects: slowing 
heart rate, lowering blood pressure, as well as a direct effect on the myocardium by 
reversing remodelling and upregulating β-receprtors (Yacoub, 2001). The 
combination of ACE inhibitor and angiotensin 1 receptor antagonists has the 
advantage of full blockade of the receptors, together with enhanced endothelial 
function due to increased concentration of bradykinin produced by ACE inhibition 
(Pitt, 1998). Apart the effect on reverse remodelling, these drugs have a direct effect 
on the sarcoplasmic reticulum which improves calcium handling and diastolic 
function (Boateng et al., 1998). The addition of spironolactone has been shown to 
enhance survival in heart failure (Pitt et al., 1999) and reduce myocardial fibrosis 
(Zannad et al., 2000).   
Once maximal reverse remodelling has been achieved, a programme of inducing 
physiological hypertrophy is instituted (second stage of pharmacologic therapy) 
(Birks et al., 2006; Yacoub, 2001). This consists of administrating the β2 agonist 
clenbuterol which has been shown to have beneficial effects on excitation-contraction 
coupling and myocardial metabolism in experimental models (Soppa et al., 2005; 
Wong et al., 1997). In addition, clenbuterol has been found to induce physiological 
hypertrophy in the myocardium (Wong et al., 1998). Such hypertrophy may actually 
confer a physiological benefit, because studies of myocardial tissue during long-term 
use of LVADs suggest that myocyte atrophy may occur in esponse to long-term 
mechanical unloading (Soloff, 1998; Zafeiridis et al., 1998). This may be prevented or 
reversed by clenbuterol (Birks et al., 2006). However, Birks and colleagues also 
stressed that some adverse effects of clenbuterol use may be present including 




blockade (Burniston et al., 2002). In their study Birks et al. (2006) reported that the 
only adverse effects were mild tremor and muscles cramp, but no serious side effects 
were observed.    
According to Maybaum et al. (2007) the Harefield strategy will be tested in a US 
multicentre study that is due to commence recruitmen  in the near future.   
6.1.6 Exercise Capacity in Patients on Left Ventricular Assist Devices 
It has been suggested that supine cycle and upright t eadmill exercise are safe during 
chronic support with LVAD (Jaski et. 1997). Cardio-pulmonary exercise testing and 
evaluation of exercise capacity is standardized procedure of heart failure evaluation in 
the most world heart transplantation centres. However, up to date there are only 
several studies which investigated functional capacity using cardiopulmonary exercise 
test in patients implanted with an LVAD. 
Murali et al. (1991) compared metabolic stress test p rformance in 7 LVAD patients 
(class IV) with those patients with NYHA class III. The mean peak oxygen 
consumption for the LVAD patients slightly exceeded that of the class III patients: 
16.2 vs. 14.8 ml.kg-1.min-1, indicating improvement in exercise tolerance in the LVAD 
patients. Furthermore Jaski et al. (1993) assessed ha modynamics and exercise 
performance in three patients one month following LVAD implantation. All three 
patients underwent graded supine bicycle exercise (maximal work load 100 to 150 W) 
with measurements of central haemodynamics, including continuous pulmonary artery 
oxygen saturation and oxygen consumption. Two of the patients also underwent 
upright treadmill exercise with oxygen consumption measurement only. During 
supine cycle exercise, the heart rate increased from 93 to 119 beats per minute. 
Oxygen consumption increased from 3.0 to 8.7 ml.kg-1.min-1. Cardiac output increased 
from 6.0 to 9.6 l .min-1. The patients assessed during treadmill exercise achieved a 
maximal oxygen consumption of 14.3 and 16.7 ml.kg-1.min-1. Jaski et al. (1993) 
concluded that significant work loads compatible with activities of daily life and 





Levin and colleagues (1994) assessed changes in NYHA class, mean arterial pressure, 
resting cardiac output, exercise oxygen consumption and exercise cardiac output in 12 
LVAD patients. Nine patients improved to NYHA class I. Resting cardiac output 
increased from 3.1 l .min-1 preoperatively to 5.7 l .min-1 at two months, and mean arterial 
pressure from 60 to 91 mm Hg at two months. Four patients underwent maximal 
treadmill exercise testing (modified Naughton protoc l) average 10 weeks after 
LVAD implantation. Patients achieved a peak exercis oxygen consumption of 15 
ml.kg-1.min-1 and cardiac output of ~9 l.min-1. These data indicated that functional 
recovery occurs during LVAD support.     
Foray and associates (1996) performed a serial assessment of submaximal exercise 
capacity in patients with LVADs early (<3 months), mid (3 to 6 months), and late (>6 
months) after device implantation to determine whether submaximal exercise capacity 
increased over the time and whether this was related to improvements in the cardiac 
output response. Additionally Foray et al. compared submaximal exercise capacity of 
LVAD patients with those of normal subjects and patients with mild to severe heart 
failure dependent on dobutamine. A six minute test with metabolic measurements was 
performed in 14 LVAD patients, 20 patients with mild to moderate congestive heart 
failure, 14 patients dependent on dubutamine and six normal subjects. The LVAD 
patients demonstrated significantly greater walked distance than dobutamine 
dependent patients and similar to that for patients wi h mild heart failure. Oxygen 
consumption was also greater in the LVAD than in dobutamine dependent or mild 
heart failure patients (16.3 vs. 9.8 vs. 11.2 ml.kg-1.min-1). Serial assessment of 
submaximal exercise capacity in LVAD patients demonstrated continued sustained 
improvement over the time. However, cardiac output response was not significantly 
changed over the time (early 8, mid 8.6, and late 8.6 l .min-1). Foray et al. concluded 
that a significant sustained improvement in submaxil exercise capacity occurs with 
chronic LVAD therapy. Lack of the alteration of cardiac output response to exercise 
suggests that functional improvement results from peripheral mechanisms.   
Mancini and colleagues (1998b) compared the exercise performance of 20 LVAD 
patients with that of 65 ambulatory heart failure patients who were transplant 
candidates. Time since device implantation averaged 2.6 moths, with a range of 1 to 5 




significantly higher in the LVAD patients (15.9 vs. 12.0 ml.kg-1.min-1) as was 
anaerobic threshold (12.2 vs. 8.1 ml.kg-1.min-1). At rest, mean arterial blood pressure 
was higher in LVAD patients (94 vs. 87 mmHg) as was c rdiac output (4.9 vs. 4.1 
l .min-1). At peak exercise, heart rate was also higher in LVAD patients (148 vs. 125 
beats per minute) as were blood pressure (96 vs. 87 mm Hg) and cardiac output (11.2 
vs. 7.6 l .min-1). Mancini et al. concluded that haemodynamic measurements at rest and 
during exercise are significantly improved in patien s with LVADs compared with 
those awaiting cardiac transplantation. Similarly, the exercise capacity of the device 
patients is better than that of transplant candidates.  
Jaski and associates (1999) compared the functional capacity of LVAD patients vs. 
heart transplant. Eighteen patients who received LVAD as a bridge to heart 
transplantation underwent treadmill testing one to three months post-LVAD and again 
post-heart transplantation. Most of the patients performed a modified Naughton 
protocol with 2-minute stages, and one patient underwent a modified Bruce protocol 
as the investigator felt this would lead to a better assessment of the patient’s 
maximum exercise capacity. Patients exercise a mean of 52 days post-LVAD, and 59 
days post-heart transplantation. Results demonstrated that peak oxygen consumption 
was 14.5 ml.kg-1.min-1 post-LVAD and 17.5 ml.kg-1.min-1 post-heart transplantation. 
Exercise duration was significantly lower in post-LVAD than post-heart 
transplantation, while the mean peak exercise systolic blood pressure and heart rate 
were not significantly different between post-LVAD and post-heart transplantation.    
De Jonge and colleagues (2001) assessed exercise capacity at different point of 
LVAD implantation and compared the results with those obtained at different points 
after heart transplantation. Fifteen patients underwent treadmill exercise testing using 
a 2-min staged Naughton protocol or modified Bruce protocol. In 10 patients exercise 
capacity was assessed at 8 and 12 weeks after LVAD implantation. Results indicated 
that peak oxygen consumption increased from 21.3 to 24.2 ml.kg-1.min-1, while peak 
minute ventilation and carbon dioxide production ratio decreased from 39.4 to 36.3. 
Anaerobic threshold was not significantly changed (14.8 vs. 15.8 ml.kg-1.min-1). 
Furthermore in nine patients peak oxygen consumption 12 weeks after LVAD 
implantation was comparable to that of 12 weeks and o e year after heart 




increased from 14.4 ml.kg-1.min-1 with a LVAD to 15.9 and 18.7 ml.kg-1.min-1  12 
weeks and one year after heart transplantation. The ventilatory responses 12 weeks 
after LVAD implantation and 12 weeks and one year after transplantation were not 
significantly different. De Jonge et al. (2001) conluded that exercise capacity in 
patients with LVADs increases over the time. Similarly, Maybaum et al. (2007) found 
that peak oxygen consumption and exercise duration increase over the time with 
LVAD support. Patients performed cardiopulmonary exercise test at 30, 60, 90 and 
120 days following LVAD insertion and peak oxygen consumption results were as 
follows: 13.7 vs. 16.1 vs. 17.4 vs. 18.9 ml.kg-1.min-1, respectively. A similar trend was 
demonstrated in time of exercise duration. Recent study by Pruijsten et al. (2008) 
compared functional and haemodynamic capacity afterLVAD implantation and after 
heart transplantation. Forty-four patients who underwent LVAD implantation 
performed an exercise test (modified Naughton or modified Bruce protocol) three 
months after implantation of the device. Of the 44 patients, 29 performed a second 
exercise test three months after heart transplantatio . Peak oxygen consumption was 
20.0 ml.kg-1.min-1 following LVAD implantation and 24.0 ml.kg-1.min-1 following 
heart transplantation. Anaerobic threshold and ventilatory response were 13.8 ml.kg-
1.min-1 and 35.6 after LVAD implantation and 15.7 ml.kg-1.min-1 and 34.7 after heart 
transplantation. The authors concluded that exercis performance in patients with 
severe end-stage heart failure, treated with a LVAD, is compatible with activities of 
normal daily life.  
Functional capacity is an important aspect of quality of life in patients with 
cardiovascular disease (Jaski et al., 1999). From the above cited investigations there is 
no doubt that most of the patients implanted with left ventricular assist devices 







6.1.7 Rationale and Purposes of the Study 
A number of cited studies have demonstrated that the use of LVAD in severe end-
stage heart failure lead to positive molecular, cellular, biochemical, and structural 
changes in the myocardium, often referred as revers remodelling that is also 
accompanied with functional improvement. Also several studies assessed exercise 
performance in patients with LVADs usually expressed as peak oxygen consumption, 
anaerobic threshold, ventilatory response, exercise duration, and walked distance. 
Non-invasive, central haemodynamic measures have been less frequently reported 
compared with other markers of exercise capacity.  
Cardiac power output (CPO) is a novel haemodynamic measure that is the product of 
simultaneously measured cardiac output and mean arterial pressure (Cotter et al., 
2003). By incorporating both pressure and flow domains of the cardiovascular system, 
CPO is an integrative measure of cardiac hydraulic pumping ability. Cardiac power 
output has been shown to be a powerful predictor of pr gnosis and mortality in 
patients with chronic heart failure and those with cardiogenic shock (Fincke et al., 
2004; Mendoza et al., 2007; Roul et al., 1995; Tan, 1986; Tan and Littler, 1990; 
Williams et al., 2001) while cardiac reserve has been shown to be a major determinant 
of exercise capacity in heart failure (Tan, 1991). Surprisingly, cardiac power output 
has not been evaluated yet in patients supported with LVADs, and those explanted 
due to myocardial recovery. 
Therefore the first purpose of the present study was to assess and compare peak 
cardiac power output and cardiac reserve between patients implanted with LVADs, 
those explanted due to recovery and patients with moderate to severe heart failure. 
Additionally, the study evaluated and compared different aspects of exercise 






6.1.8 Research Hypotheses 
H1 – There will be a significant difference in peak cardi c power output between 
patients implanted with LVADs, those explanted due to recovery and patients with 
moderate to severe HF.  
H2 – There will be a significant difference in cardiac reserve between patients 
implanted with LVADs, those explanted due to recovery and patients with moderate 
to severe HF.  
H3 – There will be a significant difference in peak oxygen consumption, anaerobic 
threshold and ventilatory response to exercise between patients implanted with 
LVADs, those explanted due to recovery and patients with moderate to severe HF. 
6.2 Methods 
6.2.1 Patients 
The study population consisted of 54 male patients who attended cardiopulmonary 
exercise testing at Harefield Hospital, Harefield, United Kingdom. Data were 
collected in period from August 2006 to May 2008. Exclusion criteria included 
inability to perform treadmill exercise tests, inability to exercise beyond anaerobic 
threshold, symptomatic angina limiting exercise, unwillingness to provide consent 
form. Out of 54 patients, 20 were patients with moderate to severe heart failure (HF), 
18 patients were implanted with LVAD (IMP) and 16 patients were explanted with 
LVAD due to myocardial recovery (EXP). Only male patients were studied as there 
were no available female patients with an LVAD in situ. Only two LVAD explanted 
female patients and only five female heart failure patients were available for exercise 
testing. These female patients were excluded from analysis in order to avoid gender 
differences in measured physical and physiological v riables. Patients’ clinical 
characteristics are presented in table 6.1. 
Patients with moderate to severe heart failure consisted of available patients who were 




failure evaluation and, where appropriate, heart trnsplantation. Forty-five percent of 
patients with moderate severe heart failure had NYHA class IV and 55% had class III 
heart failure symptomatology. The pathogenesis of heart failure was ischaemic heart 
disease in 15%, and dilated cardiomyopathy in 85% of patients. Left ventricular 
ejection fraction (LVEF) averaged 32±14%, with a range of 15 to 55% (reported by 
Dr RG). All patients were receiving treatment with medication as described in Table 
6.1. Eighteen patients had a prior exercise test as part of their heart failure evaluation, 
while two patients were performing exercise test for the first time. Patients were 
diagnosed with heart failure for a mean period of 29±7.1 months. 
Eighteen patients implanted with LVAD were studied (Table 6.1). All patients were 
implanted with a continuous blood flow left ventricular assist device. Fifteen patients 
had HeartMate II (Thoratec Corporation, CA, USA) LVAD and three patients had 
HeartWare (HeartWare Limited, Sydney, AU) LVAD. At the time of the test, 44% of 
LVAD patients were in NYHA class I, 22% in class II, 11% in class III and 22% in 
class IV. All LVAD patients had dilated cardiomyopathy. LVEF averaged 50±8%, 
with a range of 45 to 68% (reported by Dr RG). All LVAD patients had a prior 
exercise test as evaluation for cardiac transplantatio . Time since device implantation 
averaged 219±87 days, with a range of 62 to 388 days. According to Dr Birks, the 
indication for insertion of the LVAD was the development of severe heart failure that 
was not responsive to intensive medical treatment, including inotropic support, with 
evidence of impeding or actually multiorgan failure due to low cardiac output. At the 
time of data collection in all LVAD patients the device was set up at fixed speed rate 
9000 to 9600 revolutions per minute for HeartMate II LVAD and between 2600 and 
3500 revolutions per minute for HeartWare LVAD. Patien s with LVADs were 
diagnosed with heart failure for a mean period of 46±24 month.  
Sixteen patients explanted with LVAD due to myocardi l recovery were studied 
(Table 6.1). At the time when LVAD was in situ 12 patients were implanted with 
pulsatile LVAD (HeartMate XVE, Thoratec Corporation, CA, USA) and three 
patients had continuous LVAD (Jarvik 2000, Jarvik Heart, Inc., MA, USA). At the 
time of the exercise test, 87% of LVAD explanted patients were in NYHA class I, and 
13% patients were in class II, respectively. All LVAD explanted patients had dilated 




RG). All LVAD explanted patients had a prior exercise test as evaluation for cardiac 
transplantation (LVAD implantation) as well as during follow up period when LVAD 
was in situ. The mean period of LVAD support was 396 days, with a range of 22 to 
638 days. According to Dr Birks, explantation was considered if the following criteria 
were met while the LVAD was off for 15 minutes: a left ventricular end-diastolic 
diameter of less than 60 mm, a left ventricular end-systolic diameter of less than 50 
mm, and a LVEF of more than 45%; a left ventricular end-diastolic pressure (or 
pulmonary-capillary wedge pressure) of less than 12 mm Hg; a resting cardiac index 
of more than 2.8 litres per minute per square meter of body surface area; and maximal 
oxygen consumption with exercise of more than 16 ml.kg-1.min-1  and an increase in 
minute ventilation relative to the carbon dioxide production ( EV& / 2C
O
V& , ventilatory 
response) of less than 34. Patients in the present study were tested average 3.3±1.1 
years (range from 0.3 to 5.8 years) following devic explantation. All LVAD 
explanted patients completed two stages of pharmacologi  regimen suggested by 
Birks and associates (2006). Patients explanted with LVAD were diagnosed with 
heart failure for a mean period of 54±19 months.  
The study was approved by the ethics committee of the Royal Brompton and 
Harefield National Health Service. All patients who participated in the study provided 











     
Table 6.1 Clinical Characteristics of Studied Population  
    HF IMP* EXP 
No.  20 18 16 
Age, yrs  45±10 39±14 41±14 
           Range, yrs 22-64 19-58 18-63 
LVEF, % 32±14 50±08 58±14 
Aetiology of HF    
           DCM 17 18 16 
           IHD 3 - - 
NYHA class, n    
           I  - 8 14 
           II  - 4 2 
           III  11 2 - 
           IV 9 4 - 
Medical Therapy   - 
           ACE inhibitors 15 (75%) 13 (72%) 12 (75%) 
 β-blockers  17 (85%) 15 (83%) 13 (81%) 
  Diuretics  18 (90%) 16 (89%) 12 (75%) 
      Angiotensin II antagonists  7 (35%)  3 (17%)  6 (38%) 
           Aldosterone antagonists 17 (85%) 15 (83%)  9 (56%) 
           Digoxin 15 (75%) 11 (61%) 13 (81%) 
           Antiarrhythmics   5 (25%)  4 (22%)  6 (38%) 







HF, moderate to severe heart failure patients; IMP, LVAD implanted patients; EXP, LVAD 
explanted patients; DCM, dilated cardiomyopathy; ICM, ischaemic heart disease; LVEF, left 
ventricular ejection fraction; ACE inhibitors, angiotensin converting enzyme inhibitor  
*LVAD turned on with optimal operation speed: 9,000 – 9,600 rpm for HeartMate II; 2,600 – 
3,500 rpm for HeartWare. Time since LVAD was implanted averaged 219±87 days, range 62 – 
388 days.   
ACE inhibitors: Lisinopril; Ramipril; Perindopril 
β-blockers: Carvedilol; Bisoprolol 
Diuretics: Frusemide; Bendrofluazide; Bumetanide 
Angiotensin II antagonists: Losartan; Candesartan; Valsartan 
Aldosterone antagonists: Spironolactone; Eplerenone 





6.2.2 Study Design 
This study took the form of a cross sectional study in which cardiac and respiratory 
measures were compared between the three groups of atients: 1) patients with 
moderate to severe heart failure, 2) patients implanted with an LVAD, and 3) patients 
explanted with LVAD due to myocardial recovery.    
6.2.3 Testing Procedure  
Upon the arrival in the transplant exercise laboratory, the patients’ weight and height 
were measured. ECG electrodes were attached according to the standard lead 
configuration for exercise testing and the ECG cables were connected. The patient 
then sat on a chair and following a five minutes resting period, arterial blood pressure 
was assessed from the brachial artery by cuff sphygmomanometry. This was followed 
by measurement of cardiac output in a seated position using the inert gas rebreathing 
methodology (Innocor, Innovision, Denmark) as described in details in the Chapter 3. 
Following explanation, the subject performed rebreathing technique in the 
demonstration mode of the Innocor first to ensure patient’s familiarisation with 
rebreathing manoeuvre. After a three minute wash out period, while the patient 
remained in a seated position, the rebreathing test wa  performed and cardiac output 
estimated by the Innocor.  
Following cardiac output measurement the patient was connected to the Oxycon Pro 
(Jaeger, the Netherlands) Metabolic Cart via a disposable pneumotach attached to the 
face mask. Oxygen consumption ( 2OV& ), carbon dioxide production ( 2C
O
V& ) and 
minute ventilation ( EV& ) were measured. After three minutes of resting metabolic 
measurements patient with severe heart failure and those implanted with LVAD 
performed a modified Bruce protocol while those patients explanted with LVAD 
performed Bruce protocol. Continuous breath-by-breath s mpling of respiratory gases 
and heart rate measurements were made, while the last 30 seconds of each exercise 
stage arterial blood pressure was measured and Borg scale recordings for dyspnea and 
fatigue were performed (Borg, 1982). At peak exercise, cardiac output was measured 




bacterial filter was inserted into the pneumotach of the Oxycon Pro and patient was 
asked to breathe with required breathing frequency and to empty the rebreathing bag 
with each inspiration. At the same time during rebreathing manoeuvre, peak arterial 
blood pressure was measured.  
The moment of cardiac output measurement at peak exercise was determined by the 
following criteria: respiratory exchange ratio of 1.05 and higher, achievement of 
maximal oxygen consumption (the absence of a rise in 2OV&  with further increase in 
exercise intensity) and patient’s subjective feeling of high intensity work  as indicated 
on the Borg scale (>17). 
Peak 2OV&  was defined as the average 2OV&  during the last minute of exercise, 
expressed as ml per kg of body weight per min, as well as ml per kg. Oxygen 
consumption at the ventilatory (anaerobic) threshold (AT) was identified as the 
oxygen uptake before the systematic increase in the ventilatory equivalent for oxygen 
( EV& / 2OV& ), without a concomitant increase in the ventilatory equivalent for carbon 
dioxide ( EV& / 2C
O
V& ), together with the V-slope method (Beaver, 1986; Wasserman, 
1999). 
Echocardiography at rest was performed in all studied patients on the same day when 
cardiopulmonary exercise test was conducted. Most of the echocardiographic results 
(e.g. left ventricular systolic and diastolic diameters, left ventricular mass, etc.) were 
utilised for the other clinical research project. In the present study patients’ left 







6.2.4 Calculations and Statistical Analysis 
The cardiac power output was calculated from the product of cardiac output and mean 
arterial pressure using the following equation (Cooke et al., 1998): CPO = (TQ&  x 
MAP) x K, where CPO is cardiac power output in Watts (W), TQ&  is cardiac output in 
l .min-1, MAP is mean arterial pressure in mm Hg and K is the conversion factor (2.22 
x 10-3). The physiological cardiac reserve is equal to the difference in between peak 
CPO and baseline resting CPO (Cooke et al., 1998). The mean arterial pressure was 
calculated as DBP + 0.412 x (SBP – DBP), where SBP is systolic blood pressure and 
DBP is diastolic blood pressure (Meaney et al., 2000). The ventilatory response to 
exercise ( EV& / 2C
O
V&  slope) was calculated by linear regression analysis u ng the 
values of minute ventilation and carbon dioxide output as previously described (Chua 
et al., 1997). Age- and gender-adjusted maximal predict d oxygen consumption was 
determined by using the treadmill equation of Wasserman et al. (1999) as following: 
W x (56.36 – 0.413 x Age), where W is normal weight (in kg) to height (H, in cm); W 
= 0.79H x 60.7 for men.  In addition, systematic vascular resistance to blood flow 
(SVR) at peak exercise was estimated as MAP/TQ&  and as per convention multiplied 
by a factor of 80 to convert units to dyn.s-1.cm-5.  
All statistical analysis was carried out using SPSS version 13.0 (SPSS inc. Chicago, 
Illinois, USA). Prior to statistical analysis, data were checked for univariate and 
multivariate outliers using standard Z-distribution cut-offs and Mahalanobis distance 
tests respectively. Normality of distribution was asessed using a Kolmogorov-
Smirnov test. To test difference in measured variables etween patients with severe 
heart failure, those implanted and explanted with LVAD one-way analysis of variance 
(ANOVA) was used. To identify the groups that differed significantly from one 
another, a post hoc Tukey’s test was performed. Statistic l significance was indicated 






Physical characteristics of the studied patients are presented in Table 6.2. There were 
non significant differences in age and body dimensio  between patients with 
moderate to severe heart failure (HF), LVAD implanted (IMP) and LVAD explanted 
(EXP) patients (p>0.05).   
 
Table 6.2 Physical Characteristics of the Patients 
HF, N=20 LVAD IMP, N=18 LVAD EXP, N=16 
 
Mean±SD Range Mean±SD Range Mean±SD Range 
Age (yrs) 45±10 22-64 39±14 19-58 41±14 18-63 
Weight (kg) 84.6±14.1 55-108 79.3±15.3 57-88 85.4±14.2 53-116 
Height (cm) 177.7±5.5 165-194.3 177.2±6.1 153.2-172.5 178.8±7.8 153.2-194.3 
BMI (kg/m2) 26.8±4.7 20.1-29.2 25.5±4.1 19.1-31.3 26.7±4.0 19.2-29.3 
BSA (m2) 2.1±0.2 1.9-2.4 2.0±0.2 1.6-1.9 2.1±0.2 1.5-2.4 
   
6.3.1 Central Haemodynamic Measurements  
The ANOVA revealed that cardiac power output at reswas not significantly different 
between the HF, LVAD IMP and LVAD EXP patients (p>0.05). In the HF patients 
resting cardiac power output ranged from 0.38 to 1.10 W, while in the LVAD IMP 
and LVAD EXP patients ranged from 0.43 to 1.26 W and from 0.73 to 1.42 W, 
respectively. At peak exercise, cardiac power output in LVAD IMP and LVAD EXP 
patients was significantly higher compared with HF patients (p<0.01). Also peak 
cardiac power output in LVAD EXP patients was significantly higher compared with 
LVAD IMP (p<0.01) (Figure 6.3). Peak cardiac power output ranged in 1) HF 
patients from 1.15 to 2.64 W, 2) LVAD IMP patients from 1.33 to 3.71 W, and 3) 
LVAD EXP patients from 2.20 to 4.50 W.  












Figure 6-4 Cardiac power output (CPO) at rest and at peak exercise in heart failure 
(HF) patients, LVAD implanted (IMP) and LVAD explanted (EXP) patients.  
*p<0.05 IMP vs. HF, #p<0.01 EXP vs. HF, †p<0.01 EXP vs. IMP. 
The mean physiological cardiac reserve of 2.43±0.54 W in LVAD EXP patients was 
significantly higher than in LVAD IMP (1.48±0.55 W) and HF patients (1.12±0.40 
W) (p<0.01). The mean difference in cardiac reserve of 0.36 W between LVAD IMP 
and HF was not significantly different (p>0.05).   
Cardiac output at rest was significantly greater (by 1.4 l.min-1 or 25%) in the LVAD 
IMP than in the HF patients (p<0.05), as were stroke volume and cardiac index by 25 
and 30% respectively (Table 6.3). In the LVAD IMP and EXP patients, resting 
cardiac index was greater than in the HF patients (p<0.05). Resting heart rate values 
and systolic, diastolic and mean arterial blood pressures were all comparable between 




























Table 6.3 Baseline and Peak Exercise Haemodynamic Measurements in the HF, IMP 
and EXP patients   
















        
Sitting Rest       
HF 4.1±1.3 74.6±18.3 56.8±20.8 0.78±0.24 103.4±13.8  68.9±9.7 84.2±10.8 
IMP 5.5±2.1* 72.6±14.5 76.0±21.2* 0.89±0.39 94.2±20 .1 59.9±16.2 75.2±16.6 
EXP 5.2±0.8 73.2±6.6 70.8±11.9 0.96±0.22 104.6±16.8  70.9±13.6 86.2±14.1 
        
        
Peak Exercise       
HF 9.1±2.1 126.3±27.3 71.1±14.1 1.90±0.45 123.2±22. 1 75.0±12.6 95.9±16.2 
IMP 12.4±2.2* 142.2±27* 87.2±16.4** 2.37±0.55* 110.7±24.1 67.7±11.5 87.4±14.5 
EXP 14.6±2.9## 163±18.1## 89.4±15.1## 3.39±0.61##†† 137.8±22.4†† 76.6±12.7 102.8±15.0† 




At peak exercise, cardiac output was significantly higher in the IMP and EXP patients 
compared with the HF patients, as were heart rate, stroke volume and cardiac index 
(Table 6.3). At peak exercise, pressure generating capacity of the heart tended to be 
lower in LVAD IMP patients compared with the LVAD EXP and HF patients (Table 
6.3). Systematic vascular resistance at peak exercise was significantly higher (p<0.05) 
in the HF patients (845±281 dyn.s.cm-5) than in the LVAD IMP (572±155 dyn.s-1.cm-
5) and LVAD EXP patients (556±192 dyn.s-1.cm-5).    
TQ& -cardiac output, HR-heart rate, SV-stroke volume, CPO-cardiac power output, SBP-systolic 
blood pressure, DBP-diastolic blood pressure, MAP-mean arterial pressure  
*p<0.05, **p<0.01 IMP vs. HF 
 #p<0.05, ##p<0.01 EXP vs. HF 




6.3.2 Oxygen Consumption Measurements and Exercise Duration 
Oxygen consumption measured at rest was not significa tly different between the HF, 
LVAD IMP and LVAD EXP patients. Oxygen consumption at anaerobic threshold in 
LVAD EXP patients (21.4±5.0 ml.kg-1.min-1) was significantly greater than that in 
LVAD IMP (14.7±4.9 ml.kg-1.min-1) and HF patients (11.2±1.9) (p<0.01). The 
anaerobic threshold occurred at 71% of peak oxygen consumption in the HF patients. 
In the LVAD IMP and LVAD EXP patients anaerobic threshold occurred at 74 and 
76% of peak oxygen consumption. Peak oxygen consumption averaged 15.8 ml.kg-
1.min-1 (range 10.4-19.8 ml.kg-1.min-1) in HF patients, 19.8 ml.kg-1.min-1 (range 12.4-
25.1) in LVAD IMP patients, and 28.2 (range 20.5-34.8 ml.kg-1.min-1) (Figure 6.4).  
Using the modified Bruce protocol, the exercise duration was higher in the LVAD 
IMP than in the HF patients (633±207 vs. 563±172 seconds, p<0.05). The LVAD 
EXP patients scored 645±190 seconds at Bruce protocol. The Borg scale results for 
ratings of perceived exertion were not significantly different between the patients 
(HF, 18.6±1.1; IMP, 18.2±1.3; EXP, 19.2±1.2).  
The HF patients achieved 46±13% (range, 34% to 69%), whereas LVAD IMP and 
LVAD EXP patients achieved 57±16% (range, 41% to 77%) and 83±17% (range, 
52% to 93%) of maximal predicted oxygen consumption calculated as suggested by 
Wasserman et al. (1999).    
Patients reported that they terminated cardiopulmonary exercise test due to fatigue, 
dyspnoea, both or other factors. Sixty-eight percent of the HF patients, and 59 and 
74% of LVAD IMP and LVAD EXP patients were limited by fatigue. Twenty-seven 
percent of the HF patients, and 32 and 19% of LVAD IMP and LVAD EXP were 
limited by dyspnoea. Between 3 and 6% of all patients reported that they had to stop 
the exercise test due to both fatigue and dyspnoea, and between 2 and 3% of patients 















Figure 6-5 Oxygen consumption (VO2) at rest, anaerobic threshold (AT), and peak 
exercise (peak), measured by Oxycon Pro - Jaeger, in heart failure (HF) patients, 
LVAD implanted (IMP) and LVAD explanted (EXP) patients 
*p<0.05 IMP vs. HF, #p<0.01 EXP vs. HF, †p<0.01 EXP vs. IMP 
6.3.3 Ventilatory and Metabolic Measurements 
At rest, there was non significant difference in respiratory exchange ratio between the 
patients (HF, 0.86; LVAD IMP 0.83; and LVAD EXP 0.78). The mean absolute 
values for carbon dioxide output and oxygen consumption at rest were in HF patients 
338.4±62.6 and 394.5±84.6 ml. in-1, in LVAD IMP patients 337.5±53.9 and 
406.6±92.3 ml.min-1, and in LVAD EXP patients 324.5±64.1 and 415.5±87.1 ml.min-
1.  
Metabolic and respiratory measures obtained at peak exercise are summarized in 
Table 6.4. Absolute values of peak oxygen consumption, carbon dioxide output and 
minute ventilation were higher in the LVAD EXP patients than in the HF and LVAD 
IMP patients (p<0.01). Respiratory exchange ratio was similar between the patients. 
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LVAD IMP and LVAD EXP patients.  
    
Table 6.4 Metabolic and Respiratory Measurements at Peak Exercise   
 2













HF 1384±375 1591±378 1.14±0.12 53.7±10.8 35.8±7.8 
IMP 1592±554 1846±401 1.15±0.14 62.2±17.7* 30.9±9.1 * 
EXP          2511±468#† 2837±550#† 1.12±0.11 88.6±28.0#† 29.3±5.2## 
2OV& -oxygen consumption, 2C
O
V& -carbon dioxide output, RER-respiratory exchange 
ratio, EV& -minute ventilation, EV& / 2C
O
V& slope-ventilatory efficiency, all measured by 
Oxycon Pro, Jaeger.    
*p<0.05 IMP vs. HF, #p<0.01 EXP vs. HF, ##p<0.05 EXP vs. HF, †p<0.01 EXP vs. 
IMP.  
6.3.4 Longitudinal Data – A Case Report 
A twenty-year-old male patient (height 188 cm, weight 80 kg) was supported with the 
HeartMate II LVAD. After 211 days of LVAD support he was explanted due to 
sufficient cardiac recovery. Cardiopulmonary exercise tests with non-invasive cardiac 
power output measurements were performed at different time points: 90 days since 
implantation (Test I) and 47, 76 and 148 days since the device was explanted (Tests 
II, III, IV).  
Resting cardiac power output values at Tests I, II, III and IV were 0.99, 1.24, 1.23, 
1.13 W, respectively. Peak cardiac power output increased over the time (from 2.10 
W at Test I to 3.11 W at Test IV) as was peak oxygen consumption (from 17.5 ml.kg-
1.min-1 at Test I to 26.8 at Test IV) (Figure 6.5). Peak oxygen consumption at 47 days 
explanted was similar to that at 76 days explanted (24.7 and 24.4 ml.kg-1.min-1).  
Resting cardiac output and cardiac index ranged from 5.9 to 6.8 l.min-1 and from 2.7 




over the time. Cardiac output increased from 11 l.min-1 at Test I to 14.4 l.min-1 at test 
IV, whereas mean peak arterial pressure increased from 86 to 100 mm Hg.   















Figure 6-6 Cardiac power output (CPO) and oxygen consumption (VO2) measured at 
90 days since device implantation (Test I), and 47, 76 and 148 days since device was 
































Cardiac power output determined non-invasively at res and at peak exercise has not 
been previously described in patients implanted with LVADs and those to whom 
LVAD was explanted do to sufficient myocardial recovery. Together with central 
haemodynamic measurements, the present study evaluated exercise performance 
represented by peak oxygen consumption and anaerobic threshold and ventilatory 
response to exercise in patients with moderate to svere heart failure, those implanted 
and explanted with an LVAD.  
In this cross sectional study design, different physiological variables were compared 
between the three different categories of heart failure patients (moderate to severe 
heart failure, LVAD implanted and LVAD explanted patients). When comparing 
cardiac power output between different subgroups of ubjects it is very important to 
minimize the effect of body dimension using appropriate scaling model (Chantler et 
al., 2005). The reported population in the present study consisted of male patients 
only. Analysis of variance revealed that there were non significant differences in 
measured body dimension variables and age between the three groups of patients. 
This important finding allowed direct comparison of cardiac power output to be made 
between the groups of patients.  
The important findings of this study are as follows: (1) Cardiac power output was not 
significantly different between the patients at rest a  was the pressure generating 
capacity of the cardiac pump. However, blood flow generating capacity at rest was 
significantly higher in LVAD IMP than in HF patients. (2) Overall cardiac function 
represented by peak cardiac power output was significa tly higher in LVAD EXP 
than in LVAD IMP and HF patients. Similar trend of higher peak cardiac power 
output was demonstrated in LVAD IMP versus HF patients. (3) Physiological cardiac 
reserve was significantly higher in LVAD EXP than in LVAD IMP and HF patients. 
(4) Exercise capacity represented by peak oxygen cosumption and anaerobic 
threshold was also higher in LVAD EXP than in LVAD IMP and HF patients, and 
finally ventilatory response to exercise was increased in HF compared with LVAD 




6.4.1 Patients Clinical Characteristics  
Analysis of the aetiology of heart failure revealed that all LVAD implanted and 
LVAD explanted patients had nonischaemic dilated cardiomyopathy as were 85% of 
heart failure patients. This is consistent with previous studies which indicate that the 
majority of patients needed mechanical circulatory support had dilated 
cardiomyopathy. Furthermore, medication (e.g. β-blockers, ACE inhibitors, diuretics) 
were comparable between the groups. Level of the usage of angiotensin II antagonists 
were lower in LVAD implanted compared with LVAD explanted and heart failure 
patients as was digoxin. The use of aldosterone antago ists (spironolactone or 
eplerenone), however, was lower in LVAD explanted than in LVAD implanted and 
heart failure patients. The effect of medication onheart failure and exercise 
performance is described in more details in Appendix IV. 
Twenty-two percent of LVAD implanted patients used a selective β2-adrenergic 
agonist (clenbuterol). It has been shown that clenbuterol induced significant myocyte 
necrosis in the heart and soleus muscle of the rat at doses previously used to 
demonstrate its anabolic properties (Burniston et al., 2002). However, Birks et al. 
(2006) suggested that clenbuterol prevents myocardial atrophy which may be caused 
during long-term mechanical unloading of the heart with LVAD. Moreover, Wong et 
al. (1998) found that clenbuterol causes mild myocardial hypertrophy. George et al. 
(2006) evaluated the effect of high-dose clenbuterol on cardiac and skeletal muscle in 
heart failure patients during LVAD support. Results revealed that cardiac function 
(represented by left ventricular ejection fraction) and exercise capacity did not 
change, but there was improvement in skeletal muscle mass and strength. It was also 
noted that clenbuterol prevented the expected decrease in myocyte size during LVAD 
support. Similarly, one recent study by Kamalakkannan and colleagues (2008) 
determined the effect of clenbuterol on skeletal muscle function, cardiac function, and 
exercise capacity in patients with heart failure. Rsults showed that maximal strength 
increased by 27% in clenbuterol group, but patients’ endurance and exercise duration 




6.4.2 Cardiac Performance 
The results from the present study suggest that LVAD implanted patients, and 
particularly those who have been explanted due to sufficient myocardial recovery, had 
better overall cardiac function than those patients with moderate to severe heart 
failure as represented by higher peak cardiac power utput and physiological cardiac 
reserve.  The results show that in LVAD explanted patients, both the flow- and 
pressure-generating capacity of the heart were higher t an those patients with 
moderate to severe heart failure and LVAD IMP patients. This confirms previous 
finding by Birks et al. (2006) that the use of LVAD and specific pharmacologic 
therapy (so called “combination therapy”) improves cardiac function which in the 
present study has been assessed primarily by cardia power output and physiological 
cardiac reserve.  
Peak cardiac pumping capability and physiological crdiac reserve measured in 
LVAD explanted patients were similar to that in patien s with mild heart failure (~3 
and 2 W) as suggested by Williams et al. (2005). This finding is supported by the fact 
that the most of the LVAD explanted patients (77%) were in NYHA functional class I 
and 13% of the patients were in NYHA class II. Maximal cardiac pumping capability 
was higher in LVAD explanted patients by 30 and 44% compared with LVAD 
implanted and those patients with moderate to severe h art failure, respectively. 
Similarly, physiological cardiac pumping reserve was higher in LVAD explanted 
patients by 39 and 53% than in LVAD implanted and those patients with moderate to 
severe heart failure.  At peak exercise, cardiac output, heart rate and stroke volume 
were higher in LVAD explanted than in moderate to severe heart patients by 38, 23 
and 20%, respectively. 
A number of previously mentioned studies suggested that ventricular pressure and 
volume unloading provided by LVAD support led to reverse remodelling on genetic, 
biochemical, histological and functional levels. To date, however, limited numbers of 
heart transplantations centres were able to demonstrate cardiac recovery that is 
sufficient to permit explantation of the LVAD. Only few studies presented data 
obtained from cardiopulmonary exercise testing in LVAD explanted patients, while 




invasive during exercise. A report from Germany by Muller et al. (1997) identified 
five (29%) of 17 patients with dilated cardiomyopathy supported by LVAD for >160 
days in whom the device was successfully explanted and who maintain stable cardiac 
function (represented by resting LVEF only) between 52 and 594 days after 
explantation. Further Dandel et al. (2005) reported successful weaning in 32 (24%) 
out of 131 patients with dilated cardiomyopathy with a 5-year survival rate of 78%, 
respectively. Compared with the previous study from Germany (Muller et al., 1997), 
Dandel et al. (2005) reported that patients performed incremental treadmill exercise 
test (Naughton’s protocol) between the third and fourth year after weaning. However, 
only predicted metabolic and ventilatory, but not any of central haemodynamic 
variables were presented, as discussed below. Significantly lower incidence of 
myocardial recovery has been reported by Mancini (1998a) and Maybaum et al. 
(2007). In study by Mancini et al. only 5% of patients met explantation criteria which 
was defined as peak oxygen consumption >20 ml.kg-1.min-1 and cardiac output >10 
l .min-1 when LVAD contribution to circulation was decreased. However, Mancini et 
al. (1998a) did not report any cardiopulmonary exercis  test data in patients following 
weaning of the device. Similarly, Maybaum et al. (2007) successfully explanted 9% of 
their patients but they also did not report central haemodynamic data following certain 
time since device explantation. Only Birks and associates (2006) reported cardiac 
output and cardiac index but only at rest in LVAD explanted patients. One year after 
explantation cardiac output and cardiac index averaged 4.9 l.min-1 and 2.4 l.min-1.m2, 
while in the present study the mean cardiac output and cardiac index averaged 5.2 
l .min-1and 2.5 l.min-1.m2. It should be noted that the average time since the device 
explantation in the present study was 3.3 years. Data from the present case report 
suggest that cardiac function at rest is stable during the first five months since the 
device was explanted (resting cardiac power output ranged between 1.13 and 1.24). 
Resting cardiac output and cardiac index ranged from 5.9 to 6.8 l.min-1 and from 2.7 
to 3.1 l.min-1.m2  between 1.5 and 5 months since exlpantation. Higher resting cardiac 
output values may be explained by body dimensions of the studied patient (height, 
188 cm; weight, 80 kg), with the bigger body demanding higher metabolic rate. 
Importantly, data from this case report demonstrate that maximal cardiac pumping 
capability of the heart and peak oxygen consumption increased by 12% (from 2.72 W) 




explanted (Figure 6.5). This indicates that overall cardiac function and exercise 
performance improve during first months of LVAD explantation.         
Compared with limited number of studies which evaluated cardiac performance 
during exercise in LVAD explanted patients, a few studies reported central 
haemodynamics in patients supported with an LVAD. Mancini and colleagues 
(1998a) reported that Fick cardiac output measured in 15 LVAD patients increased in 
response to exercise from resting value of 5.4 l.min-1 to peak exercise value of 11.4 
l .min-1 and mean arterial pressure changed from 90 to 98 mm Hg. These results were 
obtained approximately three months after device implantation. Calculated peak 
cardiac power output based on data from Mancini’s study (~2.5 W) is similar to that 
found in the present study in LVAD IMP patients. Peak cardiac output was lower by 
0.9 l.min-1 than that found in the present study whereas peak mean arterial pressure 
was higher by 11 mmHg (98 vs. 87 mm Hg). Furthermore in a separate study, 
Mancini et al. (1998b) compared cardiac and exercis performance between patients 
with congestive heart failure (N = 65) and LVAD patients (N = 20). Cardiac output 
was higher in LVAD than patients with congestive heart failure (rest, 4.9 vs. 4.1 l .min-
1, peak exercise 11.2 vs. 7.6 l.min-1). Pressure generating capacity, however, was 
higher in LVAD than in heart failure patients, whic is in contrast with findings of the 
present study. The difference shown in mean arterial p essure between the studies by 
Mancini et al. (1998a; 1998b) and present study may possibly be explained by 
different model of the pump which was implanted. Patients in studies by Mancini and 
associates were implanted with pulsatile devices, while in the present study 
continuous-flow left ventricular assist devices were used. Pulsatile devices fill with 
and eject blood in a cyclic fashion that is equivalent to the systole and diastole of the 
native heart. On the other hand continuous-flow devices produce kinetic energy 
imparted to the blood which is drawn continuously from the left ventricular apex to 
the pump and into the ascending aorta. Continuous blood flow devices demonstrate 
difficulty in detecting vital signs in a systematic circulation with reduced pulsatility 
(Miller et al., 2007) which may possibly lead to lower blood pressure detected in the 
present study. Systolic blood pressure measured at rest was similar to that reported by 
Miller et al. (2007) who also evaluated patients implanted with continuous LVAD. At 




Hg in a study by Miller et al., while in the present study (~7 months after device 
implantation) systolic blood pressure averaged 94 mm Hg. However, Miller et al. did 
not report results from an exercise test.    
The present study differed from Mancini et al. (1998a and 1998b) in that the exercise 
test was performed at different time points since LVAD was implanted. Time since 
device implantation averaged 3 months, with a range of 1 to 5 months in Mancini et 
al. (1998a and 1998b) while in the present study time averaged ~7 months, with a 
range of ~2 to 13 months. However, cardiac output data obtained three months after 
device implantation in the present study (case report) are similar to that found by 
Mancini et al. (1998a and 1998b). There is evidence to show that the improvement in 
central haemodynamics gained within the first few months after device implantation is 
maintained in the following months. Levin and associates (1994) demonstrated that 
resting cardiac (device) output and mean arterial pressure are stable from two to 10 
months since device implantation. Foray and associates (1996) revealed that cardiac 
output was not significantly different between different time points after device 
implantation. In study by Foray et al., LVAD patients performed 6-minute walk test 
with metabolic and cardiovascular measurements at early (<3 months), mid (3 to 6 
months) and late stage (>6 months) after device implantation. Peak cardiac output, 
estimated by the device sensor, was unchanged over the time (early, 8 l.min-1; mid, 8.6 
l .min-1; and late, 8.6 l.min-1). Similar observation was also reported by Maybaum et al. 
(2007) at 30, 60, 90, and 120 days after device implantation.  
Similar average values of peak cardiac (device) output were reported elsewhere with a 
range of 7.5 and 9 l.min-1 (de Jonge et al., 2001; James et al., 1998; Jaski et al. 1999; 
Levin et al., 1994; Maybaum et al., 2007). While only a few studies (Jaski et al., 1997; 
Mancini et al., 1998a and 1998b; the present study) have reported total cardiac output 
(as measured by invasive or non-invasive methods) in LVAD patients, others (de 
Jonge et al., 2001; James et al., 1998; Jaski et al. 1999; Levin et al., 1994; Maybaum 
et al., 2007) have used the device sensor to illustrate resting but also peak exercise 
cardiac output. This sensor takes into account onlythe volume of blood which flows 
through the pump, but not the output which is ejectd directly from left ventricular 
into the aorta. The sum of the two should present total cardiac output. It is likely, 




total cardiac output at rest and during exercise. This assumption is supported by 
Mancini et al. (1998a) who found that LVAD output was lower than cardiac output 
measured by the direct Fick method (rest 5.1 vs. 5.4 l.min-1; peak exercise, 8.1 vs. 
11.6 l.min-1). Interpretation of device output leads to an underestimation of cardiac 
performance. Therefore, in order to obtain an objectiv  image of the heart function 
and performance, cardiac output, and particularly cardiac power output should be 
measured at rest but also during exercise by the use of either invasive or non-invasive 
methods rather than reporting the device output only. I  the present study patients 
were not connected to external device control unit which displays the device output 
results and, therefore, data regarding estimated LVAD output were not available for 
analysis.  
The present study demonstrates that cardiac performance, represented by cardiac 
power output and physiological cardiac reserve differentiates well during cardiac 
restoration using LVADs, and emphasizes the benefits of this therapy. The results 
confirm previous evidence that the use of LVAD in combination with specific 
pharmacologic regimen, as suggested by Birks et al. (2006) improves overall cardiac 
function and performance. A peak CPO of ~ 2 W is considered to be a “cut-off” value 
for good and poor prognosis in heart failure (Roul et al., 1995; Williams et al., 2001). 
Therefore LVAD implanted, and particularly LVAD explanted patients, appear to 
have better prognosis than heart failure patients evaluated in the present study.  
6.4.3 Peak Exercise Performance and Ventilatory Measurements 
Few studies compared exercise performance of LVAD implanted with severe heart 
failure patients (Mancini et al., 1998b) and patients after heart transplantation (de 
Jonge et al., 2001; Jaski et al., 1999; Pruijsten e al., 2008). However, this is the first 
comparison of maximal upright exercise in LVAD explanted patients with LVAD 
implanted and severe heart failure patients. The peak oxygen consumption was higher 
in LVAD explanted patients compared with LVAD implanted and heart failure 
patients. LVAD explanted patients achieved 83% of the maximal predicted oxygen 
consumption. These patients were explanted at an average of 3.3 years (range of 0.3 to 
5.8). To date, only one study is available to demonstrate exercise performance in 




performance were obtained between three and four years after device explantation. 
Seventeen patients in Dandel et al. study reached 78% of maximal predicted oxygen 
consumption what is only 5% lower than that found i the present study. The 
improvement in exercise performance of these LVAD explanted patients is extremely 
dramatic and is similar to that observed in sedentary healthy adults. Moreover, data 
from case report from this chapter indicates that peak oxygen consumption increased 
from 24.7 to 26.8 ml.kg-1.min-1 between 1.5 and 5 months after device exlpantation.  
Peak oxygen consumption has been reported in the most studies which evaluated 
exercise performance in patients implanted with LVADs. Three months following 
device implantation peak oxygen consumption ranged from 14.3 to 17.4 ml.kg-1.min-1 
(Foray et al., 1996; Haft et al., 2007; Jaski et al., 1993; Jaski et al., 1997; Levin et al., 
1994; Mancini et al., 1998a; Mancini et al., 1998b; Maybaum et al., 2007; Murali et 
al., 1991). In the present study peak oxygen consumption in LVAD patients averaged 
19.8 ml.kg-1.min-1. Several factors may account for this difference. Firstly in some of 
the cited studies (Jaski et al., 1997; Mancini et al., 1998a and 1998b) exercise testing 
was performed on a cycle ergometer compared with treadmill exercise used in the 
present study. This may render 10 to 25% lower values of peak oxygen consumption 
(Richard et al., 1999). In the rest of the cited studies, exercise performance in LVAD 
patients was measured using a treadmill protocol (e.g. Naughton or modified Bruce 
protocol) or 6-minute walk test. The difference in peak oxygen consumption between 
these and the present study is likely to be explained by different time points of 
exercise test after device implantation (~3 vs. ~7 months). This supposition that peak 
oxygen consumption improves over the time while thepatient is on mechanical 
circulatory support, is supported by Maybaum and colleagues (2007). They measured 
peak oxygen consumption at 30, 60, 90 and 120 days following LVAD implantation 
and reported values of 13.7, 16.1, 17.4 and 18.9 ml.kg-1.min-1. De Jonge and associates 
(2001) reported that peak oxygen consumption at 8 and 12 weeks after LVAD 
implantation was 21.3 and 24.2 ml.kg-1.min-1 (de Jonge et al., 2001). However it 
should be emphasized that LVAD patients performed an intensive post-implantation 
exercise training program which clearly resulted in an excellent exercise performance.                   
The oxygen consumption at the anaerobic threshold was significantly higher in LVAD 




threshold was significantly higher in LVAD than in heart failure patients. The oxygen 
consumption at anaerobic threshold in LVAD patients is imilar to that reported by de 
Jonge and colleagues three months after device implantation (15.2 vs. 14.7 ml.kg-
1.min-1). The data from the present study suggest that endura ce capacity is improved 
in LVAD implanted and particularly LVAD explanted patients compared with severe 
heart failure patients. The delay in onset of anaerobic metabolism would help to 
explain the observed improved exercise performance of the LVAD explanted and 
implanted patients. The mechanisms responsible for the delayed onset of the 
anaerobic threshold may be improved skeletal muscle perfusion. With the improved 
cardiac output at rest and throughout exercise, it is likely that skeletal muscle 
perfusion was enhanced. This assumption may be explained by findings in the present 
study that systematic vascular resistance at peak exercise was lower in LVAD 
implanted and explanted patients compared with heart failure patients. Impaired 
exercise performance in heart failure patients may be inferred not only from impaired 
haemodynamic condition, but also skeletal muscle abnormalities (Gibbs et al., 1990; 
Maskin et al., 1983; Wilson et al., 1995) like atrophy (Mancini et al., 1992), as well as 
alterations in muscle histology and biochemistry (Massie et al., 1996). 
Finally, better exercise performance found in LVAD implanted and explanted 
compared with heart failure patients was accompanied by a significant decrease in 
ventilatory response to exercise. This variable is often increased in patients with 
severe heart failure and is considered an independent and even better prognostic 
marker than reduced peak oxygen consumption (Chua et al., 1997; Robbins et al., 
1999). During exercise, patients with heart failure have an excessive ventilatory 
response, possibly due to early onset of lactic acidosis, ventilation-perfusion 
mismatching from hypoperfusion leading to an increase in dead space ventilation 
(Wasserman et al., 1999). A cut off value of 34 hasbeen proposed to differentiate 
severe heart failure patients with good and poor prgnosis (Chua et al., 1997).       
6.4.4 Study Limitations 
The present study has a number of limitations. Firstly, this study had cross-sectional 
design as only limited data obtained at different time points (e.g. baseline data prior 




and/or explantation) were available. Data from one patient only, who was implanted 
and, after sufficient recovery, explanted are presented. Secondly, this study is limited 
in that it is observational. The mechanisms which resulted in improved cardiac 
function and performance were not investigated in either LVAD implanted and/or 
explanted patients. Thirdly, the exercise test was not performed at precise time points 
(with a wide range) after LVAD implantation and explantation. This may have 
skewed results and limited generalisation of the whole population of patients. Finally, 
the Innocor system was not used for metabolic but only for cardiac output 
measurements as it was not standard equipment in the Harefield Transplant Exercise 
laboratory. Therefore in order to estimate peak cardiac power output the Innocor 
respiratory valve unit with a bacterial filter was inserted into the pneumotach of the 
Jaeger system at peak exercise. Eight patients (5 EXP, 1 IMP, 2 HF) continued 
rebreathing manoeuvre within the first few seconds following test termination. This 
may underestimate cardiac power output results obtained at peak exercise in these 
patients.         
6.5 Clinical Implications and Conclusions 
The present study demonstrated that the use of LVAD with specific pharmacologic 
regimen (so called “combination therapy” proposed by Birks and associates in 2006) 
provides patients with greater functional capacity than that observed in patients with 
moderate to severe heart failure. Moreover, those pati nts who successfully completed 
combination therapy (LVAD explanted patients) demonstrated level of central 
haemodynamics and exercise performance similar to that in patients with mild heart 
failure and sedentary healthy adults.  
The results from this study have shown that overall c rdiac function represented by 
peak cardiac power output and physiological cardiac reserve is better in LVAD 
implanted and particularly LVAD explanted patients than those with heart failure. Not 
only peak cardiac power output, but also the other powerful surrogate indicators of 
prognosis such as anaerobic threshold, ventilatory response and peak oxygen 
consumption were all shown to be significantly different in LVAD implanted and 
LVAD explanted patients compared with heart failure patients. It is, therefore, fair to 




term prognosis than HF patients.  
Furthermore, this study has shown that the absence of significant differences in 
cardiac function at rest does not necessary mean tht there is not going to be 
significant difference during exercise between LVAD implanted, explanted and heart 
failure patients. It is important to assess variables which reflect both the flow- and 
pressure-generating capacity of the heart. Cardiopulmonary exercise testing with non-
invasive measurement of central haemodynamics including cardiac power output has 
been reported for the first time in LVAD implanted and explanted patients. Results 
confirm feasibility and importance of cardiac power output measurement in these 
patients. Therefore, future LVAD investigations should evaluate central 
haemodynamics during exercise, particularly cardiac power output, which has the 
potential to be a key physiological marker of heart f ilure severity and can possibly 
guide management of LVAD patients.  
Future studies should evaluate overall cardiac functio  and exercise performance in 
LVAD patients with limited device support, assessing the response of the native heart 
to exercise. Also the association between cardiac power output and other powerful 
prognostic surrogates obtained from cardiopulmonary exercise testing in LVAD 
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CHAPTER 7: RESTING AND EXERCISE HAEMODYNAMIC 
AND METABOLIC RESPONSES TO ACUTE REDUCTION OF 
LVAD SUPPORT: ASSESSMENT OF MYOCARDIAL 
RECOVERY  
Abstract 
Introduction: Patients with left ventricular assist device (LVAD) become stable after 
a few weeks following device implantation. The LVAD explantation criteria is based 
on data obtained when the LVAD is either switched off (pulsatile LVADs) or operates 
at reduced, very low speed (continuous LVADs). It has been suggested that 
assessment of myocardial recovery during reduced LVAD support is safe and well 
tolerated. Only a few studies have reported haemodynamic and metabolic 
measurements at rest and at peak exercise in patients with reduced LVAD support, but 
none have evaluated its effect on the power generati g capacity of the heart. The 
purpose of the present study was to assess the effect o  acute reduction of continuous-
flow LVAD support on resting and peak exercise cardiac power output and other 
haemodynamic and metabolic measurements Methods: Twelve male patients (age 
37±10 yrs, weight 77±9 kg, height 178±7 cm) implanted with continuous-flow 
LVADs (Heart Mate II), visited the exercise laboratory twice during the same day 
with at least four hours rest between the two visits. During the first visit LVAD 
support was optimal with speeds ranging from 9,000 to 9,600 revolutions per minute. 
During the second visit the LVAD support was reduced and ranged from 5,800 to 
6,000 revolutions per minute. Measurements at rest and at the peak exercise of the 
modified Bruce protocol were undertaken using non-invasive, inert gas, rebreathing 
haemodynamic and respiratory gas procedures. Results: In response to reduced 
LVAD support, resting cardiac power output decreased by 21% (from 0.87 to 0.69 W, 
p=0.068) as was cardiac output by 13% (from 5.3 to 4.6 l.min-1, p=0.141) and mean 
arterial pressure by 9% (from 74.1 to 67.3 mm Hg, p=0.123). Resting stroke volume 
decreased by 18% (from 71.4 to 58.2 ml.beat-1, p=0.072) while resting heart rate 
increased by 5% (from 74 to 79 beats.min-1, p=0.126). At peak exercise most of the 
measured haemodynamic and metabolic variables decreased significantly in response 
to reduced device support. Cardiac power output decreased by 39% (from 2.31 to 1.40 




pressure by 13% (from 85.4 to 74.3 mm Hg, p=0.006), stroke volume by 24% (from 
88.4 to 67.5 ml.beats-1, p=0.039) and heart rate by 9% (from 138 to 126 beats.min-1, 
p=0.046). Peak oxygen consumption reduced by 23% (from 18.2 to 14.1 ml.kg-1.min-1, 
p=0.004) whereas exercise time decreased by 18% (from 628 to 516 seconds, 
p=0.032). None of the patients demonstrated any short- or long-term adverse effects 
after the tests. Conclusion: The present study shows that acute reduction of LVAD 
support is safe and well tolerated by the patients both at rest and during exercise. 
There is a decrease in cardiac pumping capability and exercise performance as a 
consequence of acute reduction of LVAD support. A decrease at rest and at peak 
exercise, expressed in percentages, was higher in cntral haemodynamics, particularly 
in cardiac power output, than in the conventionally measured oxygen consumption. 
This may suggest that cardiac power output is more sensitive to acute reduction of 
LVAD support than oxygen consumption. Further ‘reduced LVAD support’ studies in 
larger cohorts of patients are required to find out the “cut-off” value of peak cardiac 
power output which may indicate sufficient myocardil recovery for the LVAD to be 
explanted.    
7.1 Introduction 
Left ventricular assist devices (LVADs) have been used as an effective therapeutic 
option in patients with advanced heart failure either as a bridge to transplantation, as 
destination therapy or as a bridge to recovery (Birks et al., 2004; Birks et al., 2006; 
Frazier et al., 2001; Long et al., 2005; Stevenson et al., 2004). Improvement in 
myocyte histology and biochemistry, as well as in left ventricular anatomy, 
physiology and haemodynamics have been observed in pat ents with advanced heart 
failure receiving prolonged mechanical circulatory support (Frazier et al., 1996). The 
improvement in cardiac function may be such that the pump could be removed and 
transplantation avoided (Muller et al., 1997).  
Sufficient recovery to allow device explantation has been observed in only 5% to 24% 
of patients (Frazier et al., 1999; Dandel et al., 2005; Manicini et al., 1998). A strategy 
of combined mechanical and pharmacological therapy has been proposed with the β2-
adrenoreceptor agonist clenbuterol used to stimulate physiologic hypertrophy during 




Protocol’) resulted in sufficient myocardial recovery that allowed LVAD to be 
explanted in >70% of non-ischaemic cardiomypathy patients.  
The utility of the LVAD may depend on aetiology of advanced heart failure (e.g. 
myocarditis vs. dilated cardiomyopathy). In the case of myocarditis, the LVAD may 
simply provide the circulatory needs of the body, including improved coronary flow, 
for the time necessary to resolve the disease process naturally, or burnout the 
inflammatory process (Rose and Frazier, 1997). However, in the case of dilated 
cardiomyopathy, reverse remodelling during chronic left ventricular unloading with 
an LVAD is clearly taking place with normalization of cardiac structure (reversal of 
chamber enlargement) and function (Levin et al., 1995; Madigan et al., 2001).   
When patients with advanced heart failure implanted with an LVAD demonstrate 
restoration of heart function, according to Hetzer et al. (2001), two questions continue 
to await definitive answers. Firstly, which criteria indicate complete and long-term 
cardiac recovery while the patient is on an LVAD, and secondly what is the ideal time 
to remove the device once recovery appears to have occurred? Similarly, Farrar et al. 
(2002) argued that after the device is implanted it is not known what methods of 
patient and device management should be undertaken to optimize the chances for 
recovery.            
7.1.1 LVAD Explantation Criteria 
The LVAD explantation criteria is usually based on results obtained by 
echocardiography, cardio-pulmonary exercise testing, catheterization and myocardial 
tissue analysis. Echocardiography and cardio-pulmonary exercise testing may be 
performed when the device operates in full (optimal ode) but also when the device 
is either switched off (pulsatile device), or operat s at very low speed (continues axial 
flow device) at rest and/or during exercise. This procedure allows evaluation and 
monitoring of myocardial recovery.  
To date, only a few studies have clearly defined the LVAD explantation criteria. It is 
surprising that in a prospective big multicenter study of the LVAD working group 




criteria for device explantation. However, Liden et al. (2007) defined cardiac recovery 
as off-pump left ventricular ejection fraction (LVEF) ≥40% together with significant 
improvement in invasive haemodynamic measurements (cardiac index ≥2.5 and 
pulmonary capillary wedge pressure ≤20-23 mm Hg). Further Dandel et al. (2005) 
considered LVAD removal to be safe if, during repeated off-pump trials performed 
over several days, the maximum left ventricular end-diastolic diameter (LVEDd) was 
55 mm and the minimum LVEF 45%, while the right ventricular diameters and 
function remained stable.  
In contrast with Dandel et al. (2005) and Liden et al. (2007), the following two studies 
included data obtained from cardiopulmonary exercis test as important information 
in making the final decision for an LVAD to be explanted. Yacoub (2001) reported 
that explantation of the device was considered, if the device was ‘switched off’ and 
ventricular dimensions were normalized, LVEF ≥45%, LV end-diastolic pressure ≤8 
mmHg, cardiac index more than 2.8 l.min-1.m2, and most importantly maximal oxygen 
consumption ≥20 ml.kg-1.min-1 and ventilatory response to exercise <34. According to 
Birks et al. (2006) explantation was considered if the following criteria were met 
while the LVAD was off for 15 minutes: a left ventricular end-diastolic diameter of 
less than 60 mm, a left ventricular end-systolic diameter of less than 50 mm, and a 
LVEF of more than 45%; a left ventricular end-diastolic pressure (or pulmonary-
capillary wedge pressure) of less than 12 mm Hg; a resting cardiac index of more than 
2.8 l.min-1.m2; and maximal oxygen consumption with exercise of mre than 16 ml.kg-
1.min-1  and ventilatory response <34. Finally, Mancini and associates (1998) 
suggested that the ability to exercise at reduced LVAD support to an oxygen 
consumption of more than 20 ml.kg-1.min-1 and/or a peak cardiac output higher than 
10 l.min-1 provides sufficient cardiovascular reserve for the patient to tolerate device 
explantation. Echocardiographic parameters such as con istent aortic valve opening, 
normal shortening fraction, and absence of marked vntricular dilation are clinical 





7.1.2 Monitoring of Myocardial Recovery – ‘On Pump vs. Off Pump’ 
Studies 
Today, it is well known that myocardial recovery occurs after LVAD implantation. 
However, evaluation and monitoring of myocardial recovery of an LVAD patient still 
remains an issue (George et al., 2007). Some investgators have relied on examination 
of the patients while the device is on, after reducing the speed of the device and hence 
reducing its power, or after momentary discontinuation of the device (Hetzer et al., 
2001; Maybaum et al., 2003; Slaughter et al., 2001). However, it remains difficult to 
determine whether the heart has had significant recovery that can be sustained once 
the device has been removed. 
Hetzer and associates (2001) reported that the LVEDd and LVEF served as the main 
parameters to assess changes in cardiac performance. U der the conditions of a 
running device, an LVEDd below 60 mm and an LVEF above 40% were the criteria 
to do further echocardiographic studies. Firstly, the pump was set at the lowest 
possible pumping frequency, and eventually, the pump was stopped to evaluate the 
heart without mechanical support. To avoid thrombus formation inside the pump, 
10,000 international units of heparin were administrated before stopping the pump. 
These off-pump studies were conducted once a week aft r device placement. Hetzer et 
al. (2001), however, did not present any data to demonstrate response of the native 
heart to an acute interruption of LVAD support. They concluded that no reliable 
parameters predicts outcome after weaning and none determines the possibility of the 
device removal before implantation in advance.  
Slaughter and colleagues (2001) suggested a new method for monitoring myocardial 
recovery and weaning a pulsatile LVAD. They differentiated two phases, recovery 
and weaning phase. During recovery phase, neurohormonal markers (to include 
plasma norepinephrine and tumor necrosis factor-α) are monitored and 
echocardiography is performed. Weekly bioimpedance is performed which allows an 
accurate non-invasive assessment of the patient’s cardiac output. After the second 
postoperative week, the patients undergo cardiopulmonary exercise testing using the 
modified Naughton protocol which they performed preop ratively. This is repeated 




The weaning phase begins once an improvement in echocardiography, neurohormonal 
markers and cardiopulmonary exercise test results have been observed. During this 
phase, LVAD support gradually decreases in four steps over several days with daily 
echocardiography and bioimpedance monitoring. Once the device has reached a final 
setting for two days, the native left ventricle will have been providing a significant 
portion of total cardiac output. The patient than undergoes repeat cardiopulmonary 
exercise test, and if peak oxygen consumption remains unchanged or improved, the 
patient is scheduled for operation the following day. If the peak oxygen consumption 
decreases or the total cardiac output decreases during the weaning process, the device 
mode is changed back to full support and the recovery phase continued. Slaughter et 
al. (2001) concluded that gradual reloading of the ventricle would be ideal. This 
would avoid a sudden increase in wall stress and stretching of the myocyte. Also it 
would allow a longer period to observe the ventricle to see how it handles the new 
workload and its ability to sustain that work.   
Maybaum et al. (2003) described the assessment of my cardial recovery in a 35-year-
old male patient with acute myocarditis who required LVAD support as a bridge to 
recovery. A combination of echocardiography, right heart catheterization, exercise 
testing and serial endomyocardial biopsies was used to determine the resolution of 
myocarditis, recovery of cardiac function and timing for device explantation. 
Successful device explantation was performed after 37 days of device support. After 
two weeks postoperatively, LVAD rate was progressively decreased from full device 
support in auto mode (LVAD output of 6.5 l.min-1) to reduced LVAD support with 
flow of 2.5 l.min-1. Results revealed that there were no significant changes in LVEF, 
LVEDd, blood pressure, pulmonary capillary wedge pressure, right atrial and 
pulmonary artery pressures, and resting cardiac output. On the 36th post-operative day, 
cardiopulmonary exercise testing was performed, with s multaneous haemodynamic 
and echocardiographic measurements. The patient initially performed symptom-
limited cycle exercise testing with full device support in the auto mode. Then LVAD 
flow was reduced over the period of 40 minutes to 2litres per minute, and the patient 
repeated the exercise test with reduced LVAD flow. In response to reduced LVAD 
support, peak oxygen consumption and thermodilution cardiac output slightly 




haemodynamic response to exercise with reduced LVAD flow, device explanation 
was planned for the following day. This study demonstrates that central 
haemodynamic measures (e.g. cardiac output) rather than peak oxygen consumption 
should be used in LVAD explantation decision making process.  
George and associates (2007) from Harefield Heart Science Centre developed a test 
involving short-term interruption of LVAD support with measurements of several 
haemodynamic (heart rate and blood pressure) and echocardiographic parameters  
such as left ventricular end-systolic diameter (LVESd) and LVEDd, and LVEF at rest 
and, whenever possible, after exercise. After full heparization, the HeartMate I XVE 
device was switched off and echocardiographic measur ments were obtained at 5, 10 
and 15 minutes following device cessation. If devic cessation was tolerated for 15 
minutes, a 6-minute walk test was performed with repeat measurements thereafter to 
determine inotropic reserve. Results revealed that s ort-term discontinuation of the 
LVAD is safe and well tolerated by the patients. Cessation of the device was 
associated with an immediate drop in resting mean arteri l blood pressure, a rise in 
resting heart rate, a reduction in LVEF, and increases in ventricular dimensions. After 
an exercise test, the recovered group had a significa t rise in heart rate and LVEF and 
non-significant increase in mean arterial pressure, whereas, the non-recovered group 
had a significant drop in mean arterial pressure compensated by a rise in heart rate. 
George et al. (2007) concluded that acute discontinua on of the device to assess 
recovery is safe and well tolerated and is followed by specific changes in 
haemodynamic and echocardiographic parameters.  
Mancini and colleagues (1998) performed echocardiogaphic and haemodynamic 
measurements in patients implanted with pulsatile LVAD. Tests were performed 
when the device was operating in the auto mode (full device support) and then with 
the device at the lowest fixed rate (50 cycles per minute) with full heparization of the 
patients. The electrical device was interfaced with a pneumatic stroke volume limiter 
so that the device rate could be reduced to 20 cycles per minute. Downtitration of the 
LVAD rate by 10 cycles per minute was performed with haemodynamic and 
echocardiographic measurements every 10 minutes until the patients developed 
symptoms or a device rate of 20 cycles per minute was achieved. Because the stroke 




l .min-1. Patients then performed cycling exercise test with metabolic and invasive 
central haemodynamic measurements. During downtitration of the device, resting 
heart rate increased significantly from 99 to 106 beats per minute, whereas blood 
pressure and cardiac output decreased significantly, from 91 to 71 mmHg and from 
5.3 to 4.2 l.min-1. Only 7 out of 18 patients were able to exercise at a fixed device rate 
of 20 cycles per minute. At peak exercise heart rate, mean arterial blood pressure, 
cardiac output and oxygen consumption were significantly lower when the LVAD rate 
was reduced to 20 cycles per minute compared with auto mode. Additionally, 
reduction in LVAD support resulted in significant increase in LVEDd and LVESd 
both at rest and at peak exercise. Mancini et al. (1998) concluded that exercise testing 
may be a useful modality to identify those patients with sufficient myocardial 
recovery for the device to be explanted.   
In continuous-flow LVADs the blood flow through the pump is dependant on the 
rotation of its impeller and the differential pressure across the pump. When the 
impeller is not rotating, as when pump is off, blood may flow from the aorta to the left 
ventricle, causing shunting and ineffectual blood fl w.  
Myers and colleagues (2006) were the first to evaluate haemodynamic and patient 
safety during pump-off studies of an axial-flow LVAD. Thirty patients were 
supported with the Jarvik-2000 LVAD for the mean duration of 170 days (range from 
13 to 763 days). Patients were monitored by echocardiography during brief periods of 
no more than 5 minutes with the pump off. All patien s received anti-coagulation 
therapy to achieve an international normalized ratio (INR) of 1.5 to 2.0, and the mean 
INR value for the group was 1.5. In each case, 5,000 U of heparin was administrated 
just before the pump was turned off. When the LVAD was switched off, there was an 
regurgitant flow of 0.42 l.min-1. The systolic blood pressure was not significantly 
different with the pump on or off, whereas the diastolic and mean arterial blood 
pressures significantly decreased when the device was off. With the pump off, the 
mean values for LVEDd and LVESd were 74 and 65 mm. With the pump-on, LVEDd 
and LVESd progressively decreased as pump speed increased. When compared with 
the pump-off, these changes became significant when t  pump was operating at 
speed of ≥10,000 rpm. The LVEDd decreased to 67 mm at 10,000 rpm, and further to 




12,000 rpm. The mean heart rate and respiratory rate did not change significantly at 
any of the experimental settings. In the most of the patients, when the pump speed 
reached 12,000 rpm, the cardiac output was largely represented by the pump flow. 
Myers et al. (2006) concluded that regurgitant flow through axial-flow LVAD is 
minimal and does not have immediate clinical consequences. Whether this holds true 
when the pump is turned off for longer periods will dependent on the degree to which 
the patient’s native heart function recovers (Myers et al., 2006).  
7.1.3 Rationale and Purposes of the Study 
Monitoring of myocardial recovery after LVAD implantation remains an issue. It is, 
however, essential to know whether there is sustained recovery of the native heart in 
the LVAD patient. A number of procedures have been proposed, as described above. 
It seems that the best way to evaluate the degree of my cardial recovery in LVAD 
patients is to reduce LVAD support by switching thedevice off or reducing its speed. 
Although a number of studies evaluated the effect of reduced LVAD support on heart 
function and structure at rest, only a few have assessed cardiovascular and metabolic 
response to maximal exercise. No study, however, examined the effect of reduced 
LVAD support on power generating capacity of the heart (cardiac power output) 
either at rest or at peak exercise.  
Moreover, over the last few years continuous-flow rather than pulsatile LVADs have 
been mostly implanted in the clinics worldwide. Only Myers et al. (2006) reported 
their experience with switching off continuous-flow LVAD for a period of five 
minutes. At present, the effect of reduced speed of a continuous-flow LVAD on 
haemodynamic and metabolic measurements either at rst o  at peak exercise has not 
been assessed. 
Therefore, the purpose of the present study was to sess the effect of acute reduction 





7.1.4 Research Hypotheses  
H1 – Acute reduction of continuous-flow LVAD support will not significantly reduce 
cardiac power output, and other haemodynamic and metabolic measurements at rest. 
H2 – Acute reduction of continuous-flow LVAD support will significantly reduce 
cardiac power output, and other haemodynamic and metabolic measurements at peak 
exercise.     
7.2 Methods 
7.2.1 Patients 
In this study 12 male patients were recruited who were prospectively enrolled in the 
Harefield Bridge-to-Recovery Programme. Patients were implanted with a HeartMate 
II LVAD between August 2006 and January 2008. The cause of chronic heart failure 
was dilated cardiomyopathy. The average age of these patients was 37±10 years. 
Average weight and height were 77.3±8.7 kg and 178.1±6.7 cm, and LVEF of 44±12 
%. Duration of implant averaged 186±72 days. Eight patients were in the first phase 
of specific Harefield pharmacological regimen and they were treated with ACE 
inhibitors, β-blockers, aldosterone antagonists, angiotensin II antagonists and 
diuretics. Four patients were in the second stage of pharmacologic therapy in which 
additionally the β2-adrenergic-receptor agonist clenbuterol was administered. Patients 
who were unable to exercise above anaerobic threshold were excluded from analysis. 
The study was approved by the ethics committee of the Royal Brompton and 
Harefield National Health Service. Participants provided written informed consent.   
7.2.2 Testing Procedure  
Patients visited the transplant exercise laboratory twice during the same day with at 
least four hours rest between the two visits. During the first, morning visit (Test I), the 
LVAD support was optimal with speed ranging from 9,000 to 9,600 rpm. During the 
second, afternoon visit (Test II), the LVAD support was reduced and ranged from 




rpm. During the pump speed reduction and during the cardiopulmonary exercise test 
with reduced device support, the patients were closely observed clinically for any 
untoward symptoms such as dizziness, sweating and plpitations. During both visits, 
measurements at rest and at peak exercise of the modified Bruce protocol were 
undertaken using non-invasive, inert gas, rebreathing aemodynamic and respiratory 
gas procedures, as described in details in the Chapter 6 of this thesis. During the 
reduced LVAD support session, measurements were undertaken following pump 
speed reduction.  
7.2.3 Calculations and Statistical Analysis 
Cardiac power output (CPO), mean arterial pressure (MAP), ventilatory response to 
exercise ( EV& / 2C
O
V& ) and systematic vascular resistance (SVR) were calculated as 
described earlier in the Chapter 6.  
All statistical analysis was carried out using SPSS version 13.0 (SPSS inc. Chicago, 
Illinois, USA). Prior to statistical analysis, data were checked for univariate and 
multivariate outliers using standard Z-distribution cut-offs and Mahalanobis distance 
tests respectively. Normality of distribution was asessed using a Kolmogorov-
Smirnov test. To test difference in measured variables etween Test I (optimal LVAD 
support) and Test II (reduced LVAD support), a t-test for paired samples or Wilcoxon 
signed rank test were used. Statistical significance was indicated if p<0.05. All data 








7.3.1 Resting Measurements  
Table 7.1 shows haemodynamic and metabolic variables m asured at rest during Test 
I (morning session with optimal LVAD support) and Test II (afternoon session with 
reduced LVAD support). Although changes varied betwe n one and 21%, none of 
these changes were significantly different between the two tests. As soon as the 
LVAD speed was reduced the power generating capacity of he heart decreased by 
0.19 W. Similarly pressure and flow generating capaities of the heart decreased by 
~7 mm Hg and 0.7 l.min-1. There was slight rise in heart rate by 5 beats-1 and 
reduction in stroke volume by ~13 ml.beats-1 following a decrease of LVAD speed.   
 
Table 7.1 Resting Haemodynamic and Metabolic Variables Measured during Test I 
and Test II (N=12)  
      Test I*  Test II** % diff. p-value 
        
CPO, watts   0.87±0.36  0.69±0.26 21 0.068 
SV, ml.beat-1  71.4±16.1  58.2±12.2 18 0.072 
Innocor TQ& , l.min-1   5.3±1.7  4.6±1.4 13 0.141 
SBP, mm Hg  95.6±20.1  85.7±20.0 10 0.154 
DBP, mm Hg  60.8±16.2  54.5±10.9 10 0.179 
MAP, mm Hg  74.1±16.8  67.3±13.6 9 0.123 
2OV& , ml.kg-1.min-1    4.3±0.4  4.6±0.3 6 0.323 
HR, beats.min-1  74±16  79±13 5 0.126 
RER   0.83±0.03  0.84±0.05 1 0.791 
2OV& -oxygen consumption, RER-respiratory exchange ratio, CPO-cardiac power 
output, HR-heart rate, SV-stroke volume, TQ& -cardiac output, SBP-systolic blood 
pressure, DBP-diastolic blood pressure, MAP-mean arteri l blood pressure. *optimal 
LVAD support-operation speed 9,000-9,600 rpm, **reduced LVAD support-






7.3.2 Exercise Measurements  
At peak exercise most of the measured haemodynamic nd metabolic variables were 
significantly lower when LVAD support was reduced (Table 7.2). Peak power 
generating capacity of the heart was lower by ~0.90 W following Test II, as were 
flow- and pressure generating capacities by ~4 l.min-1 and ~11 mm Hg. Peak cardiac 
power output ranged from 1.36 to 3.51 W (Test I) and from 0.85 to 2.51 W (Test II).  
Maximal exercise time and peak oxygen consumption were lower by 112 seconds and 
~4 ml.kg-1.min-1. As a consequence of reduced LVAD support there was a significant 
increase in systematic vascular resistance and ventilatory response to exercise.    
 
Table 7.2 Exercise Haemodynamic and Metabolic Variables Measured during Test I 
and Test II (N=12) 
   Test I  Test II % diff. p-value 
        
Peak CPO, watts 2.31±0.58  1.40±0.50 39 <0.001 
Innocor Peak TQ& , l.min-1  12.2±2.1  8.6±2.5 30 <0.001 
Peak SVR, dyn.s.cm-5 612±162  823±226 26 0.008 
Peak SV, ml.beat-1 88.4±16.4  67.5±14.7 24 0.039 
Peak 2OV& , ml.kg-1.min-1   18.2±4.5  14.1±5.3 23 0.004 
Exercise time, seconds  628±192  516±119 18 0.032 
EV& / 2C
O
V& slope  35.5±4.6  41.3±7.1 16 0.038 
Peak SBP, mm Hg 110.7±24.1  96.5±23.5 13 0.016 
Peak MAP, mm Hg 85.4±15.4  74.3±14.9 13 0.006 
Peak EV& , l.min-1   58.4±6.2  52.8±9.5 10 0.046 
Peak HR, beats.min-1 138±27  126±26 9 0.046 
Peak DBP, mm Hg 59.9±16.2  54.9±10.9 9 0.015 
Peak RER  1.12±0.10  1.09±0.06 3 0.083 
2OV& -oxygen consumption, RER-respiratory exchange ratio, EV& -minute ventilation, 
EV& / 2C
O
V& -ventilatory response to exercise, CPO-cardiac power output, HR-heart 
rate, SV-stroke volume, TQ& -cardiac output, SBP-systolic blood pressure, DBP-






The ability of the patients to increase haemodynamic and metabolic responses to 
exercise from resting level was higher when LVAD support was optimal (Test I) 
compared to that when LVAD support was reduced (Test II) (Table 7.3).  
 
Table 7.3 Changes from Resting to Peak Exercise Values in Selected Haemodynamic 
and Metabolic Variables 
                         ∆ absolute ∆ % p-value 
  Test I             Test II    
        
CPO*, W  1.44±0.58             0.71±0.38  51 <0.001 
TQ& , l.min-1   6.9±2.8             4.0±2.1  42 0.001 
MAP, mm Hg  11.3±3.2             7±2.4  38 0.222 
SV, ml.beats-1  17.0±4.6             9.3±3.8  45 0.014 
2OV& , ml.kg-1.min-1    13.9±2.1             9.5±2.4  32 0.082 
HR, beats.min-1  64±9             47±8  27 0.021 
∆ absolute – difference between peak and resting value, ∆ % – percentage difference in 
∆ absolute between Test I and Test II. * – the difference between peak and resting 
cardiac power output is physiological cardiac reserve.     
All patients tolerated well acute reduction in the pump speed and were able to perform 
a cardiopulmonary exercise test. There were no short- or long-term adverse effects in 
any of the patients as a consequence of reduced LVAD support either at rest, during 










This is the first study to address the effect of acute reduction of continuous-flow 
LVAD support on cardiac pumping capability and other haemodynamic and 
metabolic measurements at rest but also at peak exercise. Others have evaluated 
myocardial recovery in ‘off-pump’ studies when patients were implanted with a 
pulsatile LVADs (George et al., 2007; Hetzer et al., 2001; Mancini et al., 1998; 
Maybaum et al., 2003; Slaughter et al., 2001), while only Myers et al. (2006) reported 
their experience with a continuous-flow LVAD. Myers et al. (2006), however, did not 
perform a ‘stress’ test.    
The major finding of the present study is that reduced continuous-flow LVAD support 
decreases cardiac pumping capability (cardiac power output) by 21% at rest and by 
39% at peak exercise. Reduced LVAD support also decreases the patients’ ability to 
increase cardiac power output from resting to peak xercise value (physiological 
cardiac reserve) by half. In non-pulsatile LVADs (a used in this study), where the 
flow is continuous, reducing the pump speed to a rate at which there is no forward or 
back flow (an ‘off-pump’ equivalent study) is an alternative for assessing recovery 
(George et al., 2006). It has been shown that the device output is <2 l.min-1 when the 
HeartMate II LVAD operates at very low speed (e.g. 6,000 rpm) (Myers et al., 2006) 
as used in the present study. Therefore cardiac output obtained with reduced LVAD 
support (speed of 6,000 rpm) is mostly produced by the native heart rather than by the 
device.  
Different approaches have been proposed in the assessment of myocardial recovery 
while a patient is implanted with an LVAD (George et al., 2007; Hetzer et al., 2001; 
Mancini et al., 1998; Maybaum et al., 2003; Myers et al., 2006; Slaughter et al., 
2001). Performing a number of echocardiographic and exercise tests measurements 
when the device is switched off or operates at low speed has commonly been used to 
evaluate a degree of myocardial recovery in LVAD patients. Some authors evaluated 
cardiac structure and function at rest only (Hetzer et al., 2001), whereas others have 
performed exercise test with measurement of central haemodinamics and oxygen 




Although there is an agreement that myocardial recov ry should be evaluated with 
reduced LVAD support, it seems that there is no consensus yet regarding the best 
measure to evaluate myocardial recovery in LVAD patients. In an attempt to address 
this issue, Dr Tan’s concept of cardiac power presented in Copenhagen (2007) will be 
described. Firstly, it should be stressed that cardiac function, rather than structure, 
should be prioritised in evaluation of myocardial recovery. Secondly, the degree to 
which the myocardium has recovered may only be objectively evaluated not with 
measurements at rest, but at peak exercise. The key rol  of the cardiac pump is to 
produce hydraulic energy to maintain physiological irculation (Tan, 1991). From 
evidence available so far only one parameter has the capacity to express hydraulic 
energy produced by the heart. That measure is cardiac power output which accounts 
not only for flow-, but also pressure-generating capacity of the heart. It is, therefore, 
not surprising that cardiac power output has been proposed to be the best, direct 
indicator of overall cardiac function (Tan, 1986). It may, therefore be suggested that 
probably the best method and measure to assess the degr e of myocardial recovery in 
LVAD patients is the measurement of cardiac power output at rest and peak exercise 
with reduced LVAD support.     
7.4.1 Optimal vs. Reduced LVAD Support at Rest 
Results from the present study show that the acute reduction of continuous-flow 
LVAD support decreases cardiac pumping capability, cardiac output, stroke volume 
and mean arterial pressure. It causes slight increase in heart rate, oxygen consumption 
and respiratory exchange ratio at rest. None of these changes were significantly 
different between optimal and reduced LVAD support. It should be noted, however, 
that some of these changes require attention as the magnitude expressed in 
percentages may have some practical implications.  
Firstly, and most importantly, as soon as LVAD support was reduced, cardiac 
pumping capability (CPO) decreased by 21% as a consequence of reduced flow (TQ& )- 
and pressure (MAP)-generating capacity of the heart by 13 and 9%. While heart rate 
increased by 5%, stroke volume decreased by 18%. Therefore reduced cardiac 




Reduced rate of pulsatile LVAD at rest is associated with a rise in the heart rate by 
~9% (George et al., 2007) or by 11% (Mancini et al., 1998). In contrast, when the 
continuous LVAD was turned off from the speed of 9,000 rpm, there was an increase 
of 3% in the heart rate (Myers et al., 2006). These findings are in agreement with 
those from the present study. Reduced LVAD support causing a decreased mean 
arterial blood pressure has also been previously shown (George et al., 2007; Mancini 
et al., 1998; Myers et al., 2006). Only Mancini et al. (1998) demonstrated that reduced 
LVAD support was associated with a reduction in direct Fick cardiac output by 1.1 
l .min-1, whereas in the present study cardiac output reduced by 0.7 l.min-1. Slight 
increase in resting oxygen consumption by 6% found in the present study is consistent 
with finding by Mancini et al. (1998).  
These resting data suggest that minimal changes associ ted with reduced LVAD 
support in routinely measured haemodynamics (e.g. heart rate, arterial pressure) do 
not mirror changes in overall cardiac function. Moreover, presenting only changes in 
either flow- or pressure-generating capacity of theheart may overestimate overall 
cardiac function. It remains an issue as to what mini al level of decrease in cardiac 
pumping capability at rest (e.g. <5%) may represent ufficient myocardial recovery. 
However, it seems reasonable to suggest that the smaller the decrease in cardiac 
power output with reduced LVAD support, the better will be the overall cardiac 
function. Stressing the heart with a cardiopulmonary exercise test with central 
haemodynamic measurements at peak exercise is probably the best method to 
determine a degree of myocardial recovery in LVAD patients.     
7.4.2 Optimal vs. Reduced LVAD Support at Peak Exercise 
The present results obtained at peak exercise demonstrate the following important 
findings. Firstly, the ability of the heart to generate hydraulic power was reduced by 
39% when LVAD support was reduced. Probably as a direct consequence of reduced 
cardiac pumping capability there was a significant reduction in exercise capacity 
(exercise time, peak oxygen consumption) and an increase in ventilatory response to 
exercise. Secondly, the results show that the ability of the patients to increase 
haemodynamic and metabolic response from rest to peak exercise was significantly 




which represents the difference between rest and peak exercise cardiac power output, 
was halved as a consequence of reduced LVAD support. Similarly, the patients’ 
ability to increase flow- and pressure-generating capa ity was lower by 42 and 38% 
with reduced LVAD support. Finally, performing a treadmill exercise test is safe and 
well tolerated in LVAD patients when the device operat s at low speed (reduced 
LVAD support).   
Only few studies have shown exercise results in respon e to reduced LVAD support. 
George et al. (2007) used a 6-minute-walk test and performed a series of 
measurements not during and/or peak exercise, but following cessation of exercise. 
Apart from echocardiography, from central haemodynamic measurements, George et 
al. (2007) only evaluated blood pressure and heart rate. They showed an increase in 
mean arterial blood pressure due to an increase in systolic, but not diastolic blood 
pressure. Also a significant increase in heart ratefollowing 6-minute-walk test was 
reported. Furthermore, Mancini and associates (1998) performed haemodynamic and 
metabolic measurements at rest but also at peak exercise (cycling) with optimal and 
reduced LVAD support. Results showed that cardiac output and peak oxygen 
consumption were lower by 25%, whereas mean arterial pressure was lower by 13% 
when LVAD support was reduced. These findings are similar to those found in the 
present study where cardiac output, peak oxygen consumption and mean arterial 
pressure were lower by 30, 23, and 13% respectively when LVAD support was 
reduced.     
Great difference in physiological cardiac reserve between optimal and reduced LVAD 
support found in the present study may indicate that insufficient reverse remodelling 
and myocardial recovery have occurred in this cohort of patients following LVAD 
implantation. This supposition may be supported by the fact that only four of 12 
patients were in the final, second phase of ‘Harefield Recovery Protocol’ which 
includes the β2-adrenoreceptor agonist clenbuterol (Birks et al., 2006). The present 
study demonstrates that cardiac pumping reserve was 0.71 W when LVAD support 
was reduced. Whether this result may indicate any myocardial recovery in this group 
of LVAD patients remains an issue as no such pre-implantation data are available.  




physiological cardiac reserve were dramatically decreased when support from a 
continuous-flow LVAD was reduced. On the other hand, the study demonstrates great 
haemodynamic and metabolic benefits when LVAD operates with optimal speed. 
More importantly, the study demonstrates feasibility of cardiac pumping capability 
measurements in LVAD patients with optimal and reduced device support. Due to the 
capacity to represent overall cardiac function directly, cardiac power output should 
become a standard measure of myocardial recovery evaluation in LVAD patients. 
This will assist in making important decisions such as LVAD explantation.  
Finally, a decrease at rest and at peak exercise, expressed in percentages, was higher 
in central haemodynamics, particularly in cardiac power output, than in 
conventionally measured oxygen consumption. This may suggest that cardiac power 
output is more sensitive to acute reduction of LVAD support than the oxygen 
consumption. This fact additionally supports the viw that cardiac power output 
should be prioritized among other more conventionally measured cardio-respiratory 
variables such as oxygen consumption.    
7.4.3 Study Limitations 
The major limitation of this study is that no baselin  (pre-implantation) data are 
available. Thus, it is difficult to suggest whether measured cardiac power output and 
physiological cardiac reserve demonstrate an improvement in myocardial function, 
particularly in situation with reduced LVAD support. This study is also limited by the 
small sample size. Although a greater number of LVAD patients was available for 
cardiopulmonary exercise testing as shown in Chapter 6, not all of them attended 
afternoon session with reduced LVAD support.  Additionally, the present study is 
descriptive. No attempt was made to identify the mechanism of improved (non-






7.5 Clinical Implications and Conclusions 
The present study shows that performing a cardiopulmonary exercise test with non-
invasive haemodynamic and metabolic measurements in patients implanted with 
continuous-flow LVAD is safe and well tolerated when the device operates at low 
speed. The results demonstrate that cardiac pumping capability at rest and peak 
exercise is dramatically impaired when continuous-flow LVAD support is reduced. 
Physiological cardiac reserve was halved in response to reduced LVAD support. This 
may indicate that insufficient myocardial recovery occurred in this cohort of patients. 
Stressing the heart with a cardiopulmonary exercise te t with central haemodynamic 
measurements at rest and peak exercise is probably the best method to determine a 
degree of myocardial recovery in LVAD patients, particularly when the device 
support is reduced. Measurement of cardiac pumping capability in LVAD patients 
with reduced LVAD support is feasible. Cardiac power output estimated at rest and 
peak exercise should become a standard measure in evaluation of myocardial recovery 
in LVAD patients based on which important decisions can be made (e.g. LVAD 
explantation). There is no reason why cardiac power output, as a direct measure of 
overall cardiac function, should not be prioritized among other cardio-respiratory 
variables (e.g. oxygen consumption, ventilatoy respon e) as the latter may be 
influenced not only by cardiac but also by non-cardiac factors (e.g. muscle 
conditioning). Results from the present study show that cardiac power output is more 
sensitive to acute reduction of LVAD support than the oxygen consumption. A 
decrease at rest and at peak exercise, expressed in p rcentages, was higher in cardiac 
power output, than in conventionally measured oxygen consumption.   
Further ‘reduced LVAD support’ studies in larger cohorts of patients are required to 
find out the “cut-off” value of peak cardiac power output which may indicate 
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CHAPTER 8: RELATIONSHIP BETWEEN PEAK CARDIAC 
PUMPING CAPACITY AND EXERCISE-DERIVED 
PROGNOSTIC INDICATORS IN PATIENTS WITH MODERATE 
TO SEVERE HEART FAILURE AND THOSE IMPLANTED AND 
EXPLANTED WITH A LEFT VENTRICULAR ASSIST DEVICE 
Abstract  
Introduction: The cardiopulmonary response to exercise in patients wi h chronic 
heart failure has been established as an important prognostic indicator. Several 
exercise-derived variables have been shown to be strong predictors of prognosis in 
chronic heart failure (peak oxygen consumption, anaerobic threshold, peak circulatory 
power, ventilatory efficiency-EV& / 2C
O
V&  slope and peak oxygen pulse). The purpose 
of the present study was to assess the relationship between peak cardiac pumping 
capacity represented by peak cardiac power output (CPO) and peak oxygen 
consumption ( 2OV& ), anaerobic threshold (AT), ventilatory efficiency slope 
( EV& / 2C
O
V& ), circulatory power (CP) and peak oxygen pulse (OP) in moderate to 
severe chronic heart failure patients (HF), and those implanted (IMP) and explanted 
(EXP) with a left ventricular assist device (LVAD). Methods: Fifty-four patients (20 
HF, 18 IMP, 16 EXP) performed a cardiopulmonary exercis  test (the Bruce or 
modified Bruce protocol) with respiratory gas and non-invasive haemodynamic 
measurements. Results: When all data were combined (n=54), peak CPO was 
strongly correlated with peak 2OV&  (r=0.87, p<0.01), AT (r=0.79, p<0.01) and 
circulatory power (r=0.82, p<0.01). Peak CPO was well correlated with peak oxygen 
pulse (r=0.69, p<0.01) and moderately with EV& / 2C
O
V&  slope (r=-0.51, p<0.01). 
Subgroup analysis revealed that the strength of relationship between peak CPO and 
other prognostic indicators was generally lower in HF patients and IMP than in EXP 
patients. Peak 2OV&  was highly correlated with peak CPO in EXP (0.85, p<0.01), 
whereas in HF and IMP this relationship was moderate (r=0.55 and r=0.53, p<0.05). 
The AT was only modestly correlated with peak CPO in HF and EXP patients  
(r=0.46 and r=0.54, p<0.05) and weakly in IMP patients (r=0.37. p<0.05). Peak CPO 
was highly correlated with peak CP in EXP patients (r=0.82, p<0.01), whereas in IMP 
and HF patients the r values were 0.63 (p<0.01) and 0.31 (p>0.05). EV& / 2C
O




was only moderately correlated with peak CPO in EXP patients (r=-0.52, p<0.05) but 
a non significant relationship was found in HF and IMP patients. Similarly the 
relationship between peak CPO and peak OP was good in EXP patients (r=0.63, 
p<0.02), but not in severe HF (r=0.45, p<0.05) and IMP patients (r=0.32, p>0.05). 
Conclusion: The present study demonstrates that the strength of t e relationship 
between direct and indirect indicators of cardiac pum ing capacity is weaker in 
patients with moderate to severe heart failure and those implanted with a LVAD, 
compared with LVAD explanted patients. It is important to assess maximal cardiac 
pumping capability directly by measuring peak cardic power output rather than using 
the other surrogates of cardiac pumping function, particularly in moderate to severe 
heart failure patients and those implanted with a LVAD.      
8.1 Introduction 
Cardiopulmonary exercise testing has been widely used in chronic heart failure 
patients to assess functional capacity, to evaluate responses to medical treatment and 
exercise therapy, to assess progression of disease proc ss, and to determine prognosis 
(Ingle, 2008). According to Wright and Tan (1999) the objectives of cardiopulmonary 
exercise testing in patients with chronic heart failure are: 1) to improve understanding 
of pathophysiological mechanisms, 2) to confirm the quantity of symptoms and their 
severity, 3) to predict prognosis, and 4) to assess therapeutic success.  
Despite surgical, technological and pharmacological advances used in management of 
heart failure patients, the prognosis remains generally poor (Nieminen et al., 2005). In 
order to identify patients who are at the highest ri k of cardiac event, researchers 
reported a number of exercise-derived parameters which ave been shown to be 
powerful prognostic indicators. Peak oxygen consumption, anaerobic threshold, 
ventilatory response to exercise (ventilatory efficien y) and circulatory power have 
been used in the prognosis of heart failure, in addition to functional and treatment 
assessment. It should, however, be emphasized, that these variables are indirectly 
related to cardiac function, and therefore can only be considered as markers of 
severity of organ failure. The practical implication is that an improvement in these 
values does not necessarily indicate an improvement in cardiac function (Williams et 




work index (Griffin et al., 1991; Metra et al., 1999), cardiac output response to 
exercise (Chomsky et al., 1996) and cardiac power output (Roul et al., 1995; Williams 
et al., 2001) have emerged as powerful independent pr dictors of prognosis over the 
more commonly reported peak oxygen consumption.     
8.1.1 Exercise-Derived Prognostic Indicators in Heart Failure  
8.1.1.1 Peak oxygen consumption in heart failure 
The prognostic value of exercise testing in the heart f ilure population is well 
established. Peak oxygen consumption (2OV& ) has consistently demonstrated 
prognostic significance (Francis et al., 2000; Mancini et al., 1991; Myers et al., 2000) 
and is the most frequently analyzed cardiopulmonary exercise test parameter 
(Gibbons et al., 1997). In conjunction with other typically more invasive evaluation 
techniques, peak 2OV&  is used to assess survival and the need for heart transplantation 
(Gibbons et al., 1997). American Heart Association consensus reports have 
recommended that peak 2OV&  be used to help determine the timing of heart 
transplantation in ambulatory patients with chronic heart failure (Costanzo et al., 
1995). Specifically, it has been suggested that a peak 2OV&  level of less than or equal 
to 14 ml.kg-1.min-1 be used as a key criterion for the acceptance of ambulatory patients 
for transplantation. This recommendation is based on several studies demonstrating 
that peak 2OV&  is a valuable prognostic marker in patients with chronic heart failure 
and that transplantation can be safely deferred in patients with peak 2OV&  levels of 
more than 14 ml.kg-1.min-1 (Mancini et al., 1991; Szlachcic et al., 1985). The 24th 
Bethesda Conference for Cardiac Transplantation listed peak 2OV&  less than 10 ml
.kg-
1.min-1 with achievement of anaerobic metabolism as an accepted indication for heart 
transplantation (Mudge et al., 1993).       
Patients with chronic heart failure have a reduced physical (exercise) capacity, which 
can be characterized by a reduction in oxygen consumption at peak exercise (Weber et 
al., 1982). Weber et al. (1982) proposed a functional classification of heart failure in 




anaerobic threshold (Table 8.1). The latter will be discussed in the section 8.1.1.2 of 
this chapter.  
 
Table 8.1 Weber Functional Classification for Heart failure 
Weber Class 
Peak 2OV&   
ml.kg-1.min-1  





A >20 >14 Mild or absent 
B 16-20 11-14 Mild-Moderate 
C 10-15 8-11 Moderate-Severe 
D <10 <8 Severe 
Oxygen uptake is determined by cellular oxygen demand and can be calculated from 
blood flow and oxygen extraction by the tissue. According to the Fick equation, 
oxygen uptake is equal to the product of cardiac output and the difference between 
arterial and venous oxygen (a-v O2). Figures 8.1 and 8.2 show central and peripheral 
determinants of maximal oxygen uptake. 
 
         
Figure 8-1 Central determinants of maximal oxygen uptake (modifie  from Myers 
and Froelicher, 1991).  
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Figure 8-2 Peripheral determinants of maximal oxygen uptake. a- v O2 difference = 
the difference between arterial and venous oxygen; Hb = haemoglobin; EV&  = minute 
vneitlation; PA O2 = partial pressure of alveolar oxygen (modified from Myers and 
Froelicher, 1991).  
The upper limit of oxygen uptake could be determined by limitations in maximal 
cardiac output, pulmonary gas exchange, or the ability of the working muscles to 
extract and use supplied oxygen. It has been traditionally believed that in the absence 
of pulmonary disease, peak 2OV&  is not limited by pulmonary gas exchange (Rowel, 
1986). In healthy individuals the most important factor limiting maximal oxygen 
uptake is the heart’s ability to deliver oxygen (Basset and Howley, 2000). In contrast 
to healthy individuals, patients with heart failure demonstrate many central, 
peripheral, and ventilatory abnormalities during exercise (Myers and Froelicher, 
1991). Therefore, peak 2OV&  in heart failure patients may be limited by central 
(systolic function, pulmonary haemodynamics, diastolic function, neurohumoral 
mechanisms), peripheral (blood flow abnormalities, vasodilatory capacity, skeletal 
muscle biochemistry) and ventilatory factors (pulmonary pressure, physiological dead 
space, ventilation-perfusion mismatch, respiratory control, breathing pattern (Clark et 
al., 1996; Myers and Froelicher, 1991). A detailed iterature review about exercise 
limitation in chronic heart failure is provided in chapter 10.         
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Central haemodynamic parameters measured at rest do not correlate with maximal 
exercise capacity represented by peak 2OV&  (Cohen-Solal et al., 1999). Earlier studies 
have shown that resting haemodynamic measurements fail to predict subsequent 
exercise performance (Bain et al., 1990; Cooke et al., 1998; Engler et al., 1982; 
Gelberg et al., 1979; Higginbotham et al., 1983; Roul et al., 1995). Left ventricular 
ejection fraction and cardiac output have not been shown to be good predictors of 
exercise capacity (Benge et al., 1980; Higginbotham et al., 1983; Franciosa et al., 
1984; Lipkin and Wilson, 1986; Weber et al., 1984), with one study showing that 50% 
of the patients with ejection fraction of less than 30% had normal exercise capacity 
(Benge et al., 1980). Calculated indices of resting left ventricular function such as pre-
ejection time, velocity of circumferential shortening, stroke volume index and stroke 
work index all fail to predict exercise capacity. Bain et al. (1990) were the first to 
correlate cardiac power output measured at rest with exercise capacity represented by 
exercise time. As with other resting heamodynamic measurements, cardiac power 
output was also a poor predictor of exercise capacity (Bain et al., 1990; Cooke et al., 
1998).   
Cohen-Solal et al. (1999) reported two main reasons t  explain the poor relationship 
between peak 2OV&  and haemodynamic parameters measured at rest: 1) none of the 
resting measurements is able to demonstrate the reserve of cardiac pump function, 
which can only be evaluated during either physiological (exercise test) or 
pharmacological (inotropic) stimulation; 2) resting haemodynamic measurements do 
not account for peripheral factors (circulatory and muscular) that appear to play an 
important role in the limitation of exercise capacity of patients with heart failure 
(Cohen-Solal et al., 1999). 
Peak 2OV&  has emerged as a powerful predictor of prognosis in patients with heart 
failure as it provides an indirect assessment of the cardiac functional reserve. 
Therefore it is not surprising that a significant positive correlation between peak 2OV&  
and maximal exercise cardiac output has been reported by several investigators 
(Franciosa et al., 1984; Higginbotham et al., 1983; Metra et al., 1990; Weber et al., 




was well correlated with peak cardiac power output and functional cardiac reserve in 
heart failure patients (Bain et al., 1990; Cooke et al., 1998; Roul et al., 1995).   
Over the years, peak 2OV&  has been used as a “gold” standard among other 
cardiopulmonary exercise measures in heart failure evaluation and prognosis. It has 
several key limitations in the assessment of cardiac function. In chronic heart failure, 
peak 2OV&  can be influenced by comorbidities and non-cardiac factors such as muscle 
conditioning, motivation for performing exercise, anaemia, abnormal reflex response, 
and obesity (Fleg and Lakata, 1988; Wilson et al., 1995). Additionally many years ago 
it was noted that the expected peak 2OV&  varies according to the age and sex of the 
individual (Becklake et al., 1965). Further, no stati ical difference in survival 
between patients with peak 2OV&  levels of 10-14 ml
.kg-1.min-1 and those with levels of 
14-18 ml.kg-1.min-1 has been shown (Stevenson et al., 1995). Myers and colleagues 
(2000) carried out a large study consisting of 664 patients during a 10 year period 
follow-up. A multivariate analysis revealed peak 2OV&  to be an independent predictor 
of mortality above and below a range of 10-17 ml.kg-1.min-1, rather than at a cut-off 
point of 14 ml.kg-1.min-1. It seems that a cut-off of 14 ml.kg-1.min-1 is no longer 
viewed as appropriate for cardiac transplantation because of improved survival in 
patients treated with beta-blockers. It has been shown that patients on beta-blockers 
with a peak 2OV&  <14 ml
.kg-1.min-1 have a better outcome than non-beta-blocked 
patients with a peak 2OV&  >14 ml
.kg-1.min-1 (Zugck et al., 2002). O’Neill et al. (2005) 
reported that peak 2OV&  is a determinant of survival in patients in heart f ilure even in 
those with beta-blockade. However, because of improved survival in patients treated 
with beta-blockers, the cut point value of 14 ml.kg-1.min-1 for referral for cardiac 
transplantation in these patients requires reevaluation, and a lower cut-off point may 
be more appropriate (O’Neill et al., 2005). 
Furthermore, Wilson et al. (1995) investigated the relationship of haemodynamic data 
(cardiac output and pulmonary wedge pressure) and peak 2OV&  in 64 patients with 
stable chronic heart failure listed for cardiac transplantation. The data showed no 




3-minute Naughton protocol. A significant proportion f the patients (44%) had only 
mild or moderate haemodynamic dysfunction despite peak 2OV&  values less than the 
previously recommended limit for transplantation (<14 ml.kg-1.min-1). Conversely, 
33% of patients with a peak 2OV&  greater than 14 ml
.kg-1.min-1 had severely impaired 
cardiac output at peak exercise. Finally, Metra et l. (1999) recruited 219 patients with 
chronic heart failure to test the hypothesis that direct assessment of the 
haemodynamic response to exercise could improve prognosis. It would also identify 
those patients in whom the main cause of reduced functional capacity is related to 
non-cardiac factors. Among the haemodynamic parameters, peak stroke work index 
was found to be the strongest predictor at both one and two-year follow-ups. Although 
peak stroke work index was correlated to peak 2OV& , the latter was a weaker 
predictor. They noted that more than 40% of the patients with normal haemodynamic 
response had a peak 2OV&  less than 14 ml
.kg-1.min-1. On this basis, they recommended 
that haemodynamic measurements during exercise be used in heart failure evaluation 
to avoid transplantation in patients whose exercise limitation is due more to muscle 
deconditioning than to pump failure. Cotter et al. (2003) argued that stroke work 
index demonstrates the heart’s ability to produce hydraulic energy, as does cardiac 
power output, but expressed per heart beat.   
The results from above cited studies should not be surprising as peak 2OV&  is only an 
indirect indicator of peak exercise cardiac output (Szlachic et al., 1985; Meiler et al., 
1987; Weber et al., 1982) and cardiac function reserve (Cotter et al., 2003).  Therefore 
peak 2OV&  must be consider with caution in interpretation of cardiac pumping 
function/dysfunction, particularly in patients with severe heart failure and heart 
transplant candidates.  
8.1.1.2 Anaerobic threshold in heart failure 
It is well known that at moderate and severe levels of muscular work, blood lactate 
concentration is increased particularly in the venous blood draining working muscle 
(Wasserman et al., 1999). This increase in venous lactate concentration, which 




working skeletal muscle was termed the anaerobic threshold (Wasserman et al., 
1999). In an early report it has been suggested that an erobic threshold represents a 
transition during exercise from a phase of aerobic metabolism to a phase of anaerobic 
metabolism (Wasserman and McIlroy, 1964). This is the point where oxygen delivery 
is not sufficient to meet oxygen consumption and anaerobic mechanisms are needed 
to supplement energy production during exercise (Reybrouck and Ghesquiere 1983; 
Wasserman et al., 1973). 
Reduced cardiac output in heart failure is responsible for decreased perfusion of 
working skeletal muscle resulting in premature anaerobic metabolism (Wilson et al., 
1984; Wiener et al. 1986). As cardiac output respone to incremental exercise is 
impaired in proportion to the severity of pump dysfunction, it has been suggested that 
determination of the anaerobic threshold may be a useful clinical tool to grade the 
severity of heart failure (Matsumura et al., 1983; Weber et al., 1982). The anaerobic 
threshold has been used as a non-invasive index of exercise tolerance, which is 
independent of patient motivation, and may be more reliable than exercise duration in 
assessing the effect of drug therapy in chronic heart failure (Matsumura et al., 1983; 
Weber et al., 1982). Furthermore, peak 2OV&  may be underestimated in clinical 
practice because of reduced patient motivation as well as premature termination of 
exercise by the examiner. Thus the anaerobic threshold (oxygen consumption at 
anaerobic threshold) has been suggested as an objective parameter of 
cardiopulmonary exercise capacity that can be derived from submaximal exercise 
testing and is therefore independent of the influences described above (Wasserman et 
al., 1999). Moreover, Lipkin et al. (1985) showed that oxygen consumption at the 
anaerobic threshold was able to predict maximal oxygen consumption in chronic heart 
failure patients (r=0.93). Similarly, Myers et al. (2006) and Ingle et al. (2008) reported 
high relationship between peak oxygen consumption and anaerobic threshold (r=0.76 
and 0.82).     
Only one study investigated the prognostic value of anaerobic threshold in heart 
failure patients. Gitt et al. (2002) compared anaerobic threshold ( 2OV&  at anaerobic 
threshold) and ventilatory response to exercise with peak 2OV&  to identify chronic 




Cardiopulmonary exercise tests were performed in 223 consecutive patients with 
chronic heart failure (114 coronary artery disease, 92 dilated cardiomyopathy, 17 
others). Peak 2OV&  ≤14 ml
.kg-1.min-1, 2OV&  at an anaerobic threshold of <11 ml
.kg-
1.min-1, and EV& / 2C
O
V&  slope of >34 were selected as threshold values for high risk of 
death. Results revealed that combined, 2OV&  at anaerobic threshold of <11 ml
.kg-
1.min-1 and EV& / 2C
O
V&  slope >34 better identified patients at high risk for early death 
from chronic heart failure than did peak 2OV& . Gitt and associates (2002) concluded 
that 2OV&  at anaerobic threshold and ventilatory response should therefore be 
considered when prioritizing patients for heart transplantation.  
8.1.1.3 Ventilatory efficiency in heart failure 
The relationship between minute ventilation and carbon dioxide production, called 
ventilaroty efficiency or ventilatory response to exercise ( EV& / 2C
O
V&  slope) is one of 
the cardiopulmonary exercise test parameters that appears to have important clinical 
value in heart failure patients. During exercise in normal subjects, there is a linear 
relation between minute ventilation (EV& ) and carbon dioxide production ( 2C
O
V& ), 
and the ventilatory response can be characterized by the slope of the relationship 
between the two (Ingle et al., 2007). In patients with chronic heart failure, the slope of 
this relation is increased so that for any given level of carbon dioxide production, 
there is greater ventilation than normal, and the EV& / 2C
O
V&  slope becomes steeper 
(Banning et al., 1995; Reindl et al., 1998). This steeper slope in chronic heart failure 
patients is associated with reduced cardiac output during exercise (Metra et al., 1992; 
Sullivan et al., 1988), increased pulmonary artery and capillary wedge pressures 
(Metra et al., 1992; Sullivan et al., 1988), increas d dead space/tidal volume ratio 
(Metra et al., 1992; Sovijarvi et al., 1992; Sullivan et al., 1988), and augmented 
chemoreceptor sensitivity (Chua et al., 1996). Chua et l. (1997) argued that it is not 
precisely known whether the increased ventilatory response to exercise (ventilatory 
inefficiency) is predominantly due to reduced pulmonary perfusion and 
haemodynamic abnormalities causing ventilation-perfusion mismatching or to the 




primary mechanism for elevated ventilatory efficiency is the impaired cardiac output 
response to exercise. A decrease in cardiac output affects both left- and right-sided 
circulation. A decline in pulmonary perfusion and carbon dioxide exchange, in the 
presence of normal alveolar ventilation, results in an elevated EV& / 2C
O
V&  (Myers, 
2005). Furthermore, the theory of peripheral muscle receptors (metabo- or 
mechanoreceptors) produce an abnormal ergoreflex resulting in an abnormal 
EV& / 2C
O
V&  slope during exercise has been used to explain breathlessness and fatigue 
in chronic heart failure (Clark et al., 1996). Witte and Clark (2007) hypothesized that 
ventilatory inefficiency is caused by weak, structurally abnormal and inefficient 
skeletal muscle which during incremental exercise produces a greater relative 
production of metabolic products leading to an increased ergoreflex in chronic heart 
failure. As a result, there is increased ventilation relative to carbon dioxide production 
demonstrated by increased EV& / 2C
O
V&  slope and reduced CO2 partial pressure (Witte 
and Clark, 2007). In summary, EV& / 2C
O
V&  depends on pulmonary haemodynamics, 
skeletal muscle ergoreceptor and peripheral chemoreceptor sensitivity, and heightened 
sympathetic activity.    
Elevated EV& / 2C
O
V&  slope is inversely related to cardiac output (Reindl et al., 1998) 
and cardiac index at peak exercise (Franciosa et al., 1984). Because of its association 
with cardiac function, the prognostic value of the EV& / 2C
O
V&  slope has been 
demonstrated in a number of studies (Francis et al., 2000; Ingle et al., 2007; Kleber et 
al., 2000). Several studies reported that the EV& / 2C
O
V&  slope may also be a better 
predictor of outcome than peak 2OV&  in a heart failure population (Arena et al., 2002; 
Corra et al., 2002; Chua et al., 1997; Francis et al., 2000; Kleber et al., 2000). The 
EV& / 2C
O
V&  has bettered peak 2OV&  in predicting mortality (Corra et al., 2002; Chua et 
al., 1997; Francis et al., 2000; Kleber et al., 2000) and hospitalization (Arena et al., 
2002). O’Neill et al. (2005) prospectively analyzed probably one of the largest 
datasets of cardiopulmonary exercise testing to date (N=2015 patients). In contrast 
with others, they found that the EV& / 2C
O
V&  slope did not predict survival in patients 




8.1.1.4 Circulatory power in heart failure 
Measurement of cardiac output is not as straightforward as that of O2 consumption, 
particularly during exercise, and therefore approximat ons of cardiac power output has 
been sought (Cotter et al., 2003; Williams et al., 2005a). Cohen-Solal et al. (2002) 
assessed the prognostic value of a new cardiopulmonary variable derived from an 
exercise test, which they believed, is a new “surrogate” variable of cardiac power 
output. The new variable is termed “circulatory power” and is the product of peak 
2OV&  and peak systolic blood pressure. Cohen-Solal and associates (2002), using a 
multivariate analysis, demonstrated that among other cardiopulmonary variables 
commonly assessed (e.g. ejection fraction, heart rate, systolic arterial pressure, peak 
2OV& , 2C
O
V& , anaerobic threshold, minute ventilation, EV& / 2C
O
V& ), the peak 
circulatory power was the best  predictor of outcome in 175 chronic heart failure 
patients. Williams et al. (2005b) assessed the relationship between circulatory power 
and cardiac power output in 219 ambulatory patients wi h chronic heart failure. The 
results revealed that circulatory power, both overall and at peak exercise, has a direct 
and consistent relationship with cardiac power output. Williams et al. (2005a) argued 
circulatory power to be an adequate measure of cardiac pumping capacity when more 
directly measured cardiac power output is not availble.      
8.1.1.5 Oxygen pulse in heart failure 
Oxygen pulse is the ratio of oxygen consumption to heart rate and reflects the amount 
of oxygen extracted by the tissue per heart beat. Oxygen pulse has often been used as 
an estimator for stroke volume as it represents the product of stroke volume and 
arterio-venous O2 difference. It seems that peak oxygen pulse is more dependant than 
peak oxygen consumption on cardiac function reserve (Cohen-Solal et al., 1997). The 
oxygen pulse increases linearly with incremental exercise in healthy adults 
(Wasserman et al., 1999). At maximal or near maximal exercise the slope flattens as it 
is assumed that the arterio-venous mixed oxygen difference is maximal (Wasserman 
et al., 1999). A low, unchanging or shallow oxygen pulse suggests poor oxygen 
extraction of the skeletal muscles and is seen in patients who may be deconditioning 




failure patients, peak oxygen pulse is reduced (Belardinelli et al., 2003). To date, only 
two studies assessed the prognostic value of peak oxygen pulse in heart failure 
patients (Cohen-Solal et al., 1997; Lavie et al., 2004). Cohen-Solal et al. (1997) 
reported that peak oxygen pulse had a lower prognostic value than peak oxygen 
consumption, whereas Lavie et al. (2004) found that pe k oxygen pulse was a stronger 
predictor for clinical event (e.g. cardiovascular death or transplantation) than any 
other exercise-derived cardiopulmonary variable, including peak 2OV& .    
8.1.2 Rationale and Purposes of the Study 
Peak oxygen consumption, anaerobic threshold, ventilatory efficiency, peak 
circulatory power and peak oxygen pulse are strong predictors of outcome in heart 
failure patients. These variables have been used to assess functional status of patients, 
effects of intervention (e.g. surgery, drug, exercise), and risk stratification in heart 
failure. Very important clinical decisions (e.g. cardi c transplantation) are considered 
on the basis of such cardiopulmonary exercise test data. This should not be a surprise 
as these variables are associated with cardiac function. It should, however, be 
emphasized that these variables may be affected by non-cardiac factors and therefore 
must be considered as indirect indicators of cardiac function. On the other hand, peak 
cardiac power output as a direct indicator of overall cardiac function, has been shown 
to be a superior in prognosis of heart failure (Williams et al., 2001; Roul et al., 1995).  
Several studies assessed the association between ovrall cardiac function, represented 
by peak cardiac power output, with other exercise derived variables in heart failure 
patients (Bain et al., 1990; Cooke et al., 1998; Roul et al., 1995; Williams et al., 
2005b). No such association was investigated in patients implanted with a left 
ventricular assist device (LVAD) and those who had an LVAD explanted due to 
sufficient myocardial recovery. Peak cardiac power output and physiological cardiac 
reserve have not been correlated yet with anaerobic threshold, ventilatory efficiency 
and peak oxygen pulse in any category of heart failure patients, including those 
implanted and explanted with a LVAD. Therefore, thepurpose of the present study 
was to assess the relationship between peak cardiac pumping capability (represented 




consumption, anaerobic threshold, ventilatory efficien y, circulatory power and peak 
oxygen pulse in severe chronic heart failure patients, and to include those implanted 
and explanted with a LVAD.           
8.1.3 Research Hypotheses  
H1 – There will be a significant positive relationship between peak cardiac power 
output and peak oxygen consumption, anaerobic threshold, peak circulatory power 
and peak oxygen pulse in severe chronic heart failure patients, and those implanted 
and explanted with a LVAD.   
H2 – There will be a significant negative relationship between peak cardiac power 
output and ventilatory efficiency in severe chronic heart failure patients, and those 
implanted and explanted with a LVAD. 
H3 – The strength of the relationship between peak cardiac power output and peak 
oxygen consumption, anaerobic threshold, peak circulatory power, ventilatory 
efficiency and peak oxygen pulse will be different between severe heart failure, 












In total 54 male patients were included in the analysis: 20 moderate to severe heart 
failure (NYHA III and IV), 18 LVAD implanted, and 16 LVAD explanted patients. 
Patients’ clinical and demographics details as well as baseline measurements are 
detailed in Chapter 6 of this thesis.  
8.2.2 Testing Procedure  
Testing procedure is detailed in Chapter 6 of this t esis, section 6.2.3. 
8.2.3 Calculations and Statistical Analysis 
Cardiac power output (CPO), mean arterial pressure (MAP) and ventilatory response 
to exercise ( EV& / 2C
O
V&  slope) were calculated as previously described in this thesis 
(Chapter 6). Circulatory power was calculated as the product of oxygen consumption 
and systolic blood pressure, expressed in mmHg.l .min-1 (Cohen-Solal et al., 2002). 
Oxygen pulse was calculated as the ratio between oxygen consumption and heart rate.      
Statistical analysis for all variables except circulatory power and oxygen pulse was 
performed as in Chapter 6. One-way ANOVA with a Tukey’s post hoc test was used 
to determine any difference in circulatory power and oxygen pulse between severe 
heart failure patients, LVAD implanted and explanted patients. The relationship of 
various parameters was assessed using Pearson’s product moment coefficient of 
correlation. The meaningfulness of coefficient of correlation was evaluated by 
calculating the coefficient of determination (R2). A p value of <0.05 was considered 







8.3.1 Resting and Peak Exercise Circulatory Power and Oxygen Pulse 
Values 
Only circulatory power and oxygen pulse values were not determined in Chapter 6. At 
rest there was non-significant difference among the groups in circulatory power (heart 
failure patients, 41±14 mmHg.l .min-1; LVAD implanted and explanted patients, 36±7 
and 42±16 mmHg.l .min-1, p>0.05) and oxygen pulse (heart failure patients, 5.3±2.1 
ml.beats-1; LVAD implanted and explanted patients, 4.7±1.9 and 5.5±2.0 ml.beats-1, 
p>0.05).  
Peak circulatory power was significantly lower in patients with moderate to severe 
heart failure compared with LVAD explanted patients (173±49 vs. 334±56 
mmHg.l .min-1, p<0.01). This was also the case in LVAD implanted patients compared 
with LVAD explanted patients (196±56 vs. 334±56 mmHg.l .min-1, p<0.01). Peak 
circulatory power between moderate to severe heart failure patients and LVAD 
implanted patients was not significantly different (p>0.05).  
Peak oxygen pulse was significantly higher in LVAD explanted patients than in heart 
failure and LVAD implanted patients (LVAD explanted, 16±2; LVAD implanted, 
12±3; severe heart failure, 11±2 ml.beats-1, p<0.01). The difference in peak oxygen 
pulse between moderate to severe heart failure and LVAD implanted patients was not 









8.3.2 Relationship between Peak Cardiac Power Output and Indirect 
Indices of Cardiac Work Capacity   
When all data were combined (n=54), peak cardiac power output was strongly 
correlated with peak oxygen consumption (r=0.87, R2=0.76, p<0.01), anaerobic 
threshold (r=0.79, R2=62, p<0.01) and circulatory power (r=0.82, R2=0.67, p<0.01). 
Peak cardiac power output was well correlated with peak oxygen pulse (r=0.69, 
R2=0.48, p<0.01) and exercise duration (r=0.58, R2=0.34, p<0.01). Modest negative 
correlation was found between peak cardiac power output and EV& / 2C
O
V&  slope (r=-
0.51, R2=-0.26, p<0.01).   
Figures 8.3 to 8.8 show subgroup analysis in the relationship between peak cardiac 
power and peak oxygen consumption, anaerobic threshold, peak circulatory power, 
ventilatory efficiency, peak oxygen pulse and exercis  duration in patients with severe 
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Figure 8-3 Relationship between peak cardiac power output and peak oxygen 
consumption in patients with moderate to severe heart failure (HF), those implanted 











0.5 1 1.5 2 2.5 3 3.5 4 4.5 5



















    
Figure 8-4 Relationship between peak cardiac power output and oxygen consumption 
at anaerobic threshold in patients with moderate to severe heart failure (HF), those 
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Figure 8-5 Relationship between peak cardiac power output and peak circulatory 
power in patients with moderate to severe heart failure (HF), those implanted (IMP) 
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Figure 8-6 Relationship between peak cardiac power output and ve tilatory efficiency 
slope ( EV& / 2C
O
V&  slope) in patients with moderate to severe heart failure (HF), those 
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Figure 8-7 Relationship between peak cardiac power output and peak oxygen pulse in 
patients with moderate to severe heart failure (HF), those implanted (IMP) and 
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Figure 8-8 Relationship between peak cardiac power output and exercise duration in 
patients with moderate to severe heart failure (HF), those implanted (IMP) and 





8.3.3 Relationship between Peak Cardiac Power Output and Central 
Haemodynamic Measures 
When all data were combined (n=54), peak cardiac power output was strongly 
correlated with peak cardiac output (r=0.93, R2=0.86, p<0.01) and peak cardiac index 
(r=0.81, R2=0.66, p<0.01). Peak cardiac power output was well correlated with peak 
heart rate (r=0.68, R2=0.46, p<0.01) and peak stroke volume (r=69, R2=0.48, p<0.01). 
There was a weak non-significant relationship betwen peak cardiac power output and 
peak mean arterial pressure (r=0.27, R2=0.07, p>0.05).  
Figures 8.9 to 8.13 show subgroup analysis in the relationship between peak cardiac 
power and peak cardiac output, peak heart rate, peak stroke volume, peak mean 
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Figure 8-9 Relationship between peak cardiac power output and peak cardiac output 
in patients with moderate to severe heart failure (HF), those implanted (IMP) and 
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Figure 8-10 Relationship between peak cardiac power output and heart rate in patients 
with moderate to severe heart failure (HF), those implanted (IMP) and explanted 
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Figure 8-11 Relationship between peak cardiac power output and stroke volume in 
patients with moderate to severe heart failure (HF), those implanted (IMP) and 
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Figure 8-12 Relationship between peak cardiac power output and peak mean arterial 
pressure in patients with moderate to severe heart failure (HF), those implanted (IMP) 
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Figure 8-13 Relationship between peak cardiac power output and peak cardiac index 
in patients with moderate to severe heart failure (HF), those implanted (IMP) and 




8.3.4 Relationship between Cardiac Pumping Reserve and Indirect and 
Direct Indices of Cardiac Work Capacity 
Resting and peak exercise values of measured variables re presented in the Results 
section of Chapter 6 in this thesis. Table 8.2 (below) shows the increase from resting 
to peak exercise value in the measured variables (physiological reserves).  
The relationship between cardiac pumping reserve (th  difference between peak and 
resting cardiac power output) and measured direct and indirect indices of cardiac 
work capacity are presented in Table 8.3. The streng h of the relationship between 
cardiac pumping reserve and peak exercise values is sim lar to that between cardiac 
pumping reserve and physiological reserves (∆ values) of other variables (Table 8.3).  
   
Table 8.2 Absolute Increase in Exercise Variables from Rest to Peak Exercise (∆ 
values)  
 Severe Heart Failure LVAD Implanted LVAD Explanted 
∆CPO, W  1.07±0.40 1.48±0.55 2.43±0.54##,†† 
∆OP, ml.beats-1 6.2±2.0 6.8±2.6 10.1±2.0##,†† 
∆CP, mmHg.l.min-1 131±50 140±48 293±78 ##,†† 
∆ TQ& , l.min-1  5.0±2.2 6.9±2.1* 9.4±2.2
##,†† 
∆HR, beats.min-1 51±27 69±21 90±13##,† 
∆SV, m.beats-1 14.0±8.2 11.1±6.7 18.6±12.4# 
∆MAP, mmHg 12±10 12±7 17±12 
∆CI, l.min.m2 2.2±1.1 3.5±1.2 4.6±1.1 ##,† 






CPO-cardiac power output, OP-oxygen pulse, CP-circulatory power, TQ& -cardiac output, 
HR-heart rate, SV-stroke volume, MAP-mean arterial pressure, CI-cardiac index, 2OV& -
oxygen consumption, ∆-the difference between peak and resting value. 
*p<0.05, **p<0.01 IMP vs. HF 




Table 8.3 Relationship between Cardiac Pumping Reserve and Measured Direct and 










 r R2 r R2 r R2 r R2 
Relation to Peak values         
CR vs CPO 0.94** 0.88 0.85** 0.72 0.92** 0.85 0.96** 0.92 
CR vs TQ&  0.85** 0.72 0.71** 0.50 0.85** 0.72 0.88** 0.77 
CR vs CI 0.80** 0.64 0.72** 0.52 0.77** 0.59 0.75** 0.56 
CR vs 2OV&   0.78** 0.61 0.63** 0.40 0.51* 0.26 0.83** 0.69 
CR vs CP 0.75** 0.56 0.19 0.04 0.62** 0.38 0.84** 0.71 
CR vs AT 0.67** 0.45 0.48* 0.23 0.19 0.04 0.51* 0.26 
CR vs SV 0.64** 0.41 0.28 0.08 0.47* 0.22 0.86** 0.74 
CR vs HR 0.61** 0.37 0.65** 0.42 0.48* 0.23 0.19 0.04 
CR vs OP  0.59** 0.35 0.28 0.08 0.21 0.04 0.65** 0.42 
CR vs ET 0.55** 0.30 0.56** 0.31 0.51* 0.26 0.65** 0.42 
CR vs EV& / 2C
O
V& slope  0.40** 0.16 0.01 0.00 -0.09 0.00 -0.53* 0.28 
CR vs MAP 0.29** 0.08 -0.04 0.00 0.23 0.05 0.27 0.07 
         
Relation to ∆ Values         
CR vs ∆ TQ&  0.87** 0.76 0.73** 0.53 0.88** 0.77 0.90** 0.81 
CR vs ∆CI 0.83** 0.69 0.70** 0.49 0.79** 0.62 0.77** 0.59 
CR vs ∆ 2OV&  0.79** 0.62 0.64** 0.41 0.52* 0.27 0.84** 0.71 
CR vs ∆CP 0.76** 0.58 0.21 0.04 0.63** 0.40 0.86** 0.74 
CR vs ∆HR 0.62** 0.38 0.68** 0.46 0.50* 0.25 0.21 0.04 
CR vs ∆OP 0.59** 0.35 0.30 0.16 0.23 0.05 0.67** 0.45 
CR vs ∆SV 0.59** 0.35 0.29 0.08 0.49* 0.24 0.87** 0.76 





CR-cardiac pumping reserve, CPO-cardiac power output, TQ& -cardiac output, CI-cardiac 
index, 2OV& -oxygen consumption, CP-circulatory power, AT-anaerobic threshold, SV-
stroke volume, HR-heart rate, OP-oxygen pulse, ET-exercise time, EV& / 2C
O
V& slope-





8.3.5 Comparison of the Relationships between Patients and Healthy 
Adults 
Table 8.4 summarizes the relationships between cardiac power output and exercise-
derived variables in moderate to severe heart failure patients, LVAD implanted and 
explanted patients and healthy adults.  
Table 8.4 Summary of the Relationships between Peak Cardiac Power Output and 
Exercise-Derived Variables in Patients (current Chapter) and Healthy Adults (Chapter 














 r R2 r R2 r R2 r R2 
Indirect Indices          
CPO vs 2OV&   0.55* 0.30 0.53* 0.28 0.85** 0.71 0.77** 0.59 
CPO vs AT 0.46* 0.21 0.37 0.14 0.54* 0.29 0.47** 0.23 
CPO vs CP 0.31 0.09 0.63** 0.37 0.82** 0.68 0.67** 0.45 
CPO vs OP 0.45* 0.20 0.31 0.09 0.63** 0.40 0.57** 0.32 
CPO vs EV& / 2C
O
V& slope -0.06 0.00 -0.08 0.19 -0.52** 0.47 - - 
CPO vs ET 0.48* 0.23 0.66** 0.44  0.80** 0.63 0.66** 0.44 
         
Central Haemodynamics     
CPO vs TQ&   0.88** 0.78 0.93** 0.87 0.91** 0.82 0.95** 0.90 
CPO vs CI 0.87** 0.76 0.88** 0.77 0.89** 0.79 0.76** 0.58 
CPO vs HR 0.75** 0.55 0.48* 0.23 0.36 0.12 0.35 0.12 
CPO vs SV 0.36 0.14 0.54** 0.28 0.79** 0.62 0.94** 0.88 
CPO vs MAP 0.01 0.00 0.17 0.04 0.21 0.05 0.23 0.05 
CPO-cardiac power output, 2OV& -oxygen consumption, AT-anaerobic threshold, CP-
circulatory power, OP-oxygen pulse, EV& / 2C
O
V& slope-ventilatory efficiency, ET-
exercise time, TQ& -cardiac output, CI-cardiac index, HR-heart rate, SV-stroke volume, 








The present study examined the relationship between p ak cardiac power output and 
indirect indexes of cardiac pumping capacity, which have also been shown to be 
strong predictors of prognosis (e.g. peak oxygen cosumption, anaerobic threshold, 
peak circulatory power, ventilatory efficiency, peak oxygen pulse), in patients with 
moderate to severe heart failure, and those implanted and explanted with a LVAD. 
When all data were combined, the results not only showed that peak cardiac power 
output was strongly correlated to peak oxygen consumption, anaerobic threshold and 
circulatory power, but also was well correlated with peak oxygen pulse when data 
from all patients were combined together. Subgroup analysis, however, revealed that 
the strength of the above relationships is reduced particularly in patients with severe 
heart failure and those implanted with a LVAD. 
8.4.1 Association between Peak Cardiac Power Output and Indirect 
Indices of Cardiac Pumping Capacity 
The finding of the present study that overall peak c rdiac power output is strongly 
correlated to peak oxygen consumption (r=0.87) in heart failure patients is in 
agreement with previous studies (Cooke at al., 1998; Roul et al., 1995). Cooke et al. 
(1998) showed that in 70 subjects with a wide range of cardiac function, from heart 
failure patients to athletes, peak cardiac power output was highly related to peak 
oxygen consumption (r=0.87). Cooke and associates also demonstrated good 
relationship between peak cardiac power output and exercise duration, similar to that 
found in the present study (r=0.62 vs. 0.58). In 52 heart failure patients (NYHA II and 
III), Roul and colleagues (1995) found the coefficient of correlation of 0.84 between 
peak cardiac power output and peak oxygen consumption. Bain et al. (1990) 
determined the relationship between cardiac power output and exercise duration in 41 
patients with moderately severe to severe chronic heart failure. Maximum cardiac 
power output and the ability to increase cardiac power output from resting to peak 
exercise value (cardiac pumping reserve or physiological cardiac reserve) were highly 
correlated with exercise duration (r=0.79 and 0.80). These three studies (Bain et al., 
1990; Cooke at al., 1998; Roul et al., 1995), however, have shown that resting cardiac 




suggesting that it is a poor predictor of cardiovascular functional potential together 
with other resting central heamodynamic measures. Williams et al. (2005b) were the 
first to evaluate the relationship between cardiac power output and its proposed 
“surrogate” – circulatory power. In 219 ambulatory patients with chronic heart failure, 
circulatory power was found to have a strong positive relation with cardiac power 
output, overall r=0.93 and at peak exercise r=0.84. This finding at peak exercise is 
consistent with the present study (r=0.84).  
Finding of the present study that ventilatory efficiency slope is inversely related (r=-
0.51) to cardiac function (cardiac power output) is in agreement with Myers et al. 
(2007) who reported similar relationship between cardiac output and EV& / 2C
O
V&  slope 
(r=-0.47). Additionally, the present study suggests for the first time that, when data 
from all patients were combined (n=54), peak cardiac power output was well 
correlated with oxygen consumption at anaerobic thres old and peak oxygen pulse. 
Moreover, anaerobic threshold and oxygen pulse explain 62% and 48% of the total 
variance in peak cardiac power output. Previous studies have shown that anaerobic 
threshold was highly correlated with peak oxygen cosumption (Ingle et al., 2008; 
Lipkin et al., 1985; Myers et al., 2006).    
In contrast with relationship results when all data were combined (n=54), subgroup 
analysis of patients (e.g. moderate to severe heart failure, LVAD implanted and 
explanted patients) revealed dramatically different strength of the relationship among 
variables, particularly in severe heart failure and LVAD implanted patients. Whereas 
in LVAD explanted patients, peak oxygen consumption explained 71% of the 
variance in peak cardiac power output, in moderate to severe heart failure and LVAD 
implanted patients peak oxygen consumption explained only 30 and 28% of the 
variance. The finding of the current study that peak c rdiac power output was not 
strongly correlated to other indirect indices of cardi c work capacity (e.g. peak 
oxygen consumption) in moderate to heart failure and LVAD implanted patients is not 
surprising as other authors have demonstrated no relationship between peak oxygen 
consumption and haemodynamic data. That peak oxygen consumption does not reflect 
the severity of cardiac dysfunction has been reportd by Wilson et al. (1995). In 64 




consumption was primarily determined by the heamodynamic response to exercise. 
Results revealed that there was no significant correlation between peak oxygen 
consumption and cardiac index or pulmonary wedge pressure, suggesting that peak 
oxygen consumption does not reliably reflect the severity of flow impairment. 
Moreover, Wilson et al. (1995) observed that 18 (28%) patients with peak oxygen 
consumption less than 14 ml.kg-1.min-1 (considered to reflect severe haemodynamic 
dysfunction) had a normal cardiac response to exercise, whereas seven (11%) patients 
with severe haemodynamic dysfunction had a peak oxygen consumption level of more 
than 14 ml.kg-1.min-1. Dissociation between peak oxygen consumption and the degree 
of cardiac dysfunction in patients with chronic heart f ilure has also been reported by 
Myers et al. (2006).  
None of the prior studies have evaluated the relationship between peak cardiac power 
output and peak oxygen consumption in patients implanted with a LVAD and those to 
whom LVAD has been removed due to sufficient myocardial recovery. It seems that 
peak oxygen consumption and its derived variables (e.g. circulatory power) do not 
reflect cardiac pumping capability in LVAD implanted and severe heart failure as 
strong as in LVAD explanted patients. Moreover, in LVAD explanted patients these 
relationships seem to be similar to that previously observed in larger number of 
subjects, ranging from healthy adults to patients i NYHA class I-IV (Cooke et al., 
1998; Roul et al., 1995; Williams et al., 2005b; Chapter 5 of this thesis). In LVAD 
implanted patients, the device itself contributes significantly to total cardiac output, 
particularly at peak exercise. Peak oxygen consumption may be influenced by a 
number of non-cardiac factors (e.g. muscle conditioning), as previously mentioned. 
This possibly may indicate the inability of working muscle to extract oxygen, 
particularly in LVAD implanted patients with optimal device support. Therefore 
modest relationship between peak cardiac power output and peak oxygen 
consumption found in LVAD implanted and severe heart f ilure patients in the 
present study should not be surprising. Similarly, variables which involve oxygen 
consumption in the calculation (e.g. circulatory power, oxygen pulse) should be 
considered with caution in the interpretation of cardi c work capacity. Interestingly, in 
LVAD implanted patients, peak circulatory power seems to reflect cardiac pumping 




Additionally, ventilatory efficiency and anaerobic threshold does not strongly reflect 
cardiac pumping capability in moderate to severe heart failure and LVAD implanted 
patients. Finally, exercise duration correlated moderately in severe heart failure 
patients, whereas in LVAD implanted and explanted patients this correlation was 
higher (r=0.66 and 0.80). When data from all patients were combined (n=54) the 
relationship between exercise duration and peak cardiac power output was only 
modest (r=0.58). The lower overall association betwe n exercise duration and peak 
cardiac power output may be explained by the fact tha LVAD explanted patients 
performed the Bruce protocol compared with LVAD implanted and those with severe 
heart failure patients who performed modified Bruce protocol (as described in Chapter 
6 of this thesis). Practically, this means that for the same duration of exercise, the 
intensity of exercise and expected cardiac power output were higher during the Bruce 
protocol compared with the modified Bruce protocol. 
Results from the present study suggest that exercise-derived prognostic indicators in 
heart failure (e.g. peak oxygen consumption, peak circulatory power, ventilatory 
efficiency and peak oxygen pulse) present a poor reflection of cardiac power output in 
patients with moderate to severe heart failure. In co trast with other measured 
variables, peak circulatory power seems to be a good predictor of cardiac pumping 
capacity in patients implanted with a LVAD. In LVAD explanted patients, however, 
the relationship between direct and indirect indices of cardiac work capacity is 
stronger than that in severe heart failure and LVAD implanted patients. Moreover, in 
LVAD explanted patients assessed relationships are comparable to those found in 
healthy subjects (Table 8.4).   
8.4.2 Association between Peak Cardiac Power Output and Central 
Haemodynamic Measures  
Findings of the present study suggest that central h emodynamic measures, 
particularly peak cardiac output and peak cardiac index, do reflect peak cardiac power 
output better than any of the indirect indexes discus ed above in patients with 
moderate to severe heart failure and those implanted and explanted with a LVAD. 
This is supported by a strong relationship between th  two variables and peak cardiac 




between peak cardiac power output and peak cardiac index (r=0.94).  
Although cardiac power output is calculated as the product of cardiac output and 
mean arterial pressure, not many studies assessed the relationship between peak 
cardiac power output and other central haemodynamic easures. As previously 
mentioned, most of the studies on the topic of cardiac power output investigated the 
relationship between cardiac power output and measur s of exercise and functional 
capacity such as exercise duration and peak oxygen consumption (Bain et al., 1990; 
Cooke et al., 1998; Roul et al., 1995). It is, however, no less important to investigate 
which component of cardiac power output (mean arteri l p essure or cardiac output) 
and cardiac output (heart rate or stroke volume) explain most of the variance in 
cardiac power output. Additionally, the question whether the strength of the 
relationship between these variables is similar in different categories of subjects 
(healthy adults, moderate to severe heart failure patients, LVAD implanted and 
explanted patients) remained unanswered until now.  
Results from the current but also from the Chapter 5 clearly suggest that most of the 
variance in cardiac power output is explained by cardiac output not by mean arterial 
pressure. In moderate to severe heart failure, LVAD implanted and explanted patients, 
as well as in healthy adults, cardiac output explains 78%, 87%, 82% and 90% of the 
variance in peak cardiac power output, respectively (Table 8.4). Further analysis 
revealed that stroke volume explains most of the variance in peak cardiac power 
output in healthy subjects (88%) and LVAD explanted patients (62%) whereas in 
severe heart failure and LVAD implanted patients only 14% and 28% respectively. In 
contrast, in moderate to severe heart failure and LVAD implanted patients, heart rate 
explains 55% and 23% of the variance in peak cardiac power output, whereas in 
LVAD explanted patients and healthy subjects, heart rate explains only 12%.   
It has been suggested that oxygen pulse may be used as an estimator of stroke volume 
(Wasserman et al., 1999). Data from the present study indicate that an estimate of 
stroke volume by the use of oxygen pulse may not adequately reflect cardiac pumping 
capacity in severe heart failure and LVAD implanted patients, but may do so in 
LVAD explanted patients and healthy subjects. This supposition is directly supported 




in LVAD explanted patients and healthy subjects than in moderate to severe heart 
failure and LVAD implanted patients. 
The other component of cardiac power output, mean arteri l pressure, was not 
significantly correlated to peak cardiac power output in any of the subgroups (Table 
8.4). Although, cardiac output itself is an excellent indicator of cardiac pumping 
capacity, the measurement of blood pressure should not be ignored from the following 
reasons: 1) in normal healthy subjects, measurement of cardiac output only may 
overestimate overall cardiac function. This is because pressure generation increases 
with ageing in healthy adults and is not allowed for when measuring only flow-
generating capacity of the heart (Chantler et al., 2006; Goldspink, 2005); 2) in patients 
with heart failure, measurement of cardiac output alone underestimates overall cardiac 
function, because both the flow and pressure generati g capacities of the heart decline 
in this patients. However, from the current results it is reasonable to suggest that 
whenever difficulties in measuring blood pressure exist (e.g. staff shortage) it is better 
to measure cardiac output alone than any other indiect or direct index of cardiac 
pumping capacity. Finally, the present study further provides evidence that 
measurement of central haemodynamics should be measured prior to all other 
exercise-derived variables in heart failure (Chomsky et al., 1996; Lang et al., 2007; 
Metra et al., 1999; Williams et al., 2001; Williams et al., 2005; Wilson et al., 1995). 
Although, the inclusion of exercise testing is mandtory when designing any study to 
evaluate treatment of chronic heart failure (Narang et al., 1996), the measurement of 
exercise haemodynamics is less frequently performed (Wright and Tan, 1999). With 
non-invasive methods available today (e.g. inert gas rebreathing, 2C
O
 rebreathing), 
and more recently bio-reactance method (Myers et al., 2007; Squara et al., 2007), 
measurement of cardiac output and cardiac power output responses to exercise should 
become a standard clinical tool for evaluation and management of chronic heart 







8.4.3 Relationship between Cardiac Pumping Reserve and Indirect and 
Direct Indices of Cardiac Work Capacity 
Earlier Dr Tan has advocated that peak cardiac power utput is a major determine of 
prognosis in heart failure, whereas cardiac pumping reserve is a major determinant of 
exercise capacity in heart failure (Tan, 1986; Tan et al., 1991). A number of later 
studies have also demonstrated that peak cardiac power utput is an excellent 
indicator of prognosis in heart failure (Roul et al., 1995; Williams et al., 2001). 
Nonetheless, cardiac pumping reserve, which is an increase in cardiac power output 
from resting to maximum value, has also been shown t  be of significant prognostic 
value during pharmacological stress in ambulatory chronic heart failure patients and 
patients with cardiogenic shock (Tan, 1986; Tan andLittler, 1990; Marmor et al., 
1997), but also during cardiopulmonary treadmill exercise testing in chronic heart 
failure patients (Williams et al., 2005b).  
Findings by Bain et al. (1990) suggest that the magnitude of the augmentation of 
cardiac power output on exercise (cardiac pumping reserve) shows good correlation 
with exercise duration (r=0.80). Similarly, Cooke et al. (1998) suggested that patients 
who had higher measured cardiac power output and therefore greater cardiac reserve 
had greater aerobic exercise capacity. The present study is the first to investigate 
cardiac pumping reserve and its relationship to a number of direct and indirect indexes 
of cardiac work capacity. For the first time also the relationship between cardiac 
pumping reserve and other physiological reserves (increase from resting to peak 
exercise value) was evaluated.  
As expected, cardiac pumping reserve was strongly related to peak cardiac power 
output, peak cardiac output and peak cardiac index (Table 8.3). Cardiac pumping 
reserve was also well associated with peak oxygen consumption and peak circulatory 
power when all data were combined together. However, subgroup analysis revealed 
that these relationships were only strong in LVAD explanted patients. Similarly, peak 
stroke volume, peak oxygen pulse and exercise duration were stronger related to 
cardiac pumping reserve in LVAD explanted than in moderate to severe heart failure 
or LVAD implanted patients. Therefore, an estimation f the heart’s ability to 




capacity may be acceptable in LVAD explanted, but not i  severe heart failure and 
LVAD implanted patients. 
Finally, the present study indicates that strength of the relationship between cardiac 
pumping reserve and other assessed physiological reserv s (cardiac output reserve, 
cardiac index reserve, oxygen consumption reserve, circulatory power reserve, heart 
rate reserve, oxygen pulse reserve, stroke volume res rve, and mean arterial pressure 
reserve) is very similar to that between cardiac pum ing reserve and peak values of 
the same variables (Table 8.3). This finding suggests that calculated physiological 
reserves of exercise-derived indexes of cardiac work capacity do not reflect better 
cardiac pumping reserve than their peak values.  
8.4.4 Study Limitations  
The study sample size was relatively small, particularly within each subgroup of 
patients. However in mitigation, this study requested every available patient who was 
referred to a major national centre for heart transplantation and/or LVAD utilisation 
over a period 22 months. The study was limited to men and it remains an issue 
whether the investigated relationships would be similar in women.  
8.5 Clinical Implications and Conclusions 
Peak oxygen consumption has been used over the years as an indirect estimate of 
cardiac pumping capacity and is an important indicator of prognosis in heart failure 
patients. In addition to peak oxygen consumption, the measured of anaerobic 
threshold, circulatory power, oxygen pulse, ventilatory efficiency slope, are also 
consistently reported in heart failure patients as surrogates of cardiac 
function/dysfunction.  
The present study clearly suggests that these indirect markers of cardiac work 
capacity do not reflect peak cardiac power output in the same way in specific 
subgroups of heart failure patients. Among other asses ed indirect indicators of 
cardiac work capacity, peak oxygen consumption and peak circulatory power were the 




output in LVAD explanted patients but not in moderat  to severe heart failure and 
LVAD implanted patients. In contrast, central haemodynamics measurements such as 
peak cardiac output and peak cardiac index explained most of the variance in cardiac 
power output not only in LVAD explanted, but also in moderate to severe heart failure 
and LVAD implanted patients. Therefore, is it important to assess maximal cardiac 
pumping capability directly measuring peak cardiac power output (or cardiac output) 
rather than using other surrogates of cardiac pumping function, particularly in 
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CHAPTER 9: REPRODUCIBILITY OF CARDIAC POWER 
OUTPUT AND SELECTED CARDIO-RESPIRATORY EXERCISE 
TEST VARIABLES IN PATIENTS WITH STABLE CHRONIC 
HEART FAILURE  
Abstract  
Introduction: The reproducibility of cardiac power output has been less frequently 
reported compared with commonly measured cardiopulmonary exercise test variables. 
The purpose of the present study was to assess the reproducibility of cardiac power 
output and other more commonly reported cardiopulmonary exercise test variables in 
patients with stable chronic heart failure. Methods: Metabolic, ventilatory, and non-
invasive central haemodynamic measurements at rest and at peak exercise of the 
modified Bruce protocol have been performed in 14 patients with stable chronic heart 
failure. The same procedure was repeated seven days later in order to assess 
reproducibility of cardiac power output (CPO), cardi c output ( TQ& ), heart rate (HR), 
mean arterial blood pressure (MAP), oxygen consumption ( 2OV& ), carbon dioxide 
production ( 2C
O
V& ), minute ventilation ( EV& ), anaerobic threshold (AT) and 
respiratory exchange ratio (RER). Results: Measured at rest, central haemodynamic 
variables had a lower coefficient of variation (CV) (ranging from 3.4% for TQ&  and 
5.6% for HR) compared with metabolic and ventilatory measurements (ranging from 
8.2% for RER and 14.2 for absolute values of 2OV& ). The CV of AT, 2OV& , 2C
O
V&  
and RER measured at peak exercise ranged from 3.8% (for AT) to 6.4% (for relative 
2OV& ), with minute ventilation having CV of 11.1%. Measured at peak exercise CPO, 
TQ& , MAP and HR had CVs of  4.1, 2.2, 6.8 and 4.4%, respectively. Conclusion: 
Cardiac power output measured at rest and at peak exercise has a high degree of 
reproducibility. Cardiac power output should be asses ed as priority compared with 
other cardiopulmonary exercise test variables in patients with heart failure due to its 
good reproducibility and the capacity to demonstrate the degree of cardiac 





Repeated measurements obtained during cardiopulmonary exercise tests have 
generally shown good reliability and reproducibility n healthy children (Figueroa-
Colon et al., 2000) and adults (Astrand and Rodahl, 1986; Skinner et al., 1999), and in 
highly trained athletes (Astrand and Rodahl, 1986; Weltman et al., 1990; Weston et 
al., 2001). A basic requirement for the clinical application of exercise-derived 
cardiopulmonary variables in follow-up investigations is high reproducibility. 
Particularly in patients with chronic heart failure, high reproducibility is of great 
importance because even small changes in cardiopulmnary data due to treatment or 
disease progression may be detected (Meyer et al., 1997).  
Several studies have assessed reproducibility of cardiopulmonary exercise variables in 
patients with chronic heart failure (Bensihmon et al., 2008; Elborn et al., 1990; 
Marburger et al., 1998; Meyer et al., 1997; Russell et al., 1998). Those studies have 
focused on commonly measured cardiopulmonary exercise test variables such as peak 
oxygen consumption, carbon dioxide production, ventilation, anaerobic threshold, 
oxygen pulse, heart rate, arterial blood pressure, respiratory exchange ratio and 
exercise time. Compared with these physiological parameters, reproducibility of 
cardiac power output and cardiac output, however, has been less frequently reported. 
9.1.1 Rationale and Purposes of the Study 
Evidence available so far suggests that there is only e study which assessed 
reproducibility of cardiac power output and cardiac output in 12 heart failure patients 
(NYHA II-III) (Cooke et al., 1998). Cooke et al. (1998) performed an exercise test in 
two stages with a 40 minutes resting period between th  two stages. The first stage 
was an incremental test to determine the maximum oxygen consumption and the 
anaerobic threshold, and a second maximum workload stage was used to make cardiac 
output measurements (the same methodology as used in Chapter 5 of this thesis).  
It seems, however, that reproducibility of cardiac output and cardiac power output, 
measured non-invasively during an incremental exercis  test, have not been evaluated 




cardiac power output and selected cardiopulmonary vriables at rest and at peak 
exercise in patients with stable chronic heart failure.     
9.1.2 Research Hypothesis  
H1 – There will be good reproducibility of cardiac power output and selected 




The study group consisted of 14 stable chronic heart failure patients with New York 
Heart Association class I-II. The patients’ demographic and clinical characteristics are 
presented in table 9.1. All patients were symptomatically stable and on the same dose 
of optimal drug therapy for the preceding two months, including an angiotensin-
converting enzyme inhibitor or angiotensin receptor bl cker and a β blocker unless a 
contraindication was present. 
The present study was a part of the clinical trial titled “Cardiac power output, heart 
rate variability and heart rate recovery in response to exercise training in heart failure 
patients” which was approved by the Hounslow and Hillingdon NHS Research Ethics 
Committee. An informed written consent form was obtained from each patient prior 
the investigation.   
9.2.2 Study Design 
In order to assess reproducibility of cardiac power output and selected 
cardiopulmonary exercise variables, patients visited he Cardiac Rehabilitation 
Department of Hillingdon Hospital twice within one week of each other. 
Measurements were performed at the same time of day under identical conditions and 
medication. Patients who were not familiar with theuse of treadmill were asked to 




protocol.       
 
Table 9.1 Study Patients’ Demographic and Clinical Characteris ics (N=14) 
Age (yrs)         62±11 
Men/Women    12/2 
Weight (kg)    79.6±17 
Height (cm)    172±10 
BMI (kg/m2)    26.6±4.0 
BSA (m2)     1.92±0.25 
Cause: ischaemic/nonischaemic   9/5 
LVEF (%)     29±12 
NYHA I/II         8/6 
BMI-body mass index, BSA-body surface area, LVEF-left ventricular ejection 
fraction, NYHA-New York Heart Association.     
9.2.3 Testing Procedure  
All patients were exercised at least two hours after any food or drink. They were 
instructed not to drink alcohol or caffeine containing beverages before the tests. The 
tests were performed at an ambient room temperature maintained at about 20°C. Upon 
the arrival in the Cardiac Rehabilitation Department of Hillingdon Hospital, the 
patients’ weight and height were measured. ECG electrodes were attached according 
to the standard lead configuration for exercise testing and the ECG cables were 
connected. The patient then sat on a chair and following a five minutes resting period, 
arterial blood pressure was assessed from the brachial artery by cuff 
sphygmomanometry (ERKA, Kallmeyer Medizintechnik, Germany). This was 
followed by measurement of resting gas exchange data over five minutes (Medical 
Graphics Corporation, St Paul, Minnesota, USA). Following five minutes of 
metabolic measurements, the face mask was taken off the patient, and cardiac output 
was measured using the inert gas rebreathing methodology while the patient was still 
in a seated position (Innocor, Innovision, Denmark). Following explanation, the 
subject performed a rebreathing technique in the demonstration mode of the Innocor 
first to ensure the patient’s familiarisation with rebreathing manoeuvre. After a three 
minute wash out period, while the patient remained in a seated position, the 




Following the cardiac output measurement, the patient was again connected to the 
Medical Graphics metabolic analyser via a disposable pneumotach attached to the 
face mask. Oxygen consumption ( 2OV& ), carbon dioxide production ( 2C
O
V& ) and 
minute ventilation ( EV& ) were measured. The patient then performed a modified Bruce 
protocol. During the test, patients were verbally encouraged to perform as long as 
possible. Continuous breath-by-breath sampling of respi atory gases and heart rate 
measurements were made, while during the last 30 seconds of each exercise stage, 
arterial blood pressure was measured and Borg scale recordings for dyspnea and 
fatigue were performed (Borg, 1982). At peak exercise, cardiac output was measured 
using the inert gas rebreathing methodology. The Innocor respiratory valve unit with 
bacterial filter was inserted into the pneumotach of the Medical Graphics system and 
the patient was asked to breathe with the required b athing frequency and to empty 
the rebreathing bag with each inspiration. At the same time during the rebreathing 
manoeuvre, peak arterial blood pressure was measured. After completion of the 
rebreathing procedure, the Innocor unit was taken off immediately from the Medical 
Graphics pneumotach, and patients were encouraged to continue the exercise test if 
they were able to do so.  
The exact moment to determine cardiac output measurment at peak exercise 
involoved the following criteria: respiratory exchange ratio of 1.05 and higher, 
achievement of maximal oxygen consumption (the absence of a rise in 2OV&  with 
further increase in exercise intensity) and patient’s subjective feeling of high intensity 
work  as indicated on the Borg scale (>17).  
Peak 2OV&  was defined as the average 2OV&  during the last minute of exercise, 
expressed as ml per kg of body weight per min, as well as ml per kg. Oxygen 
consumption at the ventilatory (anaerobic) threshold (AT) was identified by the V-





9.2.4 Statistical Analysis 
All statistical analysis was carried out using SPSS version 13.0 (SPSS inc. Chicago, 
Illinois, USA). Prior to statistical analysis, data were checked for univariate and 
multivariate outliers using standard Z-distribution cut-offs and Mahalanobis distance 
tests respectively. Normality of distribution was asessed using a Kolmogorov-
Smirnov test. To test difference in measured variables etween test I and test II, t-test 
for paired samples was used. Statistical significance was indicated if p<0.05. To 
assess the reproducibility of cardiac power output and selected cardiopulmonary 
variables, the coefficient of variation (CV) and Pearson’s correlation coefficient (r) 
were calculated.  For each variable, the coefficient of variation was defined as the 
(within-person standard deviation/within-person mean) x 100%. Additionally, Bland-
Altman plots were constructed to demonstrate reproducibility of cardiopulmonary 
exercise test variables measured at peak exercise (Bland and Altman, 1986). All data 
are presented as means ±SD unless otherwise indicate .  
9.3 Results 
All subjects completed each exercise test without any untoward events. All exercise 
tests were stopped because of dyspnoea or fatigue. Nin  patients stopped the first 
exercise test due to fatigue and five patients stopped due to dyspnoea. Two patients 
reported a different limiting symptom at the end of the second from the first test. At 
the end of the second test, seven patients stopped due to dyspnoea. 
Six patients were able to continue with the exercis test after the peak cardiac power 
output measurement during the first test and nine patients during the second test. The 
time from completion of cardiac power output measurement and termination of the 
test averaged eight seconds (range from five to 14 seconds).   




9.3.1 Reproducibility of Resting Metabolic, Ventilatory and Central 
Haemodynamic Variables 
There were no significant changes in resting metabolic, ventilatory and central 
haemodynamic variables between the two tests (Tables 9.2 and 9.3). Central 
haemodynamic variables demonstrated lower coefficient of variation and higher 
coefficient of correlation compared with metabolic and ventilatory variables between 
the two tests, suggesting better reproducibility.  
 
Table 9.2 Resting Metabolic and Ventilatory Variables  
  Test I Test II p-value r CV (%) 
2OV&  (ml
.min-1) 304±98 320±100 0.45 0.69 14.2 
2OV&  (ml
.kg-1.min-1) 3.9±0.9 4.0±0.9 0.68 0.43 11.9 
2C
O
V&  (ml.min-1) 262±87 268±94 0.66 0.83 10.3 
EV&  (l
.min-1) 12.4±4.2 12.0±4.7 0.53 0.75 14.4 
RER  0.80±0.12 0.80±0.10 0.95 0.44 8.2 
2OV& -oxygen consumption, 2C
O
V& -carbon dioxide production, EV& -minute 
ventilation, RER-respiratory exchange ratio.  
 
  
Table 9.3 Resting Haemodynamic Variables  
    Test I Test II p-value r CV (%) 
TQ&  (l
.min-1) 4.0±1.0 3.9±0.9 0.63 0.99 3.4 
HR (beats.min-1) 62±12 60±9 0.24 0.83 5.6 
SBP (mm Hg) 118±11 114±10 0.13 0.55 5.3 
DBP (mm Hg) 77±11 75±10 0.31 0.87 4.3 
MAP (mm Hg) 94±11 91±9 0.15 0.79 4.5 
CPO (W)   0.83±0.24 0.79±0.19 0.15 0.96 5.4 
TQ& -cardiac output, HR-heart rate, SBP-systolic blood pressure, DBP-diastolic blood 






9.3.2 Reproducibility of Peak Exercise Metabolic and Ventilatory 
Variables  
As listed in Table 9.4, mean exercise time, peak oxygen consumption, anaerobic 
threshold and minute ventilation increased significantly from test I to test II (p<0.05). 
The coefficient of correlation was high (r>0.90) and the coefficient of variation was 
low (<10%) between the two test for all measured variables except minute ventilation 
(CV=11.1%).  
 
Table 9.4 Exercise Metabolic and Ventilatory Variables 
    Test I Test II p-value r CV (%) 
Exercise time (s) 684±191 745±190 0.00 0.95 7.1 
2OV&  (ml
.min-1) 1792±827 1884±767 0.04 0.99 5.7 
2OV&  (ml
.kg-1.min-1) 21.7±7.0 23.0±5.8 0.03 0.97 6.4 
AT (ml.kg-1.min-1) 13.7±3.5 14.2±3.4 0.03 0.97 3.8 
2C
O
V&  (ml.min-1) 1927±951 2031±1037 0.11 0.98 5.5 
EV&  (l
.min-1) 53.4±16.9 60.2±21.7 0.02 0.90 11.1 
RER    1.06±0.12 1.09±0.15 0.13 0.91 4.2 
Borg score  16.8±2.8 17.6±2.1 0.18 0.91 3.2 
2OV& -oxygen consumption, AT-anaerobic threshold, 2C
O
V& -carbon dioxide 
production, EV& -minute ventilation, RER-respiratory exchange ratio.  
The Bland-Altman analysis revealed that the mean difference between the first and 
second test for exercise time was -61 seconds (range -196 to 29 seconds) and the 
limits of agreement were -183 to 61 (Figure 9.1).    
The mean difference between the first and the second test for peak oxygen 
consumption was -92 ml.min-1 or -1.3 ml.kg.min-1 (range -465 to 195 ml.min-1 or -5.4 
to 2.2 ml.kg.min-1) and the limits of agreement were -394 to 210 ml.min-1 or -5.3 to 2.7 
ml.kg.min-1. Figure 9.2 shows a Bland-Altman plot for absolute values of peak oxygen 
consumption.  
For anaerobic threshold (Figure 9.3), the mean difference between the two tests was -




to 1.2 ml.kg.min-1. 
For carbon dioxide production at peak exercise (Figure 9.4), the mean difference 
between the two tests was -104 ml.min-1 (range -704 to 243 ml.min-1) and the limits of 
agreement were -552 to 344 ml. in-1.  
 
Figure 9-1 Bland-Altman plot of the differences against the mans of repeated 
measurements of maximal exercise time (ET).                                                               
 
Figure 9-2 Bland-Altman plot of the differences against the mans of repeated 













Figure 9-3 Bland-Altman plot of the differences against the means of repeated 
measurements of anaerobic threshold (AT). 
 
 
 Figure 9-4 Bland-Altman plot of the differences against the means of repeated 
measurements of peak carbon dioxide production (VCO2).  
For peak minute ventilation and respiratory exchange ratio the mean differences 
between the two tests were -6.8 l.min-1 and -0.03 (range -17.2 to 8.1 l.min-1 and -0.18 
to 0.15). The limits of agreement were -19.8 to 13 l .min-1 for peak minute ventilation 




9.3.3 Reproducibility of Peak Central Haemodynamic Variables  
There was no significant difference between cardiac output, arterial blood pressures 
and cardiac power output at peak exercise in the two tests (Table 9.5). For all 
measured central haemodynamic variables there was a high coefficient of correlation 
(r≥0.90) and low coefficient of variation was (<10%).   
 
Table 9.5 Peak Exercise Haemodynamic Variables  
    Test I Test II p-value r CV (%) 
TQ&  (l
.min-1) 11.2±5.7 11.3±5.6 0.84 0.99 2.2 
HR (beats.min-1) 116±31 118±26 0.42 0.96 4.4 
SBP (mm Hg) 148±27 146±25 0.67 0.93 4.5 
DBP (mm Hg) 74±13 78±11 0.23 0.90 7.5 
MAP (mm Hg) 104±17 106±15 0.51 0.98 6.8 
CPO (W)   2.68±1.53 2.69±1.52 0.63 0.96 4.1 
TQ& -cardiac output, HR-heart rate, SBP-systolic blood pressure, DBP-diastolic blood 
pressure, MAP-mean arterial pressure, CPO-cardiac power output. 
The Bland-Altman analysis revealed that the mean difference between the first and 
second test for peak cardiac output was -0.02 l.min-1 (range -0.30 to 0.40 l.min-1) and 
the limits of agreement were -0.40 to 0.36 l.min-1 (Figure 9.5).    
The mean difference between the first and the second test for peak heart rate was -2.1 
beats.min-1 (range -16 to 17 beats.min-1) and the limits of agreement were -11.4 to 7.2 
beats.min-1 (Figure 9.6).  
For peak mean arterial pressure, the mean differenc between the two tests was -2.3 
mm Hg (range -10 to 12 mm Hg) and the limits of agreement were -7.8 to 6.1 mm Hg 
(Figure 9.7). Additionally, the mean difference forpeak systolic and diastolic blood 
pressures between the two tests was 1.9 mm Hg and -4.2 mm Hg. The difference 
ranged from -22 to 18 mm Hg for peak systolic blood pressure, and from -10 to 8 mm 
Hg for diastolic blood pressure. The limits of agreement were -11.2 to 8.8 mm Hg for 




For peak cardiac power output, the mean difference between the two tests was -0.02  
W (range –0.21 to 0.30 W) and the limits of agreement were –0.14 to 0.10 W. (Figure 
9.8). 
 
Figure 9-5 Bland-Altman plot of the differences against the mans of repeated 




                                                               
Figure 9-6 Bland-Altman plot of the differences against the mans of repeated 






Figure 9-7 Bland-Altman plot of the differences against the mans of repeated 





Figure 9-8 Bland-Altman plot of the differences against the mans of repeated 














The present study evaluated the reproducibility of cardiac power output and other 
important cardiopulmonary exercise parameters in 14 patients with chronic heart 
failure who underwent two tests within seven days of each other. The major findings 
were 1) measured at rest, central haemodynamic variables (cardiac power output, 
cardiac output, heart rate, arterial blood pressure) showed better reproducibility than 
metabolic and ventilatory variables (oxygen consumption, carbon dioxide production, 
minute ventilation, respiratory exchange ratio); 2)at peak exercise, central 
haemodynamic measurements demonstrated a high degree of producibility whereas 
maximal exercise time, peak oxygen consumption, carbon dioxide production and 
minute ventilation tended to increase on the second of two baseline tests. 
Myers and Froelicher (1990) suggested that a common ethod of assuring a 
reproducible response to exercise is to have the pati nt perform two exercise tests on 
separate days, at the same time of the day. A test is considered “reproducible” if peak 
oxygen uptake is within ±10% on both days (Myers and Froelicher, 1990).   
9.4.1 Reproducibility of Cardiac Power Output and Selected Cardio-
rerpiratory Variables Measured at Rest  
Numerous studies have evaluated reproducibility of exercise cardiopulmonary 
variables in chronic heart failure patients (Bensimhon et al., 2008; Cooke et al., 1998; 
Elborn et al., 1990; Marburger et al., 1998; Meyer et al., 1997; Russell et al., 1998). 
Only one study, however, reported repeated measurements of cardiopulmonary 
variables measured at rest (Elborn et al., 1990). This fact should not be a surprise as of 
today, resting metabolic and ventilatory measurements (e.g. oxygen consumption, 
carbon dioxide production, minute ventilation) have not been shown to have 
significant diagnostic and/or prognostic importance in heart failure patients as those 
measured during and/or at peak exercise. Elborn et al. (1990) presented the mean and 
SD values of resting oxygen consumption, carbon dioxi e production, minute 
ventilation and ventilatory rate in addition to heart rate and systolic blood pressure. 
Similarly, as in the present study, non-significant differences were found between the 




consumption) to 28% (for carbon dioxide production).   
The finding of the present study that cardiac output measured at rest by the inert gas 
rebreathing methodology is highly reproducible is in agreement with previous studies 
(Agostoni et al., 2005; Christensen et al., 2000) which also demonstrated the CV 
below 10% in heart failure patients. Additionally, the present study demonstrates for 
the first time that resting cardiac power output is highly reproducible in chronic heart 
failure patients with stable condition using an inert gas rebreathing methodology, 
having the coefficient of variation of only 5%. Although the reproducibility of blood 
pressure measurement using cuff manometry has been qu stioned (Cooke et al., 
1998), the present study suggests that measurement of this variable has also a high 
degree of reproducibility in patients with stable chronic heart failure. This is also 
consistent with Elborn et al. (1990) who reported a coefficient of variation of 7% for 
systolic blood pressure measured at rest.  
Conversely to resting metabolic and ventilatory variables, resting central 
haemodynamic measurements demonstrated a higher degree of reproducibility. 
Moreover, measurement of resting cardiac output and car iac power output may 
indicate changes in haemodynamic status caused by e.g. an intervention or progress of 
the disease, particularly in seriously ill patients.  
9.4.2 Reproducibility of Cardiac Power Output and Selected Cardio-
respiratory Variables Measured at Peak Exercise   
Reproducibility of cardiac power output has been previously assessed by one study 
only (Cooke et al., 1998). Cooke et al. (1998) repeated the treadmill exercise tests on 
12 heart failure patients (NYHA class II-III) under the same conditions at least four 
weeks apart to investigate the reproducibility of the tests and measurements. In 
contrast with methodology used in the present study, Cooke et al. (1998) performed 
exercise test in two stages with a 40 minutes resting period between the two stages. 
The first stage was an incremental test to determine the maximum oxygen 
consumption, and a second maximum workload stage was used to make cardiac 
power output measurements. Similarly as in the present tudy, cardiac output and 




tests. Reported coefficients of variations for cardiac output and cardiac power output 
were low (below 10%), but compared to the present study coefficients of variations 
were higher (for cardiac output 7.1% vs. 2.2%, for ca diac power output 9.1% vs. 
4.1%). Furthermore, the mean difference and the limits of agreement between the two 
tests for cardiac output and cardiac power output measurements reported by Cooke et 
al. (1998) were higher than in the present study (the mean difference for cardiac 
output and cardiac power output were -0.15 l.min-1 vs. 0.02 l.min-1 and -0.04 W vs. -
0.02 W; the limits of agreement for cardiac output were -2.18 to 0.98 l.min-1 vs. -0.40 
to 0.36 l.mn-1, and for cardiac power output -0.35 to 0.28 W vs. -0.14 to 0.10 W). 
Similarly to the present study, excellent reproducibility of peak heart rate 
measurement in heart failure patients has been reported elsewhere (Elborn et al., 
1990; Marburger et al.,. 1998; Meyer et al., 1997). Although Cooke et al. (1998) 
questioned reproducibility of blood arterial pressure measurement by cuff manometry, 
they did not report repeated measures of blood pressu  measurements, or 
reproducibility analysis of this variable. Elborn and associates (1990), however, 
reported the coefficient of variation of 5% for systolic blood pressure measured at 
peak exercise in chronic heart failure patients. Similarly, Meyer et al. (1997) reported 
that coefficients of variation for systolic and diastolic blood pressures at peak exercise 
in patients with severe heart failure were similar as in the present study (2.2% and 
6.1%).  Results from the present study indicate that coefficient of variation for blood 
pressure measurement is below 10% in patients with stable chronic heart failure (for 
mean arterial pressure 6.8%). Also the mean difference between the two tests for 
mean arterial blood pressure was low (2.3 mm Hg) and the limits of agreement 
acceptable (-7.8 to 6.1 mm Hg). Therefore, a good reproducibility of cardiac power 
output measured at peak exercise found in the present study is unsurprising as its both 
components (cardiac output and mean arterial pressur ) appear to have a high degree 
of reproducibility.  
Conversely to cardiac power output, reproducibility of exercise metabolic and 
ventilatory variables has been investigated by a numerous studies (Bensimhon et al., 
2008; Elborn et al., 1990; Marburger et al., 1998; Meyer et al., 1997; Russell et al., 
1998).  Some investigators have suggested that due to great variability between 




trial purposes. Elborn and associates (1990) performed three consecutive treadmill 
tests separated by two weeks on 30 patients with heart failure. Mean peak oxygen 
consumption improved significantly from the first to he second test (14.1 vs. 14.9 
ml.kg.min-1; p<0.005) with no difference in peak oxygen consumption between the 
second and the third test (14.9 vs. 14.8 ml.kg.min-1, p>0.05). The average within-
subject coefficient of variation for the three test was 6%. Additionally Elborn et al. 
(1990) reported that the first test underestimated exercise time by approximately 20%, 
and concluded that a single baseline test was not sufficient for measuring 
cardiopulmonary response to an intervention and suggested the performance of two or 
more tests for clinical research application.  
Conversely, Russell and colleagues performed a series of five baseline maximal 
treadmill tests (three with gas exchange) in 81 men and women with symptomatic 
heart failure and found that although there was a significant improvement in exercise 
time between test 1 and 3 (419 vs. 470 seconds, p<0.05), there was no significant 
change in peak oxygen consumption (1199 vs. 1105 vs. 1123 ml.min-1, p>0.05). The 
investigators concluded that a single baseline test was sufficient to measure peak 
oxygen consumption for the evaluation of therapy or assessment of the prognosis. 
Similarly, Marburger and associates (1998), in nine elderly patients with heart failure, 
found a change in peak oxygen consumption and exercise time of 63 ml.min-1 and 32 
seconds (the CV of 6.1% and 5.2%) between the two tests with one week apart. 
Respiratory exchange ratio and anaerobic threshold had coefficient of variation of 5% 
and 9%. The authors concluded that only one test was necessary to determine 
physiological responses to exercise in elderly heart failure patients. Furthermore, 
Meyer et al. (1997) also reported high reproducibility for duplicate measurements 
during stress exercise test in 11 patients with severe heart failure. The coefficient of 
variation for peak oxygen consumption, carbon dioxide production, respiratory 
exchange ratio and minute ventilation ranged from 3 to 6.4% respectively. Most 
recently, Bensihmnon and colleagues (2008) evaluated inter-subject variability of 
peak oxygen consumption over two baseline tests in the largest trial including 398 
patients with heart failure. More than 90% of patients performed two tests within 
seven days of each other. Results revealed that peak oxygen consumption was 




absolute change was 1.3 ml.kg.min-1 (the CV of 6.6%) with 46% of subjects 
increasing and 48% decreasing on the second test. The mean exercise time increased 
significantly from test 1 to test 2 by 4% (in the present study by 8%), whereas the 
mean values of anaerobic threshold were nearly identical between the two tests (10.5 
vs. 10.6 ml.kg.min-1, the CV of 7.8%). There was a very small, but stati tically 
significant, difference in peak respiratory exchange ratio between the two tests. 
Bensihmon and associates (2008) concluded that there is no need to perform more 
than one baseline cardiopulmonary exercise test in heart failure patients.       
It has been suggested that measured oxygen uptake remains relatively stable whereas 
exercise time continues to increase with serial testing (Tavazzi et al., 2001). In the 
present study, exercise time, peak oxygen consumption and peak minute ventilation 
were significantly higher during the second test. Indicating individual differences 
between test 1 and test 2 for measured variables, th  Bland-Altman analysis (1986) 
shows that the most of the patients tended to score higher values during the second 
compared with the first cardiopulmonary exercise test. However, despite this 
statistically significant difference, there was a low coefficient of variation (below 
10%) for all variables, except peak minute ventilation (the CV of 11.1%). This finding 
compares well with those previously mentioned studies which reported coefficient of 
variation for metabolic and ventilatory variables to be below 10%, indicating good 
reproducibility of metabolic and ventilatory exercise test variables (Bensihmon et al., 
2008; Marburger et al., 1998; Meyer et al., 1997).  
9.5 Clinical Implications and Conclusions 
Measurement of central haemodynamic variables and particularly cardiac power 
output is more relevant in the evaluation of the severity of cardiac dysfunction in heart 
failure patients than any other metabolic or ventilatory variable. Good reproducibility 
of commonly reported cardiopulmonary exercise tests variables such as peak oxygen 
consumption, anaerobic threshold, carbon dioxide production, minute ventilation and 
respiratory exchange ratio has been previously shown. The coefficient of variation for 
measured peak metabolic and ventilatory variables, except minute ventilation, was 
low in the present study also, ranging from 4.2% to 7.1%. However, is seems that 




metabolic and ventilatory measurements during second of the two tests.  
The present study suggests that cardiac output and c rdiac power output, as direct 
indicators of cardiac function, had lower coefficient of variation than any of the 
commonly reported gas exchange variables at rest but also at peak exercise, 
demonstrating a high degree of reproducibility. Therefore, cardiac power output could 
be assessed together with other cardiopulmonary exercise test variables. Finally, it is 
reasonable to suggest that cardiac power output should be assessed as priority 
compared with other cardiopulmonary exercise test variables due to its good 
reproducibility and the capacity to represent overall c rdiac function/dysfunction 
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CHAPTER 10: THE EFFECT OF AEROBIC VERSUS 
RESISTANCE EXERCISE TRAINING ON CARDIAC POWER 
OUTPUT AND SELECTED CARDIO-RESPIRATORY 
VARIABLES IN PATIENTS WITH STABLE CHRONIC HEART 
FAILURE  
Abstract 
Introduction: Clinical evidence suggests that both aerobic and resistance exercise 
training may improve exercise tolerance in patients wi h chronic heart failure (CHF).   
Whether the two modalities of exercise training (aerobic and resistance) have similar 
effect on heamodynamic and metabolic variables remains unclear. The purpose of this 
study was to assess the effect of aerobic and resistance exercise training on cardiac 
power output and selected cardio-respiratory variables in CHF patients. Methods: 
Patients were randomized either into aerobic exercis  training (AE) group (8 men, 3 
women; mean±SD age 65±12 years) or to a resistance exercise training (RE) group (8 
men, 2 women; age 63±10 years). At baseline and after 12 weeks of exercise 
intervention, patients underwent cardiopulmonary exercise testing with metabolic, 
ventilatory, and non-invasive central haemodynamic easurements at rest and at peak 
exercise. Results: Non-significant differences between the two groups were identified 
for any variable of interests at baseline level, either at rest or at peak exercise. Resting 
central haemodynamic or metabolic variables were not significantly changed after AE 
or RE compared with baseline. Peak cardiac power output increased following AE by 
6.2%, although not significantly (p>0.05), whereas following RE, it remained almost 
unchanged. Peak cardiac output significantly increased from baseline by 0.8 l.min-1 in 
AE group (from 11.1 to 11.9 l.min-1, p<0.05), whereas no such change was observed 
in the RE group (p>0.05). Systematic vascular resistance was significantly reduced 
following AE by 8.2% (from 742 to 684 dyn.s-1.cm-5, p<0.05) and was not 
significantly changed following RE (p>0.05). Peak oxygen consumption significantly 
increased in AE (from 23.3 to 25.1 ml.kg-1.min-1, p<0.05) but not in RE (form 22.2 to 
23.2 ml.kg-1.min-1, p>0.05). Changes in cardiac output were significantly correlated to 
changes in peak oxygen consumption following AE (r=0.82, p<0.01). Patients in AE 
group achieved an increase in anaerobic threshold of 7.8% (from 14.2 to 15.5 ml.kg-
1.min-1, p<0.05 vs. RE group). Patients in both groups significantly increased maximal 
exercise duration, peak minute ventilation and carbon dioxide production compared to 
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baseline values (p<0.05). Conclusion: In contrast with resistance, aerobic exercise 
training increases maximal flow-generating capacity of the heart and delays anaerobic 
metabolism during sub maximal exercise in patients wi h stable chronic heart failure. 
Improved peak oxygen consumption following aerobic exercise training is closely 
associated to an exercise-induced increase in cardiac output.        
10.1 Introduction 
Over the past decades considerable knowledge has accumulated concerning the 
significance of exercise in the treatment of a number of diseases, including metabolic 
syndrome-related disorders (insulin resistance, type 2 diabetes, dyslipidemia, 
hypertension, obesity), heart and pulmonary diseases (chronic obstructive pulmonary 
disease, coronary heart disease, chronic heart failure, intermittent claudication), 
muscle, bone and joint diseases (osteoarthritis, rheumatoid arthritis, osteoporosis, 
fibromyalgia, chronic fatigue syndrome) and other chronic diseases (cancer, 
depression, asthma, type 1 diabetes) (Oldridge, 2003; Pederson and Saltin, 2006; 
Roberts and Bernard, 2005). In the medical world, it is traditional to prescribe the 
evidence-based treatment known to be the most effective and entailing the fewest side 
effects or risks. The evidence available so far suggests that in selected cases, exercise 
therapy is just as effective as medical treatment, a d in special situations more 
effective or adds to the effect (Pederson and Saltin, 2006).     
Chronic heart failure or cardiac insufficiency is a clinical syndrome defined by the 
European Society of Cardiology as the presence of the following criteria: symptoms 
(dyspnoea, fatigue, ankle swelling) and objective eid nce of cardiac dysfunction at 
rest (ESC Task Force, 2005). Heart failure is subdivided into left heart failure (the 
most frequently studied) and right heart failure, as well as into acute (pulmonary 
congestion, cardiogenic shock) and chronic heart failure. Heart failure is often caused 
by ischaemic heart disease, but can also be caused by hypertension, valvular heart 
disease, and dilated cardiomyopathy.   
According to Duscha et al. (2008) pathophysiology of systolic chronic heart failure 
entails an initial injury to the heart that results in decreased left ventricular function 
and progressive declines in cardiac output. The pump function of the heart is 
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inadequate to supply sufficient blood perfusion forsystematic metabolic needs. 
Clinical consequence and the hallmark symptom of chronic heart failure (CHF) is 
exercise intolerance, often exhibited by early fatigue or shortness of breath with a 
minimal degree of exertion (Myers, 2008). The pathophysiologic features of CHF that 
underlie reduced exercise tolerance have been the focus of numerous investigations 
over the last two decades (Pina et al., 2003).       
10.2 Exercise and Chronic Heart Failure 
10.2.1 Exercise Limitations in CHF patients  
The extent to which exercise capacity is impaired in CHF is typically 30-50% relative 
to age-matched normal subjects and is 20-30% lower than that among typical patients 
with coronary artery disease (Myers, 2008). Over two decades of research have 
demonstrated that exercise intolerance in CHF is very complex and also extends to 
systems and abnormalities beyond the heart. The multiple mechanisms that are 
potentially responsible for the impairment of exercise capacity include: 1) cardiac 
dysfunction, 2) abnormalities in peripheral blood flow, 3) endothelial dysfunction, 4) 
skeletal muscle abnormalities, 5) ventilatory defects, and 6) abnormalities of 
autonomic nervous system function (McKelvie, 2008). In other words, factors that 
contribute to impaired exercise tolerance in CHF patients involve both central 
(cardiac) and peripheral (skeletal muscle and vascul r) abnormalities, including 
impaired cardiac output response to exercise, abnormal redistribution of blood flow, 
reduced mitochondrial volume and density, impaired vasodilatory capacity, and 
heightened systematic vascular resistance (Drexler and Coats, 1996; Kitzman and 
Groban, 2005; Myers and Froelicher, 1991; Pina et al., 2003).     
10.2.1.1 Central (cardiac) factors limiting exercise performance in CHF 
patients 
In normal subjects, maximal exercise capacity seems to be limited by the ability of the 
cardiovascular system to deliver oxygen to the exercising muscles (Basset and 
Howley, 2000; Saltin and Rowell, 1980). This is shown by three major lines of 
evidence: 1) when oxygen delivery is altered (by blood doping, hypoxia, or beta-
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blockade), maximal oxygen consumption changes accordingly, 2) the increase in 
maximal oxygen consumption with exercise training results primarily from an 
increase in maximal cardiac output, and 3) when a sm ll muscle mass is overperfused 
during exercise, it has an extremely high capacity for consuming oxygen (Basset and 
Howley, 2000). Maximal exercise capacity is primarily l mited by cardiac output in 
healthy adults. This is supported by the evidence that increasing the exercising muscle 
bulk by adding arm to maximal leg exercise does not result in an increase in maximal 
oxygen consumption (Jondeau et al., 1992). This suggests that cardiac output and 
oxygen delivery is already maximal (Jondeau et al., 1992). The same study, however, 
showed that in patients with CHF, the addition of arm to maximal leg exercise does 
produce a further increase to maximal oxygen consumption (Jondeau et al., 1992). 
Clark et al. (1996) suggested that the ability of the muscle to extract oxygen, for 
whatever reason, rather than the heart to deliver oxygen, is the major determinant of 
exercise capacity in patients with CHF. Clark and colleagues (1996) proposed so 
called “muscle hypothesis” according to which exercise intolerance and the reduction 
in peak aerobic power in CHF patients is primarily determined by the peripheral 
factors such as disease-induced alteration in skeletal muscle. This will be discussed in 
more details in the following subheading.  
The Fick equation makes clear that functional capacity depends both on central 
cardiac performance as well as on peripherally mediat  oxygen utilisation. The 
potential to increase cardiac output is essentially limited in heart failure patients (Pina 
et al., 2003) because the hearts of CHF patients ted o be dilated with impaired 
pumping function even at baseline (Duscha et al., 2008).  
The increase in cardiac output during maximal upright exercise is typically four to six 
fold in healthy adults. This is a consequence of a two- to four-fold increase in heart 
rate and a 20% to 50% in stroke volume.  The stroke v lume increase is accomplished 
both by the use of the Frank-Sterling mechanism to maintain left ventricular end-
diastolic volume and by more complete left ventricular emptying to reduce end-
systolic volume. Both enhanced left ventricular contractility and peripheral 
vasodilatations contribute to the more complete left v ntricular emptying observed 
during exercise (Pina et al., 2003). A hallmark of heart failure patients, as previously 
mentioned, is a reduced ability to perform aerobic exercise. This reduction in aerobic 
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capacity seems to be largely mediated by inadequate blood flow to active skeletal 
muscle secondary to impaired cardiac output (Sullivan and Cobb, 1992; Wilson et al., 
1984). Patients with CHF may achieve <50% of the maxi l cardiac output attained 
by healthy individuals at peak exercise.  
In CHF patients, peak exercise heart rate is often decreased (Clark and Coats, 1992). 
One explanation for such a decrease (apart from heart rate-lowering drugs) is that 
exercise is submaximal as it is usually stopped due to breathlessness or inadequate 
motivation. The second explanation is that the chronotropic reserve, as a major 
determinant of the increase in cardiac output, is significantly reduced (Franciosa et al., 
1984; Szlachic et al., 1985). Resting tachycardia is not the only reason for reduced 
heart rate response to exercise as some CHF patients have a fairly low resting heart 
rate associated with markedly enlarged heart and preserved stroke volume (Cohen-
Solal et al., 1999). In contrast, the kinetics of the heart rate response during exercise is 
generally abnormal with a rapid increase in more severe heart failure patients 
(Chidsey et al., 1962). There is an increase in resting sympathetic tone in CHF 
patients, but is seems to be unknown whether it is smaller or larger during exercise in 
healthy subjects (Wilson et al., 1989). The plasma noradrenalin level increases less 
than in healthy subjects (Colucci et al., 1989). The rise in sympathetic myocardial 
tone is lower than the rise in systemic tone in CHF patients (Rundqvist et al., 1997). 
Moreover, there is desensitization of β adrenergic receptors, and this is a possibly the 
main mechanism underlying the limited chronotropic response (Colucci et al., 1989; 
Bristow et al., 1986).      
Furthermore, stroke volume in CHF patients, which is already decreased at rest, rises 
only modestly up to a peak of 55 to 65 ml (Pina et l., 2003). The inability to increase 
cardiac output is related primarily to the minimal increase in stroke volume coupled 
with a lower heart rate (Sullivan and Hobb, 1992). In the dilated left ventricle and 
with reduced resting left ventricular systolic function, stroke volume typically 
increases only modestly during exercise because of a reduced ability to increase both 
left ventricular preload and ejection fraction (Sullivan and Cobb, 1992).  The reduced 
ability to augment left ventricular end-diastolic volume is explained by the fact that 
the already dilated left ventricle is operating near its maximal volume and has thus 
exhausted most of its preload reserve (Sullivan and Cobb, 1992). It has further been 
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suggested that the failure to increase left ventricular systolic emptying and thus 
augmented ejection fraction is a consequence of a cmbination of impaired intrinsic 
contractility, reduced β-adrenergic responsiveness, elevated systemic vascular 
resistance due to increased activity of the sympathetic and rennin-angiotensin 
systems, and minimal peripheral arterial vasodilator response to exercise (Pina et al., 
2003).         
10.2.1.2 Peripheral factors limiting exercise performance in CHF patients 
Although the focus is often on abnormalities of the art, it is well known that 
peripheral abnormalities, especially involving skeleta  muscles, significantly 
contribute to the functional impairment and reduced exercise tolerance in CHF 
patients. Nonetheless, due to a compromised cardiac output, characteristics of skeletal 
muscle become relatively more important in determining maximal oxygen 
consumption in CHF patients (Duscha et al., 2008). Systematic reviews on peripheral 
factors limiting exercise performance commonly describe abnormalities of 
vasodilatory capacity, endothelial function, ergoreflex activation and distribution of 
cardiac output (Pina et al., 2003).  
The failure of muscle blood flow to increase normally during exercise in patients with 
CHF is due not just to a reduction in cardiac output but also due to an abnormality in 
peripheral vasodilatation (Pina et al., 2003). In patients with CHF, systematic vascular 
resistance is higher at rest than in normal subjects. The reduction in resistance during 
exercise is only slightly less marked than in normal subjects, but nonetheless, 
systematic vascular resistance always remain higher than in normal subjects at a given 
workload (Isnard et al., 1996; Roubin et al, 1990; Sullivan and Cobb, 1992). The 
impairment in vasodilatory capacity has been attribu ed to excessive sympathetic 
stimulation causing vasoconstriction, activation of the plasma renin-angiotensin 
system, and higher than normal levels of endothelin (McMurray et al., 1992; Zelis et 
al., 1988). An additional mechanism may involve vascular stiffness secondary to 
increased vascular sodium content (Pina et al., 2003). This is supported by the 
observations that the capillary basement membranes may be thickened in CHF 
patients (Longhurst et al., 1975) and that vascular responsiveness is partially 
improved by diuretic therapy (Sinoway et al., 1987).  
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It has been suggested that endothelium plays an important role in tissue perfusion in 
heart failure (Pina et al., 2003).   The vascular endothelium releases vasoactive 
substances that play an important regulatory role in peripheral vasomotor tone 
(Cohen-Solal et al., 1999). Vasodilating and vasoconstricting factors, including nitric 
oxide, endhotelins, and prostaglandins derived from the endothelium, are released in 
response to various chemical, pharmacological, mechani al, and exercise stimuli 
(Pina et al., 2003). Endothelium-dependent dilation of the vasculature is impaired in 
heart failure. This is supported by the evidence that ere is a reduction in release in 
nitric oxide in response to acetylcholine (Drexler et al., 1992, Kubo et al., 1991). The 
release of nitric oxide, an important mediator of flow-dependent vasodilation, is 
stimulated by exercise in healthy individuals but seems to be attenuated in heart 
failure patients (Drexler et al., 1992). This may contribute to a reduction in peripheral 
vasodilation and thus tissue perfusion (Pina et al., 2003). It has been shown that the 
impairment of endothelial-dependent vasodilation is correlated with the degree of 
exercise intolerance and the severity of New York Heart Association class (Nakumura 
et al., 1994). Exercise training has been shown to improve endothelial nitric oxide 
formation and endothelial-dependent vasodilation of skeletal muscle vasculature 
(Hambrecht et al., 1998).    
Patients with CHF compensate for reduced cardiac output with an increased arterio-
venous oxygen difference, such that resting and submaximal exercise oxygen 
consumption are similar to that of normal subjects (Duscha et al., 2008). Despite this 
increase, CHF patients have increased lactate producti n, even during submaximal 
exercise (Weber and Janicki, 1985; Wilson et al., 1984). Early blood lactate 
production is a function of intramuscular acidosis and not reduced lactate clearance 
(Wiener et al., 1986). It seems that a prolonged decrease in left ventricular function 
causes skeletal muscle abnormalities. It is possible, however, that these skeletal 
muscle changes may be independent of left ventricular f nction (Duscha et al., 2008). 
The primary function of the capillary bed in skeleta  muscle is to supply oxygen to 
muscle fibres. It seems, however, that patients with CHF have reduced capillary 
density in the skeletal muscles between 17% and 32% (Drexler et al., 1992; Duscha et 
al., 1999; Sullivan et al., 1990; Williams et al., 2004). This finding further supports 
the argument that peripheral abnormalities play an important role in impaired exercise 
tolerance in CHF patients. 
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Further abnormalities in skeletal muscles of CHF patients involve 10-20% decrease in 
oxidative (red) type I muscle fibre with an increas in glycolitic (white) type IIb 
muscle fibre compared with normal subjects (Drexler et al., 1992; Lipkin et al., 1988; 
Sullivan et al., 1990). These shifts have been correlated to peak oxygen consumption 
and leg fatigue during isokinetic knee extension (Magnusson et al., 1996; Mancini et 
al., 1989). Furthermore, it has been reported that myosin heavy-chain type I isoforms 
are decreased in proportion to peak oxygen consumption in CHF patients (Sullivan et 
al., 1997). Although levels of glycolytic enzymes seem to be unchanged in CHF, 
levels of oxidative enzymes are decreased (Sullivan et al., 1990). Specifically, 
mitochondrial enzymes (citrate synthase and succinic dehydrogenase) and enzymes 
involved in β-oxidation of fatty acids (3-hydroxyl CoA dehydrigenase) have been 
shown to be decreased (Sullivan et al., 1990). Interes ingly, an inverse relationship 
between oxidative enzyme activity and blood lactate accumulation was found during 
exercise (Sullivan et al., 1991). In that study CHF patients had less phosphocreatine 
depletion and lactate accumulation at peak exercise than normal subjects, raising the 
possibility that intrinsic skeletal muscle abnormalities may be responsible for early 
anaerobic metabolism (Duscha et al., 2008). Althoug, the most important 
determinant in maximal oxygen consumption in healthy subjects is cardiac output 
(Saltin and Rowell, 1980), it seems that sub-maximal indices rely on skeletal muscle 
capacity (e.g. mitochondria content) (Holloszy and Coyle, 1984). Mitochondria 
generate most of a cell’s adenosine-three-phosphate and therefore play an intricate 
role in skeletal muscle energy metabolism. Only Drexler et al. (1992) measured 
mitochondria in CHF patients compared with healthy subjects. They demonstrated 
that oxygen consumption correlates with a reduced mitochondrial volume and surface. 
A decline in mitochondrial number and size indicates a reduced oxidative capacity of 
the muscle and has been offered as explanation for the apid fatigue that occurs in 
CHF patients (Drexler et al., 1992). Taken together, these findings suggest that 
alterations in skeletal muscle may contribute to abnormal oxygen extraction or 
substrate delivery/utilization and may further limit exercise tolerance in CHF patients. 
In skeletal muscles, there are ergoreceptors, small afferent nerve fibres that are 
sensitive to changes in metabolism (Piepoli et al., 1996; Ponikowski et al., 2001; Scott 
et al., 2002). Muscle metabolic abnormalities with overproduction and accumulation 
of metabolites (a.g. H+, 2C
O
, bradykin) during exercise activate afferents of the
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ergoreflex, which leads to an exaggerated increase of ventilatory, haemodynanmic, 
and sympathetic nervous system activity to exertion (Scott et al., 2002). In CHF 
patients, it has been found that there is an increased activation of the ergoreflex 
compared with normal subjects, with evidence of more pronounced exercise 
hyperventilation and more severe symptoms (Piepoli et al., 1996; Ponikowski et al., 
2001). These findings suggest that increased activation of the ergoreflex during 
exercise in CHF is closely related to exercise intolerance (Ponikowski et al., 2001).  
The finding of skeletal muscle abnormalities and increased activation of the 
ergoreflex has provided substantial support for the sk letal muscle hypothesis as an 
explanation for the exercise intolerance (Piepoli et al., 1996). In this hypothetical 
model, left ventricular dysfunction reduces blood flow to the periphery and activates a 
catabolic state causing skeletal muscle myopathy, which contributes to fatigue and 
dyspnoea. This, in turn, stimulates ergoreceptors in the skeletal muscles leading to 
increased ventilation and sympathoexcitation with vagal withdrawal. The resultant 
vasoconstriction and increased afterload cause further deterioration of left ventricular 
function, forming a vicious cycle (Piepoli et al., 1996). This results in further 
worsening of exercise tolerance, skeletal muscle myopathy, and may eventually lead 
to a progressive adverse effect on left ventricular remodelling (Piepoli et al., 1996).             
Finally, exercise tolerance depends not only on the capacity of the cardiopulmonary 
system to deliver oxygen to the working muscles, but also on regional blood flow (e.g. 
the capacity of the vasculature to redistribute cardiac output to the muscles during 
exercise). In healthy normal adults, up to 85% of the total cardiac output is directed 
toward active skeletal muscle at high levels of exercis , with flow to leg muscles 
usually receiving the greatest increases in blood fl w (Knight et al., 1992). Although 
some evidence suggests that muscle blood flow is reduced in proportion to the 
reduction in cardiac output in CHF patients (Yamabe et al., 1995), several studies 
have demonstrated the reduction in flow to the muscles during exercise occurs to a 
degree out of proportion to the reduction in cardiac output. Sullivan and Cobb (1992) 
reported that the percentage of cardiac output distributed to both lower extremities 
during maximal exercise was attenuated in patients with CHF when compared with 
healthy subjects (51% vs. 71%). Vascular resistance fails to decrease normally during 
exercise in patients with CHF, and flow to the nonexercising tissues may be 
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preferentially maintained at the expense of hypoperfusion in the exercising muscles 
(Sullivan et al., 1989; Wada et al., 1997).      
10.2.2 Modes of Exercise Training and Their Effect on Clinical 
Outcomes, Exercise Performance and Cardiac Function in CHF 
Patients   
Prior to the late 1980s, bed rest and restricted physical activity were recommended for 
all stages and forms of heart failure (Working Group Report, 2001). However, 
prolonged bed rest and physical inactivity can lead to skeletal muscle atrophy, 
pulmonary embolism, venous thrombosis, and a further reduction in exercise 
tolerance and exacerbation of symptoms (Working Group Report, 2001). The concept 
of exercise training in patients with CHF was initiated in the late 1980s. Coats et al. 
(1990), in the first randomized study of training patients with stable heart failure, 
showed that eight weeks of exercise training led to an increase in exercise capacity 
and to an improvement of the abnormal sympathovagal balance. Research over the 
past 20 years has expanded understanding and knowledge of the role of exercise 
training in patients with left ventricular dysfunction and heart failure. Over the time it 
has become clear that patients with CHF may benefit so much from exercise training 
that it has been recommended by a number of international scientific organizations 
such as American Heart Association and European Society of Cardiology (Pina et al., 
2003; Working  Group Report, 2001). It has been shown that exercise training is 
firstly safe in CHF patients (Smart and Marwick, 2004) and can improve peak oxygen 
consumption (Duscha, 2008; Pina et al, 2003; Working Group Report, 2001), muscle 
strength and mass (Braith and Beck, 2008), New York Heart Association Class 
(Hambrecht et al., 2000), quality of life (Belardinelli et al., 1999), but also reduces 
hospital admission and mortality rate (Piepoli et al., 2004). Different modalities of 
exercise may have different effects on cardiovascular function in CHF. Therefore, 
authors have been interested in the effects of different exercise modalities on clinical 
outcomes, exercise performance and cardiac function. Three modes of exercise in 
CHF patients have been utilized such as aerobic, resistance and combined.  
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10.2.2.1 Aerobic exercise training in CHF patients  
Most of the studies which assessed the effect of exercise training in CHF patients 
utilized aerobic training modalities (e.g. walking, jogging, cycling, rowing, arm 
ergometer, step aerobic exercises, etc) (Coats, 2000, Duscha et al., 2008). The rational 
for aerobic training in cardiac patients was originally premised on expectations for 
improved inotropic and chronotropic capacities (Duscha et al., 2008). Historically, 
aerobic exercise is implanted in cardiac rehabilitation programs in an attempt to 
resolve oxidative enzymatic abnormalities (Bylund et al., 1977) and thereby increase 
exercise tolerance (Braith et al., 2005).  
Numerous systematic reviews and meta analyses showed that aerobic exercise 
training improves exercise tolerance and functional capacity in chronic heart failure 
patients (Coats et al., 2000; Duscha et al., 2008; Haykowsky et al., 2007; McKelvie, 
2008; Pina et al., 2003; Smart and Marwick, 2004; Working Group Report 2001). In a 
meta-analysis of 14 trials (812 patients) performed by Haykowsky et al. (2007), an 
overall improvement in peak oxygen consumption of ~20% was reported. Moreover, 
aerobic training was associated with statistically significant increase in peak oxygen 
consumption of ~3 ml.kg.min-1 (from 9 randomized trials with 538 patients). In this 
meta-analysis, studies that utilized an aerobic training modality demonstrated these 
beneficial effects, whereas studies that used combined exercise modality did not. The 
authors suggested that this may be because of the heightened systolic and diastolic 
pressure loading that occurs with strength training (Cheetham et al., 2002; Keren et 
al., 1989; McKelvie et al., 1995).  
The other systematic review of 57 studies that measur d peak oxygen consumption 
directly (Smart and Marwick, 2004) suggests that the mean improvement was 16.8% 
(95% confidence interval: 13.7-17.9%). Authors however noted that studies of aerobic 
exercise training demonstrated a greater increment in peak oxygen consumption 
(16.5%) compared with studies that employed strength training alone (9.3%). 
However, this review suggests that the mean increment in peak oxygen consumption 
following aerobic exercise training only slightly exceeded the combined mode of 
exercise training (by 1.5%).  
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Several mechanisms that may occur in response to aerobic exercise training may 
contribute to significant increase in exercise tolerance in CHF patients. Firstly, 
aerobic exercise training increases capillary density, promotes the synthesis and 
release of nitric oxide, improves angiogenesis, vasodilation and endothelial function, 
reduces oxidative stress and peripheral vascular resistance, and increases metabolic 
capacity and musculoskeletal blood flow (Adamopoulos et al., 2003; Duscha et al., 
2008; Wisloff et al., 2007). Secondly, aerobic exercise training in CHF patients is 
associated with lower blood lactate threshold and blood lactate concentration at 
standardized submaximal workload levels (Belardinelli t al., 1995), reduced 
depletion and more rapid resynthesis of phosphocreatine (Adamopoulos et al., 2003), 
and increased citrate syntheses activity (Duscha et l., 2008). Following aerobic 
training, the mitochondrial total volume density is increased, mitochondrial enzymatic 
activity and skeletal muscles’ oxidative capacity are enhanced (Belardinelli et al., 
1995; Duscha et al., 2008; Piepoli et al., 1998). In addition, recent data suggest that 
aerobic training improves phase II O2 kinetics, which is an indirect index of muscle 
oxidative capacity (Roditis et al., 2007). Also, some studies have shown a shift from 
IIb to IIa muscle fibre type (Duscha et al., 2008) and a modest increase in type I 
muscle fibres (Hambrecht et al., 1997).  
Finally, most single centre exercise training studies of heart failure patients did not 
include end-points such as hospitalizations and survival. However, a European 
collaborative meta-analysis examined death from all c uses in 805 patients data sets 
from 41 exercise training trials of heart failure (Piepoli et al., 2004). They found that 
exercise training significantly reduced both mortality and death plus hospital 
admission. Importantly, eight of nine trials included in their analysis incorporated 
aerobic exercise training. Now, a large, multicentr, andomized clinical trial 
(sponsored by the USA National Heart, Lung, and Blood Institute) has been 
undertaken to assess the effect of exercise training on the clinically relevant end-
points of mortality, hospitalisation, and quality of life with heart failure: HF-ACTION 
(Heart Failure: A Controlled Trial Investigating Outcomes of Exercise Training) 
(Whellan et al., 2007). Following baseline assessment to determine whether they can 
safely exercise, 3000 patients were randomized to either usual care or exercise 
training, the latter consisting of supervised facility-based aerobic (cycling or walking) 
exercise training sessions. After completing the supervised sessions, patients initiated, 
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and then transitioned to, solely home-based exercise. The followed-up period of up to 
4 years has been proposed. A number of substudies were planned. The outcome of 
this study should have a profound effect on this issue.          
Interval vs. steady-state (continuous) training. The rational for developing interval 
training methods for cardiac patients was to apply more intense exercise stimuli on 
peripheral muscles than that obtained during steady-state training methods, but 
without inducing greater cardiovascular stress (Working Group Report, 2001). This is 
possible by using short bouts of work phases in repeated sequence followed by short 
recovery phases. Chronic heart failure patients with very low baseline aerobic 
capacity demonstrated an improvement in ventilatory h eshold by 24% on average, 
and peak oxygen consumption by 20% after only three w ks of interval training 
(Meyer et al., 1996a). This finding is similar to tha  reported by other studies but after 
much longer training periods (8-24 weeks) using steady-state method (Belardinelli et 
al., 1995; Belardinelli et al., 1998; Coats et al., 1992; Hambrecht et al., 1995; 
Kavanagh et al., 1996; Keteyian et al., 1996). Although ejection fraction, mean 
arterial blood pressure and heart rate during interval t aining are similar to that seen in 
steady-state exercise, blood lactate is significantly higher during interval exercise, 
indicating a greater peripheral training stimulus (Meyer et al., 1998). Therefore, 
interval training allows more intense exercise stimul  on peripheral muscles with no 
greater left ventricular stress than when using a ste dy state training method (Working 
Group Report, 2001). A superior cardiovascular effect of aerobic interval training 
versus moderate continuous aerobic training in heart failure patients was shown 
recently by Wisloff et al. (2007). Patients were randomized to either moderate 
continuous training group (exercise intensity of 70% of peak heart rate) or aerobic 
interval training (95% of peak heart rate) three times per week for 12 weeks or to a 
control group. Peak oxygen consumption increased more with aerobic interval 
training than moderate continuous training (46% vs.14%, p<0.001), and was 
associated with reverse left ventricular remodelling (left ventricular end-diastolic and 
end-systolic volumes declined with aerobic interval tr ining only, by 18% and 25%, 
respectively). The authors concluded that exercise intensity is an important factor for 
reversing left ventricular remodelling and improving aerobic capacity. Finally, that 
interval training leads to more pronounced improvement in central haemodynamics 
compared with continuous exercise has been shown by Necwatal et al. (2002). Effect 
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of exercise on central adaptation in CHF patients will be detailed below in section 
10.2.3.       
10.2.2.2 Resistance exercise training in CHF patients  
Additionally to central and peripheral abnormalities described above, skeletal muscle 
atrophy may also contribute to the reduced exercise apacity in CHF patients 
(Williams et al., 2004). These patients also exhibit reduced muscle strength due at 
least partly to the significant muscle atrophy (Harrington and Coats, 1997). 
Conversely to aerobic exercise training, which has little influence on muscle mass 
(Meredith et al., 1989), resistance training is an exercise modality that has the most 
potential to increase muscle mass which appears to affect exercise capacity in CHF 
patients (Williams et al., 2004). Moreover, it has been reported that muscle strength, 
and specifically leg strength, is a parameter that independently predicts survival in 
patients with severe CHF (Hulsmann et al., 2004).          
Resistance training has traditionally been discouraged due to concerns for furthering 
impairment of left ventricular function and adverse left ventricular remodelling 
caused by increased afterload and blood pressure during lifting phase (Braith and 
Beck, 2008). In reality, however, due to the low intensity at which patients with CHF 
perform resistance training, the haemodynamic responses do not exceed levels 
attained during standard treadmill testing (McKelvi et al., 1995) and adverse left 
ventricular remodelling after resistance training has not been demonstrated (Pu et al., 
2001). Moreover, performance of the left ventricle during strength testing and 
resistance training has been assessed by echocardiogr phy. Most studies agree that 
absolute haemodynamic responses (heart rate, systolic blood pressure, ejection 
fraction, cardiac output, left ventricular end-diastolic volume) are higher during 
treadmill testing than during strength testing or resistance training (at least up to 15 
repetitions at up to 60% of one maximal  repetition) (Delagardelle et al., 1999; 
Delagardelle et al., 2002; Karlsdottir et al., 2002; Levinger et al., 2005; McKelvie et 
al., 1995; Pu et al., 2001; Werber-Zion et al., 2004). Additionally, it has been shown 
that during rhythmic double leg press exercise (at lo ds of 60% and 80% maximum 
voluntary contraction using interval modes with 60 s work phases of 12 repetitions 
each and 120 s rest phases) CHF patients demonstrated increased left ventricular 
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stroke work index and decreased systematic vascular resistance, suggesting enhanced 
left ventricular function (Meyer et al., 1999). This might be due to a rhythmic 
sequence of submaximal isometric muscle contractions, which help to maintain 
venous return, reduce systemic vascular resistance, maintain blood flow, and meet 
muscle metabolic need (Working Group Report, 2001).    
In CHF patients there is a global reduction of muscle mass, even in mild CHF 
patients, and further reduction in mass are associated with severity of disease 
(Mancini et al., 1992; Minoti et al., 1993). Decreas d muscle mass could potentially 
explain the observed exercise intolerance in CHF and correlations studies have shown 
a link between muscle volume and exercise capacity in CHF patients (Harrington and 
Coats, 1997). However, there is evidence that muscle mass only partially influences 
endurance (Mancini et al., 1992) and strength (Minotti et al., 1993) in patients with 
CHF. Nonetheless, resistance training, as previously mentioned, has potential to 
increase muscle mass in CHF patients (Baith and Becks, 2008).  
Resistance training independently improves both aerobic (oxidative) and anaerobic 
(glycolytic) performance of skeletal muscle (Braith et al., 2005). Six months of 
resistance training independently increased both citrate enzyme, a marker of oxidative 
(i.e. aerobic) Kreb’s Cycle activity, and lactate dehydrogenase, a marker of glycolytic 
(i.e. anaerobic) activity (Braith et al., 2005). Additionally, it has been suggested that 
resistance training may influence changes in muscle morphology caused by the heart 
failure. This includes shift from glycolytic type II fibre toward oxidative type I fibre 
in patients who suffer skeletal muscle myopathy (Braith et al., 2005). Regarding 
cardiac function, is has been found that resistance training elicited improvements in 
left ventricular ejection fraction (LVEF) by 13% and 17.8% (Feiereisen et al., 2007; 
Levinger et al., 2005). Levinger et al. (2005) asses ed the effects of eight weeks 
resistance training on the left ventricular structure and function in CHF patients. This 
study revealed that resistance training does not cause  reduction of left ventricular 
contractility function as measured by ejection fraction and fractional shortening. 
Compared with the control group, the resistance training group also elicited an 
increase in stroke volume by 13.1%, measured at rest. 
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Feiereisen et al. (2007) compared the efficacy of three training modalities on peak 
oxygen consumption in three groups of 15 patients wi h CHF. Patients underwent 
either resistance training, aerobic training, or combined aerobic plus resistance 
training during 40 sessions, three times weekly for 45 minutes. Surprising result of the 
study was that the three exercise modes were comparably effective in improving peak 
oxygen consumption (resistance group +16.7%, aerobic group +11.1%, and combined 
group +14.2%). Additionally, resistance training elicited significant improvements in 
peripheral muscle strength but aerobic training did not. The 16% increase in peak 
oxygen consumption is remarkable, since in healthy, sedentary individuals, resistance 
training increases peak oxygen consumption by only 3% (Tanaka and Swensen, 
1998). This finding is in accordance with the literature, where others have shown that 
patients with CHF achieve 10-18% increases in peak oxygen consumption during 
resistance training and 15-20% after aerobic training (Meyer, 2006). A significant 
increase in peak oxygen consumption (14.5%) was observed after 12 weeks of 
training using weight collars in patients with CHF awaiting heart transplantation 
(Grosse et al., 2001). In contrast, others have report d no improvement in peak 
oxygen consumption despite lower oxygen consumption at submaximal workloads 
after 11-week resistance training in patients with moderate CHF (mean EF: 26%, 
NYHA class II-III) and significant improvement in ex rcise time (13%) (Pu et al., 
2001) and maximal exercise capacity (10%) (Magnusson et al., 1996) in patients with 
CHF after 8 weeks of resistance training.  Interestingly, one study reported that leg 
strength accounted for 81% of the variability in peak oxygen consumption among 
heart transplant recipients but only accounted for 42% of the variability in healthy 
age-matched controls (Braith et al., 1993). Thus, peak oxygen consumption in 
individuals with normal leg strength is likely to be restricted by cardiovascular 
reserve, whereas in patients with CHF myopathy phenotype of leg muscles may be a 
primary factor limiting aerobic power (Okita et al., 1998; Vescovo et al., 1998). 
10.2.2.3 Combined (aerobic plus resistance) exercise training in CHF patients   
Although confounded by utilization of two exercise modes, comparative studies have 
shown that the combination of resistance and aerobic exercise training results in better 
adaptation of peak oxygen consumption than aerobic tra ning alone. Maiorana et al. 
(2000) found increases in peak oxygen consumption of 13% following a 12-week 
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combined exercise training in CHF patients (mean EF: 26%, NYHA class I-III). 
Delagardelle et al. (1999) also used combined exercise training for 24 weeks in 
outpatients with CHF (mean EF: 36%, NYHA class II) and observed a 10% increase 
in peak oxygen consumption. In a follow-up study, the same authors randomized 
patients into either aerobic or combined exercise training (Delagardelle et al, 2002). 
Peak oxygen consumption was significantly increased during combination training 
(+7.8%) but remained unchanged (+0.2%) in the group that performed only cycling. 
Selig et al. (2004) reported a 21% improvement of peak oxygen consumption in a 
prospective, randomized study after three months of combined exercise training in 
CHF patients (mean EF: 27%, NYHA class II-III). It has been suggested that 
combined training improves both oxidative and glycoitic skeletal muscle capacity 
(Braith and Beck, 2008), increases the cross-sectional area of skeletal muscles 
(Belardinelli et al., 1995), and improves neuromuscular function, all leading to a 
significant increase in muscle strength and endurance (Braith and Beck, 2008; 
Williams et al., 2007).     
10.2.3 Central Adaptation to Exercise Training in CHF patients  
Since data about central adaptation to resistance training in CHF patients are limited, 
only adaptations to aerobic training will be described. In comparison with a great 
number of studies which assessed skeletal muscle adaptation to exercise training 
programmes, relatively few papers (eight) have studied the cardiac output response to 
aerobic training in CHF patients (Belardinelli et al., 1995; Belardinelli et al., 1996; 
Coats et al., 1992; Dubach et al., 1997; Hambrect et al., 1995; Hambrecht et al., 2000; 
Necwatal et al., 2002; Sullivan et al., 1988). Small number of studies which evaluated 
central adaptation to exercise training is mainly due to methodological issues, as the 
gold standard for cardiac output measurement is right heart catheterization, an 
invasive procedure with possible risks for the patients. Since new, non-invasive, easy 
to use methods for measurement of cardiac output have become available over the last 
years (e.g. inert gas rebreathing, bio-reactance), the previous fact regarding 
methodological limitations should not be used as a strong argument for lack of central 
heamodynamic measurements in CHF patients. Nonetheless, the authors of the 
previously mentioned “muscle hypothesis” (Clark et al., 1996) concluded their work 
saying that measurement of central haemodynamics is not unimportant as in the 
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genesis of the heart failure “an initial cardiac abnormality is essential”.  
Most of the above mentioned studies have demonstrated  significant increase of 
cardiac output at peak exercise with respect to pre-training values. As is well known, 
cardiac output is the product of heart rate and stroke volume. Therefore, the increase 
of cardiac output could be due to different combinations of heart rate and stroke 
volume relative changes, with significant increase only in stroke volume (Nechwatal 
et al., 2002), of heart rate only (Hambrecht et al., 1995), of both volume and heart rate 
(Coats et al., 1992), or with little, not significant increases of both resulting in a 
significant increase of their product (Dubach et al., 1997). It has also been shown that 
central adaptation to aerobic exercise training is po sible in patients with severe heart 
failure (NYHA class III). Failure to demonstrate a significant improvement in peak 
cardiac output is often associated with a weaker study design (Belardinelli et al., 
1995; Sullivan et al., 1988) and lower training inte sities (Belardinelli et al., 1995).  
Evidence available so far suggests there are only two meta-analyses which assessed 
the effect of exercise training on cardiac function in heart failure patients. Van Tol et 
al. (2006), using a meta-analysis, assessed the effects of exercise training on cardiac 
performance. From 35 randomized controlled trials, 24 used aerobic exercise 
programmes (either continuous or interval or both), eight used combined and only 
three resistance exercise programmes. The average training period lasted for 13 weeks 
with a mean duration of 50 minutes per session and an average frequency of four 
times per week. Results revealed that resting diastol c blood pressure and end-
diastolic volume showed a significant improvement following exercise intervention, 
decreasing by 2.7% and 1.2%. A decrease in resting heart rate (by 2.6 beats.min-1 or 
3.3%) and an increase in resting cardiac output and LVEF by 6.4% (0.32 l.min-1) and 
by 2.9% was not statistically significant. During maximal exercise, however, heart 
rate, systolic blood pressure and cardiac output increased significantly after exercise 
training by 2.5% (3.5 beats.min-1), by 3.3% (5.4 mmHg) and by 21.1% (2.51 l.min-1), 
respectively. A decrease in diastolic blood pressure of 3.2% (2.9 mmHg) was not 
significantly different and there were insufficient data to obtain results of the left 
ventricular ejection fraction during exercise. It should be noted that the above 
mentioned data have been collected during pre-beta-blockers era. Consequently, the 
effect of beta-blocking therapy on the cardiac output response to aerobic exercise has 
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not been well studied. However, some studies have demonstrated an improvement of 
peak oxygen consumption after aerobic training in CHF patients on beta-blockers 
similar to that of patients off these drugs (Curnier et al., 2001; Forissier et al., 2001). 
Given the above, and if one assumes that beta-blockers are not expected to 
significantly modify peripheral oxygen extraction, the linear relationship between 
relative changes in cardiac output and peak oxygen consumption should be preserved 
also in beta-blocked CHF patients (Mezzani et al., 2008). The only available study 
evaluating the cardiac output response to aerobic tra ning in CHF patients on beta-
blockers seems to confirm this hypothesis, at least in patients undergoing interval 
training sessions (Nechwatal et al., 2002).      
The second meta-analysis, performed by Haykowsky et al. (2007), assessed the effect 
of exercise training on left ventricular remodelling on heart failure patients. Fourteen 
randomized trials were identified. Most (nine) incorp rated aerobic training at 
intensity between 60% and 80% of baseline peak oxygen consumption for 20 to 60 
minutes per session. Four trials examined the effect of ombined strength and aerobic 
training, and one trial examined strength training alone. The length of the training 
programme varied between two and 12 months. The results from aerobic trials 
demonstrated that exercise training was associated wi h improvement in LVEF (~3%) 
whereas combined or resistance training did not show t is improvement. Furthermore, 
whereas aerobic exercise training was associated with a significant decrease in end-
diastolic and end-systolic volumes (by ~11 ml and ~13 ml), the effects of combined 
aerobic and strength training were inconclusive. The authors suggested that aerobic 
exercise training reverses ventricular remodelling i  clinically stable heart failure 
patients. Moreover, it has been suggested that favour ble changes in left ventricular 
volume and ejection fraction associated with aerobic training were supplementary to 
pharmacological benefits; that is they occurred despit  the patients being prescribed 
medications with a proven anti-remodelling effect.      
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10.2.4 Principles of Exercise Prescription in CHF Patients  
According to Myers (2008) exercise prescription essentially describes the process 
whereby a person’s recommended regimen of physical a tivity is designed in a 
systematic and individualized manner. This implies specific strategies to optimize 
return to work or activities of daily living, reduction of risk factors for future cardiac 
events, and maximization of the patient’s capacity to maintain an active lifestyle 
(Myers, 2008). Most patients with reduced left ventricular function who are clinically 
stable and have reduced exercise tolerance are candidates for exercise programmes 
(Pina te al., 2003; Working Group Report, 2001). Stability can be assured by the 
absence of recent changes in body weight, the absence of recent changes in 
symptoms, and control of comorbid conditions (Myers, 2008). Is seems that, the 
benefits of exercise training are not dependent on the aetiology of CHF, or standard 
clinical measures such as baseline peak oxygen consumption or ejection fraction 
(Myers, 2000; Working Group Report, 2001). Absolute and relative contraindications 
to exercise specific to CHF patients are summarised in table 10.1. 
The major principles of exercise prescription are mode (type), frequency, duration, 
and intensity of exercise. These principles apply to healthy but also to diseased 
populations. An exercise prescription must consider th  patient’s goals, health status, 
and availability of time in addition to practical consideration such as cost, availability 
of equipment and facilities. Additionally the overload, specificity and reversibility 
principles are key considerations in developing an effective exercise programme 
(Arena et al., 2008). The overload principle relates o the fact that the training 
stimulus must be greater than what the physiological systems (e.g. cardiovascular and 
skeletal muscle) are accustomed to, for positive change to occur. The specificity 
principle states that physiological improvements are unique to the mode of exercise 
performed. Lastly, the reversibility principle states that positive training adaptations 
are not maintained if an individual returns to a sedentary behaviour pattern of life 
style. There is no single programme that is the best for all patients or even one patient 
over the time. Therefore, the development of an appropriate exercise prescription to 
meet the individual patient’s needs has a sound scientific foundation, but there is also 
an art to effective exercise programming (Myers, 2008).  
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Table 10.1 Relative and Absolute Contraindications to Exercise Training Among 
Patients with Stable CHF (Working Group Report, 2001) 
Relative contraindications 
1. ≥1.8 kg increase in body mass over previous 1-3 days 
2. Concurrent continuous or intermittent dobutamine therapy 
3. Decrease in systolic blood pressure with exercise 
4. New York Heart Association Class IV 
5. Complex ventricular arrhythmias at rest or appearing with exertion 
6. Supine resting heart rate ≥100 beats.min-1 
7. Preexisting comorbitis 
 
Absolute contraindications 
1. Progressive worsening of exercise tolerance or dyspnoea 
    at rest or on exertion over previous 3-5 days 
2. Significant ischaemia at low work rates (<2 METS, or ~50 W) 
3. Uncontrolled diabetes 
4. Acute systematic illness or fewer 
5. Recent embolism 
6. Thrombophlebitis 
7. Active pericarditis or myocarditis 
8. Moderate or severe aortic stenosis 
9. Regurgitant valvular heart disease requiring surgery 
10. Myocardial infarction within previous three weeks 
11. New onset atrial fibrillation 
The general frequency, duration and intensity recommendations for aerobic exercise 
in CHF patients are 3-5 days per week, 30-60 minute and 50-80% of maximal aerobic 
capacity (Myers, 2008; Pina et al., 2003). Previously it has been suggested that 
training intensity does not seem to influence the magnitude of the increase in exercise 
tolerance directly (Meyer et al., 1996). More recently, however, Wisloff et al. (2007) 
demonstrated that higher intensity interval training led to more functional 
improvement than that obtained with lower continuous type of training. The exercise 
intensity may be expressed as % of peak oxygen consumption, % of peak heart rate 
and a rate of perceived exertion. In terms of peak oxygen consumption, an intensity of 
40-80% of peak oxygen consumption was applied succesfully (Pina et al., 2003; 
Working Group Report, 2001). Since intensity and duration of exercise training are 
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closely interrelated in terms of training effect exp cted, low intensity can partly be 
compensated by the training sessions of longer duration, or higher frequency. In terms 
of using heart rate it has been suggested that exercise intensities of 60-80% heart rate 
reserve and 60-80 % of peak heart rate (Working Group Report, 2001) should be 
applied. It has been further suggested that exercise intensities ranging from 40-80% of 
peak oxygen consumption, are generally equivalent to 50-90% of the maximal heart 
rate (Pollock et al., 1998). However, heart rate-derived exercise intensities may be 
inaccurate in advanced CHF patients (Pina et al., 2003). In the current era of β-
blockers, heart rate alone as a measure of intensity may not be practical, particularly 
in patients with atrial fibrillation (Schuchert, 2005). Therefore, the Borg scale of rate 
of perceived exertion (scores from 6 to 20) (Borg, 1970) can be quite useful in 
prescribing exercise intensity, especially in patients on β-blockers (Pina et al., 2003). 
Exercise intensities corresponding to a perceived exertion level between 12 and 14 
(13 somewhat hard) have been shown to be well-tolerated and associated with 
favourable training responses in patients with CHF (Keteyian et al., 1996). In addition 
to aerobic exercise, interval training seems to be beneficial in CHF patients. This is 
the mode of exercise in which short bouts of work phases in repeated sequences are 
followed by short recovery phases. Work phases of 30 seconds and recovery phases of 
60 seconds are useful, using an intensity of 50% of maximum short term exercise 
capacity for work phases. During the recovery phase patients may perform exercise at 
a lower intensity (Working Group Report, 2001). Although cycle egrometry is 
preferred for applying interval training, this method can also be performed on a 
treadmill, or even other devices which allow aerobic exercise (e.g. skiing machine, 
stepper). In this case, a practical way is to choose work and recovery phases of 60 
seconds each (Working Group Report, 2001).    
Regarding resistance exercise training in CHF patients, it has been usually performed 
in the form of circuit training (Braith and Beck, 2008). According to this method there 
are several working stations on which patients perform exercise followed by a resting 
period. Common exercises include leg press, knee ext nsion, bicep curls, etc. To 
approximate the appropriate limb-specific weight load for resistance training, 
Williams et al. (2007) recommended determination of the maximum weight that can 
be used to complete 1-RM (one repetition maximum) for a given exercise. An initial 
intensity that corresponds to 30% to 40% of 1-RM for the upper body and 50% and 
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60% of 1-RM for the hips and legs is recommended (Williams et al., 2007). 
Recommendations for designing resistance training programmes for patients with 
CHF are summarized in Table 10.2 according to the available literature (Braith and 
Beck, 2008).             
Each exercise session should include the warm-up period (10 to 15 minutes), followed 
by the main part of training (20 to 30 minutes) at the desired intensity. A cool-down 
period is also advised (Pina et al., 2003). Most studies used three to five times per 
week as the optimal training frequency. Although the first benefits of aerobic exercise 
in CHF patients are seen after just three weeks of the exercise programme (Meyer et 
al., 1996a), most of exercise programmes varied from eight to 24 weeks (Working 
Group Report, 2001).   
 
Table 10.2 Recommendations for Designing Resistance Training Programs for 
Patients with CHF (Braith and Beck, 2008)   
Characteristic NYHA class I NYHA class II and III 
Frequency 2-3 days/week 1-2 days/week 
Duration 10-30 min 15-20 min 
Intensity 50-60% 1RM 40-50% 1RM 
Contraction speed 6 s (3 concentric+3 eccentric) 6 s (3 concentric+3 eccentric) 
Work: rest ratio (duration) 60 s or longer (1:2) 60 s or longer (1:2) 
Number of exercise stations 4-9  3-4  
Number of sets per station 2-3  1-2  
Number of repetition per set 6-15  4-10  
Involve muscle mass Unilateral and/or bilateral Unilateral and/or bilateral 
Mode of training Segmental training mainly,  
then whole body training  
when/if tolerated 
 
Segmental training during the  
introductory phase (first 
months) whole body training 
rarely, when  tolerated  
Flexibility Daily as tolerated Daily as tolerated 




Finally, the need for monitoring prescribed exercise programmes in CHF patients has 
not been systematically studied (Pina et al., 2003). The design of most studies ranged 
from monitored to supervised to home based exercise without supervision. It has been 
recommended that the setting should be one of direct monitoring and supervision, 
especially during initial training sessions (Haskell, 1994). A supervised programme 
allows for education, including advice on recognition of symptoms, nutrition 
guidelines, the disease process, and the importance of ompliance (Haskell, 1994). 
Home training should follow this early supervised period, which may vary from 
patient to patient according to the level of deconditioning and disease stability (Pina et 
al., 2003).   
10.2.5 Rationale and Purposes of the Study 
As detailed above, both aerobic and resistance exercise programs may improve 
exercise capacity, represented by peak oxygen consumption and exercise duration, in 
patients with CHF. Additionally, it has been demonstrated that aerobic exercise 
training may even reverse left ventricular remodelling and improve cardiac function in 
heart failure patients (Haykowski et al., 2007; vanTol et al., 2006).  
The effect of exercise training on cardiac power output so far has only been evaluated 
in a few studies, none of which recruited patients with stable CHF. Marshal and 
colleagues (2001) assessed healthy middle-aged individuals and Hodges et al. (2008) 
patients with atherosclerotic disease. Furthermore, Wright et al. (2002) assessed the 
effect of exercise on cardiac function in patients following coronary bypass surgery, 
whereas Patwala et al. (2006) assessed whether exercise rehabilitation enhances the 
benefits of cardiac resynchronisation therapy. Finally, Carroll et al. (2007) evaluated 
the effect of lifestyle intervention on peak cardiac power output and reserve in 
premenopausal obese women.    
Although a few studies evaluated the effect of aerobic exercise on peak cardiac output 
(Mezzani et al., 2008), it appears that a limited number of studies, if any, assessed the 
effect of resistance training on central heamodynamic measures such as cardiac output 
or cardiac power output. Therefore, the first purpose f the present study was to assess 
the effect of aerobic and resistance exercise programs on cardiac power output and 
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other central haemodynamic measures. Secondly, the study evaluated the effect of the 
two exercise programmes on peak oxygen consumption and selected cardio-
respiratory variables obtained from gas exchange measur ments.      
10.2.6 Research Hypotheses   
H1 – There will be a non-significant effect of either aerobic or resistance exercise on 
resting heamodynamic or metabolic measurements.     
H2 – There will be a significant improvement in maximal cardiac pumping capability 
following aerobic, but not following resistance exercise program. 
H3 – There will be a significant improvement in peak oxygen consumption and 
selected cardio-respiratory variables following both, aerobic and resistance exercise 
program.  
10.3 Methods 
10.3.1 Study Design 
The study was originally proposed to be a prospectiv , randomized trial to assess the 
effect of two different 12-week exercise programmes (aerobic and resistance) on 
cardiac power output and selected cardio-respiratory va iables. The present study was 
part of the clinical trial “Cardiac power output, heart rate variability and heart rate 
recovery in response to exercise training in heart failure patients” approved by the 
Hounslow and Hillingdon NHS Research Ethics Committee in March 2007. 
Originally proposed number of patients was 72 (36 to perform exercise: 18 aerobic 
and 18 resistance patients, and 36 to be control).  
The sample size was calculated for each key variable (cardiac power output, heart rate 
variability and heart rate recovery). Sufficient sample size that provides high power of 
the study for cardiac power output was half of the above mentioned number (detailed 
below in 10.3.4). However, from the aspect of heart rate variability sample size of 72 
was needed.   
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The project commenced in July 2007 and finished at the end of December 2008. The 
initial list of patients available to take part in the study included six patients only. The 
control group has been postponed due to concerns expressed by the panel member of 
the above mentioned Ethics Committee. They stressed that every patient should be 
offered to take part in exercise programme. According to them, control group may 
include those patients who do not want to exercise, or due to some other reasons (e.g. 
work commitments) are not able to participate in an exercise programme.     
After six months, the researchers realized that the number of patients already recruited 
and involved in cardiac rehabilitation was dramatically below that expected and 
originally proposed. Following consultation with the principal investigator (DAB) and 
cardiologist (RGM), is was decided to do a cross-over study in order to increase the 
number in each group. This was approved by the above mentioned Ethics Committee. 
In order to ensure more patients, there was an attemp  to recruit patients from other 
local hospitals (Wexham Park Hospital, Wycombe General Hospital). Due to travel 
costs and time issues, certain contacted patients (N=7) were not able to undertake the 
exercise programme, nor used as controls.            
Not all patients recruited were able to complete th cross-over study design, mostly 
due to time issues. Therefore, the originally proposed prospective, randomized trial, 
study was changed to a prospective, treatment only randomized, semi cross-over 
design. A proper randomization into aerobic or resistance group, with a computerized 
random numbers table, was undertaken only on the first s x patients available at the 
beginning of the project and before baseline tests were performed. As this was 
“rolling programme” each new available patient was allocated into the aerobic or 
resistance group consequently. This was the only way to ensure the same number of 
patients in each group.  
In this study design each patient was tested twice before starting the exercise 
programme and following 12 weeks of exercise training. Two baseline 
cardiopulmonary exercise tests were undertaken to ensur  the reliability of 
measurements (Chapter 9). The average of two measurements was taken as the 
baseline. All patients who underwent the cross-over d sign had a 12-week “non-
exercising” period. Before and after the “non-exercising” period patients performed a 
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cardiopulmonary exercise test.   
10.3.2 Patients 
The study group consisted of 16 stable chronic heart failure patients (13 men, 3 
women; mean±SD age 64±10 years) randomized into aerbic (N=8) or resistance 
group (N=8). Patients’ demographic and clinical characteristics and medications are 
presented in table 10.3, according to the report by Dr RGM. Medications were not 
altered during the study. Inclusion criteria were reduced left ventricular ejection 
fraction (<40%) as assessed by echocardiography, and New York Heart Association 
(NYHA) class I and II. Additionally, all patients had to be in a clinically stable 
condition and on the same dose of optimal drug therapy for at least two months before 
entry in to the study. Exclusion criteria were exercise-induced myocardial ischaemia 
or uncontrolled arrhythmias, valvular heart disease, congestive heart failure, 
uncontrolled hypertension (resting systolic blood pressure above 160 mmHg, and/or 
resting diastolic blood pressure above 105 mmHg), peripheral vascular disease, 
chronic obstructive pulmonary disease and orthopaedic or other condition precluding 
regular participation in exercise sessions. All patients gave informed written consent 



















Age (yrs)  65±12 63±10 0.64 
Weight (kg)  74±15 78±18 0.54 
Height (cm)  171±11 172±12 0.98 
BMI (kg/m2)  25±4 26±5 0.36 
BSA (m2)  1.86±0.25 1.91±0.26 0.66 
LVEF (%)  31±6 28±5 0.69 
NYHA I/II  4/4 3/5  
Men/Women  5/3 6/2  
Aetiology:         
IHD  1 2  
  DCM  7 6  
     
Medication:  N of patients  N of patients  
ACE inhibitors  5 6  
β-blockers  6 7  
Diuretics  4 2  
ARBs   2 1  
Digoxin  3 2  
Antiarrhythmics  3 5  
Aspirin   2 5  
Warfarin  2 1  
Spironolactone  1 1  
BMI-body mass index, BSA-body surface area, LVEF-left ventricular ejection 
fraction, NYHA-New York Heart Association, IHD-ischaemic heart disease, DCM-
dilated cardiomyopathy, ARBs-angiotensin II receptors blockers.      
 
10.3.3 Testing Procedure and Exercise Programme   
The testing procedure is detailed in the previous Chapter of this thesis, section 9.2.3. 
Briefly, each patient undertook two baseline cardiopulmonary exercise tests (modified 
Bruce protocol) one week apart. Metabolic and ECG data were recorded from the 
Cardio 2O  metabolic analyser (Medical Graphics Corporation, Minnesota, USA) at 
rest and throughout the exercise test. Cardiac output was measured at rest and at peak 
exercise using the inert gas rebreathing methodology (Innocor, Innovision, Denmark). 
Blood pressure was also measured at rest, during and at peak exercise. The mean 
value of two exercise tests for all analyzed variables was taken as a baseline value in 
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the current study.       
The exercise training programmes, both aerobic and resistance, included five sessions 
per week for a period of 12 weeks. One session was undertaken in Hillingdon 
Hospital Cardiac Rehabilitation Unit and this was a supervised exercise session which 
occurred every Monday during a 12-week exercise program. Additional four exercise 
sessions were performed at home (home based exercise) according to instructions 
provided by researchers (see below). Patients were ask d to complete a daily exercise 
diary which was analysed every Monday just before a supervised exercise session. 
Before each supervised exercise session “pre-exercise” assessment was undertaken 
(e.g. measurement of blood pressure, health status, medication, home exercises 
adherence, etc.) Each supervised exercise session lasted between 50 and 60 minutes. 
This included a warm-up period (10-15 minutes), themain part of the training – 
aerobic or resistance exercise (25-35 minutes) and a cool-down period and stretching 
(10-15 minutes), with a further 15 minute post exercise monitoring period. The first 
session for each participant was a learning session where the correct technique and 
exercise intensities were demonstrated. For those partici ants who were severely de-
conditioned, initial exercise intensity was set at approximately 40-50% of peak 
oxygen consumption, with a Rating of Perceived Exertion (Borg Scale) set at 11 – 12. 
An interval approach was used to ensure periods of active recovery which allowed the 
participant to exercise for longer. Participants who had a greater baseline peak oxygen 
consumption were encouraged to exercise approximately 60-80% of peak oxygen 
consumption, with a Rating of Perceived Exertion set between 11 – 13. The exercise 
prescription were progressed individually, as condition ng took place, with the 
emphasis placed on duration before intensity.    
10.3.3.1 Aerobic exercise programme 
The circuit aerobic training consisted of two circuts, each including seven cardio-
vascular stations (e.g. treadmill, bike I, cross-trainer (ski-machine), backward lunges, 
bike II, step-ups, and mini-trampoline). The work – rest ratio intervals started as 1:1 
(60 seconds of exercise followed by 60 seconds of active recovery), with further 
change in ratio to 1.5:1 as conditioning took place. Active recovery was performed off 
the exercise station and included low intensity exercis  (e.g. marching on spot). 
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Exercise intensity was between 40 and 50% or between 60 and 80% of maximal 
aerobic capacity, depending on initial peak oxygen co sumption. In most of the 
patients this was equivalent to the Borg scale of between 11 – 12 and 12 – 13, as 
indicated during the baseline tests. The level of exercise intensity (rate of perceived 
exertion) was monitored on each exercise stations at 30 nd 60 seconds by the use of 
the Borg scale, and periodic adjustments of exercis intensity were made according to 
individual exercise-capacity progression. 
Home based aerobic exercise training (four days per week) essentially included a 
brisk walk taking between 20 and 40 minutes with a rate of perceived exertion of 11 
to 13 (Borg scale). The first few weeks of exercise training duration were shorter (e.g. 
20 minutes) with further increases in duration according to individual exercise-
capacity progression. Each training session could be broken down into 15 or 10 
minute segments if necessary in order to keep the required intensity level.        
10.3.3.2 Resistance exercise programme 
Resistance exercises included the use of body weight xercise, various strength of 
therabands, light hand and leg weights. Specifically, circuit resistance training 
consisted of two circuits, each included six exercise stations (e.g. biceps curls, calf 
raises, wall chest press, leg extension, lateral raises and hamstring curls). The 
principle of work – rest ratio intervals were the same as in the aerobic group. Active 
recovery was performed off the exercise station and included low intensity exercise 
(e.g. marching on spot). The exercise intensity targeted 12 to 15 repetitions per 
exercise station with sufficient weight that the patient score results were between 11 
and 13 on the Borg scale. Exercise progressions were introduced gradually either by 
increasing the intensity (weight) or the number of sets for a given intensity.  The level 
of exercise intensity was monitored at the end of each exercise, and periodic 
adjustments of exercise intensity were made according to individual exercise-capacity 
progression. 
Home based resistance exercise (four sessions per week) of 30 minutes consisted of 
warm up and stretch (five to six minutes) followed by resistance exercises mentioned 
above with a work-rest ratio 1:1 (60 seconds of exercis  followed by 60 seconds of 
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active recovery).    
10.3.4 Study Power, Calculations and Statistical Analysis 
The present study proposed to assess cardiac power output (CPO) before and after a 
12 week exercise intervention period in patients with stable chronic heart failure. 
Sample size was calculated a priori (Faul et al., 2007) for a two-sided test where 
alpha and beta were 0.05 and 0.8, respectively. Due to the nature of cardiac power 
output measurements values, the majority effects that are observed are small and 
ranged from 0.34 (Wright et al., 2002) to 0.87 W (Patwala et al., 2006). This study 
proposed high statistical power (0.8 or more). Patwala et al. (2006) assessed CPO in a 
group of cardiac patients before and after exercise int rvention (N = 14). In the 
exercise group, CPO increased from 2.46 (0.23) W to 3.33 (0.26) W. Calculated effect 
size for pre/post CPO in rehab group was 3.54 (high effect size). The power of the 
study was high (Beta = 1). Based on this study it seems that 10 subjects per exercise 
group will provide a high power of the study (0.92).          
The cardiac power output was calculated from the product of cardiac output and mean 
arterial pressure using the following equation (Cooke et al., 1998): CPO = (TQ&  x 
MAP) x K, where CPO is cardiac power output in Watts (W), TQ&  is cardiac output in 
l .min-1, MAP is mean arterial pressure in mm Hg and K is the conversion factor (2.22 
x 10-3). The physiological cardiac reserve is equal to the difference in between peak 
CPO and baseline resting CPO (Cooke et al., 1998). The mean arterial pressure was 
calculated as DBP + 0.412 x (SBP – DBP), where SBP is systolic blood pressure and 
DBP is diastolic blood pressure (Meaney et al., 2000). Systematic vascular resistance 
to blood flow (SVR) at peak exercise was estimated as MAP/ TQ&  and as per 
convention multiplied by a factor of 80 to convert units to dyn.s-1.cm-5. Peak exercise 
arteriovenous O2 content difference (a-v O2dif.), expressed as vol.%, was calculated 
as ( 2OV& peak/ TQ& peak) x 100.    
All statistical analysis was carried out using SPSS version 13.0 (SPSS inc. Chicago, 
Illinois, USA). Prior to statistical analysis, data were checked for univariate and 
multivariate outliers using standard Z-distribution cut-offs and Mahalanobis distance 
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tests respectively. Normality of distribution was asessed using a Kolmogorov-
Smirnov test. The difference between the groups at baseline level was identified using 
independent -tests or Mann Whitney U test, as appropriate. Furthermore, a repeated 
measures analysis of variance was constructed to analyse the effect of primary interest 
by time (pre and post) for each group and was also used to examine the effect of 
treatment (aerobic and resistance) over time (pre and post) between the two group. 
Where significant main effect (group or time) were id ntified, paired or unpaired t-
tests as appropriate, were used to locate the specific ffects (Williams et al., 2007). A 
p value of less than 0.05 was designated to indicate statistical significance. If 
significant change was found before and after exercis  intervention in peak cardiac 
output, peak oxygen consumption and peak arteriovenous O2 content difference, than 
Pearson’s moment of correlation was used to assess th  relationship between exercise-
induced-changes in the aforementioned variables. All data are presented as means 
±SD unless otherwise indicated. As this was not fully crossed-over study design (only 
three and two patients crossed-over from one to the ot r group), recommended 
procedure for cross-over study design by Hills and Armitage (1979) has not been used 
due to insufficient number of patients in each group (two and three). These data are 
graphically presented. 
10.4 Results 
10.4.1 Pre Training Comparison 
All 16 patients completed the exercise programme and five patients took part in the 
cross-over design following a 12-week “non-exercising” period. Three patients from 
the resistance training group crossed over to the aerobic training group following a 
“non-exercising” period of 12-weeks. Similarly, two patients from aerobic exercise 
group crossed over to resistance exercise training group following a “non-exercising” 
period. This increased the number of patients in each group; the aerobic group 
consisted of 11 (three female), whereas the resistance group consisted of 10 (two 
female) patients. During the exercise programme patients remained in a clinically 
stable condition without changing their medication. Overall attendance at the exercise 
sessions was very good, and patients from both aerobic and resistance exercise group 
performed ~90% of planned exercise sessions.      
 333 
No significant differences were found pre training between the groups for age and 
body anthropometry (Table 10.3). Additionally, no significant difference between 
aerobic and resistance exercise group was found for any heamodynamic or metabolic 
variables measured at rest or at peak exercise, respectively (Table 10.4).  
 
Table 10.4 Baseline Resting and Peak Exercise Haemodynamic and Metabolic 
Measurements   
    Sitting at rest  Peak exercise 














Haemodynamics        
CPO (W)   0.74±0.21 0.77±0.25 0.50  2.56±1.78 2.58±0.82 0.39 
HR (beats.min-1)  60±9 63±11 0.51  125±25 123±28 0.58 
TQ&  (l.min-1)  3.7±1.1 3.8±1.1 0.81  11.1±6.7 10.9±4.1 0.27 
SV (ml.beat-1)  63.2±19.1 60.4±15.3 0.71  89.6±51.5 88.2±29 0.48 
DBP (mm Hg)  73±8 72±9 0.18  71±11 76.7±11.2 0.22 
SBP (mm Hg)  116±15 117±12 0.44  146±25 147±22 0.86 
MAP (mm Hg)  91±10 92±7 0.23  102±15 106±14 0.55 
CR (W)  - - -  1.82±1.22 1.78±0.43 0.26 
         
Metabolics        
2OV&  (ml.min-1)  285±79 331±106 0.26  1778±861 1726±610 0.87 
2OV&  (ml.kg-1.min-1)   3.9±0.7 4.2±1.0 0.50  23.3±6.5 22.2±5.3 0.63 
2C
O
V&  (ml.min-1)   210±69 258±85 0.17  1879±902 1822±651 0.79 
RER  0.73±0.10 0.78±0.11 0.27  1.06±0.1 1.07±0.1 0.56 
EV&  (l.min-1)  10.2±2.3 11.8±3.1 0.48  42.4±12.1 41.9±7.5 0.91 
a- v O2 dif, vol.%  - - -  15.5±2.8 15.6±2.9 0.31 
AT (ml.kg-1.min-1)  - - -  14.2±3.9 13.1±2.2 0.41 
Exercise time (s)   - - -  687±279 743±104 0.54 
CPO-cardiac power output, CR-cardiac reserve, HR-heart rate, TQ& -cardiac output, 
SV-stroke volume, DBP-diastolic blood pressure, SBP-systolic blood pressure, MAP-
mean arterial blood pressure, 2OV& -oxygen consumption, 2C
O
V& -carbon dioxide 
production, RER-respiratory exchange ratio, EV& -minute ventilation, AT-anaerobic 
threshold.  






10.4.2 Effect of Exercise Training on Resting Haemodynamic and 
Metabolic Measurements   
Repeated measures analysis of variance showed that there were no significant 
reductions in body weight following either aerobic or resistance exercise. Repeated 
measures analysis of variance revealed that there was non-significant difference 
between the two groups over the time (test for interaction, p>0.05) for all variables 
measured at rest. Resting cardiac power output, cardiac output, heart rate and stroke 
volume were not significantly different before and after either aerobic or resistance 
exercise training (p>0.05). Resting arterial blood pressure and metabolic 
measurements did not change significantly as a result of the aerobic or resistance 
exercise, as shown in Table 10.5.      
Table 10.5 Pre (Baseline)– and Post (End Point)– Exercise Intrvention Resting 
Haemodynamic and Metabolic Measurements 
    Aerobic Group (N=11)  Resistance Group (N=10) 
  Baseline End Point %  Baseline End Point % 
Haemodynamics        
CPO (W)  
 0.74±0.21 0.75±0.28 1.1  0.77±0.25 0.75±0.25 -2.2 
HR (beats.min-1) 
 60±9 61±8 1.2  63±11 65±12 2.9 
TQ&  (l.min-1)  3.7±1.1 3.9±1.3 4.8  3.7±1.1 3.8±0.9 3.8 
SV (ml.beat-1) 
 63.4±19.1 64.1±26.8 1.3  60.2±15.3 58.9±14.3 -3.1 
DBP (mm Hg) 
 73±8 71±8 -4.9  72±9 70±11 -2.6 
SBP (mm Hg) 
 114±15 111±11 -3.1  117±12 114±16 -2.1 
MAP (mm Hg) 
 91±10 87±8 -4.6  92±7 88±13 -3.9 
         
Metabolics        
2OV&  (ml.min-1)  285±79 329±129 7.6  331±106 313±135 -5.8 
2OV&  (ml.kg-1.min-1)   3.9±0.7 4.4±1.0 7.7  4.2±1.0 3.9±1.0 -7.5 
2C
O
V&  (ml.min-1)   210±69 241±112 15.1  258±85 252±117 -3.2 
RER 
 0.73±0.10 0.75±0.13 5.3  0.78±0.11 0.80±0.10 2.1 
EV&  (ml.min-1)   10.2±2 11.04±4.0 7.6   11.8±3.1 10.4±4.6 11.9 
%-percentage change from baseline, CPO-cardiac power utput, HR-heart rate, TQ& -
cardiac output, SV-stroke volume, DBP-diastolic blood pressure, SBP-systolic blood 
pressure, MAP-mean arterial blood pressure, 2OV& -oxygen consumption, 2C
O
V& -
carbon dioxide production, RER-respiratory exchange ratio, EV& -minute ventilation. 
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10.4.3 Effect of Exercise Training on Peak Exercise 
Haemodynamic and Metabolic Measurements   
Table 10.6 shows the effect of aerobic and resistance exercise programs on peak 
heamodynamic and metabolic variables. Peak cardiac power output increased by 6.2% 
following aerobic exercise, whereas following resistance training remained 
unchanged. Peak cardiac output significantly increased in the aerobic group (by 0.8 
l .min-1, p<0.05) but not in resistance exercise group. This increase in peak cardiac 
output following aerobic exercise was associated with an increase in peak stroke 
volume by ~6%. No significant change, however, was identified in any of the 
measured haemodynamic variables following resistance exercise training (Table 
10.6). Post training cardiac output and stroke volume of the aerobic group was 
significantly higher compared with the resistance ex rcise group (11.9 vs. 10.8 l.min-1, 
and 94.9 vs. 86.9 ml.beat-1, p<0.05), respectively. Similarly, systematic vascular 
resistance following aerobic exercise was significantly lower compared with that 
following resistance exercise (684 vs. 806 dyn.s-1.cm-5).    
Following aerobic exercise training, peak oxygen consumption and anaerobic 
threshold increased significantly from baseline values by 7.1% and 7.8%. No 
significant increase for the same variables was found following resistance training. An 
increase in anaerobic threshold following aerobic exercise was significantly higher 
than that following resistance exercise (p<0.05). Exercise time increased significantly 
following both aerobic and resistance exercise training, as were peak minute 







Table 10.6 Pre (Baseline)– and Post (End Point)– Exercise Intervention Peak Exercise 
Haemodynamic and Metabolic Measurements 
  Aerobic Group (N=11)   Resistance Group (N=10) 
 Baseline End Point %  Baseline End Point % 
Haemodynamics        
CPO (W)  
2.56±1.78 2.72±1.61 6.2  2.58±0.82 2.59±0.62 0.8 
CR (W) 
1.82±1.22 1.98±1.12 5.9  1.80±0.43 1.81±0.51 0.6 
HR (beats.min-1) 
125±25 126±22 0.9  123±28 125±27 1.6 
TQ&  (l.min-1) 11.1±6.7 11.9±6.4* 7.1  10.9±4.1 10.8±2.2† -0.8 
SV (ml.beat-1) 
89.6±51.8 94.9±53.8* 6.1  88.2±29.4 86.9±28.2† -1.7 
DBP (mm Hg) 
71±11 72±10 1.2  76±11 76±14 -0.7 
SBP (mm Hg) 
146±25 147±27 0.3  147±22 152±23 2.3 
MAP (mm Hg) 
102±15 103±16 0.6  106±14 108±18 1.1 
SVR (dyn.s-1.cm-5) 
742±231 684±212* -8.2  771±179 806±186† 3.8 
 
       
Metabolics 
       
2OV&  (ml.min-1) 1778±861 1889±896** 5.7  1726±610 1796±537 4.6 
2OV&  (ml.kg-1.min-1)  23.3±6.5 25.1±6.7* 7.1  22.2±5.3 23.2±3.6 4.9 
2C
O
V&  (ml.min-1)  1879±902 2132±1049** 11.8 
 
1822±651 1988±630* 8.8 
RER 1.06±0.10 1.13±0.10** 6.4  1.07±0.10 1.12±0.11* 4.7 
EV&  (ml.min-1) 42.4±12.1 60.8±26.2** 29.4  41.9±7.5 62.3±18.4** 32.1 
a- v O2 dif, vol.% 15.5±2.8 15.6±2.8 0.7  15.6±2.9 15.9±3.0 1.2 
AT (ml.kg-1.min-1)  14.2±3.9 15.5±4.5** 7.8  13.1±2.2 14.0±2.7
† 5.8 
Exercise time (s) 721±279 803±260** 10.4  743±104 799±100* 6.9 
%-percentage change from baseline, CPO-cardiac power utput, CR-cardiac reserve, 
HR-heart rate, TQ& -cardiac output, SV-stroke volume, DBP-diastolic blood pressure, 
SBP-systolic blood pressure, MAP-mean arterial blood pressure, SVR-systematic 
vascular resistance, 2OV& -oxygen consumption, 2C
O
V& -carbon dioxide production, 
RER-respiratory exchange ratio, EV& -minute ventilation, a-v O2dif-arteriovenous O2 
difference, AT-anaerobic threshold.  
*Denotes p<0.05 vs. baseline 
**Denotes p<0.01 vs. baseline  




A high positive correlation was found between changes in peak cardiac output and 
changes in peak oxygen consumption following aerobic exercise training (r=0.82, 
p<0.01).  
It is important to emphasize that statistical analysis for key exercise variables (e.g. 
cardiac power output, cardiac output, mean arterial pressure, peak oxygen 
consumption and anaerobic threshold), in addition to one described before, was also 
performed with groups consisted of eight patients. Analysis of variance revealed that 
results were not differed from those when groups consisted of 11 and 10 patients 
(when two/three patients performed the opposite exercise programme following a 12 
week “non-exercising” period).  
10.4.4 Cross-Over Study Design Results 
As previously mentioned, the main reason for asking patients to take part in the 
“cross-over” design was to increase number of patients in each exercise group. Only 
two patients from the aerobic exercise group took part in the “cross-over” design. 
Since they completed the aerobic exercise programme, they were allowed a 12-week 
“non-exercising” period, following which they perfomed a baseline exercise test. 
Consequently, they were enrolled into resistance exrcise group for a 12-week 
exercise programme followed by cardiopulmonary exercis  test.  
Figure 10.1 illustrates changes in key variables (peak cardiac power output, peak 
oxygen consumption, anaerobic threshold and peak cardiac output) over the time in 















Figure 10-1 Changes in key variables (peak oxygen consumption, 2OV& ; anaerobic 
threshold, AT; peak cardiac power output, CPO; and peak cardiac output, TQ& ) 
following aerobic and resistance exercise programmes separated by a 12-week “non-
exercising” period (N=2).     
Figure 10.2 shows mean results for three patients (mean age, 69 yrs; weight, 74 kg; 
height, 172 cm; NYHA class, II) who firstly performed resistance exercise followed 









Figure 10-2 Changes in key variables (peak oxygen consumption, 2OV& ; anaerobic 
threshold, AT; peak cardiac power output, CPO; and peak cardiac output, TQ& ) 
following resistance and aerobic exercise programmes separated by a 12-week “non-
exercising” period (N=3). 
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10.5 Discussion 
The present study describes changes that occur in central haemodynamic and selected 
cardio-respiratory variables in response to different, clinically relevant modalities of 
exercise. The main finding of this study suggests that aerobic exercise training was 
generally associated with positive changes in central haemodynamic and metabolic 
variables, whereas resistance exercise training had little effect on the same variables.  
10.5.1 The Effect of Aerobic Exercise Training on Cardiac Power 
Output and Selected Cardio-Respiratory Variables  
A limited number of studies has assessed the effect o  an aerobic exercise programme 
on cardiac power output in heart failure patients. This should not be surprising as only 
a few investigations measured cardiac output at peak exercise before and after an 
exercise intervention in heart failure patients (Mezzani et al., 2008). 
It has been demonstrated that aerobic exercise training of eight weeks (cycling five 
days per week with an intensity of 75-80% of the 2OV&  max for 20 minutes) resulted 
in an increase of 16% in peak cardiac power output, 21% in cardiac reserve, and 11% 
in stroke volume in healthy middle-aged volunteers (Marshal e al., 2001). It has also 
been shown that even a low intensity, short-term (six weeks) aerobic exercise 
programme led to an improvement in overall cardiac function in ischaemic cardiac 
patients following coronary artery bypass graft surgery (Wright et al., 2002). Peak 
cardiac power output and cardiac reserve increased significantly by 10% and 12%. 
This was mostly due to increase in cardiac output by 0.9 l.min-1. Patwala et al. (2006) 
assessed the effect of aerobic exercise (three times per week treadmill walking up to 
20 minutes and cycling of 10 minutes) on cardiac power output in patients three and 
six months following cardiac resynchronization therapy. Results showed that peak 
cardiac power output increased more in patients who participated in exercise 
programme than those who were in the control group. The present study also indicates 
that aerobic exercise training had a positive effect on overall cardiac function in 
patients with stable chronic heart failure. This is demonstrated by an increase in peak 
cardiac power output and cardiac reserve by 6.2%, and 5.9%. Most of these changes 
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in cardiac power output are associated with changes in flow-generating capacity of the 
heart (cardiac output). On average, peak cardiac output increased by 0.8 l.min-1 
following aerobic exercise training.                       
The finding of the present study that aerobic exercis  training increases peak cardiac 
output is consistent with previous studies (Coats et al., 1992; Hambrecht et al., 1995; 
Hambrect et al., 2000; Sullivan et al., 1988). This increase in cardiac output found in 
the present study is mainly due to increase in stroke volume, whereas heart rate 
remained almost unchanged.  
Sullivan et al. (1988) assessed the effect of four t  six months aerobic exercise 
training in 12 patients with stable CHF. Patients exercised (cycling, walking, jogging, 
stair climbing) approximately four hours per week at heart rate corresponding to 75% 
of peak oxygen consumption. Exercise training result d in a 10% and 23% in 
maximal cardiac output and peak oxygen consumption (fr m 8.9 to 9.9 l.min-1, and 
from 16.8 to 20.6 ml.kg-1.min-1). Left ventricular ejection fraction, end-diastolic and 
end-systolic volume were unchanged, whereas peak stro e volume tended to increase. 
Coats et al. (1992) evaluated the effect of eight weeks exercise training (cycling 20 
minutes, five days per week, with intensity between 60 to 80% of 2OV& peak) in 17 
male patients with stable moderate to severe CHF. Training significantly increased 
peak cardiac output and peak oxygen consumption (frm 6.3 to 7.1 l.min-1 and 13.9 to 
16.5 ml.kg-1.min-1), whereas non significant change was found before and after 
training in peak mean arterial pressure. Further, Hambrecht et al. (1995) determined 
heamodynamic and functional response to six months aerobic exercise training (daily 
cycling for approximately 40 minutes at 70% of 2OV& peak) in 12 patients with CHF. 
After training, patients demonstrated a significant increase in cardiac output, peak 
oxygen consumption and oxygen consumption at anaerobic threshold by 19%, 23% 
and 31%. No significant difference before and after training was found for mean 
arterial blood pressure either at rest or at peak exercise, whereas peak heart rate 
increased significantly after training (from 163 to 172 beats.min-1 or 3%).  
In a subsequent study, Hambrecht et al. (2000) evaluated the effects of six months 
aerobic exercise training (daily cycling at heart ra e corresponding to 70% of 
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2OV& peak for 20 minutes). In contrast with previous and present studies, Hambrecht 
and colleagues found an increase in resting cardiac output by 0.3 l.min-1 which was 
associated with an increase in stroke volume by ~18%. As in the present study, 
Hambrecht et al. (2000) did not find significant changes in mean arterial pressure at 
rest nor at peak exercise following exercise intervention compared with baseline 
values. Furthermore in a study by Hambrecht and colleagues, peak exercise cardiac 
output and stroke volume increased by ~16% and ~13%, respectively, whereas in the 
present study by 7.1% and 6.1%. Similarly with the pr sent study, they reported a 
significant reduction in systematic vascular resistance following aerobic training, 
suggesting training-induced afterload modifications. A  suggested by Hambrecht et al. 
(1998), these changes are likely to be due to a corre tive effect of aerobic training on 
the endothelial dysfunction typical in CHF. In addition, Hambrecht and associates 
(2000) demonstrated significant increase in peak oxygen consumption and anaerobic 
threshold from 18.2 to 23 ml.kg-1.min-1 and from 10.4 to 13.8 ml.kg-1.min-1 following a 
six-month aerobic training.  
It seems that more functional improvement is associated with an exercise training 
programme of greater intensity and duration as suggested by Rees et al. (2004). That 
low intensity aerobic exercise training has little effect on haemodynamic measures has 
been demonstrated by Belardinelli et al. (1995). Eighteen patients with mild CHF 
underwent a low intensity (40% of 2OV& peak) training programme (cycling) three 
times per week for eight weeks. 2OV& peak and anaerobic threshold increased by 17% 
(from 16.1 to 18.9 ml.kg-1.min-1) and 20% compared with baseline in the training, but 
not in the control group. Cardiac output at rest, submaximal exercise or at peak 
exercise was not significantly different before and after exercise training. 
Interestingly, from skeletal muscle biopsy, Belardinelli et al. (1995) found that there 
was an increase in volume density of mitochondria, and subsequently high correlation 
was found between changes in peak oxygen uptake and in volume density of 
mitochondria (r=0.77) and between changes in lactate threshold and volume density 
of mitochondria (r=0.81). Peripheral changes in respon e to aerobic exercise training 
have been detailed in section 10.2.2.1 of this Chapter.  
In contrast to Belardinelli et al. (1995), Dubach et al. (1997) evaluated the effects of a 
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two month high intensity aerobic exercise training (four sessions per week of 40 
minutes cycling at 70% and 80% of 2OV& peak in addition to every day two hours 
walking). In this, as in the present study, resting cardiac output was not significantly 
changed before and after training. Similarly, nor arterial pressure either at rest or peak 
exercise. Peak cardiac output, however, increased significantly by 12% (from 12 to 
13.7 l.min-1). Also, 2OV& peak increased by 23 % after one month of exercise, and by 
an additional 6% after two months.  
Based on studies of Belardinelli et al. (1995) and Dubach et al. (1997), but also 
considering those previously mentioned in this section, it may be argued that only 
aerobic exercise training of higher intensity (e.g. >70% of 2OV& peak) will  enhance 
cardiac function and improvement in maximal cardiac output. The present study also 
intended that patients perform a higher intensity exercise as indicated on the Borg 
scale between 12 and 13. This Rate of Perceived Exertion was expected to 
demonstrate an exercise intensity of 60% to 80% of 2OV& peak, as shown during the 
baseline exercise test. Therefore an increase in peak cardiac output by 0.8 l.min-1 is 
not unexpected.             
It should be noted that most of the above cited stuies which evaluated the effect of 
exercise on cardiac output were performed in pre-beta lockers era. In Hambrecht and 
colleagues’ study (2000) only eight percents of patients were on β-blockade therapy, 
whereas in the present study 75% of patients in the aerobic group used β-blockers. 
Currently, only one more study evaluated cardiac output response to exercise 
following an aerobic exercise intervention in patien s on β-blockers (Nachwatel et al., 
2002). Specifically, they assessed the effect of short-term (three weeks) interval 
versus continuous aerobic exercise on metabolic and h emodynamic data. Although 
both modalities had similar positive effects on 2OV& peak and anaerobic threshold, 
continuous short-term exercise had no impact on cardiac index. In contrast, after 
interval training, cardiac index increased significantly by 9%. These studies, 
therefore, demonstrate that aerobic exercise training may improve peak cardiac output 
in patients on β-blockers as in patients without this medication. Iterestingly, the 
present study suggests that most of the improvement in peak cardiac output is due to 
an increase in stroke volume, whereas peak heart rate before and after aerobic 
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exercise training remained unchanged.              
Consistent with the above cited studies, the present tudy also demonstrates that 
aerobic exercise training significantly increased 2OV& peak. The percentage difference 
before and after training of 7.1% (1.8 ml.kg-1.min-1) is, however, lower than 
previously reported. Most studies observed an improvement in 2OV& peak, ranging 
from 10% to 30% (Rees et al., 2004) or ~3 ml.kg-1.min-1 (Haykowsky et al., 2007).  It 
should be noted, however, that patients in the present tudy had a higher baseline 
2OV& peak values (23.3 ml
.kg-1.min-1) compared with patients in most of the previous 
studies (<20 ml.kg-1.min-1), suggesting better overall functional capacity of the 
patients before starting the aerobic exercise programme. This is likely to explain 
smaller percentage improvement in 2OV& peak between the present and previous 
studies. Similarly, anaerobic threshold was also significantly higher compared with 
baseline value in aerobic group, but also compared with the resistance exercise group.    
Theoretically, the underlying mechanisms responsible for the increase in 2OV& peak 
can be divided into mechanisms responsible for improvement in cardiac output and 
factors that improve oxygen extraction (arteriovenous O2 content difference). The 
latter has not significantly changed following aerobic training. The change in maximal 
cardiac output was highly correlated with the change in peak oxygen consumption, 
suggesting that central haemodynamic adaptations cotribute to improved exercise 
performance after aerobic exercise training in the present study. A similar finding to 
this was also observed by Hambrecht et al. (1995) following aerobic exercise 
intervention.  
The findings of the present study further suggest that maximal cardiac pumping 
capability (peak cardiac power output) and peak cardiac pumping reserve (cardiac 
reserve), both improved by ~6% following aerobic exercise training. Peak mean 
arterial pressure remained unchanged, as was peak heart rate, and therefore, slight 
improvement in overall cardiac function is likely to be explained by an improvement 
in stroke volume. From literature available, it seems that there are several mechanisms 
which may possibly explain improvement in stroke volume. Stroke volume is 
calculated from the following formulae (Mezzani et al., (2008): SV=[LVEDV x 
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LVEF X (1-MRF)], where SV is stroke volume, LVEDV is left-ventricular end-
diastolic volume, LVEF is left ventricular ejection fraction, and MRF is mitral 
regurgitant fraction.  
The meta-analysis mentioned previously, which assessed the effect of exercise 
training on cardiac performance (van Tol et al., 2006), demonstrated a small but 
significant improvement in resting LVEDV (mean decrase of 3.1 ml) and resting 
diastolic blood pressure (mean decrease of 2.7 mm Hg) after aerobic training (mean 
duration 13±8 weeks) in CHF patients. Also, Haykowsky et al. (2007) in another 
meta-analysis, reported that aerobic exercise training reverses left ventricular 
remodelling in clinically stable CHF patients. It has been found that aerobic exercise 
training significantly improved ejection fraction by 3%, and decreased end-diastolic 
and end-systolic volumes by ~11% and ~13%, respectively. Moreover, Haykowsky et 
al. (2007) suggested that favourable changes in left ventricular volumes and ejection 
fraction associated with aerobic training were supplementary to pharmacological 
benefits (e.g. they occurred despite patients being prescribed medications with a 
proven antiremodeling effect). The mechanisms for such antiremodelling effects are 
not entirely understood. However, Haykowsky suggested that it may be due to the 
reduction in vasoconstricitve neurohormones or a declin  in haemodynamic loading.  
Braith et al. (1999) reported that aerobic training reduces resting plasma angiotensin 
II, aldosterone, vasopressin, atrial natriuretic peptide, brain natriuretic peptide, 
epinephrine, and norepinephrine levels. Coats et al. (1992) also reported that short-
term aerobic training is associated with a decrease in sympathetic tone and a 
concomitant increase in vagal activity in stable CHF patients. Haykowsky et al. 
(2007) argued that improved symphatovagal balance, coupled with a decline in 
vasoconstrictive neurohormones, is associated with a reduction in vascular load that 
may attenuate left ventricular remodelling. Indeed, Hambrecht et al. (1995, 2000) 
have shown that the reduction in resting left ventricular end-diastolic volume and 
increase in peak exercise stroke volume that occurred with aerobic training were 
related to the decline in resting and peak exercise systemic vascular resistance 
(Hambrecht et al., 1995). Additionally, Belardinelli et al. (1996,1998) demonstrated 
that aerobic training improves myocardial contractility and diastolic filling in heart 
failure patients. In patients with dilated cardiomyopathy of ischaemic origin, aerobic 
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traning may improve blood flow supply to left ventricular areas of hibernating 
myocardium ultimately leading to some degree of recov ry of regional contractility 
and regression of unfavourable remodelling (Gianuzzi et al., 2003). Improvement of 
endothelial function, regression of coronary atherosclerosis, collateral formation, and 
increased vasculogenesis have all been proposed as mechanisms favouring training-
induced increase in myocardial perfusion both in normal and patients with coronary 
artery disease (Linke et al., 2006; Nakamura et al., 2002). Aerobic training is 
associated with an improvement of left ventricular diastolic filling by an increase of 
diastolic filling time and increased relaxation velocity in CHF patients (Belardinelli et 
al., 1996). Mechanisms used to explain training-induced enhancement of diastolic 
function in CHF are increased calcium uptake by the sarcoplasmic reticulum (Moore 
et al., 1995), an improved perfusion of myocardium (Linke et al., 2006), more 
efficient myocardial bioenergetics (Ventura-Clapier et al., 2007), and reduction of left 
ventricular diastolic asynchrony (Belardinelli et al., 1996). 
The present study demonstrates that training-induced afterload modifications at peak 
effort in patients with CHF (e.g. peripheral vascular resistance decreased by ~60 
dyn.s-1.cm-5). Similar finding was reported previously by Dubach et al. (1997) and 
Hambrecht et al. (2000). These adaptations are likely to be due to the possible 
corrective effect of aerobic training on endothelial dysfunction typical of CHF 
(Hambrecht et al., 1998).    
Finally, besides the increases in peak cardiac output and peak oxygen consumption, 
there was a ~7% statistically significant increase in anaerobic threshold, ~12% in peak 
carbon dioxide production, ~10% in maximal exercise t me and, ~30% in maximal 
minute ventilation, respectively. These findings are similar to those by Hambrecht et 
al. (2000), and they are also reported elsewhere (Pina et al., 2003; Working Report 
Group, 2000). Several mechanisms that may occur in response to aerobic exercise 
training may contribute to significant increase in exercise tolerance and anaerobic 
threshold in CHF patients. Firstly, aerobic exercise training increases capillary 
density, promotes the synthesis and release of nitric oxide, improves angiogenesis, 
vasodilation and endothelial function, reduces oxidative stress and peripheral vascular 
resistance, and increases metabolic capacity and musculoskeletal blood flow 
(Adamopoulos et al., 2003; Duscha et al., 2008; Wisloff et al., 2007). Secondly, 
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aerobic exercise training in CHF patients is associated with lower blood lactate 
threshold and blood lactate concentration at standardized submaximal workload levels 
(Belardinelli et al., 1995), reduced depletion and more rapid resynthesis of 
phosphocreatine (Adamopoulos et al., 2003), and increased citrate syntheses activity 
(Duscha et al., 2008). Following aerobic training, the mitochondrial total volume 
density is increased, mitochondrial enzymatic activity and skeletal muscles’ oxidative 
capacity are enhanced (Belardinelli et al., 1995; Duscha et al., 2008; Piepoli et al., 
1998). In addition, it has been suggested that aerobic training improves phase II O2 
kinetics, which is an indirect index of muscle oxidat ve capacity (Roditis et al., 2007). 
Also, some studies have shown a shift from IIb to IIa muscle fibre type (Duscha et al., 
2008) and a modest increase in type I muscle fibres (Hambrecht et al., 1997). 
Although the present study was not proposed to evaluate any of the above mentioned 
underlying mechanisms which may be responsible for positive changes in metabolic 
variables, there is no reason why some of these changes could occur in the studied 
cohort of patients.  
To summarize this section, it is clear that aerobic exercise training as utilised in the 
present study is associated with improvement in key haemodynamic and exercise 
tolerance variables such as cardiac output, oxygen consumption, anaerobic threshold 
and exercise duration.     
10.5.2 The Effect of Resistance Exercise Training on Cardiac 
Power Output and Selected Cardio-Respiratory Variables 
The findings of the present study clearly suggest tha resistance exercise training did 
not have significant effect on any of the central hemodynamic variables measured at 
rest or at peak exercise, nor on peak oxygen consumption and anaerobic threshold. 
There was, however, a significant increase in carbon dioxide production, minute 
ventilation and exercise duration following resistance exercise training.    
Two decades ago, a study by Elkayam and colleagues (1985) raised a fear that 
isometric exercise significantly deteriorates cardic performance in some patients with 
advanced chronic heart failure. They reported that during isometric exercise 
systematic vascular resistance increases while cardiac index and stroke volume index 
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decreases. The findings of this study caused a great concern regarding the suitability 
of resistance training for chronic heart failure patients. The protocol in their study 
however, examined the patients response to 5-7 minutes of isometric exercise at 30% 
of maximal voluntary contraction (Elkayam et al., 1985) which today is not 
recommended for any population (Pollock et al., 2000). It has been suggested that 
during a lower intensity of resistance exercise, th haemodynamic responses do not 
exceed levels attained during standard treadmill test (McKelvie et al., 1995), and 
adverse left ventricular remodelling after resistance training has not been 
demonstrated (Pu et al., 2001).  
Exercise intolerance in CHF patients may partially be explained by a reduction of 
muscle mass and strength of skeletal muscles (Harrington and Coats, 1997). 
Therefore, it has been suggested that in contrast to aerobic, resistance exercise 
training has potential to increase muscle mass and subsequently enhance exercise 
performance (Baith and Becks, 2008). Moreover, Williams and associates (2007) 
argued that effects of resistance training in heart f ilure appear to be directed at 
improving skeletal muscle ultrastructurural abnormalities and/or neuromuscular 
function rather than simply increasing muscle mass.    
Conversely to a number of studies which evaluated th  effect of aerobic exercise in 
CHF patients, a few investigations evaluated the eff ct of resistance exercise training 
on functional improvement in CHF patients. Two studies only (Levinger et al., 2005; 
Feiereisen et al., 2007) assessed central haemodynamics, although measured at rest. 
Levinger et al. (2005) assessed the effect of eight weeks resistance training on the left 
ventricular structure and function in patients with CHF (baseline 2OV& peak of 14.4 
ml.kg-1.min-1). Patients performed three sessions per week which in luded nine 
different exercises for the major muscle groups. Initial intensity corresponded to 40-
60% of maximal strength (one set of 15 to 20 repetitions). The intensity was gradually 
increased during the eight-week programme by increasing the weight and reducing the 
number of repetitions. Results revealed that ejection fraction and stroke volume at rest 
increased significantly by ~13% in comparison with baseline value, respectively. 
Non-significant differences were found in end-diastolic and end-systolic volume 
before and after training. The authors concluded that e resistance training was a 
suitable method of training in patients with CHF since it does not cause a reduction of 
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left ventricular contractility function or enhance myocardial deterioration. 
Furthermore, Feiereisen et al. (2007) reported that resistance exercise training 
improved LVEF, and decreased left ventricular end-diastolic and end-systolic 
volumes, indicating for the first time that resistance exercise training may have an 
antiremodelling effect. Authors believed that exercise training could potentially add to 
the effect of medication by inducing endothelium-dependent vasodilation, reducing 
peripheral vascular resistance and afterload and resulting in a further increase in 
LVEF. The present study, however, did not show significant difference in systematic 
vascular resistance nor in diastolic blood pressure, suggesting that resistance training 
did not enhance afterload of the left ventricle.      
It should be noted that apart from resting echocardiog aphy, Levinger and associates 
(2005) as well as Feiereisen et al. (2007) were not able to demonstrate any measure of 
cardiac performance during exercise or at peak exercise. It is well documented that no 
association exists between resting and peak exercise measures of cardiac performance 
(Pina et al., 2003). The present study suggests tha resistance exercise training did not 
significantly increase any central haemodynamic measure either at rest or at peak 
exercise. In these cited studies, most of the patients were on β-blockers; patients had 
considerably different levels of peak oxygen consumption at baseline level (14.6 and 
15.6 vs. 22.3 ml.kg-1.min-1 in the present study). This may indicate that patients who 
possess better functional capacity at baseline level ar  unlikely to benefit from 
resistance exercise training, at least using the methodology as in the present study. 
Nonetheless, in the already mentioned meta-analysis, Haykowsky et al. (2007) 
suggested that the favourable effect of aerobic exercise training on left ventricular 
remodelling has not been shown in those studies which combined aerobic or 
resistance modes of exercise. This may be because of the heightened systolic and 
diastolic pressure loading that occur with strength training (Cheetham et al., 2002; 
McKelvie et al., 1995). These studies also suggested that strength-training-mediated 
increase in left ventricular wall stress, coupled with the impaired contractile and 
preload reserve could explain why stroke volume and ejection fraction do not increase 
when heart failure patients perform this type of exercise (Cheetham et al., 2002; 
McKelvie et al., 1995).  
The effect of resistance training on peak oxygen cosumption has been better 
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documented than its effect on central haemodynamic easures. Some studies 
demonstrated improvement in maximal oxygen consumption, whereas some studies 
reported no changes in peak oxygen consumption before and after training. Feiereisen 
et al. (2007) compared the efficacy of three training modalities on peak oxygen 
consumption in three groups of 15 patients with CHF. Patients underwent either 
resistance training, aerobic training, or a combinatio  of aerobic plus resistance 
training during 40 sessions, three times weekly for 45 minutes. Surprising result of the 
study was that the three exercise modes were comparably effective in improving peak 
oxygen consumption (resistance group +16.7%, aerobic group +11.1%, and combined 
group +14.2%). Additionally, resistance training elicited significant improvements in 
peripheral muscle strength but aerobic training did not. The 16% increase in peak 
oxygen consumption is remarkable, since in healthy, sedentary individuals, resistance 
training increases peak oxygen consumption by only 3% (Tanaka and Swensen, 
1998). This finding is in accordance with the literature, where others have shown that 
patients with CHF achieve 10-18% increases in peak oxygen consumption during 
resistance training and 15-20% after aerobic training (Meyer, 2006). A significant 
increase in peak oxygen consumption (14.5%) was observed after 12 weeks of 
training using weight collars in patients with CHF awaiting heart transplantation 
(Grosse et al., 2001).  
In contrast, the present study and others have reported no improvement in peak 
oxygen consumption. Pu et al. 2001 did not find significant changes in 2OV& peak after 
an 11-week resistance training in patients with moderate CHF (mean EF: 26%, 
NYHA class II-III) but reported a significant improvement in exercise time (by 13%). 
Similarly, Magnusson et al. (1996) demonstrated significant improvement in maximal 
exercise capacity (by 10%) in patients with CHF after eight weeks of resistance 
training but did not report any changes in 2OV& peak. The present study also suggests 
that resistance training improved exercise duration in addition to peak minute 
ventilation and peak carbon dioxide production but not peak oxygen consumption or 
anaerobic threshold. This improvement in exercise capa ity may be due to a number 
of peripheral factors, including possible increase in muscle strength, endurance, type I 
fibre area, and oxidative enzyme capacity as suggested by Pu et al. (2001). They also 
demonstrated no changes in any resting central haemodynamic factors or 2OV& peak 
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following resistance exercise training.  
The resistance training as used in the present study did not alter any measured central 
haemodynamic variable, not also variables of aerobic capacity such as peak oxygen 
consumption and anaerobic threshold.               
10.5.3 “Cross-Over” Results 
Graphically presented results for the few patients who participated in a “cross-over” 
design, supported the major finding of this study that improved cardiac function and 
peak oxygen consumption was associated with aerobic but not with the resistance 
exercise training. .  
More specifically, Figure 10.1 demonstrated that the aerobic exercise programme led 
to more functional improvement than the resistance ex rcise programme. It also 
showed that during a 12-week “non-exercise” period there is a decline in all variables. 
It should be, however, noted that this decline is more pronounced in metabolic 
variables such as oxygen consumption and anaerobic threshold, than that in central 
haemodynamic measures such as cardiac power output or cardiac output. In other 
words, is seems that improvement in cardiac functio following aerobic exercise is 
more preserved during the “non-exercising” period compared with peak oxygen 
consumption or anaerobic threshold. Figure 10.1 also suggests that the resistance 
exercise programme performed in the present study ha  little effect on either central 
haemodynamic or metabolic variables. The resistance exercise training used in the 
present study had little effect on metabolic and haemodynamic data as illustrated in 
Figure 10.2. 
It is recognised that this section is based on a very small sample and its inclusion is 




10.5.4 Study Limitations 
The present study has several limitations. Firstly, apart from the small sample size, 
there was a lack of the control group originally proposed. Although all efforts were 
made to overcome this early recognized limitation (e.g. contacting other hospitals in 
the area) the study has finished with no control grup. It should be, however, noted 
that most studies which observed an improvement in haemodynamic and functional 
capacity of patients assigned into an exercise intervention group, did not find the same 
improvement in a control group (Belardinelli et al., 1995; Dubach et al., 1997; 
Hambrecht et al., 1995; Hambrecht et al., 2000). Secondly, this was not full cross-
over trial as it was intended after the study commenced. This is associated with the 
fact that only a few patients were able to participate in the cross-over design for a 
variety of reasons (e.g. work commitments, travel), as well as the fact that this study 
had its own time framework due to the approaching deadline for submission of this 
thesis. Finally, the present study may have limitations from a methodological point of 
view. It is recognised that insertion of the Innocor respiratory valve unit into the 
CardioO2 metabolic analyser’s pneumotach is not ideal as it may reduce the patient’s 
concentration at peak exercise, as well as introduce a small resistance to breathing 
from a bacterial filter. Although the rebreathing procedure lasts for only a few 
seconds it may cause additional discomfort to the patient, particularly when the 
patient was asked to control his rebreathing frequency, and hold the breath for a 
second. However, the use of both systems, the Innocor for cardiac output 
measurement and CardioO2 for metabolic and ECG recordings, was necessary due the 
following two reasons. Firstly, the Innocor systems easures heart rate by pulse 
oxymetry. The use of this methodology is limited during cardiopulmonary exercise 
test when there is excessive motion (e.g. fast treadmill walking). Additionally, 
metabolic data, particularly 2C
O
V& , measured by the Innocor were significantly 
different from those obtained from the Cardio2O  system (Chapter 2). Secondly, as 
previously mentioned this clinical trial was a group project, in which one of the 
researchers particularly looked at heart rate recovry and O2 kinetics matched with 
heart rate. As the latter could not be performed accurately with the Innocor system 
alone, it was decided to use both systems.  
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10.6 Clinical Implications and Conclusions 
It has been well documented that patients with CHF may benefit from exercise 
training. Different modalities of exercise such as aerobic, resistance or combined may 
improve functional capacity of CHF patients, particularly peak oxygen consumption, 
anaerobic threshold and exercise duration. Over the years, researchers have 
demonstrated that a variety of central and peripheral adaptations occur in response to 
exercise training that are responsible for improvement in functional capacity in these 
patients. 
The most frequently reported variables used to assess the effect of an exercise 
intervention in CHF patients are those obtained from a cardiopulmonary exercise test 
procedure with gas exchange measurements (e.g. peak oxygen consumption). It seems 
that even an exercise programme of only three weeks is sufficient to demonstrate 
significant improvement in this variable, possibly y exercise-induce alteration within 
the skeletal muscle.  
Unlike metabolic and structural adaptations induced by exercise training, changes in 
central haemodynamic measurements, particularly cardiac output and cardiac power 
output, have been evaluated by a limited number of studies. This is mainly due to 
methodological issues surrounding cardiac output measurements, particularly during 
or at peak exercise. Nonetheless, several studies have demonstrated positive effect of 
exercise training on cardiac function.  
The primary indication of heart failure is cardiac dysfunction. It is recognised that “in 
the genesis of the heart failure, an initial cardiac abnormality is essential”. Therefore, 
most other interventions in heart failure patients (e.g. drugs, surgery) have been 
introduced to enhance cardiac function. Therefore a l gitimate question to ask is 
whether the first aim of exercise intervention in patients with chronic heart failure 
should be to improve cardiac or skeletal muscle functio ?  
The primary aim of each exercise intervention in CHF patients should be 
improvement in overall cardiac function as its deterioration is the primary cause of the 
disease. In order to achieve this goal it seems that a more scientific approach to 
 353 
exercise training prescription (intensity, duration, mode of exercise, proper training 
periodization, etc.) as well as “super-sophisticated” quipment for cardiac output 
measurement at rest and during all levels of exercis , are needed. Such a “more-
scientific” approach may enhance the peripheral adaptations at the same time and 
possibly before improvements in cardiac function.          
The current study assessed the effect of aerobic and resistance exercise training on, 
firstly overall cardiac function, represented by cardi c power output, but also on 
selected cardio-respiratory variables. The present study suggests that resistance 
exercise training did not induce any significant changes in either central or peripheral 
determinants of exercise performance in patients with mild CHF. Although the 
resistance training has been shown to improve some f the skeletal muscle 
characteristics, based on this but also on the previous studies, it is reasonable to 
suggest that its effect on power generating capacity of the heart is limited. 
In conclusion aerobic, in contrast with resistance ex rcise training, increases maximal 
flow-generating capacity of the heart and delays anaerobic metabolism during sub 
maximal exercise in patients with stable chronic heart failure. Improved peak oxygen 
consumption following aerobic exercise training is closely associated to an exercise-
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CHAPTER 11: SUMMARY AND CONCLUSIONS 
 
Instead of summarising this thesis in the conventional continuous prose style, it was 
recommended to follow the model used in the British Medical Journal and others. 
This was to summarise each chapter in the form of brie ullet points relating to what 
is known on the topic and what the research adds to the topic. The result is a ‘tighter’ 
set of ‘take home massages’ which provides an executiv  summary. It is hoped that 

























CHAPTER 2: LACK OF AGREEMENT BETWEEN GAS EXCHANGE 
VARIABLES MEASURED BY TWO METABOLIC SYSTEMS  
 
WHAT IS ALREADY KNOWN  
• The use of automated metabolic gas analysis systems has become common 
in cardiopulmonary exercise testing throughout the world 
• CardioO2 (Medical Graphics Corporation, Minnesota, USA) metabolic 
analyser is a valid and reliable instrument for gas exchange measurements 
• Recently introduced Innocor (Innovision, Denmark) metabolic system has 
no published data on its performance for measuring gas exchange variables 
 
WHAT THIS CHAPTER ADDS   
• Data are now available on gas exchange variables for the Innocor system 
• Limits of agreement between gas exchange variables m asured by the 
CardioO2 and Innocor appear to be wide and unacceptable 
• The Innocor and the CardiO2 metabolic systems cannot be used 





































CHAPTER 3: COMPARISON OF CARDIAC OUTPUT DETERMINED BY 
DIFFERENT REBREATHING METHODS AT REST AND AT PEAK 
EXERCISE 
 
WHAT IS ALREADY KNOWN  
• The non-invasive determination of cardiac output is of value in human 
physiology, especially clinical cardiology 
• Popular rebreathing methods today are the carbon dixide rebreathing 
methods and the inert gas rebreathing method 
 
WHAT THIS CHAPTER ADDS                                                                      
• The inert gas rebreathing method seems to be more valid than the 
exponential and equilibrium CO2 methods for measuring cardiac output at 
rest  
• At peak exercise the exponential and inert gas rebreathing methods 
produced similar results and showed acceptable limits of agreement  
• The exponential and inert gas rebreathing methods may be used 
interchangeable at peak exercise. 
CHAPTER 4: CARDIAC POWER OUTPUT IN HEALTHY AND 
DISEASED POPULATIONS – A LITERATURE REVIEW  
 
WHAT IS ALREADY KNOWN  
• Cardiac power output is a unique central haemodynamic measure which 
accounts for both pressure- and flow-generating capa ities of the heart 
• Cardiac power output is an indicator of overall cardiac function and strong 
predictor of prognosis in patients with heart failure 
• A limited number of studies have evaluated cardiac power output in healthy 
and in diseased populations    
 
WHAT THIS CHAPTER ADDS                                                                    
• The relationship between peak cardiac power output and a number of 
cardio-respiratory variables in healthy and heart failure patients has not 
been identified    
• Cardiac power output has not been evaluated in patients implanted with a 
left ventricular assist device  
• The effect on cardiac power output of different modalities of exercise 




































CHAPTER 5: RELATIONSHIP BETWEEN PEAK CARDIAC POWER 
OUTPUT AND SELECTED CARDIO- RESPIRATORY VARIABLES IN 
HEALTHY ADULTS  
 
WHAT IS ALREADY KNOWN  
• Peak cardiac power output is highly correlated with peak oxygen 
consumption and circulatory power in healthy adults 
• The strength of the relationship between peak cardiac power output and 
other routinely measured cardio-respiratory variables in healthy subjects is 
unknown   
 
WHAT THIS CHAPTER ADDS                                                                      
• Peak cardiac power output is modestly related to anaerobic threshold, 
carbon dioxide production, oxygen pulse and minute ventilation 
• These variables explained between 22% and 41% of the variance in peak 
cardiac power output in healthy adults  
• Central haemodynamic measures such as peak cardiac output and peak 
stroke volume, but not peak heart rate, are strong predictors of peak cardiac 
power output  
CHAPTER 6: COMPARISON OF CARDIAC POWER OUTPUT AND 
EXERCISE PERFORMANCE IN PATIENTS WITH LEFT VENTRICU LAR 
ASSIST DEVICES, EXPLANTED (RECOVERED) PATIENTS AND THOSE 
WITH SEVERE HEART FAILURE  
 
WHAT IS ALREADY KNOWN  
• The use of a left ventricular assist device (LVAD) with specific 
pharmacologic therapy may restore cardiac function o a level that the 
device may be explanted   
• Some patients implanted with a left ventricular assist device demonstrate 
better exercise performance than patients with severe h art failure  
 
WHAT THIS CHAPTER ADDS                                                                      
• Cardiac power output differentiates well during cardi c restoration using 
LVADs and emphasizes the benefits of this therapy  
• Cardiac power output and exercise performance are significantly higher in 
patients implanted with a LVAD than those with sever  heart failure 
• LVAD explanted (recovered) patients demonstrated higher cardiac power 
output values and exercise performance than those with severe heart failure 




































CHAPTER 7: RESTING AND EXERCISE HAEMODYNAMIC AND 
METABOLIC RESPONSES TO ACUTE REDUCTION OF LVAD 
SUPPORT: ASSESSMENT OF MYOCARDIAL RECOVERY  
 
WHAT IS ALREADY KNOWN  
• Myocardial recovery occurs after LVAD implantation 
• Performing a cardiopulmonary exercise test in patients with an LVAD when 
the device functions at reduced performance is safe and allows non-invasive 
assessment of myocardial recovery 
 
WHAT THIS CHAPTER ADDS                                                                      
• As a consequence of acute reduction of LVAD support there is a decrease 
in cardiac pumping capability at rest and particularly t peak exercise 
• A decrease at rest and at peak exercise, expressed in percentages, was 
higher in central haemodynamics, particularly in cardiac power output, than 
in the conventionally measured oxygen consumption 
• Cardiac power output seems to be more sensitive to acute reduction of 
LVAD support than oxygen consumption. 
CHAPTER 8: RELATIONSHIP BETWEEN PEAK CARDIAC PU MPING 
CAPACITY AND EXERCISE- DERIVED PROGNOSTIC INDICATORS IN 
PATIENTS WITH SEVERE HEART FAILURE AND THOSE IMPLAN TED 
AND EXPLANTED WITH A LEFT VENTRICULAR ASSIST DEVICE  
 
WHAT IS ALREADY KNOWN  
• Several exercise-derived variables have been shown t  be strong predictors 
of prognosis in chronic heart failure 
• Peak oxygen consumption does not necessarily reflect cardiac function 
/dysfunction in patients with severe heart failure 
 
WHAT THIS CHAPTER ADDS                                                                       
• The strength of the relationship between direct andindirect indicators of 
cardiac pumping capacity is weaker in patients with severe heart failure and 
those implanted with an LVAD, compared with LVAD explanted patients 
• This justifies the need for assessment of maximal cardiac pumping 
capability directly by measuring cardiac power output rather than using 




































CHAPTER 9: REPRODUCIBILITY OF CARDIAC P OWER OUTPUT AND 
SELECTED CARDIO- RESPIRATORY EXERCISE TEST VARIABLES IN 
PATIENTS WITH STABLE CHRONIC HEART FAILURE  
 
WHAT IS ALREADY KNOWN  
• Commonly measured cardio-respiratory variables such as peak oxygen 
consumption, anaerobic threshold, carbon dioxide production, minute 
ventilation and respiratory exchange ratio demonstrate good reproducibility 
in patients with chronic heart failure  
 
WHAT THIS CHAPTER ADDS                                                                      
• Measurement of central haemodynamic variables and particularly cardiac 
power output is more relevant in the evaluation of the severity of cardiac 
dysfunction in heart failure patients than any other m tabolic or ventilatory 
variable 
• Cardiac output and cardiac power output, as direct indicators of cardiac 
function, had lower coefficients of variation than y of the commonly 
reported gas exchange variables at rest, but also at pe k exercise, 
demonstrating a high degree of reproducibility 
CHAPTER 10: THE EFFECT OF AEROBIC VERSUS RESISTANCE 
EXERCISE TRAINING ON CARDIAC POWER OUTPUT AND 
SELECTED CARDIO- RESPIRATORY VARIABLES IN PATIENTS WITH 
STABLE CHRONIC HEART FAILURE  
 
WHAT IS ALREADY KNOWN  
• Exercise training in heart failure patients may improve exercise tolerance, 
functional capacity, quality of life, and also may reduce hospital admission 
and mortality rate 
• Both aerobic and resistance exercise training may improve exercise 
tolerance in patients with chronic heart failure 
 
WHAT THIS CHAPTER ADDS                                                                        
• In contrast with resistance training, aerobic exercis  training increases 
maximal flow-generating capacity of the heart and delays anaerobic 
metabolism during submaximal exercise in patients with stable chronic 
heart failure 
• Improvement in peak oxygen consumption following aerobic exercise 
training is closely associated with an exercise-induced increase in cardiac 




































INTEGRATED CONCLUSIONS FROM THIS THESIS  
• Gas exchange variables obtained from different metabolic analysers should 
be considered with caution  
• The inert gas rebreathing method for cardiac output measurement has the 
capacity to evaluate cardiac output at rest and at peak exercise more 
precisely than CO2 rebreathing methods 
• Cardiac power output should be assessed as a priority compared with other 
cardio-respiratory variables in the evaluation of cardiac 
function/dysfunction due to: 1) its capacity to demonstrate both pressure- 
and flow-generating capacities of the heart, 2) its strong prognostic value, 
and 3) its excellent reproducibility  
• Peak oxygen consumption, together with other commonly reported cardio-
respiratory variables does not necessarily reflect cardiac function 
/dysfunction, particularly in severe heart failure and LVAD patients  
• Cardiac power output, and particularly peak cardiac power output 
differentiates well during cardiac restoration using left ventricular assist 
devices and therefore can be used in management of LVAD patients 
• In contrast with resistance training, aerobic exercis  training improves 
maximal flow-generating capacity of the heart and consequently improves 
peak cardiac power output        
RECCOMMENDATIONS FOR FUTURE RESEARCH  
• Weber et al. (1982) proposed a functional classification of heart failure 
patients in four stages based on the peak oxygen consumption and oxygen 
consumption at anaerobic threshold. Future research should investigate the 
possibility of providing a functional classification table of heart failure 
patients based on peak cardiac power output, as a more appropriate measure 
of cardiac function/dysfunction than peak oxygen cosumption. 
• Future ‘reduced LVAD support’ studies in larger cohorts of patients are 
required to find out the “cut-off” value of peak cardiac power output which 
may indicate sufficient myocardial recovery for thedevice to be explanted 
• Investigations are required to assess whether an exercise programme soon 
after LVAD implantation may enhance cardiac function and exercise 
capacity and consequently accelerate the recovery protocol in LVAD 
patients 
• Future research is needed to optimise the exercise programme which will 
target an improvement in cardiac function in heart failure patients as a 
priority. Key components of exercise programme such as exercise intensity, 
duration, mode of the exercise and training periodization should be 
carefully considered  
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APPENDIX I: STAGE BY STAGE RESPIRATORY DATA 
Table I.1 Differences in measured gas exchange variables at the end of stage one of 




 mean + SD 
CardiO2 
mean + SD 
t  p 
Cronbach’s  
Alpha 
FeO2 (%) 16.40±1.36 17.23±0.35* -2.39 0.03 0.16 
FeCO2 (%) 2.95±0.71 3.70±0.35** -4.01 0.00 0.20 
2OV&  (ml.kg-1.min-1) 15.19±2.42 15.36±2.53 -1.80 0.09 0.99 
2OV&  (l.min-1) 1.03±0.33 1.10±0.29 -1.87 0.08 0.94 
EV&  (l.min-1) 23.09±5.80 22.97±5.01 0.12 0.91 0.84 
2C
O
V&  (l.min-1) 0.67±0.17 0.85±0.20** -6.64 0.00 0.91 
RER 0.67±0.09 0.78±0.07** -4.29 0.00 0.35 
 * Indicates the Innocor result is significantly (p<0.05) different from the CardiO2 system 
** Indicates the Innocor result is significantly (p<0.01) different from the CardiO2 system 
 
Table I.2 Differences in measured gas exchange variables at the end of stage two of 




 mean + SD 
CardioO2 
mean + SD 
t  p 
Cronbach’s 
Alpha 
FeO2 (%) 16.74±0.65 16.94±0.34 -1.46 0.17 0.64 
FeCO2 (%) 3.18±0.42 3.99±0.34** -9.50 0.00 0.77 
2OV&  (ml.kg-1.min-1) 20.7±3.77 21.13±3.35 -0.58 0.57 0.80 
2OV&  (l.min-1) 1.49±0.43 1.50±0.35 -0.29 0.78 0.93 
EV&  (l.min-1) 35.25±7.33 32.71±7.04 1.95 0.07 0.86 
2C
O
V&  (l.min-1) 1.13±0.31 1.31±0.31** -4.15 0.00 0.92 
RER 0.77±0.8 0.88±0.12* -3.35 0.01 0.22 
* Indicates the Innocor result is significantly (p<0.05) different from the CardiO2 system 
** Indicates the Innocor result is significantly (p<0.01) different from the CardiO2 system 
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Table I.3 Differences in measured gas exchange variables at the end of stage three of 
Bruce protocol between Innocor and CardiO2 (N=15) – Paired samples t-test (t) and 




 mean + SD 
CardioO2 
mean + SD 
t (z) p 
Cronbach’s 
Alpha 
FeO2 (%) 16.82±0.71  16.73±0.35 0.72 0.48 0.77 
FeCO2 (%) 3.65±0.73 4.14±0.25* -2.69 0.02 0.26 
2OV&  (ml.kg-1.min-1) 28.81±4.41 29.08±4.21 -0.36 0.72 0.87 
2OV&  (l.min-1) 2.06±0.51 2.05±0.39 0.17 0.87 0.95 
EV&  (l.min-1) 49.98±8.84 48.98±9.30 1.04 0.32 0.96 
2C
O
V&  (l.min-1) 1.85±0.63 2.04±0.43* -2.56 (z) 0.01 0.84 
RER 0.91±0.3 0.99±0.09* -2.56 (z) 0.01 0.61 
* Indicates the Innocor result is significantly (p<0.05) different from the CardioO2 system  
 
Table I.4 Differences in measured gas exchange variables at the end of stage four of 




 mean + SD 
CardioO2 




FeO2 (%) 17.16±0.39 17.12±0.43 0.51 0.62 0.90 
FeCO2 (%) 3.45±0.70 4.04±0.25* -3.14 0.01 0.35 
2OV&  (ml.kg-1.min-1) 35.4±6.08 34.15±5.0 1.14 0.28 0.86 
2OV&  (l.min-1) 2.67±0.75 2.54±0.63 1.46 0.17 0.95 
EV&  (l.min-1) 68.19±18.93 67.74±19.52 0.31 0.76 0.98 
2C
O
V&  (l.min-1) 2.37±0.84 2.75±0.83** -3.25 0.00 0.94 
RER 0.91±0.6 1.07±0.10** -6.25 0.00 0.58 
* Indicates the Innocor result is significantly (p<0.05) different from the CardiO2 system 
** Indicates the Innocor result is significantly (p<0.01) different from the CardiO2 system 
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APPENDIX II: INNOCOR AND CARDIO 2 DESCRIPTION 
II.1 Innocor Description 
II.1.1 Measurement of airflow 
The in/expiration flow is measured by a pressure difference pneumotach, returning a 
voltage related to the actual flow (Innovision, 2005). The relationship is nonlinear in 
nature and therefore a multi stroke calibration is performed to obtain a linear relation.    
The manufacturer suggested that the calibration is performed according to   
computerized determination of pneumotachometer chara teristics described by Yeh et  
al. (1982). The result of the calibration is a set of calibration factors (sticks) equally  
spaced along the complete voltage range of the pneumotach sensor. The resulting flow 
is found as: Flowstick = (X-offset) * Fstick(X), where X is value from pneumotach                                                              
sensor, offset is offset value of the pneumotach sensor (value at zero flow), and Fstick 
is a function to calculate stick related to value X (Innovision, 2005). The set of sticks  
reflects the characteristics of the specific pneumotach and valve, and is assumed valid            
until some hardware is exchanged. However, the actual gain on the system varies over 
time and therefore the following formula is used: Flow = G(X) * Flowstick, where G                                                                                                                                                                  
(X) is a function to return separate linear gain factors for in- and expired air, while X 
is a value from pneumotach sensor. The flow signal is ways searched backwards for 
breaths, and therefore the steps for detecting a bre th are: 1) find the expiration end 
point, 2) find the expiration start point (the inspiration end point), and 3) find the 
inspiration start point (the end point of the preceding expiration). Detailed analysis of 
these steps can be obtained from the manufactures.    
II.1.2 Gas sampling system 
The gas sampling is taken at the mouthpiece on the RVU. The gas moves through a 
Nafion Tube, which equilibrates the gas to the environment with respect to humidity. 
A Nafion sampling tube ensures equilibrium of the water vapour pressure of the 
sampled gas with that of the ambient air. Further, the gas passes a filter, which 
protects the analysers from dust and small particles. N xt the gas passes the Oxigraf, 
where the oxygen level is analysed, and the photo acoustic gas analyser (PGA), where 
the other gas components are analysed. The PGA contains a flow regulator, which 
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controls the flow to approximately 120 l.min-1. The gas passes an attenuator and 
finally the pump before the gas leaves the outlet placed on the back of the Innocor. 
The purpose of the attenuator is to damp the pulsation from the pump.  
II.1.3 Innocor principle of carbon dioxide measurement 
It is well known that among the gas species of interest in physiological examinations 
all except monoatomic gases, noble gases, nitrogen and oxygen absorb specific 
wavelengths of light in the infrared (IR) spectrum by intermolecular bindings. 
Therefore in acoustic gas measurement for medical app ic tions, Photo Acoustic 
Spectroscopy (PAS) is used to determine all concentrations except for oxygen. When 
the gas is subjected to intermittent infrared (IR) light of different gas-dependent, 
acoustic signals are produced and detected by a microphone.  
Absorption of light means absorption of energy and causes a heating of the 
gases/vapour and thereby a rise in pressure. By pulsation of the energy applied to the 
gas, the rise in pressure will be intermittent, thus causing a pressure fluctuation. By 
choosing the pulsation frequency in the audible range, the pressure fluctuation 
becomes an acoustic signal, and it is possible to pick up the signal using a 
microphone. In terms of rise time and ambient noise suppression, a high pulsation 
frequency is desirable, but when choosing the pulsation frequency it has to be taken 
into consideration, that a high frequency results in a short time for energy to have its 
effect on the gas. This in turn means that a small signal is generated and that the 
sensitivity will be limited. With an appropriate pulsation frequency, the amplitude of 
the signal is equivalent to the amount (concentration) of molecules in the measuring 
chamber.   
Light from an IR-source is reflected from gold-plated elliptic mirror towards a 
window in a measuring chamber. Before it enters the measuring chamber is passes 
individual optical filters. Each optical filter allows only a specific wavelength of light 
to pass through, and different wavelengths of light correspond to the IR-absorption 
spectra of gases/vapours, the system is designed to measure. The IR-light beams 
differing in both pulsating frequency and wavelength enter the measuring chamber 
through a window and excite the different gases they ar  optimized for by the optical 
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filters. Due to absorption of energy the gas will expand in the chamber at frequencies 
equal to the pulsating frequencies of the IR-light beams. The periodic expansions of 
the gas/vapour are within audible range (approx. 150-350 Hz) and a single highly 
sensitive microphone picks up the signals (Innovisin, 2005). Finally the different 
pressure signals are distinguished electronically.   
II.1.4 Innocor principle of oxygen measurement 
The oxygen analyser is the Oxigraf O2 sensor model X1004/X2004 from Oxigraf Inc. 
US. The patented Oxygraf sensor uses laser diode absorption spectroscopy in the 
visible spectrum, similar to the absorption method used to measure carbon dioxide in 
the infrared spectrum. However, oxygen absorption is in a region of the visible 
spectrum (760 nm) where there is no interference or absorption by other ventilation 
gases. Also the emission line width of the laser and the absorption line with of O2 are 
very narrow, less than 0.01 nm, compared with perhaps 100 nm for the CO2 
absorption band at atmospheric pressure (Innovision, 2005). The spectrally pure laser 
is thermally tuned precisely to the oxygen absorptin line. As the oxygen 
concentration increases, the light intensity is attenuated. The photo detector response 
varies linearly with the oxygen concentration.   
II.2 CardiO2 Description 
II.2.1 Gas volume measurement 
Measurement of airflow breath-by-breath during human ventilation has been 
accomplished historically with pneumotachometers with precision reported to be +3-4 
% (Porszasz et al., 1994). These authors introduced a new technique for measuring 
flow during breathing based on the principle of thedifferential pressure between two 
symmetrically disposed pitot tubes. Pitot tubes measure the pressure of gas flowing 
against a series of small tubes mounted at 90° to the direction of the gas flow. The 
pressures are dependant upon the density of the gas and the square of its velocity. The 
design involves a non-linear relationship between pressure differences and airflow, 
which is confounded by sensitivity to changes in gas density produced by changing 
gas composition. Commercial pitot tubes are very light, robust and cheap. Their 
linearity and sensitivity to changing compositions of expired and inspired gases 
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requires sophisticated software correction to linearis  their output. The software 
correction is based on the measured gas (O2 and CO2) concentrations and is 
implemented in the data acquisition program of the system.  
Conversion of the pressure measurement of the flow meter into airflow is 
accomplished in the software by the use of a shape t bl  containing several points 
spanning a wide range of flows. This is then multiplied by a correction factor 
determined during calibration. The correction factor is calculated as the mean of five 
correction factors generated for five strokes of a calibrated syringe of known volume 
that are performed at different flow rates. This spans a physiological spectrum of 
flows. This procedure reduces any variability that m y exist between flow meters. The 
integrated airflow measured by the pitot tube flow meter to obtain tidal ventilation 
proved to be reproducible and accurate to within 2% during exercise studies as 
suggested by Porszasz et al. (1994).    
II.2.2 Gas concentration measurements 
Different strategies have been used to measure gas concentrations necessary for 
breath-by-breath analysis (Hodges, 2004). Roca et al. (1997) suggested using an 
analyser capable of measuring all relevant gases, or using separate analysers for each 
gas species. The essential requirement for the gas an lyser is to be accurate and able 
to give a quick response. Roca et al. indicated two separates components for analyser 
response. The first is transport delay time (time required for the gas to traverse the 
distance from the sampling site to the analyser which is usually from 0.2 to 0.5s. The 
second component is analyser response which represents the kinetics of response to 
change in gas composition introduced to the analyser. The analyser response often 
takes the form of an exponential or sigmoid response to a stepwise change gas 
composition.   
II.2.3 CardiO 2 principle of carbon dioxide measurement 
The CardiO2 metabolic analyser uses an infrared carbon dioxide analyser, which relies 
on the fact that carbon dioxide absorbs infrared radiation. Dual beams of infrared 
radiation are sent through a reference cell and a par llel sample cell containing the test 
gas at constant flow. A mechanical system interrupts the two beams as they reach the 
 380 
signal in the detector, providing an oscillating signal. The magnitude of the 
oscillations is proportional to the differences in the concentrations of the reference 
and test gas. Infrared carbon dioxide analysers are considered to be accurate and 
robust for most cardiovascular measurements, although care is needed to prevent 
contamination of the sample chamber by fluids (Macfarlane, 2001).   
II.2.4 CardiO 2 principle of oxygen measurement 
The CardiO2 system uses a zirconia fuel cell. This is an electrochemical galvanic cell 
consisting of calcium stabilised zirconium oxide electrolyte with porous platinum 
electrodes (Mcfarlane, 2001). At its operating temprature (750-850°C) the electrolyte 
acts as a semi-permeable membrane that is selective for oxygen ions. The output 
voltage follows the Nernst equation, which is based on the logarithm of the partial 
pressure of oxygen in the sample and reference gas (M cfarlane, 2001). These 
analysers have the benefit of requiring little maintenance and of being both stable and 
accurate. Zirconia fuel cells are very fast responding (<100 ms) and require relatively 













































(l .min -1) 
EQU 
(l .min -1) 
IGR 
(l .min -1) 
1 9.1 8.6 5.0 5.2 4.2 4.5 8.9 5.1 4.4 
2 10.2 10.0 7.1 6.5 4.7 4.8 10.1 6.8 4.8 
3 12.1 12.9 9.0 9.2 5.2 5.1 12.5 9.1 5.2 
4 10.4 10.0 6.2 6.9 4.8 5.4 10.2 6.6 5.1 
5 14.2 13.0 9.6 9.0 4.6 4.9 13.6 9.3 4.8 
6 13.6 16.4 6.1 5.5 4.5 6.1 15.0 5.8 5.3 
7 10.5 9.8 5.3 5.1 4.7 4.3 10.2 5.2 4.5 
8 9.2 8.8 7.0 6.9 5.6 5.5 9.0 6.7 5.6 
9 12.8 11.8 6.4 6.1 6.0 5.7 12.3 6.3 5.9 
10 15.3 15.1 6.3 6.0 4.0 4.0 15.2 6.2 4.0 
11 7.0 6.7 5.0 5.1 4.2 4.8 6.9 5.1 4.5 
12 9.2 9.3 7.1 6.8 5.5 6.2 9.3 7.0 5.9 
13 10.4 9.9 5.8 5.3 5.9 5.5 10.2 5.6 5.7 
14 15.6 14.9 9.4 9.1 6.4 6.2 15.3 9.3 6.3 
15 8.7 12.2 7.0 6.7 6.1 5.9 10.5 6.9 6.0 
16 10.5 11.8 5.2 4.5 4.0 3.8 11.2 4.9 3.9 
17 6.0 5.8 5.5 5.8 4.2 4.5 5.9 5.7 4.5 
          
Mean+SD 10.9±2.7 11±2.9 6.7±1.5 6.5±1.5 5±0.8 5.1±0.9 10 .9±2.8 6.6±1.5* 5.1±0.7* 
Min 6 5.8 5 4.5 4 3.8 5.8 4.5 3.9 
Max 15.6 16.4 9.6 9.2 6.4 6.2 15.1 9.1 6.3 
Range 9.6 10.6 4.6 4.7 2.4 2.4 9.3 4.6 2.4 
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Table III.2 Individual and mean peak TQ&  values measured by the exponential and 
inert gas rebreathing methods 
 TQ&  (l.min-1)  
Subject IGR EXP Mean  
Difference  
1 18.6 18.7 -0.1 
2 21.3 20.6 0.7 
3 20 19.9 0.1 
4 19.8 20.1 -0.3 
5 28.7 28.3 0.4 
6 14.5 14.3 0.2 
7 14.3 14.1 0.2 
8 22.4 22.6 -0.2 
9 21.3 20.7 0.6 
10 14.8 14.9 -0.1 
11 21.9 21.5 0.4 
12 20.8 20.9 -0.1 
Mean±SD 19.87±4.05 19.72±3.97 # 0.15 
Min 14.3 14.1 -0.3 
Max 28.7 28.3 0.7 













IGR – inert gas rebreathing method; EXP – exponential rebreathing method; # - 
indicates p value (p = 0.136).   
 383 
 
APPENDIX IV: Pharmacological therapy in heart failure 
Evidence for drugs use and its effect on heart failure are described below according to 
ACC/AHA Guideline (2005) and the ESC Task Force (2005). 
1. Angiotensin-converting enzyme inhibitors (ACE-inhibitors, ACEi) are 
recommended as first line therapy in all patients with heart failure, with or without 
symptoms, who have reduced LVEF (<40-45%).  It is not clear whether the effects of 
ACEi can be explained by solely by the suppression of angiotensin II production, 
because ACE inhibition not only interferes with the rennin-angiotensin system but 
also enhances the action of kinins and augmented kinin-mediated prostaglandin 
production. Systematic reviews of randomised controlled trials comparing ACE 
inhibitor to placebo have found that ACE inhibitor therapy in patients with heart 
failure due to left ventricular systolic dysfunction increases life expectancy. The effect 
is more marked in patients with more severe left ventricular systolic impairment, or 
more severe symptoms, although there is benefit for all NYHA classes. ACE inhibitor 
therapy also reduces the risk of hospitalisation. The symptoms of heart failure in 
patients with chronic heart failure due to left ventricular systolic dysfunction improve 
on therapy with an ACE inhibitor. There is some evid nce from a randomised 
controlled trial that quality of life improves with ACE inhibitor therapy in heart 
failure patients. High doses of ACE inhibitors lower blood pressure more than lower 
doses but do not necessary confer greater benefit i terms of improving symptoms or 
life expectancy. Exercise performance has not consistently been shown to improve 
with ACE inhibitor therapy for all patients with heart failure due to left ventricular 
systolic dysfunction. Although ACE inhibitors improve functional status of patients 
with heart failure in general, small benefits in exercise capacity occur. 
2. Diuretics are essential for symptomatic treatment when fluid overload is present 
and manifest as pulmonary congestion or peripheral oedema. The ultimate goal of 
diuretic treatment is to eliminate clinical evidenc of fluid retention, such as jugular 
venous pressure elevation and peripheral oedema. Diuretics interfere with the sodium 
retention of heart failure by inhibiting the reabsortion of sodium or chloride at specific 
sites in the renal tubules. Bumetanide, furosemide, and torsemide act at the loop of 
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Henle (thus, they are called loop diuretics) whereas, thiazides, metolazone, and 
potassium-sparing agents (e.g. spironolactone) act in the distal portion of the tubule. 
These two classes of diuretics differ in their pharm cological actions. The loop 
diuretics increase sodium excretion up to 20% to 25% of the filtered load of sodium, 
enhance free water clearance, and maintain their efficacy unless renal function is 
severely impaired. In contrast, the thiazide diuretcs increase the fractional excretion 
of sodium to only 5% to 10% in the filtered load, tend to decrease free water 
clearance, and lose their effectiveness in patients wi h impaired renal function. 
Therefore the loop diuretics have emerged as the preferred diuretic agents for use in 
most patients with heart failure Thiazide diuretics may be preferred in hypertensive 
heart failure patients, with mild fluid retention because they confer more persistent 
antihypertensive effects. Potassium-sparing diuretics (e.g. amiloride, triamterene) 
should only be used if hypokalaemia persists despit ACE-inhibition, or in severe 
heart failure despite the combination ACE-inhibition and low-dose spironolactone. In 
short-term studies, diuretics have led to a reduction in jugular venous pressure, 
pulmonary congestion, peripheral oedema, and body weight, all of which were 
observed within days if initiation of therapy. In itermediate-term studies, diuretics 
have been shown to improve cardiac function, symptos (dyspnoea), and exercise 
performance in patients with heart failure.  
3. Beta-adrenergic receptor blockers (β-blockers) act principally to inhibit the 
adverse effects of the sympathetic nervous system in patients with heart failure, and 
these effects overcome their well-known negative inotropic effects. Whereas cardiac 
adrenergic drive initially supports the performance of the failing heart, long-term 
activation of the sympathetic nervous system exerts deleterious effects that can be 
antagonized by the use ofβ-blockers. Sympathetic activation can increase ventricular 
volumes and pressure by causing peripheral vasoconstriction and by impairing sodium 
excretion by the kidneys. Norepinephrin can also induce cardiac hypertrophy but 
restrict the ability of the coronary arteries to supply blood to thickened ventricular 
wall, leading to myocardial ischaemia. Activation of the sympathetic nervous system 
can also provoke arrhythmias by increasing the automa icity of cardiac cells, 
increasing triggered activity of the heart, and promoting the development of 
hypokalaemia. Norepinephrin can also increase heart rate and potentiate the activity 
and actions of other neurohormonal systems. Finally, by stimulating growth and 
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oxidative stress in terminally differentiated cells, norepinephrine can trigger 
programmed cell death or apoptosis. Beta-blocking agents are recommended for the 
treatment of all patients (in NYHA class II-IV) with stable, mild, moderate, and 
severe heart failure from ischaemic or non-ischaemic cardiomyopahties and reduced 
LVEF on standard treatment, including diuretics and ACE-inhibitors. Beta-blocking 
therapy reduces hospitalization, improves the functio al class and leads to less 
worsening of heart failure. This beneficial effect has been consistently observed in 
subgroups of different age, gender, functional class, LVEF, and ischaemic or non-
ischaemic aetiology. Beta-blockers are the only heart failure drugs that cause a 
significant improvement in LVEF, which occurs both in patients with ischaemic or 
non-ischaemic aetiology of heart failure. However, the improved left ventricular 
systolic function does not constantly result in a better exercise capacity probably 
because of the negative chronotropic effects of beta- lockers. There is evidence to 
show that long-term beta-blocker therapy increases ex rcise time but not peak oxygen 
consumption, and reduces peak carbon dioxide producti n (Witte et al., 2005, 
European Journal of Heart Failure, 7: 612-617). 
4. Aldosterone antagonists. Although short-term therapy with ACEi can lower 
circulating levels of aldosterone, such suppression may not be sustained during long-
term treatment. The lack of long-term suppression may be important because the 
aldosterone exerts adverse effects on the structure and function of the heart, 
independently of and in addition to the deleterious effects produced by angiotensin II. 
It is understood that aldosterone has an important ole in the pathophysiology of heart 
failure. It promotes vascular and myocardial fibrosis, potassium and magnesium 
depletion, sympathetic activation, parasympathetic inhibition, and baroreceptor 
dysfunction. Aldosterone antagonists (e.g. spironolact ne, eplerenone) are 
recommended in addition to ACEi, β-blockers, and diuretics in advanced heart failure 
(NYHA III-IV) to improve survival and morbidity irrespective of aetiology. The use 
of spironolactone (25 mg daily for six months) in 30 stable chronic heart failure 
patients had a positive effect on gas diffusion andexercise capacity (peak oxygen 
consumption) (Agostoni et al. 2005, European Heart Journal, 26: 159-164).  
5. Angiotensin II receptor antagonists (ARBs) can be used as an alternative to ACE-
inhibition in symptomatic patients intolerant to ACE inhibitors to improve morbidity 
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and mortality. ARBs and ACE inhibitors seem to have similar efficacy in chronic 
heart failure on mortality and morbidity. ARBs can be considered in combination with 
ACE inhibitors in patients who remain symptomatic. Addition of ARBs aswell as 
ACE inhibitors improves morbidity and mortality, reduces hospitalization and 
improves signs/symptoms of heart failure and quality of life. 
6. Digitalis glycosides (e.g. digoxin) exert their effects in patients with heart failure by 
virtue of their ability to inhibit sodium-potassium (Na+-K+) adenosine triphosphatase 
(ATPase). Inhibition of this enzyme in cardiac cells results in an increase in the 
contractile state of the heart. Increased intracellular sodium promotes sodium-calcium 
exchange, leading to a rise in the intracellular calcium concentration. This results in 
improved isolated myocyte contractile performance (increased shortening velocity) 
and overall left ventricular systolic function. For many decades, the benefits of 
digitalis in heart failure were ascribed exclusively to this positive inotropic action. 
However, recent evidence suggests that the benefits of digitalis may be related in part 
to enzyme inhibition in noncardiac tissue. Inhibition of Na+-K+ ATPase in vagal 
afferent fibers acts to sensitize cardiac baroreceptors, which in turn reduces 
sympathetic outflow from the central nervous system. In addition, by inhibiting Na+-
K+ ATPase in the kidney, digitalis reduces the renal tubular reabsorption of sodium; 
the resulting increase in the delivery of sodium to the distal tubules leads to the 
suppression of rennin secretion from the kidneys. These observations have let to the 
hypothesis that digitalis acts in heart failure primarily by attenuating the activation of 
neurohormonal systems and not as a positive inotropic drug. The treatments with 
digoxin for one to three months can improve symptoms, quality of life, and exercise 
tolerance in patients with mild to moderate heart filure regardless of the cause of 
heart failure or concomitant therapy (with or without ACE inhibitors). In a long-term 
trial that enrolled patients who primarily had class II or III symptoms, treatment with 
digoxin for two to five years had no effect on mortality but modestly reduced the 
combined risk of death and hispitalization. Digoxin may prevent deterioration in 
maximal exercise performance for patients with heart failure due to left ventricular 
systolic function, and withdrawal may lead to deterioration in maximal, but not 
submaximal, exercise performance.    
 
 
